0001628280-22-028782.txt : 20221108 0001628280-22-028782.hdr.sgml : 20221108 20221108092526 ACCESSION NUMBER: 0001628280-22-028782 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221108 DATE AS OF CHANGE: 20221108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: R1 RCM Inc. /DE CENTRAL INDEX KEY: 0001910851 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT SERVICES [8741] IRS NUMBER: 874340782 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41428 FILM NUMBER: 221367495 BUSINESS ADDRESS: STREET 1: 434 W. ASCENSION WAY, 6TH FLOOR CITY: MURRAY STATE: UT ZIP: 84123 BUSINESS PHONE: (312) 324-7820 MAIL ADDRESS: STREET 1: 434 W. ASCENSION WAY, 6TH FLOOR CITY: MURRAY STATE: UT ZIP: 84123 FORMER COMPANY: FORMER CONFORMED NAME: PROJECT ROADRUNNER PARENT INC. DATE OF NAME CHANGE: 20220211 10-Q 1 ah-20220930.htm 10-Q ah-20220930
false2022Q30001910851December 31R1 RCM Inc. /DEP3MP1YP1YP1YP1YP1YP3Y00019108512022-01-012022-09-3000019108512022-11-04xbrli:shares00019108512022-09-30iso4217:USD00019108512021-12-310001910851srt:AffiliatedEntityMember2022-09-300001910851srt:AffiliatedEntityMember2021-12-31iso4217:USDxbrli:shares00019108512022-07-012022-09-3000019108512021-07-012021-09-3000019108512021-01-012021-09-300001910851us-gaap:CommonStockMember2021-12-310001910851us-gaap:TreasuryStockCommonMember2021-12-310001910851us-gaap:AdditionalPaidInCapitalMember2021-12-310001910851us-gaap:RetainedEarningsMember2021-12-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001910851us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100019108512022-01-012022-03-310001910851us-gaap:CommonStockMember2022-01-012022-03-310001910851us-gaap:TreasuryStockCommonMember2022-01-012022-03-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001910851us-gaap:RetainedEarningsMember2022-01-012022-03-310001910851us-gaap:CommonStockMember2022-03-310001910851us-gaap:TreasuryStockCommonMember2022-03-310001910851us-gaap:AdditionalPaidInCapitalMember2022-03-310001910851us-gaap:RetainedEarningsMember2022-03-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100019108512022-03-310001910851us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000019108512022-04-012022-06-300001910851us-gaap:CommonStockMember2022-04-012022-06-300001910851us-gaap:TreasuryStockCommonMember2022-04-012022-06-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001910851us-gaap:RetainedEarningsMember2022-04-012022-06-300001910851us-gaap:CommonStockMember2022-06-300001910851us-gaap:TreasuryStockCommonMember2022-06-300001910851us-gaap:AdditionalPaidInCapitalMember2022-06-300001910851us-gaap:RetainedEarningsMember2022-06-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000019108512022-06-300001910851us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001910851us-gaap:AdditionalPaidInCapitalMemberah:CoyCo2Member2022-07-012022-09-300001910851ah:CoyCo2Member2022-07-012022-09-300001910851us-gaap:CommonStockMember2022-07-012022-09-300001910851us-gaap:TreasuryStockCommonMember2022-07-012022-09-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001910851us-gaap:RetainedEarningsMember2022-07-012022-09-300001910851us-gaap:CommonStockMember2022-09-300001910851us-gaap:TreasuryStockCommonMember2022-09-300001910851us-gaap:AdditionalPaidInCapitalMember2022-09-300001910851us-gaap:RetainedEarningsMember2022-09-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001910851us-gaap:CommonStockMember2020-12-310001910851us-gaap:TreasuryStockCommonMember2020-12-310001910851us-gaap:AdditionalPaidInCapitalMember2020-12-310001910851us-gaap:RetainedEarningsMember2020-12-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100019108512020-12-310001910851us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100019108512021-01-012021-03-310001910851us-gaap:CommonStockMember2021-01-012021-03-310001910851us-gaap:TreasuryStockCommonMember2021-01-012021-03-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001910851us-gaap:RetainedEarningsMember2021-01-012021-03-310001910851us-gaap:CommonStockMember2021-03-310001910851us-gaap:TreasuryStockCommonMember2021-03-310001910851us-gaap:AdditionalPaidInCapitalMember2021-03-310001910851us-gaap:RetainedEarningsMember2021-03-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100019108512021-03-310001910851us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000019108512021-04-012021-06-300001910851us-gaap:CommonStockMember2021-04-012021-06-300001910851us-gaap:TreasuryStockCommonMember2021-04-012021-06-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001910851us-gaap:RetainedEarningsMember2021-04-012021-06-300001910851us-gaap:CommonStockMember2021-06-300001910851us-gaap:TreasuryStockCommonMember2021-06-300001910851us-gaap:AdditionalPaidInCapitalMember2021-06-300001910851us-gaap:RetainedEarningsMember2021-06-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000019108512021-06-300001910851us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001910851us-gaap:CommonStockMember2021-07-012021-09-300001910851us-gaap:TreasuryStockCommonMember2021-07-012021-09-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001910851us-gaap:RetainedEarningsMember2021-07-012021-09-300001910851us-gaap:CommonStockMember2021-09-300001910851us-gaap:TreasuryStockCommonMember2021-09-300001910851us-gaap:AdditionalPaidInCapitalMember2021-09-300001910851us-gaap:RetainedEarningsMember2021-09-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-3000019108512021-09-300001910851ah:CoyCo2Member2022-01-012022-09-300001910851ah:CoyCo2Member2021-01-012021-09-300001910851ah:CloudmedMember2022-01-012022-09-300001910851ah:CloudmedMember2021-01-012021-09-300001910851ah:VisitPayIncMember2022-01-012022-09-300001910851ah:VisitPayIncMember2021-01-012021-09-300001910851ah:SeniorTermLoanMember2022-01-012022-09-300001910851ah:SeniorTermLoanMember2021-01-012021-09-300001910851us-gaap:RevolvingCreditFacilityMember2022-01-012022-09-300001910851us-gaap:RevolvingCreditFacilityMember2021-01-012021-09-300001910851ah:CloudmedMember2022-06-21xbrli:pure0001910851ah:CloudmedMember2022-06-212022-06-210001910851us-gaap:SubsequentEventMemberah:CloudmedMember2022-10-012022-10-310001910851us-gaap:AccountingStandardsUpdate202108Memberah:CloudmedMember2022-04-010001910851ah:CloudmedAcquisitionMember2022-06-212022-06-210001910851us-gaap:RestrictedStockUnitsRSUMemberah:CloudmedAcquisitionMember2022-06-212022-06-210001910851ah:CloudmedMemberah:CloudmedAcquisitionMember2022-06-212022-06-210001910851ah:CloudmedAcquisitionMember2022-06-210001910851us-gaap:CustomerRelationshipsMemberah:CloudmedAcquisitionMember2022-06-212022-06-210001910851us-gaap:TechnologyBasedIntangibleAssetsMemberah:CloudmedAcquisitionMember2022-06-212022-06-210001910851ah:CloudmedAcquisitionMemberus-gaap:LeasesAcquiredInPlaceMarketAdjustmentMember2022-06-212022-06-210001910851ah:CloudmedAcquisitionMember2022-07-012022-09-300001910851ah:CloudmedAcquisitionMember2022-01-012022-09-300001910851ah:RevWorksAcquisitionMember2021-07-012021-09-300001910851ah:RevWorksAcquisitionMember2022-08-012022-08-310001910851ah:RevWorksAcquisitionMember2020-12-31ah:payment0001910851ah:RevWorksAcquisitionMember2020-01-012020-12-310001910851ah:RevWorksAcquisitionMember2022-09-300001910851ah:CloudmedAndVisitPayAcquisitionsMember2022-07-012022-09-300001910851ah:CloudmedAndVisitPayAcquisitionsMember2021-07-012021-09-300001910851ah:CloudmedAndVisitPayAcquisitionsMember2022-01-012022-09-300001910851ah:CloudmedAndVisitPayAcquisitionsMember2021-01-012021-09-300001910851us-gaap:CustomerRelationshipsMember2022-09-300001910851us-gaap:CustomerRelationshipsMember2021-12-310001910851us-gaap:TechnologyBasedIntangibleAssetsMember2022-09-300001910851us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-310001910851us-gaap:TradeNamesMember2022-09-300001910851us-gaap:TradeNamesMember2021-12-310001910851us-gaap:LeasesAcquiredInPlaceMarketAdjustmentMember2022-09-300001910851us-gaap:LeasesAcquiredInPlaceMarketAdjustmentMember2021-12-310001910851ah:NetOperatingFeesMember2022-07-012022-09-300001910851ah:NetOperatingFeesMember2021-07-012021-09-300001910851ah:NetOperatingFeesMember2022-01-012022-09-300001910851ah:NetOperatingFeesMember2021-01-012021-09-300001910851ah:IncentiveFeesMember2022-07-012022-09-300001910851ah:IncentiveFeesMember2021-07-012021-09-300001910851ah:IncentiveFeesMember2022-01-012022-09-300001910851ah:IncentiveFeesMember2021-01-012021-09-300001910851ah:ModularAndOtherMember2022-07-012022-09-300001910851ah:ModularAndOtherMember2021-07-012021-09-300001910851ah:ModularAndOtherMember2022-01-012022-09-300001910851ah:ModularAndOtherMember2021-01-012021-09-300001910851us-gaap:InvestorMember2022-09-300001910851us-gaap:InvestorMember2021-12-310001910851ah:ContractWithCustomerLiabilityIncludingAdvancedBillingsMember2022-01-012022-09-300001910851ah:ContractWithCustomerLiabilityIncludingAdvancedBillingsMember2021-01-012021-09-300001910851us-gaap:AccountsReceivableMember2022-09-300001910851us-gaap:AccountsReceivableMember2021-09-300001910851ah:NetOperatingFeesMember2022-10-012022-09-3000019108512022-10-01ah:IncentiveFeesMember2022-09-300001910851ah:NetOperatingFeesMember2023-01-012022-09-3000019108512023-01-01ah:IncentiveFeesMember2022-09-300001910851ah:NetOperatingFeesMember2024-01-012022-09-300001910851ah:IncentiveFeesMember2024-01-012022-09-300001910851ah:NetOperatingFeesMember2025-01-012022-09-3000019108512025-01-01ah:IncentiveFeesMember2022-09-300001910851ah:NetOperatingFeesMember2026-01-012022-09-300001910851ah:IncentiveFeesMember2026-01-012022-09-300001910851ah:NetOperatingFeesMember2027-01-012022-09-3000019108512027-01-01ah:IncentiveFeesMember2022-09-300001910851ah:NetOperatingFeesMember2028-01-012022-09-300001910851ah:IncentiveFeesMember2028-01-012022-09-300001910851ah:NetOperatingFeesMember2022-09-300001910851ah:IncentiveFeesMember2022-09-3000019108512022-10-012022-09-3000019108512023-01-012022-09-3000019108512024-01-012022-09-3000019108512025-01-012022-09-3000019108512026-01-012022-09-3000019108512027-01-012022-09-3000019108512028-01-012022-09-300001910851ah:PhysicianCustomerMember2022-07-012022-09-300001910851ah:PhysicianCustomerMember2022-09-300001910851ah:CloudmedMemberus-gaap:AccountingStandardsUpdate201613Member2022-06-300001910851ah:CloudmedMemberus-gaap:AccountingStandardsUpdate201613Member2021-06-300001910851ah:CloudmedMemberus-gaap:AccountingStandardsUpdate201613Member2021-12-310001910851ah:CloudmedMemberus-gaap:AccountingStandardsUpdate201613Member2020-12-310001910851us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-09-300001910851us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-12-310001910851ah:SeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMember2022-09-300001910851ah:SeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMember2021-12-310001910851ah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMember2022-09-300001910851ah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMember2021-12-310001910851us-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2022-09-300001910851us-gaap:LineOfCreditMemberah:SecondARCreditAgreementMemberah:ExistingSeniorSecuredTermLoanAMember2022-06-210001910851ah:IncrementalSeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-06-210001910851ah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-06-210001910851us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-06-210001910851ah:IncrementalSeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851us-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-06-21ah:offer0001910851us-gaap:LineOfCreditMemberah:SecondARCreditAgreementMemberus-gaap:FederalFundsEffectiveSwapRateMember2022-06-212022-06-210001910851ah:InterestRateOptionBasisSpreadOneMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:InterestRateOptionBasisSpreadOneMembersrt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:InterestRateOptionBasisSpreadOneMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMembersrt:MaximumMember2022-06-212022-06-210001910851ah:InterestRateOptionBasisSpreadOneMemberah:SeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:InterestRateOptionBasisSpreadOneMemberah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:SeniorSecuredTermLoanAMemberah:InterestRateOptionBasisSpreadTwoMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:SeniorSecuredTermLoanBMemberah:InterestRateOptionBasisSpreadTwoMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:SeniorSecuredTermLoanBMemberah:InterestRateOptionBasisSpreadTwoMembersrt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:SeniorSecuredTermLoanBMemberah:InterestRateOptionBasisSpreadTwoMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMembersrt:MaximumMember2022-06-212022-06-210001910851ah:SeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-09-300001910851ah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-09-300001910851us-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMembersrt:MaximumMember2022-06-212022-06-210001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-01-012022-09-300001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-07-012022-09-300001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-07-012021-09-300001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-01-012021-09-300001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-09-300001910851us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-01-012022-09-300001910851us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-07-012022-09-300001910851us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-07-012021-09-300001910851us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-01-012021-09-300001910851us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-09-300001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-12-310001910851us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-12-3100019108512021-01-012021-12-310001910851ah:ThirdPartyMember2022-07-052022-07-050001910851us-gaap:CostOfSalesMember2022-07-012022-09-300001910851us-gaap:CostOfSalesMember2021-07-012021-09-300001910851us-gaap:CostOfSalesMember2022-01-012022-09-300001910851us-gaap:CostOfSalesMember2021-01-012021-09-300001910851us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300001910851us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300001910851us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300001910851us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300001910851ah:OtherMember2022-07-012022-09-300001910851ah:OtherMember2021-07-012021-09-300001910851ah:OtherMember2022-01-012022-09-300001910851ah:OtherMember2021-01-012021-09-300001910851us-gaap:RestrictedStockUnitsRSUMember2021-12-310001910851us-gaap:PerformanceSharesMember2021-12-310001910851us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001910851us-gaap:PerformanceSharesMember2022-01-012022-09-300001910851us-gaap:RestrictedStockUnitsRSUMember2022-09-300001910851us-gaap:PerformanceSharesMember2022-09-300001910851us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001910851us-gaap:PerformanceSharesMember2021-01-012021-09-300001910851ah:RestrictedStockUnitsRSUsAndPerformanceSharesMemberah:CloudmedAcquisitionMember2022-06-212022-06-210001910851srt:MinimumMemberus-gaap:PerformanceSharesMember2022-01-012022-09-300001910851us-gaap:PerformanceSharesMembersrt:MaximumMember2022-01-012022-09-300001910851ah:FormerClassPUnitsMember2022-06-212022-06-210001910851ah:ManagementUnitsMember2022-06-212022-06-210001910851ah:ManagementUnitsMember2022-01-012022-09-300001910851us-gaap:InvestorMemberus-gaap:WarrantMember2022-01-012022-09-300001910851us-gaap:InvestorMemberus-gaap:WarrantMember2022-07-012022-09-300001910851ah:IntermountainMemberus-gaap:WarrantMember2022-07-012022-09-300001910851ah:IntermountainMemberus-gaap:WarrantMember2022-01-012022-09-300001910851us-gaap:InvestorMemberus-gaap:WarrantMember2021-07-012021-09-300001910851ah:IntermountainMemberus-gaap:WarrantMember2021-01-012021-09-300001910851us-gaap:PendingLitigationMemberah:TCPASCRecapitalizationLitigationMember2021-04-132021-04-19ah:claim0001910851ah:TCPASCACHISeriesLLLPMemberus-gaap:CommonStockMembersrt:AffiliatedEntityMember2021-05-272021-05-280001910851ah:TCPASCACHISeriesLLLPMemberus-gaap:CommonStockMembersrt:AffiliatedEntityMember2021-05-280001910851ah:TCPASCACHISeriesLLLPMembersrt:AffiliatedEntityMember2021-05-280001910851ah:TCPASCACHISeriesLLLPMembersrt:MinimumMembersrt:AffiliatedEntityMember2021-05-280001910851ah:TCPASCACHISeriesLLLPMembersrt:AffiliatedEntityMembersrt:MaximumMember2021-05-28ah:segment0001910851us-gaap:SalesRevenueNetMemberah:AscensionMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001910851us-gaap:SalesRevenueNetMemberah:AscensionMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001910851us-gaap:SalesRevenueNetMemberah:AscensionMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001910851us-gaap:SalesRevenueNetMemberah:AscensionMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001910851us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberah:CustomerNotAffiliatedwithAscensionHealthMember2022-07-012022-09-300001910851us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberah:CustomerNotAffiliatedwithAscensionHealthMember2021-07-012021-09-300001910851us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberah:CustomerNotAffiliatedwithAscensionHealthMember2022-01-012022-09-300001910851us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberah:CustomerNotAffiliatedwithAscensionHealthMember2021-01-012021-09-300001910851us-gaap:AccountsReceivableMemberah:AscensionMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001910851us-gaap:AccountsReceivableMemberah:AscensionMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-31


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q

(Mark One)

    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the quarterly period ended September 30, 2022
OR
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from to
COMMISSION FILE NUMBER: 001-41428
R1 RCM INC.
(Exact name of registrant as specified in its charter)
Delaware87-4340782
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
434 W. Ascension Way
84123
6th Floor
Murray
Utah
(Address of principal executive offices)(Zip code)
(312324-7820
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.01 per shareRCMNASDAQ
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ     No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes þ    No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerý
Accelerated filerNon-accelerated filerSmaller reporting companyEmerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes      No 
As of November 4, 2022, the registrant had 416,510,858 shares of common stock, par value $0.01 per share, outstanding.






Table of Contents




PART I — FINANCIAL INFORMATION
Item 1.Financial Statements
3


R1 RCM Inc.
Consolidated Balance Sheets
(In millions, except share and per share data)

(Unaudited)
 September 30,December 31,
 20222021
Assets
Current assets:
Cash and cash equivalents$131.1 $130.1 
Accounts receivable, net of $14.5 million and $2.4 million allowance as of September 30, 2022 and December 31, 2021, respectively
209.0 131.3 
Accounts receivable, net of $0.1 million and $0.1 million allowance - related party as of September 30, 2022 and December 31, 2021, respectively
29.7 26.1 
Current portion of contract assets74.4  
Prepaid expenses and other current assets96.9 77.2 
Total current assets541.1 364.7 
Property, equipment and software, net163.0 94.7 
Operating lease right-of-use assets98.9 48.9 
Non-current portion of contract assets30.8  
Non-current portion of deferred contract costs27.5 23.4 
Intangible assets, net1,567.5 265.4 
Goodwill2,549.3 554.7 
Non-current deferred tax assets9.4 51.8 
Other assets93.6 45.7 
Total assets$5,081.1 $1,449.3 
Liabilities
Current liabilities:
Accounts payable$25.0 $17.7 
Current portion of customer liabilities67.8 41.5 
Current portion of customer liabilities - related party5.6 7.9 
Accrued compensation and benefits105.7 97.0 
Current portion of operating lease liabilities20.8 13.5 
Current portion of long-term debt49.5 17.5 
Other accrued expenses71.6 59.1 
Total current liabilities346.0 254.2 
Non-current portion of customer liabilities5.3 3.3 
Non-current portion of customer liabilities - related party14.1 15.4 
Non-current portion of operating lease liabilities99.2 53.4 
Long-term debt1,728.1 754.9 
Non-current deferred tax liabilities98.2 4.2 
Other non-current liabilities22.4 17.2 
Total liabilities2,313.3 1,102.6 
Stockholders’ equity:
Common stock, $0.01 par value, 750,000,000 shares authorized, 439,386,709 shares issued and 417,722,143 shares outstanding at September 30, 2022; 500,000,000 shares authorized, 298,320,928 shares issued and 278,226,242 shares outstanding at December 31, 2021
4.4 3.0 
Additional paid-in capital3,104.4 628.5 
Accumulated deficit(84.8)(64.3)
Accumulated other comprehensive loss(4.0)(5.3)
Treasury stock, at cost, 21,664,566 shares as of September 30, 2022; 20,094,686 shares as of December 31, 2021
(252.2)(215.2)
Total stockholders’ equity2,767.8 346.7 
Total liabilities and stockholders’ equity$5,081.1 $1,449.3 
See accompanying notes to consolidated financial statements.
4


R1 RCM Inc.
Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)
(In millions, except share and per share data)

 
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Net services revenue ($218.1 million and $657.8 million for the three and nine months ended September 30, 2022, respectively, and $227.5 million and $661.4 million for the three and nine months ended September 30, 2021, respectively, from related party)
$496.0 $379.7 $1,273.6 $1,075.7 
Operating expenses:
Cost of services403.1 304.0 1,009.7 858.2 
Selling, general and administrative60.8 33.2 120.6 87.8 
Other expenses30.1 11.4 136.1 34.2 
Total operating expenses494.0 348.6 1,266.4 980.2 
Income from operations2.0 31.1 7.2 95.5 
Net interest expense23.7 6.5 35.3 13.8 
Income (loss) before income tax provision (benefit)(21.7)24.6 (28.1)81.7 
Income tax provision (benefit)7.8 7.6 (7.6)20.5 
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Net income (loss) per common share:
Basic$(0.07)$0.06 $(0.06)$(2.03)
Diluted$(0.07)$0.05 $(0.06)$(2.03)
Weighted average shares used in calculating net income (loss) per common share:
Basic417,700,782 278,655,269 330,877,880 262,209,929 
Diluted417,700,782 320,617,086 330,877,880 262,209,929 
Consolidated statements of comprehensive income (loss)
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Other comprehensive income (loss):
Net change on derivatives designated as cash flow hedges, net of tax9.2 0.5 8.1 0.9 
Foreign currency translation adjustments(2.2) (6.8)(1.0)
Total other comprehensive income (loss), net of tax$7.0 $0.5 $1.3 $(0.1)
Comprehensive income (loss)$(22.5)$17.5 $(19.2)$61.1 
Basic:
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Less dividends on preferred shares   (592.3)
Net income (loss) available/allocated to common shareholders - basic$(29.5)$17.0 $(20.5)$(531.1)
Diluted:
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Less dividends on preferred shares   (592.3)
Net income (loss) available/allocated to common shareholders - diluted$(29.5)$17.0 $(20.5)$(531.1)
See accompanying notes to consolidated financial statements.
5


R1 RCM Inc.
Consolidated Statements of Stockholders’ Equity (Unaudited)
(In millions, except share and per share data)

 Common StockTreasury StockAdditional
Paid-In
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Loss
Total
 SharesAmountSharesAmount    
Balance at December 31, 2021298,320,928 $3.0 (20,094,686)$(215.2)$628.5 $(64.3)$(5.3)$346.7 
Share-based compensation expense— — — — 10.2 — — 10.2 
Issuance of common stock related to share-based compensation plans1,757,955 — — — — — — — 
Exercise of vested stock options77,438 — — — 0.4 — — 0.4 
Acquisition of treasury stock related to share-based compensation plans— — (727,768)(18.7)— — — (18.7)
Repurchases of common stock— — (8,000)(0.2)— — — (0.2)
Net change on derivatives designated as cash flow hedges, net of tax of $0.0 million
— — — — — — 0.1 0.1 
Foreign currency translation adjustments— — — — — — (1.4)(1.4)
Net income— — — — — 29.4 — 29.4 
Balance at March 31, 2022300,156,321 $3.0 (20,830,454)$(234.1)$639.1 $(34.9)$(6.6)$366.5 
Share-based compensation expense— — — — 11.6 — — 11.6 
Issuance of common stock related to share-based compensation plans505,371 — — — — — — — 
Issuance of common stock135,929,742 1.4 — — 2,386.1 — — 2,387.5 
Replacement awards issued in conjunction with acquisitions— — — — 11.3 — — 11.3 
Exercise of vested stock options395,425 — (2,282)(0.1)2.1 — — 2.0 
Acquisition of treasury stock related to share-based compensation plans— — (153,157)(3.5)— — — (3.5)
Net change on derivatives designated as cash flow hedges, net of tax of $0.4 million
— — — — — — (1.2)(1.2)
Foreign currency translation adjustments— — — — — — (3.2)(3.2)
Net loss— — — — — (20.4)— (20.4)
Balance at June 30, 2022436,986,859 $4.4 (20,985,893)$(237.7)$3,050.2 $(55.3)$(11.0)$2,750.6 
Share-based compensation expense— — — — 24.8 — — 24.8 
CoyCo 2 share-based compensation expense— — — — 3.0 — — 3.0 
Issuance of common stock related to share-based compensation plans189,566 — — — — — — — 
Issuance of common stock1,403,687 — — — 24.3 — — 24.3 
Exercise of vested stock options806,597 — — — 2.1 — — 2.1 
Acquisition of treasury stock related to share-based compensation plans— — (84,547)(1.9)— — — (1.9)
Repurchases of common stock— — (594,126)(12.6)— — — (12.6)
Net change on derivatives designated as cash flow hedges, net of tax of $3.1 million
— — — — — — 9.2 9.2 
Foreign currency translation adjustments— — — — — — (2.2)(2.2)
Net loss— — — — — (29.5)— (29.5)
Balance at September 30, 2022439,386,709 $4.4 (21,664,566)$(252.2)$3,104.4 $(84.8)$(4.0)$2,767.8 
See accompanying notes to consolidated financial statements.
6


R1 RCM Inc.
Consolidated Statements of Stockholders’ Equity (Unaudited)
(In millions, except share and per share data)

 Common StockTreasury StockAdditional
Paid-In
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Loss
Total
 SharesAmountSharesAmount    
Balance at December 31, 2020137,812,559 $1.4 (16,668,521)$(139.2)$393.7 $(161.5)$(6.5)$87.9 
Share-based compensation expense— — — — 12.8 — — 12.8 
Issuance of common stock related to share-based compensation plans6,497 — — — — — — — 
Issuance of common stock324,212 — — — 7.0 — — 7.0 
Exercise of vested stock options539,795 — — — 3.5 — — 3.5 
Acquisition of treasury stock related to share-based compensation plans— — (2,201)— — — — — 
Net change on derivatives designated as cash flow hedges, net of tax of $0.2 million
— — — — — — 0.5 0.5 
Foreign currency translation adjustments— — — — — — (0.4)(0.4)
Conversion of preferred shares117,706,400 1.2 — — 250.3 — — 251.5 
Inducement dividend— — — — (592.3)— — (592.3)
Issuance of common stock related to inducement21,582,800 0.2 — — 487.1 — — 487.3 
Net income— — — — — 25.8 — 25.8 
Balance at March 31, 2021277,972,263 $2.8 (16,670,722)$(139.2)$562.1 $(135.7)$(6.4)$283.6 
Share-based compensation expense— — — — 24.0 — — 24.0 
Issuance of common stock related to share-based compensation plans539,884 — — — — — — — 
Exercise of vested stock options396,250 — — — 1.3 — — 1.3 
Acquisition of treasury stock related to share-based compensation plans— — (167,832)(4.5)— — — (4.5)
Net change on derivatives designated as cash flow hedges, net of tax of $0.0 million
— — — — — — (0.1)(0.1)
Foreign currency translation adjustments— — — — — — (0.6)(0.6)
Exercise of warrants pursuant to cashless provisions16,750,000 0.2 — — (0.2)— —  
Net income— — — — — 18.4 — 18.4 
Balance at June 30, 2021295,658,397 $3.0 (16,838,554)$(143.7)$587.2 $(117.3)$(7.1)$322.1 
Share-based compensation expense— — — — 25.8 — — 25.8 
Issuance of common stock related to share-based compensation plans54,524 — — — — — — — 
Exercise of vested stock options172,587 — — — 0.7 — — 0.7 
Acquisition of treasury stock related to share-based compensation plans— — (16,555)(0.3)— — — (0.3)
Repurchases of common stock— — (1,538,077)(31.7)— — — (31.7)
Net change on derivatives designated as cash flow hedges, net of tax of $0.1 million
— — — — — — 0.5 0.5 
Net income— — — — — 17.0 — 17.0 
Balance at September 30, 2021295,885,508 $3.0 (18,393,186)$(175.7)$613.7 $(100.3)$(6.6)$334.1 
See accompanying notes to consolidated financial statements.
7


R1 RCM Inc.
Consolidated Statements of Cash Flows (Unaudited)
(In millions)

 Nine Months Ended September 30,
 20222021
Operating activities
Net income (loss)$(20.5)$61.2 
Adjustments to reconcile net income (loss) to net cash (used in) provided by operations:
Depreciation and amortization107.8 56.8 
Amortization of debt issuance costs2.2 0.8 
Share-based compensation46.5 62.0 
CoyCo 2 share-based compensation3.0  
(Gain)/loss on disposal and right-of-use asset write-downs3.9 (0.3)
Provision for credit losses10.7 0.6 
Deferred income taxes(9.1)18.0 
Non-cash lease expense10.5 7.4 
Other1.5 0.8 
Changes in operating assets and liabilities:
Accounts receivable and related party accounts receivable(29.7)(18.8)
Contract assets(12.8) 
Prepaid expenses and other assets(38.3)(19.8)
Accounts payable(23.9)4.5 
Accrued compensation and benefits(79.6)34.3 
Lease liabilities(11.4)(9.9)
Other liabilities(3.2)(8.9)
Customer liabilities and customer liabilities - related party2.9 30.1 
Net cash (used in) provided by operating activities(39.5)218.8 
Investing activities
Purchases of property, equipment, and software(74.6)(33.4)
Acquisition of Cloudmed, net of cash acquired(847.7) 
Acquisition of VisitPay, net of cash acquired (294.7)
Proceeds from disposal of assets0.4 2.6 
Net cash used in investing activities(921.9)(325.5)
Financing activities
Issuance of senior secured debt, net of discount and issuance costs1,016.6 698.6 
Borrowings on revolver30.0 120.0 
Payment of debt issuance costs(1.0)(1.9)
Repayment of senior secured debt(13.1)(484.6)
Repayments on revolver(30.0)(90.0)
Payment of contingent consideration liability
 (4.8)
Deferred payment related to acquisition of RevWorks (12.5)
Inducement of preferred stock conversion (105.0)
Payment of equity issuance costs(2.0) 
Exercise of vested stock options4.6 6.3 
Purchase of treasury stock(12.5)(29.5)
Shares withheld for taxes(26.9)(4.8)
Other(0.2)(0.1)
Net cash provided by financing activities965.5 91.7 
Effect of exchange rate changes in cash, cash equivalents and restricted cash(3.1)(0.6)
Net increase (decrease) in cash, cash equivalents and restricted cash1.0 (15.6)
Cash, cash equivalents and restricted cash, at beginning of period130.1 174.8 
Cash, cash equivalents and restricted cash, at end of period$131.1 $159.2 
Supplemental disclosures of cash flow information
Property, equipment and software purchases not paid$27.4 $25.7 
See accompanying notes to consolidated financial statements.
8



R1 RCM Inc.
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in millions, except per share data)

1. Business Description and Basis of Presentation
Business Description
R1 RCM Inc. (the “Company”) is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. The Company helps healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for its customers.

Cloudmed Acquisition

On June 21, 2022, pursuant to the Transaction Agreement and Plan of Merger (the “Transaction Agreement”), dated as of January 9, 2022, among R1 RCM Inc. (f/k/a Project Roadrunner Parent Inc.), R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.), a wholly-owned subsidiary of the Company (“Old R1 RCM”), Project Roadrunner Merger Sub Inc., formerly a wholly-owned subsidiary of the Company (“R1 Merger Sub”), Revint Holdings, LLC (“Cloudmed”), CoyCo 1, L.P. (“CoyCo 1”), CoyCo 2, L.P. (“CoyCo 2” and, together with CoyCo 1, the “Sellers”), and, solely for certain purposes set forth therein, NMC Ranger Holdings, LLC, the Company purchased Cloudmed, a leader in Revenue Intelligence™ solutions for healthcare providers, and affiliated entities (collectively, the “Cloudmed entities”), through (i) a merger of R1 Merger Sub with and into Old R1 RCM with Old R1 RCM as the surviving entity, which resulted in Old R1 RCM becoming a wholly-owned subsidiary of the Company (the “Holding Company Reorganization”) and (ii) the Sellers contributing 100% of the equity of a blocker parent corporation of the Cloudmed entities in exchange for an aggregate of 135,929,742 shares of common stock, par value $0.01 per share, of the Company (“Company Common Stock”), subject to certain adjustments following the closing as set forth in the Transaction Agreement (the “Cloudmed Acquisition”, and together with the Holding Company Reorganization, the “Transactions”). For further details on the total consideration paid, refer to Note 2, Acquisitions. In October 2022, the Company finalized those adjustments, resulting in an additional 55,846 shares issued to the Sellers.

Cloudmed’s revenue intelligence platform combines cloud-based data architecture and deep domain expertise with intelligent automation to analyze large volumes of medical records, payment data, and complex medical insurance models to identify opportunities to deliver additional revenue to customers. The Company believes this transaction will enable the Company to further its ability to deliver transformative value to healthcare providers through a more fulsome platform of differentiated capabilities by creating a scaled leader across both end-to-end revenue cycle management (“RCM”) and technology-driven revenue intelligence.

Holding Company Reorganization

Pursuant to the Transaction Agreement, immediately prior to the completion of the Cloudmed Acquisition, Old R1 RCM implemented the Holding Company Reorganization, which resulted in the Company owning all of the capital stock of Old R1 RCM. Each share of Old R1 RCM’s common stock that was issued and outstanding immediately prior to the Holding Company Reorganization was automatically exchanged into an equivalent corresponding share of Company Common Stock, having the same designations, rights, powers, and preferences and the qualifications, limitations, and restrictions as the corresponding share of common stock of Old R1 RCM being converted. Accordingly, upon consummation of the Holding Company Reorganization, all Old R1 RCM stockholders became stockholders of the Company. Immediately prior to the consummation of the Holding Company Reorganization, the name of Old R1 RCM was changed to “R1 RCM Holdco Inc.” and the name of the Company was changed to “R1 RCM Inc.” The Company is the successor issuer to Old R1 RCM pursuant to Rule 12g-3(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The shares of Company Common Stock, as successor to Old R1 RCM, began trading on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “RCM” on June 22, 2022.

9


Basis of Presentation
The accompanying unaudited consolidated financial statements reflect the Company’s financial position as of September 30, 2022, the results of operations of the Company for the three and nine months ended September 30, 2022 and 2021, and the cash flows of the Company for the nine months ended September 30, 2022 and 2021. These financial statements include the accounts of R1 RCM Inc. and its wholly-owned subsidiaries, including Cloudmed and its subsidiaries since the date of the acquisition. All material intercompany amounts have been eliminated in consolidation. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial reporting and as required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the interim financial information, have been included. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2022.
When preparing financial statements in conformity with GAAP, the Company makes a number of significant estimates, assumptions, and judgments in the preparation of the financial statements. Actual results could differ from those estimates. For a more complete discussion of the Company’s significant accounting policies and other information, the unaudited consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements included in the Company’s 2021 Form 10-K.
Recently Issued Accounting Standards and Disclosures

In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 requires companies to apply Topic 606, Revenue from Contracts with Customers, to recognize and measure contract assets and contract liabilities obtained in a business combination. The ASU amendments will generally result in the recognition of contract assets and contract liabilities by the acquirer at amounts consistent with those recorded by the acquiree immediately before the acquisition date. The Company prospectively adopted ASU 2021-08 effective April 1, 2022 and preliminarily recognized contract assets of $92.4 million and contract liabilities of $3.3 million as part of the Cloudmed Acquisition.

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual sale restriction on an equity security should not be considered in measuring the security’s fair value. The Company will adopt ASU 2022-03 prospectively effective January 1, 2024 and is currently evaluating the impact of the standard on its consolidated financial statements.

2. Acquisitions

Assets acquired and liabilities assumed in a business combination are recorded at their estimated fair value on the date of the acquisition. The difference between the purchase price amount and the net fair value of assets acquired and liabilities assumed is recognized as goodwill on the balance sheet if the purchase price exceeds the estimated net fair value or as a bargain purchase gain on the income statement if the purchase price is less than the estimated net fair value. The allocation of the purchase price may be modified up to one year after the acquisition date as more information is obtained about the fair value of assets acquired and liabilities assumed.

Cloudmed

On June 21, 2022, the Company completed the acquisition of Cloudmed for a purchase price of $3.3 billion. The following table summarizes the fair value of the total consideration paid:

10


Fair Value
Stock consideration transferred to the Sellers (1)$2,389.5 
Cash consideration (2)879.8 
Replacement awards issued to Cloudmed equity award holders (3)11.3 
Total consideration3,280.6 

(1) The stock consideration fair value includes a preliminary discount for lack of marketability factor related to an 18-month lock-up period during which the Sellers may not sell their Company common stock.
(2) Cash consideration includes the repayment of Cloudmed’s pre-existing credit facility that was paid off at closing and was not assumed by the Company.
(3) Represents the pre-acquisition service portion of the fair value of 1,536,220 replacement restricted stock units (“RSUs”) issued to Cloudmed equity award holders at closing.

The Company funded the cash consideration component and the Company’s associated transaction expenses with a combination of cash on hand and the incurrence of additional indebtedness (see Note 8, Debt).

The purchase price has been provisionally allocated to assets acquired and liabilities assumed based on their fair value as of the acquisition date. The fair value estimate of assets acquired and liabilities assumed is pending the completion of various elements, including gathering further information about the identification and completeness of all assets and liabilities acquired, the finalization of an independent appraisal and valuation of the fair value of the assets acquired and liabilities assumed, and final review by the Company’s management. Some of the more significant amounts that are not yet finalized relate to the fair value of intangible assets (including goodwill), contract assets, contract liabilities, and income and non-income related taxes. Accordingly, management considers the balances shown in the following table to be preliminary, and there could be adjustments to the consolidated financial statements, including changes in our amortization expense related to the valuation of intangible assets acquired and their respective useful lives, among other adjustments.

The preliminary fair value of assets acquired and liabilities assumed is:
11


Purchase Price Allocation
Total purchase consideration$3,280.6 
Allocation of consideration to assets acquired and liabilities assumed:
Cash and cash equivalents$32.1 
Accounts receivable61.8 
Current portion of contract assets68.5 
Property, equipment and software5.0 
Operating lease right-of-use assets25.3 
Non-current portion of contract assets23.9 
Intangible assets1,370.1 
Goodwill1,994.7 
Other assets6.4 
Accounts payable(31.9)
Customer liabilities(3.3)
Accrued compensation and benefits(91.8)
Operating lease liabilities(25.4)
Deferred income tax liabilities(142.0)
Other liabilities(12.8)
Net assets acquired$3,280.6 

The intangible assets identified in conjunction with the Cloudmed Acquisition and their preliminary fair values are as follows:

Useful LifeGross Carrying Value
Customer Relationships
18 years
$318.0 
Technology
7 years
$1,052.0 
Favorable leasehold interestsLife of lease$0.1 

The goodwill recognized is primarily attributable to growth and cost reduction synergies that are expected to be achieved from the integration of Cloudmed. None of the goodwill is expected to be deductible for income tax purposes.

Included in the Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2022 are net sales of $120.2 million and $133.5 million, respectively, and net income before taxes of $1.3 million and $0.9 million, respectively, related to the operations of Cloudmed since the acquisition date of June 21, 2022.

Measurement period adjustments

The Company had various measurement period adjustments due to additional information received since the Cloudmed Acquisition, none of which were material.

12


Prior Acquisitions

During 2021, the Company acquired the following business:

Company NameDescription of the BusinessDescription of the Acquisition
iVinci Partners, LLC d/b/a VisitPay (“VisitPay”)
Provider of digital payment solutions
Purchased all outstanding equity interests

In 2020, the Company purchased certain assets relating to the RevWorks services business from Cerner Corporation. In accordance with the purchase agreement, the Company paid the first deferred payment of $12.5 million in the third quarter of 2021. The remaining deferred payment of $12.5 million was payable on the second anniversary of the closing date (August 2022) and is included in other accrued expenses on the Consolidated Balance Sheet as of September 30, 2022 as it had not been paid as of such date.

The two deferred payments related to the RevWorks acquisition were contractual obligations of the Company; however, they are refundable to the Company if certain RevWorks customer revenue targets defined in the purchase agreement for the first two years following the acquisition are not achieved. At the time of the acquisition, the Company recorded an asset for the fair value of the contingently refundable consideration of $22.3 million. As of September 30, 2022, the entire amount of the contingently refundable consideration of $25.0 million is included in prepaid expenses and other current assets on the Consolidated Balance Sheet. The parties are currently engaging in arbitration to finalize the remaining deferred payment and contingently refundable consideration amounts.

Pro Forma Results

The following table summarizes, on a pro forma basis, the combined results of the Company as though the Cloudmed Acquisition had occurred as of January 1, 2021 and the VisitPay acquisition had occurred as of January 1, 2020. These pro forma results are not necessarily indicative of the actual consolidated results had the acquisitions occurred as of those dates or of the future consolidated operating results for any period. Pro forma results are:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net services revenue$496.0 $464.6 $1,476.9 $1,321.5 
Net loss$(22.9)$(20.3)$(21.5)$(112.4)

Adjustments were made to earnings to adjust depreciation and amortization to reflect the fair value of identified assets acquired, to adjust share-based compensation expense for awards granted in connection with the acquisitions, to record the effects of extinguishing the debt of the acquired companies and replacing it with the debt of the Company, to adjust timing of acquisition related costs incurred by the Company, and to record the income tax effect of these adjustments.

3. Intangible Assets

The following table provides the gross carrying value and accumulated amortization for each major class of definite-lived intangible assets at September 30, 2022 and December 31, 2021:

13


September 30, 2022December 31, 2021
Gross Carrying ValueAccumulated AmortizationNet Book ValueGross Carrying ValueAccumulated AmortizationNet Book Value
Customer relationships$418.0 $(30.4)$387.6 $100.0 $(20.8)$79.2 
Technology1,267.5 (88.3)1,179.2 215.5 (30.2)185.3 
Tradename1.0 (0.4)0.6 1.0 (0.1)0.9 
Favorable leasehold interests0.1  0.1    
Total intangible assets$1,686.6 $(119.1)$1,567.5 $316.5 $(51.1)$265.4 

Intangible asset amortization expense was $49.2 million and $68.0 million for the three and nine months ended September 30, 2022, respectively, and $7.1 million and $15.8 million for the three and nine months ended September 30, 2021, respectively. Amortization expense for intangible assets is included in cost of services on the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss). The Company has no indefinite-lived intangible assets.

Estimated annual amortization expense related to intangible assets with definite lives as of September 30, 2022 is as follows:

Remainder of 2022$49.0 
2023196.3 
2024194.5 
2025192.9 
2026192.9 
2027192.9 
Thereafter549.0 
Total$1,567.5 

4. Goodwill

Changes in the carrying amount of goodwill for the nine months ended September 30, 2022 were:

Goodwill
Balance as of December 31, 2021
$554.7 
Cloudmed Acquisition1,994.7 
Change in foreign currency rates(0.1)
Balance as of September 30, 2022
$2,549.3 

5. Revenue Recognition
Revenue is measured based on consideration specified in a contract with a customer, and presented net of any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a service to a customer, which is typically over the contact term. Estimates of variable consideration are included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved.

Disaggregation of Revenue

In the following table, revenue is disaggregated by source of revenue:
14



Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net operating fees$324.2 $308.5 $965.3 $879.8 
Incentive fees20.8 41.5 80.9 108.0 
Modular and other (1)151.0 29.7 227.4 87.9 
Net services revenue$496.0 $379.7 $1,273.6 $1,075.7 

(1) Modular and other revenue primarily consists of service fees related to Cloudmed and R1 EntriTM Pay, physician advisory services (“PAS”), practice management (“PM”) services, and software subscription revenue.

Contract Balances

The following table provides information about contract assets and contract liabilities from contracts with customers:

September 30, 2022December 31, 2021
Contract assets
Current$74.4 $ 
Non-current30.8  
Total contract assets$105.2 $ 
Contract liabilities
Current (1)$28.4 $10.3 
Non-current (2)19.4 18.7 
Total contract liabilities$47.8 $29.0 

(1) Current contract liabilities include $26.5 million and $7.8 million classified in the current portion of customer liabilities and $1.9 million and $2.5 million classified in the current portion of customer liabilities - related party as of September 30, 2022 and December 31, 2021, respectively.
(2) Non-current contract liabilities include $5.3 million and $3.3 million classified in the non-current portion of customer liabilities and $14.1 million and $15.4 million classified in the non-current portion of customer liabilities - related party as of September 30, 2022 and December 31, 2021, respectively.

The contract assets balance will increase or decrease based on the timing of invoices and recognition of revenue. Prior to the Cloudmed Acquisition, the Company did not have significant contract assets. Significant changes in the carrying amount of contract assets for the three months ended September 30, 2022 were as follows:

Contract Assets
Balance as of June 30, 2022$89.6 
Revenue recognized84.4 
Amounts billed(73.0)
Other (1)4.2 
Balance as of September 30, 2022
$105.2 

(1) Other primarily includes measurement period adjustments to the contract assets acquired from the Cloudmed Acquisition.
15



The Company recognized revenue of $93.4 million and $99.7 million during the nine months ended September 30, 2022 and 2021, which amounts were included in contract liabilities on January 1 of the respective periods. These revenue amounts include $85.8 million and $88.1 million for the nine months ended September 30, 2022 and 2021, respectively, related to advanced billings which become accounts receivable and contract liabilities on the first day of the respective service period.

Refer to Note 2, Acquisitions, for the preliminary contract assets acquired and contract liabilities assumed as part of the Cloudmed Acquisition.

Transaction Price Allocated to the Remaining Performance Obligation

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. The estimated revenue does not include amounts of variable consideration that are constrained.

Net operating feesIncentive fees
Remainder of 2022$36.1 $17.8 
2023109.6 23.3 
202491.2  
202539.2  
202638.5  
202732.9  
Thereafter122.0  
Total$469.5 $41.1 
    
The amounts presented in the table above include variable fee estimates of the Company’s physician groups RCM services contracts, fixed fees, and forecasted incentive fees. Fixed fees are typically recognized ratably as the performance obligation is satisfied and forecasted incentive fees are measured cumulatively over the contractually defined performance period.

Estimates of revenue expected to be recognized in future periods exclude unexercised customer options to purchase services within the Company’s PAS contracts that do not represent material rights to the customer.

The Company does not disclose information about remaining performance obligations with an original expected duration of one year or less and has elected an exemption to the disclosure requirements related to estimate variable consideration and an exemption where the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the entity’s performance completed to date.

6. Accounts Receivable and Allowance for Credit Losses

Accounts receivable is comprised of unpaid balances pertaining to modular services and end-to-end RCM customers, net receivable balances for end-to-end RCM customers after considering cost reimbursements owed to such customers, including related accrued balances, and amounts due from physician RCM and PM customers.

16


The Company evaluates its accounts receivable for expected credit losses quarterly. The Company maintains an estimated allowance for credit losses to reduce its accounts receivable to the amount that it believes will be collected. This allowance is based on the Company’s historical experience, its assessment of each customer’s ability to pay, the length of time a balance has been outstanding, input from key Company resources assigned to each customer, the status of any ongoing operations with each applicable customer, and business and industry factors such as significant shifts in the healthcare environment which the Company believes may have impacted or will impact its customers’ financial health and ability to pay.

During the three months ended September 30, 2022, the Company increased the allowance for credit losses related to a physician customer by $9.5 million due to the customer facing financial challenges and its resulting inability to make a contractually required payment on September 30, 2022. As a result of reviewing the potential expected outcomes related to this customer, the Company recorded an allowance for credit losses of $10.0 million related to an overall receivable balance of $33.3 million as of September 30, 2022.

The Company has presented the rollforward below on a consolidated basis as the currently expected credit losses for its large integrated healthcare system customers are not anticipated to be material.

Movements in the allowance for credit losses are as follows (in millions):

 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Beginning balance$4.4 $2.3 $2.5 $3.8 
Cumulative effect of Cloudmed ASC 326 adoption
  1.8  
Provision (recoveries)10.4 0.4 10.7 0.6 
Write-offs(0.2)(0.3)(0.4)(2.0)
Ending balance$14.6 $2.4 $14.6 $2.4 

7. Leases

The components of lease costs are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Operating lease cost$6.9 $4.0 $16.8 $12.1 
Sublease income(0.4)(0.6)(1.3)(1.7)
Total lease cost$6.5 $3.4 $15.5 $10.4 

Supplemental cash flow information related to leases are as follows:

Nine Months Ended September 30,
20222021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases$17.6 $18.6 
Right-of-use assets obtained in exchange for operating lease obligations:67.6 13.6 

Refer to Note 2, Acquisitions, for the preliminary right-of-use assets acquired and lease liabilities assumed as part of the Cloudmed Acquisition.

Maturities of lease liabilities as of September 30, 2022 are as follows:
17



Operating Leases
Remainder of 2022$9.3 
202324.6 
202423.9 
202522.6 
202616.8 
202710.8 
Thereafter40.8 
Total148.8 
Less:
Imputed interest(28.8)
Present value of lease liabilities$120.0 
.

8. Debt

The carrying amounts of debt consist of the following:

September 30, 2022December 31, 2021
Senior Revolver (1)$80.0 $80.0 
Term A Loans1,222.5 695.6 
Term B Loan500.0  
Unamortized discount and issuance costs(24.9)(3.2)
Total debt1,777.6 772.4 
Less: Current maturities(49.5)(17.5)
Total long-term debt$1,728.1 $754.9 

(1) As of September 30, 2022, the Company had $80.0 million in borrowings, $0.9 million letters of credit outstanding, and $519.1 million of availability under the Senior Revolver.

Second Amended and Restated Senior Secured Credit Facilities

On June 21, 2022, the Company, Old R1 RCM, and certain of its subsidiaries entered into a second amended and restated senior credit agreement (the “Second A&R Credit Agreement”) with Bank of America, N.A., as administrative agent, and the lenders named therein, governing the Company’s second amended and restated senior secured credit facilities (the “Senior Secured Credit Facilities”), consisting of the $691.3 million existing senior secured term loan A facility (the “Existing Term A Loan”), a $540.0 million senior secured incremental term loan A facility (the “Incremental Term A Loan”, and together with the Existing Term A Loan, the “Term A Loans”), a $500.0 million senior secured term loan B facility (the “Term B Loan”, and together with the Term A Loans, the “Senior Term Loans”), and a $600.0 million senior secured revolving credit facility (the “Senior Revolver”). In conjunction with entering into the Second A&R Credit Agreement, the Company incurred $7.2 million and capitalized $6.4 million of debt issuance costs.

The Incremental Term A Loan has a five-year maturity and the Term B Loan has a seven-year maturity. The Existing Term A Loan and Senior Revolver mature on July 1, 2026. The Second A&R Credit Agreement provides that the Company may make one or more offers to the lenders, and consummate transactions with individual lenders that accept the terms contained in such offers, to extend the maturity date of the lender’s term loans and/or revolving commitments, subject to certain conditions, and any extended term loans or revolving commitments will constitute a separate class of term loans or revolving commitments.
18



Borrowings under the Senior Secured Credit Facilities bear interest, at the Company’s option, at: (i) an Alternate Base Rate (“ABR”) equal to the greater of (a) the prime rate of Bank of America, N.A., (b) the federal funds rate plus 0.50% per annum, and (c) the Term Secured Overnight Financing Rate (“SOFR”) for an interest period of one-month beginning on such day plus 100 basis points, plus between 0.25% and 1.50% dependent on the Company’s total net leverage ratio (provided that the Term SOFR rate applicable to the Term A Loans shall not be less than 0.00% per annum, and the Term SOFR rate applicable to the Term B Loan shall not be less than 0.50% per annum); or (ii) the Term SOFR rate (provided that the Term SOFR rate applicable to the Term A Loans shall not be less than 0.00% per annum, and the Term SOFR rate applicable to the Term B Loan shall not be less than 0.50% per annum), plus between 1.25% and 2.50%, dependent on the Company’s total net leverage ratio. The interest rate as of September 30, 2022 was 5.28% for the Term A Loans and Senior Revolver and 6.03% for the Term B Loan. The Company is also required to pay an unused commitment fee to the lenders under the Senior Revolver at a rate between 0.20% and 0.40% of the average daily unutilized commitments thereunder dependent on the Company’s total net leverage ratio.

The Second A&R Credit Agreement requires the Company to make mandatory prepayments, subject to certain exceptions, with: (i) beginning with fiscal year ending December 31, 2023, 50% (which percentage will be reduced upon the Company’s achievement of certain total net leverage ratios) of the Company’s annual excess cash flow, (ii) 100% of net cash proceeds of all non-ordinary course asset sales or other dispositions of property or casualty events, subject to certain exceptions and thresholds, and (iii) 100% of the net cash proceeds of any debt incurrence, other than debt permitted under the Second A&R Credit Agreement.

The Second A&R Credit Agreement contains a number of financial and non-financial covenants. The Company was in compliance with all of the covenants in the Second A&R Credit Agreement as of September 30, 2022. The obligations under the Second A&R Credit Agreement are secured by a pledge of 100% of the capital stock of certain domestic subsidiaries owned by the Company and a security interest in substantially all of the Company’s tangible and intangible assets and the tangible and intangible assets of certain domestic subsidiaries.

The proceeds from the new Senior Secured Credit Facilities were or will be used, in addition to cash on hand, (1) to refinance, in full, all existing indebtedness under the Amended and Restated Credit Agreement, dated as of July 1, 2021, by and among Old R1 RCM and certain of its subsidiaries, Bank of America, N.A., as administrative agent, and the lenders named therein, and amend and restate all commitments thereunder (the “Refinancing”), (2) to pay certain fees and expenses incurred in connection with the entry into the Second A&R Credit Agreement and the Refinancing, (3) to fund the Transactions, and to pay the fees, premiums, expenses, and other transaction costs incurred in connection therewith, and (4) to finance working capital needs of the Company and its subsidiaries for general corporate purposes. Debt amounts presented as of December 31, 2021 were incurred under the 2021 Amended and Restated Credit Agreement.

Debt Maturities

Scheduled maturities of the Company’s long-term debt are summarized as follows:

19


Scheduled Maturities
Remainder of 2022$12.4 
202353.9 
202467.0 
202567.0 
2026698.3 
2027430.2 
Thereafter473.7 
Total$1,802.5 

For further details on the Company’s 2021 Amended and Restated Credit Agreement, refer to Note 10 of the Company’s 2021 Form 10-K.
9. Derivative Financial Instruments

The Company utilizes cash flow hedges to manage its currency risk arising from its global business services centers. As of September 30, 2022, the Company has recorded $1.2 million of unrealized losses in accumulated other comprehensive loss related to foreign currency hedges. The Company estimates that $1.1 million of losses reported in accumulated other comprehensive loss are expected to be reclassified into earnings within the next 12 months. Amounts reclassified into cost of services were a net loss of $0.7 million and $0.6 million during the three and nine months ended September 30, 2022, respectively, and a net gain of $0.4 million and $1.0 million during the three and nine month periods ended September 30, 2021, respectively. As of September 30, 2022, the Company’s currency forward contracts have maturities extending no later than December 31, 2023, and had a total notional value of $76.8 million.

The Company also utilizes cash flow hedges to reduce variability in interest cash flows from its outstanding debt. As of September 30, 2022, the Company has recorded $12.9 million of unrealized gains in accumulated other comprehensive loss related to interest rate swaps. The Company estimates that $3.7 million of gains reported in accumulated other comprehensive loss are expected to be reclassified into earnings within the next 12 months. Amounts reclassified into interest expense were a net loss of $0.4 million and $0.9 million during the three and nine months ended September 30, 2022, respectively and a net loss of $0.3 million and $1.1 million during the three and nine month periods ended September 30, 2021, respectively. As of September 30, 2022, the Company’s interest rate swaps extend no later than June 30, 2025, and had a total notional value of $500.0 million.

The location and fair value of derivative instruments designated as hedges in the Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 are as follows:

September 30, 2022December 31, 2021
Foreign currency forward contracts
Prepaid expenses and other current assets$ $1.7 
Other accrued expenses1.2  
Total foreign current forward contracts$1.2 $1.7 
Interest rate swaps
Prepaid expenses and other current assets$3.7 $ 
Other assets9.2  
Other accrued expenses 0.7 
Total interest rate swaps$12.9 $0.7 
20



As of September 30, 2022 and December 31, 2021, the accumulated gain, net of tax, recognized in accumulated other comprehensive loss was $8.8 million and $0.7 million, respectively.

The Company classifies cash flows from its derivative programs as cash flows from operating activities in the consolidated statements of cash flows. Fair values for derivative financial instruments are based on prices computed using third-party valuation models and are classified as Level 2 in accordance with the three-level hierarchy of fair value measurements.
On July 5, 2022, the Company entered into an agreement with a third party regarding the potential purchase of a business that would expand the service capabilities of the Company. This agreement is effective through approximately the end of 2023 and allows the other party to sell the business to the Company for $150.0 million, subject to the negotiation of a definitive agreement and the satisfaction of agreed upon closing conditions, including the requirement that the purchase price be deemed to be fair value at the time of the potential transaction. The parties, assuming an agreement is reached, would also need to reach agreement as to whether the purchase price would be paid in cash or shares of common stock of the Company.

10. Share-Based Compensation

The share-based compensation expense relating to the Company’s stock options, RSUs, and performance-based restricted stock units (“PBRSUs”) for the three months ended September 30, 2022 and 2021 was $27.8 million and $25.5 million, respectively, with related tax benefits of approximately $4.6 million and $5.1 million, respectively. The share-based compensation expense relating to the Company’s stock options, RSUs, and PBRSUs for the nine months ended September 30, 2022 and 2021 was $49.5 million and $62.0 million, respectively, with related tax benefits of approximately $8.5 million and $12.2 million, respectively.

The Company accounts for forfeitures as they occur. Excess tax benefits and shortfalls for share-based payments are recognized in income tax expense (benefit) and included in operating activities. The Company recognized $4.3 million and $0.6 million of income tax benefit from windfalls associated with vesting and exercises of equity awards for the three months ended September 30, 2022 and 2021, respectively. The Company recognized $9.2 million and $7.2 million of income tax benefit from windfalls associated with vesting and exercises of equity awards for the nine months ended September 30, 2022 and 2021, respectively.
Total share-based compensation costs that have been included in the Company’s consolidated statements of operations were as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Share-Based Compensation Expense Allocation Details:
Cost of services$12.3 $15.8 $21.7 $38.8 
Selling, general and administrative15.4 9.7 27.7 23.2 
Other0.1  0.1  
Total share-based compensation expense$27.8 $25.5 $49.5 $62.0 
The Company uses the Black-Scholes option pricing model to estimate the fair value of its service-based options as of their grant dates. The Company assesses current performance on performance-based PBRSUs by reviewing historical performance to date, along with any adjustments which have been approved to the reported performance, and changes to the projections to determine the probable outcome of the awards. The current estimates are then compared to the scoring metrics and any necessary adjustments are reflected in the current period to update share-based compensation expense to the current performance expectations.
21


Stock options
A summary of the options activity during the nine months ended September 30, 2022 is shown below:

OptionsWeighted-
Average
Exercise
Price
Outstanding at December 31, 20214,386,205 $3.37 
Granted24,344 22.19 
Exercised(1,279,460)3.67 
Canceled/forfeited(13,408)4.59 
Expired(7,500)8.71 
Outstanding at September 30, 20223,110,181 $3.38 
Outstanding, vested and exercisable at September 30, 20223,084,188 $3.22 
Outstanding, vested and exercisable at December 31, 20214,365,759 $3.33 
Restricted stock units and performance-based restricted stock units    
A summary of the RSU and PBRSU activity during the nine months ended September 30, 2022 is shown below:
Weighted-
Average Grant
Date Fair Value
RSUsPBRSUsRSUPBRSU
Outstanding and unvested at December 31, 20212,218,651 3,203,013 $16.28 $16.45 
Granted2,249,157 5,230,483 20.62 19.83 
Performance factor adjustment 876,109  10.46 
Vested(574,564)(1,878,328)14.49 11.19 
Forfeited(164,414)(201,544)17.41 19.87 
Outstanding and unvested at September 30, 20223,728,830 7,229,733 $19.12 $19.44 
Shares surrendered for taxes for the nine months ended September 30, 2022
182,080 783,392 
Cost of shares surrendered for taxes for the nine months ended September 30, 2022 (in millions)
$4.1 $20.0 
Shares surrendered for taxes for the nine months ended September 30, 2021
186,588  
Cost of shares surrendered for taxes for the nine months ended September 30, 2021 (in millions)
$4.8 $ 
Upon consummation of the Holding Company Reorganization, outstanding restricted units of Cloudmed were replaced by an aggregate 1,536,220 RSUs of the Company. The Company also issued an aggregate of 3,173,184 inducement RSUs and PBRSUs to certain employees of Cloudmed under Nasdaq Listing Rule 5635(c)(4) pursuant to its newly adopted 2022 Inducement Plan.

The Company’s RSU and PBRSU agreements allow employees to surrender to the Company shares of common stock upon vesting of their RSUs and PBRSUs in lieu of their payment of the required personal employment-related taxes. Shares surrendered for payment of personal employment-related taxes are held in treasury.
22



Outstanding PBRSUs vest upon satisfaction of both time-based and performance-based conditions. Depending on the award, performance condition targets may include cumulative adjusted EBITDA, end-to-end RCM agreement growth, modular sales revenue, or other specific performance factors. Depending on the percentage level at which the performance-based conditions are satisfied, the number of shares vesting could be between 0% and 200% of the number of PBRSUs originally granted. Based on the established targets, the maximum number of shares that could vest for all outstanding PBRSUs is 14,412,591.
CoyCo 2, L.P. Limited Partnership Units    

As part of the transactions contemplated by the Transaction Agreement, equity awards held by certain employees of Cloudmed (“Former Class P Units”) were modified, through a series of transactions, into awards (“Management Units”) of CoyCo 2. The Management Units issued by CoyCo 2 are treated as share-based compensation under ASC 718, Compensation —Stock Compensation.

The Former Class P Units were originally issued to employees of Cloudmed and its affiliates (“Participants”) in connection with and as a part of the compensation and incentive arrangements between Cloudmed and such Participants prior to the consummation of the Cloudmed Acquisition. A portion of the Former Class P Units immediately vested upon the closing of the Cloudmed Acquisition; however, certain Former Class P Units that were subject to performance-based vesting conditions did not become vested upon the closing of the Cloudmed Acquisition (“Unvested Units”). However, in connection with the Cloudmed Acquisition, Cloudmed caused the Former Class P Units, including the Unvested Units, to be converted into Management Units. At the time of the closing of the Cloudmed Acquisition, 97,875 Unvested Units were converted into 514,986 Management Units.

In general, Unvested Units vest upon the achievement of certain performance criteria, including achievement by the Sellers’ owner, New Mountain Capital, L.L.C. (“New Mountain”), of (i) specified multiples of Base Equity Value (“BEV”) (i.e., generally the aggregate equity value of New Mountain’s investment in Cloudmed as of the original grant date), or (ii) specified Multiples on Invested Capital (“MIC”) with respect to New Mountain Capital’s pre-Cloudmed Acquisition investment in Cloudmed, and subject to continued service with the Company and its affiliates, including Cloudmed through the applicable vesting date. The awards are not awards of the Company and the Participants will receive no additional shares of the Company upon satisfaction of the vesting criteria. However, GAAP requires the Company recognize the cost of share-based compensation granted by an investor (CoyCo 2) to the Company’s employees and service providers for services that benefit the Company’s operations, and a corresponding capital contribution because the costs are incurred on the Company’s behalf.

A Monte Carlo simulation was used to estimate the fair value of the Unvested Units which is being amortized over a period of 4 years on a straight-line basis.
11. Other Expenses

Other expenses are incurred in connection with acquisition and integration costs, various exit activities, transformation initiatives, and organizational changes to improve our business alignment and cost structure. The following table summarizes the other expenses (income) recognized for the three and nine months ended September 30, 2022 and 2021.
23


Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Severance and related employee benefits (1)$ $0.3 $ $2.1 
Business acquisition costs (2)0.2 2.3 74.4 4.2 
Integration costs (3)8.8  18.3 2.6 
Strategic initiatives (4)6.2 2.5 9.0 6.4 
Global business services center expansion project in the Philippines (5)10.0  20.0  
Customer employee transition and restructuring expenses (6) 3.2 (0.4)3.2 
Facility-exit charges (7)1.3  7.3 2.9 
Other (8)3.6 3.1 7.5 12.8 
Total other expenses$30.1 $11.4 $136.1 $34.2 
(1) These costs relate to restructuring and business reorganization events.
(2) These are costs, including legal, consulting, and bank fees, that are directly related to the close of the Cloudmed Acquisition on June 21, 2022 and the close of the VisitPay acquisition on July 1, 2021 and include changes to contingent consideration, if applicable.
(3) These costs reflect efforts to integrate acquisitions from a systems, processes, and people perspective. Costs include consulting fees, IT vendor spend, severance, early lease termination of Cloudmed facilities, and certain payroll costs.
(4) These costs relate to performing portfolio and capital structure analyses and transactions and other business transformation projects (including large scale system projects) as part of the Company’s growth strategy. Costs include vendor spend, employee time and expenses spent on activities, severance, and retention amounts.
(5) These costs include legal and consulting fees related to the establishment of the Company’s inaugural global business services center in the Philippines as well as severance costs for personnel whose roles are being relocated. The entry into the Philippines is the first new organic global business services center country expansion by the Company in approximately 15 years.
(6) As part of the transition of customer personnel to the Company under certain operating partner model contracts, the Company agreed to reimburse the customer, or directly pay affected employees, for severance and retention costs related to certain employees who were not transitioned to the Company, or whose jobs were relocated after the employee transitioned to the Company.
(7) As part of evaluating its footprint, the Company has exited certain leased facilities. Costs include asset impairment charges, early termination fees, and other costs related to exited leased facilities.
(8) For the three and nine months ended September 30, 2022, other includes $0.7 million and $1.8 million, respectively, of expenses related to the COVID-19 pandemic. For the three and nine months ended September 30, 2021, other includes $2.7 million and $7.1 million, respectively, of expenses related to the COVID-19 pandemic.
12. Income Taxes

Income tax provisions for interim periods are based on estimated annual income tax rates, adjusted to reflect the effects of any significant and infrequent or unusual items which are required to be discretely recognized within the current interim period. The effective tax rates in the periods presented are largely based upon the projected annual pre-tax earnings by jurisdiction and the allocation of certain expenses in various taxing jurisdictions where the Company conducts its business. These taxing jurisdictions apply a broad range of statutory income tax rates. The global intangible low-taxed income (“GILTI”) provisions impose taxes on foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company elected to account for GILTI tax in the period in which it is incurred.

24


The Company recognized income tax expense for the three months ended September 30, 2022 and income tax benefit for the nine months ended September 30, 2022 on the year-to-date pre-tax loss. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for foreign taxes, GILTI, non-deductible expenses, and discrete items.

The Company recognized income tax expense for the three and nine months ended September 30, 2021 on the year-to-date pre-tax income. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for state taxes, GILTI, non-deductible expenses, and discrete items.
The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. U.S. federal income tax returns since 2018 are currently open for examination. State jurisdictions vary for open tax years. The statute of limitations for most states ranges from three to six years.

At December 31, 2021, the Company had gross deferred tax assets of $123.7 million, of which $54.7 million related to net operating loss (“NOL”) carryforwards. The Company expects to be profitable, allowing the Company to utilize its NOL carryforwards and other deferred tax assets.

13. Earnings (Loss) Per Share
Basic net income (loss) per share is computed by dividing net income (loss), less any dividends, accretion or decretion, redemption or induced conversion on the preferred stock, by the weighted average number of common shares outstanding during the period.
Diluted net income (loss) per share is calculated by adjusting the denominator used in the basic net income (loss) per share computation by potentially dilutive securities outstanding during the period plus, when their effect is dilutive, incremental shares consisting of shares subject to stock options and shares issuable upon vesting of RSUs and PBRSUs.
Basic and diluted net income (loss) per common share are calculated as follows:
Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Basic EPS:
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Less dividends on preferred shares (1)   (592.3)
Net income (loss) available/(allocated) to common shareholders - basic$(29.5)$17.0 $(20.5)$(531.1)
Diluted EPS:
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Less dividends on preferred shares (1)   (592.3)
Net income (loss) available/(allocated) to common shareholders - diluted$(29.5)$17.0 $(20.5)$(531.1)
Basic weighted-average common shares417,700,782 278,655,269 330,877,880 262,209,929 
Add: Effect of dilutive equity awards 7,281,436   
Add: Effect of dilutive warrants 34,680,381   
Diluted weighted average common shares417,700,782 320,617,086 330,877,880 262,209,929 
Net income (loss) per common share (basic)$(0.07)$0.06 $(0.06)$(2.03)
Net income (loss) per common share (diluted)$(0.07)$0.05 $(0.06)$(2.03)
25


(1) The 2021 dividend on preferred shares includes amounts related to the conversion of the preferred shares. See Note 16 of the Company’s 2021 Form 10-K for more information.
Because of their anti-dilutive effect, 21,251,602 common share equivalents comprised of stock options, PBRSUs, and RSUs have been excluded from the diluted earnings per share calculation for the three and nine months ended September 30, 2022. Additionally, for the three and nine months ended September 30, 2022, TCP-ASC ACHI Series LLLP’s (“TCP-ASC” or the “Investor”) and IHC Health Services, Inc.’s (“Intermountain”) exercisable warrants to acquire up to 40.5 million and 1.5 million shares, respectively, of the Company’s common stock have been excluded from the diluted earnings per share calculation because they were anti-dilutive.
For the three and nine months ended September 30, 2021, 890,717 and 15,155,288 common share equivalents, respectively, have been excluded from the diluted earnings per share calculation because of their anti-dilutive effect. Additionally, for the nine months ended September 30, 2021, the Investor’s and Intermountain’s exercisable warrants to acquire up to 40.5 million and 1.5 million shares, respectively, of the Company’s common stock have been excluded from the diluted earnings per share calculation because they were anti-dilutive.

14. Commitments and Contingencies

Legal Proceedings

Other than as described below, the Company is not presently a party to any material litigation or regulatory proceeding and is not aware of any pending or threatened litigation or regulatory proceeding against the Company which, individually or in the aggregate, could have a material adverse effect on its business, operating results, financial condition or cash flows.

On April 13, 2021 and April 19, 2021, respectively, certain purported stockholders of the Company filed two complaints in the Delaware Court of Chancery regarding the Company’s January 15, 2021 recapitalization transaction with TCP-ASC. Both complaints allege that TCP-ASC, Ascension Health (“Ascension”), and TowerBrook Capital Partners (“TowerBrook”) controlled the Company and breached their fiduciary duties by using that alleged control to force the Company to overpay in redeeming TCP-ASC’s preferred stock as part of the recapitalization transaction. The plaintiffs seek an unspecified amount of damages against TCP-ASC, Ascension, and TowerBrook. The plaintiffs also allege that the Company and TCP-ASC entered into amendments to the Investor Rights Agreement that the plaintiffs contend contains provisions that are void under the Company’s charter, bylaws, and the Delaware General Corporation Law. The cases have since been consolidated into a single action. All defendants have answered the complaint and discovery has commenced.

On February 18, 2022, plaintiffs filed a supplement to their complaint, naming certain additional defendants and asserting additional claims related to the Company’s agreement to acquire Cloudmed, which was announced on January 10, 2022. The additional claims assert that: (i) TCP-ASC, Ascension, and TowerBrook, along with the Company’s directors (“Individual Defendants”), breached their fiduciary duties by causing the Company to enter into and approving the Cloudmed acquisition, respectively, which plaintiffs claim will perpetuate TCP-ASC’s, Ascension’s, and TowerBrook’s control over the Company and entrench the Individual Defendants by virtue of certain agreements entered into as part of the transaction, including a Second Amended Investor Rights Agreement with TCP-ASC (the “Seconded Amended Investor Rights Agreement”) and an Investor Rights Agreement with Cloudmed (the “Cloudmed Investor Rights Agreement”); and (ii) Cloudmed’s stockholders aided and abetted such breaches. Plaintiffs also allege that certain provisions in the Cloudmed Investor Rights Agreement and the Second Amended Investor Rights Agreement are void under the Company’s charter, bylaws, and the Delaware General Corporation law. The plaintiffs seek a declaratory judgment and an unspecified amount of damages, as well as attorneys’ fees and costs. The Company believes it has meritorious defenses to all claims against it and intends to vigorously defend itself against these claims.

26


In May 2016, the Company was served with a False Claims Act case brought by a former emergency department service associate who worked at a hospital of one of the Company’s customers, MedStar Inc.’s Washington Hospital Center (“WHC”), along with WHC and three other hospitals that were PAS customers and a place holder, John Doe hospital, representing all PAS customers (U.S. ex rel. Graziosi vs. Accretive Health, Inc. et. al.), and seeking money damages, False Claims Act penalties, and plaintiff’s attorneys’ fees. The Third Amended Complaint alleges that the Company’s PAS business violates the federal False Claims Act. The case was originally filed under seal in 2013 in the federal district court in Chicago and presented to the U.S. Attorney in Chicago, and the U.S. Attorney declined to intervene. The Company believes that it has meritorious defenses to all claims in the case and intends to vigorously defend itself against these claims. Both the Company’s and plaintiff’s motions for summary judgment were denied in December 2020, and the parties have completed damage and expert discovery. Additional dispositive motions are expected to extend through 2022, with trial, if necessary, in June 2023.
15. Related Party Transactions
This note encompasses transactions between Ascension and its affiliates, including AMITA Health, and the Company pursuant to the Master Professional Services Agreement, including all supplements, amendments, and other documents entered into in connection therewith. For further details on the Company’s agreements with Ascension, see Note 1 and Note 19 of the Company’s 2021 Form 10-K. In conjunction with the Cloudmed Acquisition, New Mountain became a new related party. There were no material transactions with New Mountain subsequent to the Cloudmed Acquisition.
Net services revenue from services provided to Ascension, as well as corresponding accounts receivable and customer liabilities are presented in the Consolidated Statements of Operations and Comprehensive Income (Loss) and the Consolidated Balance Sheets. Since Ascension is the Company’s largest customer, a significant percentage of the Company’s cost of services is associated with providing services to Ascension. However, due to the nature of the Company’s global business services and information technology operations, it is impractical to assign the dollar amount associated with services provided to Ascension.

On May 27, 2021 and May 28, 2021, the Company issued 16,750,000 shares of common stock to TCP-ASC upon the cashless exercise of a warrant to purchase 19,535,145 shares of common stock at an exercise price of $3.50 per share based upon a market value of $24.54 to $24.64 per share as determined under the terms of the warrant.
16. Segments and Customer Concentrations
The Company has determined that it has a single operating segment in accordance with the way that management operates and views the business. All of the Company’s significant operations are organized around the single business of providing end-to-end management services of revenue cycle operations for U.S.-based healthcare providers. Accordingly, for purposes of segment disclosures, the Company has only one operating and reportable segment.
Customers comprising greater than 10% of net services revenue are as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
Customer Name2022202120222021
Ascension and its affiliates44 %60 %52 %61 %
Intermountain Healthcare11 %14 %13 %14 %
The loss of customers within the Ascension health system or Intermountain network could have a material adverse impact on the Company’s operations.
As of September 30, 2022 and December 31, 2021, the Company had a concentration of credit risk with Ascension, representing 12% and 17% of accounts receivable, respectively.
27


17. Supplemental Financial Information
The following table summarizes the allocation of depreciation and amortization expense related to property, equipment and software between cost of services and selling, general and administrative expenses:
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Cost of services$14.7 $13.6 $39.0 $38.8 
Selling, general and administrative0.3 0.6 0.8 2.2 
Total depreciation and amortization$15.0 $14.2 $39.8 $41.0 
28



Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations
Unless the context indicates otherwise, references in this Quarterly Report on Form 10-Q to “R1,” “the Company,” “we,” “our,” and “us” mean R1 RCM Inc., and its subsidiaries.

The following discussion and analysis is an integral part of understanding our financial results and is provided as an addition to, and should be read in connection with, our consolidated financial statements and the accompanying notes.

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Undue reliance should not be placed on these statements. All statements, other than statements of historical facts, included in this Quarterly Report on Form 10-Q are forward-looking statements. The words “anticipate,” “believe,” “designed,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “will” or “would” and similar expressions or variations are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements include, among other things, statements about the acquisition of Cloudmed, our strategic initiatives, our capital plans, our costs, our ability to successfully implement new technologies, our future financial performance, and our liquidity. Such forward-looking statements are based on management’s current expectations about future events as of the date hereof and involve many risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in our forward-looking statements. Subsequent events and developments, including actual results or changes in our assumptions, may cause our views to change. We do not undertake to update our forward-looking statements except to the extent required by applicable law. Readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements included herein are expressly qualified in their entirety by these cautionary statements. Our actual results and outcomes could differ materially from those included in these forward-looking statements as a result of various factors, including, but are not limited to, geopolitical, economic, and market conditions, including heightened inflation, slower growth or recession, changes to fiscal and monetary policy, higher interest rates, currency fluctuations, and challenges in the supply chain; our ability to retain existing customers or acquire new customers; the development of markets for our revenue cycle management offering; variability in the lead time of prospective customers; our ability to integrate Cloudmed’s business into our operations in a timely and efficient manner; failure to realize the anticipated benefits of the Cloudmed acquisition; volatility in our stock price, including in connection with the integration and results of Cloudmed; competition within the market; breaches or failures of our information security measures or unauthorized access to customer’s data; delayed or unsuccessful implementation of our technologies or services, or unexpected implementation costs; disruptions in or damages to our global business services centers and third-party operated data centers; the ongoing impact of the 2019 Novel Coronavirus (“COVID-19”) pandemic on our business, operating results, and financial condition; and the factors discussed elsewhere in this Quarterly Report on Form 10-Q, and those set forth in Part I, Item 1A of our 2021 Form 10-K and our other filings with the SEC. The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. Subsequent events and developments may cause our views to change. While we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.
Overview
Our Business
We are a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. Our services help healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for our customers.
29



We achieve these results for our customers by managing healthcare providers’ revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers. We do so by leveraging our extensive healthcare domain experience, innovative technology and intelligent automation, and process excellence. We assist our revenue cycle management (“RCM”) customers in managing their revenue cycle operating costs while simultaneously increasing the portion of the maximum potential services revenue they receive. Together, these benefits can generate significant and sustainable improvements in operating margins and cash flows for our customers.
Our primary offerings consist of end-to-end or modular RCM services for health systems, hospitals, and physician groups. We deploy our end-to-end offering through an operating partner relationship or a co-managed relationship. Under an operating partner relationship, we provide comprehensive revenue cycle infrastructure to providers, including all revenue cycle personnel, technology solutions, and process workflow. Under a co-managed relationship, we leverage our customers’ existing RCM staff and processes, and supplement them with our infused management, subject matter specialists, proprietary technology solutions, and other resources. Under the operating partner model, we record higher revenue and expenses due to the fact that almost all of the revenue cycle personnel are our employees and more third-party vendor contracts are controlled by us. Under the co-managed model, the majority of the revenue cycle personnel and third-party vendor contracts remain with the customer and those costs are netted against our co-managed revenue. For the nine months ended September 30, 2022 and 2021, substantially all of our net operating and incentive fees from end-to-end RCM services were generated under the operating partner model.

Our modular offerings allow customers to engage us for specific components of RCM services, such as revenue intelligence solutions (which were enhanced through the acquisition of Revint Holdings, LLC (“Cloudmed”)), automation solutions, patient experience (R1 EntriTM Pay), physician advisory services (“PAS”), clinical documentation integrity (“CDI”), coding management, revenue integrity solutions (“RIS”), business office services, and practice management (“PM”). Our patient experience offering, R1 EntriTM Pay, unifies scheduling, clearance, intake, and payments into one welcoming experience.

Once implemented, our technology solutions, processes, and services are deeply embedded in our customers’ day-to-day revenue cycle operations. We believe our service offerings are adaptable to meet an evolving healthcare regulatory environment, technology standards, and market trends.
We operate our business as a single segment configured with our significant operations and offerings organized around the business of providing revenue cycle operations for healthcare providers.
Leadership Succession
On November 8, 2022, the Company announced that Joseph Flanagan, Chief Executive Officer and member of the Board, will step down from the position of Chief Executive Office effective as of January 1, 2023. Mr. Flanagan will assume the non-executive role of Executive Advisor to the Chief Executive Officer and remain a member of the Board. The Company also announced that Lee Rivas, currently the President of the Company, will succeed Mr. Flanagan in the role of Chief Executive Officer and will become a member of the Board as of January 1, 2023. John Sparby, currently the Executive Vice President, Operations & Delivery and Chief Operating Officer, will succeed Mr. Rivas in the role of President of the Company effective as of January 1, 2023.
30



Macroeconomic Environment

Growth in economic activity and demand for goods and services, alongside labor shortages and supply chain complications, have contributed to high levels of inflation in 2022. We expect inflation to persist in 2023, which would negatively impact our costs for wages and other materials. Inflation may also impact the economic health of our customers, including their ability to pay amounts owed to us. In response to rising inflation, the Federal Reserve Board has raised interest rates and signaled that it will continue to raise rates. Our credit facility interest, in part, is based on a variable interest rate structure which can result in increased cost in periods of rising interest rates. To date, rising interest rates have not had a material impact on our results of operations.

Our incentive fees were impacted by deterioration in payer-reimbursement turnaround times. We currently anticipate continued impact on our performance into 2023 from payer turnaround times. In addition, we are observing the following trends, which we expect will persist in 2023: (i) we expect the inflationary effect on our labor and cost structure to be higher than payer rate increases flowing to our customers’ revenue and cash collections; (ii) we expect reduced growth in our physician business serving emergency department physicians due to regulatory changes that are impacting some of the large groups in the industry; and (iii) with recessionary concerns increasing, we could see potential weakness in consumer collections as healthcare bills are de-prioritized.

Other adverse macroeconomic conditions, including but not limited to changes to fiscal and monetary policy and currency fluctuations, could impact macro-level consumer spending trends, which could affect the amount of volumes processed on our platform and result in fluctuations to our revenue streams. Certain of our customers may be negatively impacted by these events. Further, while patient volumes are largely in line with pre-COVID-19 levels, the COVID-19 pandemic continues to evolve, continuing to affect the population. In addition, our business and customers continue to face challenges relating to a tight labor market and increased turnover rates. The extent to which these macroeconomic conditions will affect our business is uncertain and will depend on political, social, economic, and regulatory forces that are outside of our control. We continue to assess fluctuating macroeconomic events to manage our response.

Cloudmed Acquisition

On June 21, 2022, we completed the acquisition of Cloudmed pursuant to the Transaction Agreement and Plan of Merger, dated as of January 9, 2022, (the “Cloudmed Acquisition”). The purchase price was $3.3 billion. We funded the cash consideration component of the purchase price and the Company’s associated transaction expenses with a combination of cash on hand and the incurrence of additional indebtedness.

Cloudmed’s revenue intelligence platform combines cloud-based data architecture and deep domain expertise with intelligent automation to analyze large volumes of medical records, payment data, and complex medical insurance models to identify opportunities to deliver additional revenue to customers. We believe this transaction will enable us to further our ability to deliver transformative value to healthcare providers through a more fulsome platform of differentiated capabilities by creating a scaled leader across both end-to-end revenue cycle management and technology-driven revenue intelligence.
CONSOLIDATED RESULTS OF OPERATIONS
The following table provides consolidated operating results and other operating data for the periods indicated:
31



 Three Months Ended September 30,2022 vs. 2021
Change
Nine Months Ended September 30,2022 vs. 2021
Change
 20222021Amount%20222021Amount%
 (In millions, except percentages)
Consolidated Statement of Operations Data:
Net operating fees$324.2 $308.5 $15.7 %$965.3 $879.8 $85.5 10 %
Incentive fees20.8 41.5 (20.7)(50)%80.9 108.0 (27.1)(25)%
Modular and other151.0 29.7 121.3 408 %227.4 87.9 139.5 159 %
Total net services revenue496.0 379.7 116.3 31 %1,273.6 1,075.7 197.9 18 %
Operating expenses:
Cost of services403.1 304.0 99.1 33 %1,009.7 858.2 151.5 18 %
Selling, general and administrative60.8 33.2 27.6 83 %120.6 87.8 32.8 37 %
Other expenses30.1 11.4 18.7 164 %136.1 34.2 101.9 298 %
Total operating expenses494.0 348.6 145.4 42 %1,266.4 980.2 286.2 29 %
Income from operations2.0 31.1 (29.1)(94)%7.2 95.5 (88.3)(92)%
Net interest expense23.7 6.5 17.2 265 %35.3 13.8 21.5 156 %
Net income (loss) before income tax provision (benefit)(21.7)24.6 (46.3)(188)%(28.1)81.7 (109.8)(134)%
Income tax provision (benefit)7.8 7.6 0.2 %(7.6)20.5 (28.1)(137)%
Net income (loss)$(29.5)$17.0 $(46.5)(274)%$(20.5)$61.2 $(81.7)(133)%
Adjusted EBITDA (1)$124.0 $89.3 $34.7 39 %$300.5 $248.5 $52.0 21 %

(1) Refer to the Non-GAAP Financial Measures section below for a reconciliation of our financial results reported in accordance with GAAP to non-GAAP financial results.
Use of Non-GAAP Financial Information
In order to provide a more comprehensive understanding of the information used by our management team in financial and operational decision-making, we supplement our consolidated financial statements that have been prepared in accordance with GAAP with the non-GAAP financial measure of adjusted EBITDA. Adjusted EBITDA is utilized by our Board and management team as (i) one of the primary methods for planning and forecasting overall expectations and for evaluating actual results against such expectations; and (ii) as a performance evaluation metric in determining achievement of certain executive incentive compensation programs, as well as for incentive compensation plans for employees.
Adjusted EBITDA
We define adjusted EBITDA as net income (loss) before net interest income/expense, income tax provision/benefit, depreciation and amortization expense, share-based compensation expense, CoyCo 2, L.P. (“CoyCo 2”) share-based compensation expense, and other expense items detailed in Note 11, Other Expenses, to the Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, including business acquisition costs, integration costs, strategic initiatives, and the global business services center expansion project in the Philippines.
We understand that, although non-GAAP measures are frequently used by investors, securities analysts, and others in their evaluation of companies, these measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results of operations as reported under GAAP. Some of these limitations are:
Adjusted EBITDA does not reflect:
32



Changes in, or cash requirements for, our working capital needs;
Share-based compensation expense (including CoyCo 2 share-based compensation expense);
Income tax expenses or cash requirements to pay taxes;
Interest expenses or cash required to pay interest;
Certain other expenses which may require cash payments;
Although depreciation and amortization charges are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted EBITDA does not reflect cash requirements for such replacements or other purchase commitments, including lease commitments; and
Other companies in our industry may calculate adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.
Reconciliation of GAAP and Non-GAAP Measures
The following table represents a reconciliation of adjusted EBITDA to net income (loss), the most closely comparable GAAP measure, for each of the periods indicated:
 Three Months Ended September 30,2022 vs. 2021
Change
Nine Months Ended September 30,2022 vs. 2021
Change
 20222021Amount%20222021Amount%
 (In millions, except percentages)
Net income (loss)$(29.5)$17.0 $(46.5)(274)%$(20.5)$61.2 $(81.7)(133)%
  Net interest expense23.7 6.5 17.2 265 %35.3 13.8 21.5 156 %
  Income tax provision (benefit)7.8 7.6 0.2 %(7.6)20.5 (28.1)(137)%
  Depreciation and amortization expense 64.2 21.3 42.9 201 %107.8 56.8 51.0 90 %
  Share-based compensation expense (1)24.7 25.5 (0.8)(3)%46.4 62.0 (15.6)(25)%
CoyCo 2 share-based compensation expense (2)3.0 — 3.0 100 %3.0 — 3.0 100 %
  Other expenses (3)30.1 11.4 18.7 164 %136.1 34.2 101.9 298 %
Adjusted EBITDA (non-GAAP)$124.0 $89.3 $34.7 39 %$300.5 $248.5 $52.0 21 %
(1)        Share-based compensation expense represents the expense associated with stock options, restricted stock units, and performance-based restricted stock units granted, as reflected in our Consolidated Statements of Operations and Comprehensive Income (Loss). See Note 10, Share-Based Compensation, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for the detail of the amounts of share-based compensation expense.
(2) CoyCo 2 share-based compensation expense represents the expense associated with CoyCo 2 limited partnership units, as reflected in our Consolidated Statements of Operations and Comprehensive Income (Loss). See Note 10, Share-Based Compensation, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for the detail of the amounts of CoyCo 2 share-based compensation expense.
(3)        Other expenses are incurred in connection with acquisition and integration costs, various exit activities, transformation initiatives, and organizational changes to improve our business alignment and cost structure. See Note 11, Other Expenses, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for the detail of the amounts included in other expenses.
Three Months Ended September 30, 2022 Compared to Three Months Ended September 30, 2021
Net Services Revenue
Net services revenue increased by $116.3 million, or 31%, from $379.7 million for the three months ended September 30, 2021, to $496.0 million for the three months ended September 30, 2022. The increase was driven by a $120.2 million contribution from Cloudmed and $15.7 million increase in net operating fees driven by new customers, partially offset by lower incentive fees of $20.7 million due to longer payer-reimbursement turnaround times and execution issues at two operating partner customers.
33



Cost of Services
Costs of services primarily consists of wages and benefits of personnel that perform services for our customers and any related supplies, equipment, or facility costs utilized by these employees. It also includes cost of services provided to our customers by vendors directly contracted by R1 or assigned to R1 at contract inception. Cost of services increased by $99.1 million, or 33%, from $304.0 million for the three months ended September 30, 2021, to $403.1 million for the three months ended September 30, 2022. The increase in cost of services was primarily driven by the Cloudmed Acquisition, expansion of deployment capacity, and onboarding of new customers.
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased by $27.6 million, or 83%, from $33.2 million for the three months ended September 30, 2021, to $60.8 million for the three months ended September 30, 2022. The increase was driven by the Cloudmed Acquisition, higher share-based compensation expense, and a $9.5 million increase in allowance for credit losses related to a physician customer that was unable to make a contractually required payment on September 30, 2022, is currently facing financial challenges, and is in an active debt refinancing process. As a result of reviewing the potential expected outcomes related to this customer, we recorded an allowance for credit losses of $10.0 million related to an overall receivable balance of $33.3 million as of September 30, 2022.
Other Expenses
Other expenses increased by $18.7 million, or 164%, from $11.4 million for the three months ended September 30, 2021, to $30.1 million for the three months ended September 30, 2022. See Note 11, Other Expenses, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for the details of the costs included in this total for the comparative periods.
Income Taxes
Income tax provision increased by $0.2 million from $7.6 million for the three months ended September 30, 2021, to $7.8 million for the three months ended September 30, 2022, primarily due to higher GILTI and non-deductible expenses. Our effective tax rate (including discrete items) was approximately (36)% and 31% for the three months ended September 30, 2022 and 2021, respectively. Our tax rate is also affected by discrete items that may occur in any given year but are not necessarily consistent from year to year.
Nine Months Ended September 30, 2022 Compared to Nine Months Ended September 30, 2021
Net Services Revenue
Net services revenue increased by $197.9 million, or 18%, from $1,075.7 million for the nine months ended September 30, 2021, to $1,273.6 million for the nine months ended September 30, 2022. The increase was driven by a $133.5 million contribution from Cloudmed and net operating fees from new end-to-end customers, partially offset by lower incentive fees.
Cost of Services
Costs of services primarily consists of wages and benefits of personnel that perform services for our customers and any related supplies, equipment, or facility costs utilized by these employees. It also includes cost of services provided to our customers by vendors directly contracted by R1 or assigned to R1 at contract inception. Cost of services increased by $151.5 million, or 18%, from $858.2 million for the nine months ended September 30, 2021, to $1,009.7 million for the nine months ended September 30, 2022. The increase in cost of services was primarily driven by the Cloudmed Acquisition and onboarding of new customers, which are reflected in our current revenue growth.
34



Selling, General and Administrative Expenses
Selling, general and administrative expenses increased by $32.8 million, or 37%, from $87.8 million for the nine months ended September 30, 2021, to $120.6 million for the nine months ended September 30, 2022. The increase was driven by the Cloudmed Acquisition, higher share-based compensation expense, and a $9.5 million increase in allowance for credit losses related to a physician customer that was unable to make a contractually required payment on September 30, 2022, is currently facing financial challenges, and is in an active debt refinancing process. As a result of reviewing the potential expected outcomes related to this customer, we recorded an allowance for credit losses of $10.0 million related to an overall receivable balance of $33.3 million as of September 30, 2022. These increases were partially offset by lower accrued compensation expense.
Other Expenses
Other expenses increased by $101.9 million, or 298%, from $34.2 million for the nine months ended September 30, 2021, to $136.1 million for the nine months ended September 30, 2022. See Note 11, Other Expenses, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for the details of the costs included in this total for the comparative periods.
Income Taxes
Income tax benefit improved by $28.1 million from a $20.5 million income tax provision for the nine months ended September 30, 2021, to a $7.6 million income tax benefit for the nine months ended September 30, 2022, primarily due to pre-tax loss. Our effective tax rate (including discrete items) was approximately 27% and 25% for the nine months ended September 30, 2022 and 2021, respectively. Our tax rate is also affected by discrete items that may occur in any given year, but are not necessarily consistent from year to year.
CRITICAL ACCOUNTING ESTIMATES
Management considers an accounting estimate to be critical if the accounting estimate requires management to make particularly difficult, subjective, or complex judgments about matters that are inherently uncertain. A summary of our critical accounting estimates is included in Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Application of Critical Accounting Estimates” of our 2021 Form 10-K. There have been no material changes to the critical accounting estimates disclosed in our 2021 Form 10-K.
NEW ACCOUNTING PRONOUNCEMENTS
For additional information regarding new accounting guidance, see Note 1, Business Description and Basis of Presentation, to our consolidated financial statements included in this Quarterly Report on Form 10-Q, which provides a summary of our recently adopted accounting standards and disclosures.
LIQUIDITY AND CAPITAL RESOURCES
Our primary sources of liquidity include our cash flows from operations and borrowings under our second amended and restated senior credit agreement (the “Second A&R Credit Agreement”). As of September 30, 2022 and December 31, 2021, we had total available liquidity of $650.2 million and $499.6 million, respectively, reflecting our cash and cash equivalents as well as remaining availability under our senior secured revolving credit facility (the “Senior Revolver”).
Our liquidity is influenced by many factors, including timing of revenue and corresponding cash collections, the amount and timing of investments in strategic initiatives, our investments in property, equipment and software, and the use of cash to pay tax withholding obligations upon surrender of shares upon vesting of equity awards. We continue to invest capital in order to achieve our strategic initiatives and successfully integrate acquired companies. In addition, we plan to enhance customer service by continuing our investment in technology to enable our systems to more effectively integrate with our customers’ existing technologies in connection with our strategic initiatives.
35



We plan to continue to deploy resources to strengthen our information technology infrastructure, including automation, in order to drive additional value for our customers. We also expect to continue to invest in our global business services infrastructure and capabilities, including by expanding into the Philippines, and selectively pursue acquisitions and/or strategic relationships that will enable us to broaden or further enhance our offerings. New business development remains a priority as we plan to continue to boost our sales and marketing efforts. Additionally, we expect to incur costs associated with implementation and transition costs to onboard new customers.
We expect cash and cash equivalents, cash flows from operations, and our availability under the Senior Revolver to continue to be sufficient to fund our operating activities and cash commitments for investing and financing activities, including debt maturities and material capital expenditures, for at least the next 12 months and beyond. Similar to previous material acquisitions, future potential acquisitions may be funded through the incurrence of additional debt if our current credit facilities do not have the required capacity.
Our material cash requirements include the following contractual and other obligations:
Debt
Our indebtedness materially increased as a result of the Cloudmed Acquisition. As of September 30, 2022, we had outstanding debt of $1.8 billion with contractual payments extending through 2029, with $49.5 million payable within 12 months. Future interest payments associated with our debt total $463.0 million, with $99.1 million payable within the next 12 months, based on the floating rates as of September 30, 2022.
Leases
Our significant leasing activity encompasses leases for real estate, including corporate offices, operational facilities, and global business services centers. As of September 30, 2022, we had fixed future lease payments of $148.8 million, with $27.7 million payable within 12 months.
Software Purchase and Services Obligations
Our primary purchase obligations relate to contracts entered into with vendors that supply various software services and products. As of September 30, 2022, we had purchase obligations related to software and service contracts of $233.5 million, with $70.6 million payable within 12 months.
As of September 30, 2022 and December 31, 2021, we had cash and cash equivalents of $131.1 million and $130.1 million, respectively. Cash flows from operating, investing, and financing activities, as reflected in our consolidated statements of cash flows, are summarized in the following table:
 Nine Months Ended September 30,
 20222021
 (In millions)
Net cash used in (provided by) operating activities$(39.5)$218.8 
Net cash used in investing activities$(921.9)$(325.5)
Net cash provided by financing activities$965.5 $91.7 
Cash Flows from Operating Activities
Cash used in operating activities increased by $258.3 million from cash provided of $218.8 million for the nine months ended September 30, 2021, to cash used of $39.5 million for the nine months ended September 30, 2022. Cash used in operating activities increased due to a larger cash bonus payout related to the 2021 bonus plan compared to the 2020 bonus plan, payment of Cloudmed compensation amounts, and decreased net income of $81.7 million.
36



Cash Used in Investing Activities
Cash used in investing activities primarily includes our investments in property, equipment and software and our inorganic growth initiatives. Outflows for significant acquisitions are typically offset by cash inflows from financing activities related to obtaining new debt.
Cash used in investing activities increased by $596.4 million from $325.5 million for the nine months ended September 30, 2021, to $921.9 million for the nine months ended September 30, 2022. The increase in cash usage is primarily due to the difference in cash payments for the Cloudmed Acquisition in 2022 compared to the VisitPay acquisition in 2021 and the timing of payments for property, equipment and software.
Cash Flows from Financing Activities
Cash flows from financing activities primarily relate to borrowings and repayments of debt. In conjunction with acquisitions, we typically borrow additional debt to fund the consideration, either by increasing our existing facilities or refinancing with new facilities. We utilize our revolver to ensure we have sufficient cash on hand to support the needs of the business at any given point in time. Cash flows from financing activities also include cash received from exercises of stock options and the use of cash to pay tax withholding obligations upon surrender of shares upon vesting of equity awards, as well as other financing activities.
Cash provided by financing activities increased by $873.8 million from $91.7 million for the nine months ended September 30, 2021, to $965.5 million for the nine months ended September 30, 2022. This change is primarily due to 2022 borrowings made under the Second A&R Credit Agreement and smaller debt repayments in 2022, partially offset by higher amounts of cash required to pay tax withholding obligations upon surrender of shares upon vesting of equity awards in 2022. In addition, there were no inducement payments made during the nine months ended September 30, 2022, compared to $105.0 million used during the nine months ended September 30, 2021 to pay for the inducement of the conversion of our preferred stock
Debt and Financing Arrangements
On June 21, 2022, we entered into a Second A&R Credit Agreement with Bank of America, N.A., as administrative agent, and the lenders named therein, governing the Company’s second amended and restated senior secured credit facilities (the “Senior Secured Credit Facilities”), consisting of the $691.3 million existing senior secured term loan A facility (the “Existing Term A Loan”), a $540.0 million senior secured incremental term loan A facility (the “Incremental Term A Loan”, and together with the Existing Term A Loan, the “Term A Loans”), a $500.0 million senior secured term loan B facility (the “Term B Loan”, and together with the Term A Loans, the “Senior Term Loans”), and a $600.0 million Senior Revolver. The Existing Term A Loan requires quarterly payments. Commencing December 31, 2022, we are also required to repay the Incremental Term A Loan and Term B Loan in quarterly principal installments. The Senior Secured Credit Facilities bear interest at a floating rate, which was 5.28% for the Term A Loans and Senior Revolver and 6.03% for the Term B Loan as of September 30, 2022.

As of September 30, 2022, we had drawn $80.0 million and had $519.1 million of remaining availability on our Senior Revolver.

The proceeds from the new Senior Secured Credit Facilities were or will be used, in addition to cash on hand, (1) to refinance, in full, all existing indebtedness under the Amended and Restated Credit Agreement, dated as of July 1, 2021, by and among Old R1 RCM and certain of its subsidiaries, Bank of America, N.A., as administrative agent, and the lenders named therein, and amend and restate all commitments thereunder (the “Refinancing”), (2) to pay certain fees and expenses incurred in connection with the entry into the Second A&R Credit Agreement and the Refinancing, (3) to fund the Cloudmed Acquisition and a holding company reorganization, and to pay the fees, premiums, expenses and other transaction costs incurred in connection therewith, and (4) to finance our working capital needs for general corporate purposes.

37



The Second A&R Credit Agreement contains a number of financial and non-financial covenants. We are required to maintain minimum consolidated total net leverage and consolidated interest coverage ratios. The Company was in compliance with all of the covenants in the Second A&R Credit Agreement as of September 30, 2022.

See Note 8, Debt, to our consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information.

Item 3.Qualitative and Quantitative Disclosures about Market Risk
Interest Rate Sensitivity. Our results of operations and cash flows are subject to fluctuations due to changes in interest rates due to our debt and banking arrangements, which can result in fluctuations in our interest income and expense. As of September 30, 2022, we have hedged $500.0 million of our $1.8 billion outstanding floating rate debt to a fixed rate of 3.01% plus the applicable spread defined in the Second A&R Credit Agreement. The remaining $1.3 billion outstanding is subject to average variable rates of 5.28% for the Term A Loans and Senior Revolver and 6.03% for the Term B Loan as of September 30, 2022. Assuming the current level of borrowings, a one percentage point increase or decrease in interest rates would increase or decrease our annual interest expense on the $1.3 billion subject to variable rates by approximately $13.0 million.
Our interest income is primarily generated from variable rate interest earned on operating cash accounts.
Foreign Currency Exchange Risk. Our results of operations and cash flows are subject to fluctuations due to changes in the Indian rupee and Philippine peso because a portion of our operating expenses are incurred by our subsidiaries in India and the Philippines and are denominated in Indian rupees and Philippine pesos, respectively. We do not generate significant revenues outside of the United States. For the nine months ended September 30, 2022 and 2021, 8% and 9% of our expenses were denominated in foreign currencies, respectively. As of September 30, 2022 and 2021, we had net assets of $77.6 million and $65.6 million in foreign entities, respectively. Before the impact of our foreign currency hedging activities discussed below, the reduction in earnings from a 10% change in foreign currency spot rates would be $11.9 million and $9.6 million at September 30, 2022 and 2021, respectively.
For designated cash flow hedges, gains and losses currently recorded in accumulated other comprehensive loss will be reclassified into earnings at the time when certain anticipated intercompany charges are accrued as cost of services. As of September 30, 2022, it was anticipated that approximately $0.8 million of losses, net of tax, currently recorded in accumulated other comprehensive loss will be reclassified into cost of services within the next 12 months.

We use sensitivity analysis to determine the effects that market foreign currency exchange rate fluctuations may have on the fair value of our hedge portfolio. The sensitivity of the hedge portfolio is computed based on the market value of future cash flows as affected by changes in exchange rates. This sensitivity analysis represents the hypothetical changes in value of the hedge position and does not reflect the offsetting gain or loss on the underlying exposure. A 10% change in the levels of foreign currency exchange rates against the U.S. dollar (or other base currency of the hedge if not a U.S. dollar hedge) with all other variables held constant would have resulted in a change in the fair value of our hedge instruments of approximately $6.2 million as of September 30, 2022.

38



Item 4.Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management including its principal executive officer and principal financial officer to allow timely decisions regarding required disclosures.

In connection with the preparation of this report, our management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2022. Our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2022, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the third quarter of 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

39



PART II — OTHER INFORMATION
Item 1.Legal Proceedings

Other than the litigation described in Note 14, Commitments and Contingencies, to our consolidated financial statements included in this Quarterly Report on Form 10-Q, we are presently not a party to any material litigation or regulatory proceeding and are not aware of any pending or threatened litigation or regulatory proceeding against us which, individually or in the aggregate, could have a material adverse effect on our business, operating results, financial condition or cash flows.

Item 1A.Risk Factors

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A of our 2021 Annual Report on Form 10-K. Except as set forth below, there have been no material changes in our risk factors from those disclosed in our 2021 Form 10-K.

Risks Related to the Acquisition of Cloudmed

If we do not integrate the businesses successfully, we may lose customers and fail to achieve our financial objectives.

Achieving the benefits of the Cloudmed Acquisition will depend in part on the successful integration of Cloudmed’s business into our operations in a timely and efficient manner. In order for us to provide our customers with the same level of service after the Cloudmed Acquisition, we will need to integrate our product lines and development organizations with those of Cloudmed. This may be difficult, unpredictable, and subject to delay because the businesses have been developed independently and were designed without regard to such integration. In addition, Cloudmed is still in the process of integrating certain of its recent acquisitions. If we cannot successfully integrate the businesses and products and continue to provide customers with products and new product features in the future on a timely basis, we may lose customers and our business and operating results may be harmed.

We may not realize the anticipated benefits from the Cloudmed Acquisition.

The Cloudmed Acquisition involves the integration of two companies that have previously operated independently. We expect the combined company to result in financial and operational benefits, including increased cost savings and other financial and operating benefits from the Cloudmed Acquisition. There can be no assurance, however, regarding when or the extent to which we will be able to realize these increased cost savings or benefits. The companies must integrate or, in some cases, replace numerous systems, including those involving management information, purchasing, accounting and finance, sales, billing, employee benefits, payroll, and regulatory compliance, many of which are dissimilar. Difficulties associated with integrating the post-acquisition entity could have a material adverse effect on us and the market price of our common stock.

We have incurred significant transaction and merger-related costs in connection with the Cloudmed Acquisition and will remain liable for significant transaction costs, including legal, accounting, and other costs.

We have incurred and expect to continue to incur a number of non-recurring costs associated with combining the operations of the two companies which cannot be estimated accurately at this time. Although we expect that the elimination of duplicative costs, as well as the realization of other efficiencies related to the integration of the businesses, may offset incremental transaction and transaction-related costs over time, this net benefit may not be achieved in the near term, or at all.

40



The Cloudmed Acquisition could cause us to lose key personnel, which could materially affect our business and require us to incur substantial costs to recruit replacements for lost personnel.

As a result of the Cloudmed Acquisition, current and prospective R1 employees could experience uncertainty about their future roles within the combined company. This uncertainty may adversely affect our ability to attract and retain key management and operational personnel. Any failure to attract and retain key personnel could have a material adverse effect on our business.

The trading price of our common stock has been volatile and may continue to be volatile.

Since March 1, 2020, our common stock has traded at a price per share as high as $31.28 and as low as $7.12. Market prices for securities of companies that have undergone significant acquisitions may be volatile. The trading price of our common stock may be highly volatile in the future and could be subject to wide fluctuations in response to various factors. In addition to the risks described in this section, factors that may cause the market price of our common stock to fluctuate include: fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us; changes in estimates of our financial results or recommendations by securities analysts, if any, who cover our common stock, or failure to meet expectations of such securities analysts; the loss of service agreements with customers; lawsuits filed against us by governmental authorities or stockholders; unfavorable publicity concerning our operations or business practices; investors’ general perception of us; changes in local, regional or national economic conditions; changes in demographic trends; increased labor costs, including healthcare, unemployment insurance, and minimum wage requirements; the entry into, or termination of, material agreements; changes in general economic, industry, regulatory, and market conditions not related to us or our business; the availability of experienced management and hourly-paid employees; issues in operating the company; future sales of our securities, including sales by our significant stockholders; and other potentially negative financial announcements, including delisting of our common stock from The Nasdaq Global Select Market, changes in accounting treatment or restatement of previously reported financial results, delays in our filings with the SEC or failure to maintain effective internal control over financial reporting.

In addition, if the stock market in general experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition, or operating results.

Our consolidated indebtedness has increased substantially following completion of the Cloudmed Acquisition. This increased level of indebtedness could adversely affect us, including by decreasing our business flexibility.

Our consolidated indebtedness as of December 31, 2021 was approximately $775.6 million. In conjunction with the Cloudmed Acquisition, we entered into the Second A&R Credit Agreement, which increased our consolidated indebtedness by $1.0 billion. The increased indebtedness has had the effect of increasing our interest payments and could have the effect of, among other things, reducing our flexibility to respond to changing business and economic conditions. The increased level of indebtedness could also reduce funds available for capital expenditures, share repurchases and dividends, and other activities and may create competitive disadvantages for us relative to other companies with lower debt levels.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds
Unregistered Sale of Equity Securities
On July 5, 2022, the Company issued 1,403,687 shares of its common stock to Sutter Health as consideration for certain real property acquired by the Company from an affiliate of Sutter Health at a value of $24.3 million. The foregoing securities were issued in reliance upon the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.
41



Issuer Purchases of Equity Securities
The following table provides information about our repurchases of common stock during the periods indicated:
PeriodNumber of Shares  Purchased (1) Average Price Paid per Share (1), (2)Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)  Maximum Dollar Value of Shares that May Yet be Purchased Under Publicly Announced Plans or Programs (in millions) (2)
July 1, 2022 through July 31, 2022 157,133   $22.26 73,976   $490.3 
August 1, 2022 through August 31, 202237,380 22.38 35,990 489.5 
September 1, 2022 through September 30, 2022484,160 20.92 484,160 479.3 
Total purchases678,673 $21.31 
(1)Includes the surrender of shares of our common stock related to employees’ tax withholding upon vesting of restricted stock or option exercise. See Note 10, Share-Based Compensation, to our consolidated financial statements included in this Quarterly Report on Form 10-Q.
(2)On October 22, 2021, the Board authorized the repurchase of up to $200.0 million of our common stock from time to time in the open market or in privately negotiated transactions (the “2021 Repurchase Program”). On January 9, 2022, the Board increased the authorization under the 2021 Repurchase Program to an aggregate amount of up to $500.0 million. The average price paid per share of common stock repurchased under the 2021 Repurchase Program is the execution price, including commissions paid to brokers. The timing and amount of any shares repurchased under the 2021 Repurchase Program will be determined by our management based on its evaluation of market conditions and other factors. The 2021 Repurchase Program may be suspended or discontinued at any time.

42



Item 6.Exhibits

The following are filed or incorporated by reference as a part of this Quarterly Report on Form 10-Q:

(a)
Exhibit NumberExhibit Description
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.LABXBRL Taxonomy Extension Label Linkbase Document
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Furnished herewith.
+Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission upon request.
43



SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
R1 RCM INC.
By:/s/ Joseph Flanagan
Joseph Flanagan
Chief Executive Officer
By:/s/ Rachel Wilson
Rachel Wilson
Chief Financial Officer and Treasurer
Date: November 8, 2022
    

44
EX-10.1 2 ascensionhealth-r1xamendme.htm EX-10.1 Document
Exhibit 10.1
CONFIDENTIAL
FINAL

AMENDMENT NO. 6 TO
AMENDED AND RESTATED MASTER PROFESSIONAL SERVICES AGREEMENT
BY AND BETWEEN
ASCENSION HEALTH AND R1 RCM INC.
    This Amendment No. 6 to the Master Professional Services Agreement (this “Amendment”) by and between Ascension Health (d/b/a Ascension Healthcare) (“Ascension Health”) and R1 RCM Holdco Inc. (f/k/a R1 RCM Inc., f/k/a Accretive Health, Inc.) (“Supplier”) is entered into as of the last date of execution hereof, and effective as of July 1, 2022 (the “Amendment Effective Date”). Ascension Health and Supplier are sometimes referred to in herein as a “Party” or collectively as the “Parties”. All capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Ascension MPSA or AMITA MPSA (as each is defined below).
    WHEREAS, the Parties entered into that certain Amended and Restated Master Professional Services Agreement, dated February 16, 2016, as amended, restated, supplemented or otherwise modified (the “Ascension MPSA”), which sets out a framework pursuant to which Supplier and Ascension Health and other Eligible Recipients may enter into Supplements for the provision of Services by Supplier;
    WHEREAS, the Parties, together with Alexian Brothers − AHS Midwest Region Health Co (doing business as AMITA Health) (“AMITA”) and Adventist Health System Sunbelt Healthcare Corporation (“AdventHealth”) entered into that certain Master Professional Services Agreement, dated November 1, 2018, as amended, restated, supplemented, or otherwise modified (the “AMITA MPSA”), which sets out a framework under which Supplier:
(a) provides Dependent Acute Services and Physician Advisory Services for the benefit of Acute Care facilities that are owned or controlled by Legacy Presence, pursuant to Supplement One to the AMITA MPSA (“Supplement #1”),
(b) provides Dependent Acute Services and Physician Advisory Services for the benefit of Acute Care facilities that are owned or controlled by certain Alexian Affiliates, pursuant to Supplement Two to the AMITA MPSA (“Supplement #2”);
(c) provides Dependent Provider Services for the benefit of Owned Eligible Medical Groups owned, controlled or employed by Legacy Presence, pursuant to Supplement Three to the AMITA MPSA (“Supplement #3”),
(d) provides Dependent Provider Services for the benefit of Owned Eligible Medical Groups owned, controlled or employed by certain Alexian Affiliates, pursuant to Supplement Four to the AMITA MPSA (“Supplement #4”);
    WHEREAS, as of even date herewith, the Parties, together with AMITA and AdventHealth, entered into that certain Contract Migration Agreement (“Contract Migration Agreement”), pursuant to which the Parties agreed to terminate the AMITA MPSA and migrate Supplier’s obligations with respect to the Presence Acute Group (including under Supplement #1), the Alexian Acute Group (including under Supplement #2), the Presence Provider Group (including under Supplement #3), and the Alexian Provider Group (including under Supplement #4), from the AMITA MPSA to the Ascension MPSA in accordance with the terms and conditions set forth herein; and
    WHEREAS, the Parties now desire to add new Supplements to be governed under the Ascension MPSA and make certain other related changes as set forth in this Amendment.
    NOW THEREFORE, in consideration of the mutual promises and covenants contained in this Amendment, and of other good and valid consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
1.Additional Definitions and Eligible Recipients
1.01For the avoidance of doubt, the Alexian Acute Group, the Presence Acute Group, the Alexian Provider Group and the Presence Provider Group, as well as any Entities that control any Migrated Group, are each Eligible Recipients under the Ascension MPSA. However, the Presence Acute Group and the Alexian Acute Group are neither Additional Book Eligible Recipients nor Current Book Eligible Recipients under the Ascension MPSA.
.- 1 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


1.02The definition of “Cost to Collect Factor,” as set forth in Exhibit 1 of the Ascension MPSA, is hereby deleted and replaced in its entirety with the following:

Cost to Collect Factor” means the Additional Book Cost to Collect Factor, the Current Book Cost to Collect Factor, the Presence Acute Cost to Collect Factor or the Alexian Acute Cost to Collect Factor as applicable.

1.03The following definitions are hereby added to Exhibit 1 of the Ascension MPSA:

Acute Group” means either the Presence Acute Group or the Alexian Acute Group.

Alexian Acute Cost to Collect Factor” has the meaning given in Supplement 29.

Alexian Acute Group” means the Entities set forth on Schedule A to this Amendment, each of which is, as of the Amendment Effective Date, Controlled by Alexian Brothers.

Alexian Brothers” means Alexian Brothers Hospital Network.

Alexian Provider Group” has the meaning given in EMG Services Addendum [#13] to Supplement 26 to the Ascension MPSA.

Legacy Presence” means Presence Care Transformation Corporation (or any successor Entity thereto) or any Covered Affiliate that is Controlled by Presence Care Transformation Corporation (or any successor Entity thereto).

Migrated Group” means any of (a) the Alexian Acute Group, (b) the Presence Acute Group, (c) the Presence Provider Group or (d) the Alexian Provider Group.

Presence Acute Group” means the Entities set forth on Schedule A to this Amendment, each of which is, as of the Amendment Effective Date, Controlled by Legacy Presence.

Presence/Alexian Acute Care Units” shall mean the Acute Care facilities included in the Acute Presence/Alexian Group.

Presence Acute Cost to Collect Factor” has the meaning given in Supplement 28.

Presence/Alexian Acute Group” shall mean, collectively, the Alexian Acute Group and the Presence Acute Group.

Presence/Alexian Cost to Collect Factor” shall mean either (a) the Alexian Acute Cost to Collect Factor or (b) the Presence Acute Cost to Collect Factor.

Presence Provider Group” has the meaning given in EMG Services Addendum [#14] to Supplement 26.

2.Addition of Supplements and Exhibits to Ascension MPSA and EMG Services Addenda and Exhibits to Supplement 26.
2.01     New Supplements and EMG Services Addenda - Effective as of the Amendment Effective Date, the Parties have entered into Supplement 28 to the Ascension MPSA (for the Presence Acute Group), Supplement 29 to the Ascension MPSA (for the Alexian Acute Group), EMG Services Addendum #13 to Supplement 26 to the Ascension MPSA (for the Presence Provider Group) and EMG Services Addendum #14 to Supplement 26 to the Ascension MPSA (for the Alexian Provider Group).
.- 2 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


2.02     EMG Services for the Alexian Provider Group and Presence Provider Group - Effective as of the Amendment Effective Date, Exhibit 1-A to Supplement 26 (EMG Services – For the Alexian Provider Group and the Presence Provider Group) is hereby added to Supplement 26, as set forth in Addendum 1 attached hereto. For the avoidance of doubt, Exhibit 1-A to Supplement 26 will apply solely to the Alexian Provider Group and the Presence Provider Group and will not apply to any other Eligible Medical Groups.
2.03    Acute Care Service Levels for the Alexian Acute Group and Presence Acute GroupEffective as of the Amendment Effective Date (but without limiting the retroactive effect of certain Services Levels as expressly set forth in Addendum 2), Exhibit 3-A (Service Levels - For the Alexian Acute Care Group and Presence Acute Care Group) is hereby added to the Ascension MPSA, as set forth in Addendum 2 attached hereto. For the avoidance of doubt, Exhibit 3-A will apply solely to the Presence Acute Group and the Alexian Acute Group and will not apply to the Current Book Eligible Recipients or the Additional Book Eligible Recipients.
2.04    EMG Service Levels for the Alexian Provider Group and Presence Provider GroupEffective as of the Amendment Effective Date (but without limiting the retroactive effect of certain Services Levels as expressly set forth in Addendum 3), Exhibit 4-A to Supplement 26 (Service Levels – For the Alexian Provider Group and the Presence Provider Group) is hereby added to Supplement 26, as set forth in Addendum 3 attached hereto. For the avoidance of doubt, Exhibit 4-A to Supplement 26 will apply solely to the Alexian Provider Group and the Presence Provider Group and will not apply to any other Eligible Medical Groups.
2.05     EMG Incentive Fees - Effective as of the Amendment Effective Date, Exhibit 3-A to Supplement 26 (EMG Incentive Fees – For the Alexian Provider Group and the Presence Provider Group) is hereby added to Supplement 26, as set forth in Addendum 4 attached hereto. For the avoidance of doubt, Exhibit 3-A to Supplement 26 will apply solely to the Alexian Provider Group and the Presence Provider Group and will not apply to any other Eligible Medical Groups and, in lieu of the calculations set forth in Exhibit 3 to the AMG Supplement, the EMG Incentive Fees for each of the Alexian Provider Group and Presence Provider Group will be determined in accordance with Addendum 4 attached hereto; provided that (a) the Appendices to Exhibit 3 to Supplement 26 will apply to the Alexian Provider Group and the Presence Provider Group, and (b) for purposes of Appendix B of Exhibit 3 of Supplement 26, the Alexian Provider Group and Presence Provider Group shall be deemed included in the “Phase 1 Group”.
3.Acute Services - Modifications to Dependent Services Exhibit for Presence Acute Group and Alexian Acute Group.
Effective as of the Amendment Effective Date, the following is hereby added as Dependent Services to Section 1(a) of Exhibit 2-A (Dependent Services) to the Ascension MPSA that Supplier is obligated to provide solely for the Presence Acute Group and the Alexian Acute Group and for no other Eligible Recipients, except to the extent otherwise agreed by the Parties in writing:
Scheduling (including inpatient, outpatient, and diagnostics) – In accordance with Ascension Health Standards and each individual hospital’s technical systems, policies, and practices ensure that critical information and all core set of data elements are obtained from either the patient or the referring physician practice to enable successful subsequent front end processes. To aid scheduling processes, provide patient in advance with instructions based on the scheduled medical procedure, manage physician orders as directed by such physician for scheduled medical procedures, manage Ascension Health medical procedure facility schedule as directed, and provide follow up or reminders of scheduled visits.
BCBSIL UPP Reimbursement Management” -- Supplier shall undertake the following activities solely for the benefit of the Presence Acute Group and the Alexian Acute Group: Utilize Blue Cross Blue Shield Illinois experience reports as provided by Ascension Health or the Presence/Alexian Acute Care Units to validate actual reimbursements compared to expected reimbursement for underpayment and denial recovery
.- 3 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


.IL Medicaid and State Payor AR Management -- Supplier shall undertake the following activities solely for the benefit of the Presence Acute Group and the Alexian Acute Group: As made available by State of Illinois programs defined as traditional Medicaid, managed care organizations, and all commercial payors funded by the State. Supplier will request, monitor and maintain payor ‘promise to pay’ status on adjudicated but unpaid claims for accounts receivable management and reporting to finance departments of the Presence Acute Group and the Alexian Acute Group to assist with identifying accounts receivable with delayed payment due to State funding.
4.Acute Incentive Fees - Modifications to Incentive Fees for Alexian Acute Group and Presence Acute Group
4.01     Subject to the Performance Targets, Metric Weights and Upper Bounds and Lower Bounds for each Operating Metric set forth in Supplement 28 and Supplement 29, respectively, and Sections 4.02 through 4.04 below, the Incentive Payment for each of the Presence Acute Group and the Alexian Acute Group will be determined in accordance with Exhibit 4-B to the MPSA (as amended); provided that the changes to Exhibit 4-B described in Section 4.02 through 4.04 below will only apply through [*****]. For the avoidance of doubt, the [*****] that is planned to become effective on [*****].

4.02     Notwithstanding Section 1.2 of Exhibit 4-B to the MPSA, from [*****] through [*****], with respect to each of the Presence Acute Group and the Alexian Acute Group, the numeral in sub-clause (ii) in each of the definitions of “Balance Sheet Incentive Payment” and “Income Statement Incentive Payment” in Exhibit 4-B is hereby modified to be [*****] instead of [*****].
4.03     Notwithstanding Section 6 of Exhibit 4-B to the MPSA, from [*****] through [*****], with respect each of the Presence Acute Group and the Alexian Acute Group, the definitions of “Performance Score” and “Performance Target” are hereby revised as follows.
Performance Score” means the percentage value assigned to the Operating Metric based on the relationship of the Actual Performance for the Operating Metric as compared to the Performance Target and the Lower Bound and the Upper Bound. For any Operating Metric, the Performance Score resulting from Actual Performance shall equal the result of the following equation (expressed as a percentage): the sum of (A) the result of (x) the difference of the Actual Performance with respect to such Operating Metric minus the Performance Target, divided by (y) the difference of the applicable Upper Bound minus the applicable Performance Target, which result will be multiplied by (z) [*****], and (B) [*****].
[*****] = Performance Score

For example, an Actual Performance of [*****] for an Operating Metric that has a Lower Bound of [*****], a Performance Target of [*****] and an Upper Bound of [*****] would result in a Performance Score of [*****] since:
[*****]
Notwithstanding the foregoing, the maximum Performance Score is [*****] and the minimum Performance Score is [*****]
Performance Target” means, with respect to any Operating Metric, the Actual Performance for such Operating Metric that would result in a Performance Score for such Operating Metric of the fraction [*****] expressed as a percentage.
4.04     Notwithstanding Section 8.5 of Exhibit 4-B to the MPSA, from [*****] through [*****], with respect to each of the Presence Acute Group and the Alexian Acute Group, the table in Section 8.5 to Exhibit 4-B is hereby revised as shown below.
.- 4 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


#Metric0% Target[*****]100% Target
1)Metric Removed
2)[*****][*****]
Pursuant to Section 3.3
[*****]
3)[*****]
4)[*****][*****]
Pursuant to Section 3.3
[*****]
5)[*****][*****]
Pursuant to Section 3.3
[*****]
6)[*****]
7)[*****][*****]
Pursuant to Section 3.3
[*****]
8a)[*****][*****]
Pursuant to Section 3.3
[*****]
8b)[*****][*****]
Pursuant to Section 3.3
[*****]
9)[*****][*****]
Pursuant to Section 3.3
[*****]
10)[*****]

5.Implementation Fees for Legacy Presence and Alexian Brothers
5.01     During the period running from [*****] through [*****], if Legacy Presence, Alexian Brothers or any Entity in the Presence Acute Group or Alexian Acute Group acquires a new Eligible Recipient Unit for Acute Care, then the references to [*****] in Section 5 of Exhibit 4-A to the Ascension MPSA will be modified to be [*****] for purposes of calculating the Implementation Fee. For clarity, with respect to any Eligible Recipient Unit acquired by any Entity in the Presence Acute Group or Alexian Acute Group after [*****], (a) the foregoing modification will not apply, and (b) the [*****] from Section 5 of Exhibit 4-A to the Ascension MPSA shall be used for purposes of calculating the Implementation Fee.
6.Limitation of Liability.
Effective as of the Amendment Effective Date, Section 18.2(b) of the Ascension MPSA is hereby deleted and replaced in its entirety with the below.
Liability Cap. Except as provided in this Section 18.2, the total aggregate liability of either Party, for claims asserted by the other Party under or in connection with this Agreement, regardless of the form of the action or the theory of recovery, shall be limited to [*****] per calendar year. For avoidance of doubt, this annual liability cap is an aggregate liability cap for this Agreement and all Supplements.”

7.Compliance.
Effective as of the Amendment Effective Date, Section 3.2 of Exhibit 11 of the Ascension MPSA is hereby deleted in its entirety.
8.Approved Data Subcontractors for Legacy Presence and Alexian Brothers.
8.01     Ascension Health hereby approves Supplier’s use of [*****] as Data Subcontractors under the Ascension MPSA, in each case, subject to the terms and conditions set forth in the Data Subcontractor Acknowledgements entered into between AMITA and Supplier on [*****] and [*****], respectively, but solely for the provision of the applicable approved categories of services (as set forth in each Data Subcontractor Acknowledgment) for Legacy Presence and Alexian Brothers.

9.Miscellaneous.
.- 5 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


9.01    The Parties agree and acknowledge that, except as otherwise expressly amended by this Amendment, (a) the Ascension MPSA remains in full force and effect according to its terms and conditions, (b) except as expressly set forth herein, this Amendment shall not affect any rights of a Party that accrued with respect to the Ascension MPSA prior to the Amendment Effective Date and (c) this Amendment shall not release a Party from any obligations, liabilities, or other claims that may have arisen under the Ascension MPSA prior to the Amendment Effective Date. The Parties agree that this Amendment represents compliance with all obligations relating to the Presence and Alexian Contract Migration, as defined in and set forth in the Contract Migration Agreement.
9.02    Prior to [*****], the Parties agree to discuss in good faith potential amendments to the MPSA for purposes of: (a) simplifying the Subcontractor approval process, while maintaining all relevant controls currently specified therein; and (b) modernizing the terms related to information security and each Party’s Intellectual Property Rights (e.g., to reflect the delivery of certain technologies as software-as-a-service).
9.03    This Amendment may be executed in several counterparts, all of which taken together will constitute one single agreement between the Parties.

[signature page follows]

.- 6 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15



IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their respective duly authorized representatives as of the Amendment Effective Date.

Agreed to and Accepted by:
R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.)

By:    /s/ John Sparby

Name:    John Sparby

Title: Executive Vice President and Chief Operating Officer


Date: July 1, 2022
Ascension Health (d/b/a Ascension Healthcare)

By:    /s/ Jon Sohn

Name:    Jon Sohn

Title: Senior Vice President, Chief Revenue Officer, Ascension, on behalf of Ascension Health d/b/a Ascension Healthcare

Date: July 1, 2022


.- 7 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Schedule A
List of Entities in Presence Acute Group and Alexian Acute Group
Presence Acute Group:

1.Presence Chicago Hospitals Network d/b/a Presence Holy Family Medical Center;
2.Presence Chicago Hospitals Network d/b/a Presence Resurrection Medical Center
3.Presence Chicago Hospitals Network d/b/a Presence Saint Francis Hospital
4.Presence Chicago Hospitals Network d/b/a Presence Saint Joseph Hospital – Chicago
5.Presence Chicago Hospitals Network d/b/a Presence Saint Elizabeth Hospital
6.Presence Chicago Hospitals Network d/b/a Presence Saint Mary of Nazareth Hospital
7.Presence Central and Suburban Hospitals Network d/b/a Presence Mercy Medical Center
8.Presence Central and Suburban Hospitals Network d/b/a Presence Saint Joseph Hospital – Elgin
9.Presence Central and Suburban Hospitals Network d/b/a Presence Saint Joseph Medical Center
10.Presence Central and Suburban Hospitals Network d/b/a Presence St. Mary’s Hospital – Kankakee

Alexian Acute Group:

1.Alexian Brothers Medical Center
2.St. Alexius Medical Center
3.Alexian Brothers Behavioral Health Hospital



.- 8 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Addendum 1
Exhibit 1-A to Supplement 26
(EMG Services– For the Alexian Provider Group and the Presence Provider Group)
The EMG Services described below are being undertaken for the purposes of optimizing the Revenue Cycle Operations process to maximize compliant collections from the amounts billable as a result of operations of the Alexian Provider Group or Presence Provider Group, as applicable. None of the EMG Services described below are being undertaken to manage medical decisions or business operations of the Alexian Provider Group or Presence Provider Group, nor are any of the Services intended to increase the volume of operations of the Alexian Provider Group or Presence Provider Group.

With respect to each function in the revenue cycle operations of the Alexian Provider Group or Presence Provider Group, Annex A to this Exhibit 1-A attached hereto sets forth ownership, applicable technology, and whether Supplier is responsible for implementing related processes and performance improvement.

1.EMG Services. In accordance with Section 4.1 of the MPSA, Supplier shall provide the following EMG Services, subject to the allocation of tasks set forth in Annex A to this Exhibit 1-A.
a.Medical Group Market Services. For purposes of this Addendum, “Medical Group Market Services” shall include the following functional areas:
i.PRE-SERVICE – Supplier will provide leadership, management oversight, staffing and technical expertise of:

Authorization/Referral (Verification) – Supplier will (i) perform authorization clearance services for patients to verify that an authorization is in place, and (ii) document all required authorizations.

Insurance Eligibility Verification (Financial Clearance) – Once the payer is identified, check benefit eligibility and obtain verification from insurance (governmental or commercial) that the patient reported insurance for the applicable service is still in force and will reimburse the provider for the service.

ii.TIME OF SERVICE - Supplier will directly provide leadership, management oversight, staffing and technical expertise of, or indirectly support through implementation of “best practices” and process standardization, the following services:

Self-Pay Financial Advocacy and Eligibility of Services (e.g., self-pay conversions) (Financial Counseling) – For those patients that are unaware of what insurance they have, or declare they have no insurance, work diligently and use proprietary tools to gather information to understand what might be an acceptable source of reimbursement.

Registration – Obtaining all required patient liability (i.e., outstanding balance), clinical, demographic, and financial information from patients that was not obtained during scheduling or pre-registration when the patient is present for service regardless of status (scheduled or walk-in). Obtaining information necessary to obtain financial clearance at time of service (to include collection of co-pay, deductible, or co-insurance).

.- 9 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Collection of Residuals – Support and monitor the patient education and communication process, present the opportunity for patients to pay their patient balances as both a convenience and improvement to patient flow at the point of service.

iii.CHARGING/CODING - Supplier will directly provide leadership, management oversight, staffing and technical expertise of, or indirectly support through implementation of “best practices” and process standardization, the following services:

Physician Coding Review/Audit – For operations that result in reviewing of medical records; Medical records are reviewed in order to determine appropriate charges billed, CPT and/or ICD-10 coding, and that providers are in accordance with any and all regulatory guidelines.

Physician Education-  For operations that result in educating and training providers based on audit findings and trends to ensure proper coding and supported documentation. In addition, ensuring that providers are educated on applicable regulatory coding changes.

Abstract Coding- Ensuring that once a medical record of service is completed, coders have used the appropriate ICD- 10 CM, CPT, HCPCS codes and modifiers as supported by documentation.

iv.POST-SERVICE - Supplier will directly provide leadership, management oversight, staffing and technical expertise of, or indirectly (depending on the applicable patient accounting system) support through implementation of “best practices” and process standardization, the following services:

Coding Supported Accounts Receivable Management – Once a medical record coding and/or charge entry is completed and submitted for billing, identify and remedy billing deficiencies in accordance with payer requirements and compliant billing practices. When required, utilize certified coding professional to review and correct billing editor rejections and payer denials to correct and resubmit claims.

Charge Capture/ Pre-Bill, Post-Bill (Charge Optimization) - Use automated and manual methods, including retrospectively, to correctly bill gross revenue and to capture applicable and authorized charges on the bill that is sent to the payer/ patient, while remaining in compliance with all applicable laws and guidelines. For retrospective review, analyze claims after the bill has been sent to look for incorrect or missing charges or codes, and initiate confirmation and rebill processes to ensure all applicable and authorized charges have been captured by clinical departments and re-billed to the payer/ patient.

b.Platform-Specific Services – For purposes of this Addendum, “Platform-Specific Services” shall include the following functional areas:

POST-SERVICE – Supplier will directly provide leadership, management oversight, staffing and technical expertise of, or indirectly (depending on the applicable patient accounting system) support through implementation of “best practices” and process standardization, the following services:

.- 10 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Billing/Claims Processing, Claims Scrubbing/Preparation/Claims Submission - Send all required information to the billing editor application or system so that a claim proceeds to the applicable payer. Though the goal is to have no bill editor rejects, Supplier shall oversee processes to resolve all discrepancies in a timely manner for resubmission of the bill to the applicable payer. Once the insurance balance is resolved, confirm that the applicable patient billing system sends a bill for the residual patient responsibility. Recommend billing edits and bridge routines to improve the number of claims sent to the payer without intervention and/or to reduce denials.

Credits (Refund Processing) - Research credit balances and reasons for credit balances (e.g., over-contractualization, system processing issues, actual over-payments, etc.), and prepare appropriate payment alterations where no refund is due. Supplier shall process credit balances for refund payment for Ascension Affiliates’ review and consent. Implement processes necessary to comply with state escheatment laws for uncashed refund payments.

Unpostables – Research and gather all information necessary to support posting an “Unpostable” to the correct account. “Unpostables” are unidentified remittances, whether made by check, cash payment, remit or individual account balance, which do not contain sufficient information to accurately process and post such payments to a patient account.

Credit Card Processing – Manage and/or support processes for patient and payer credit card processing.
Cash Posting and Processing (Lockbox and Payment Posting) – Electronically and manually post cash from both payers’ and patients’ accounts and reconcile outstanding accounts receivable in a timely and accurate manner. Reconcile daily cash at patient account level to the extent reasonably feasible (except Ascension will be responsible for general ledger and patient accounting reconciliation). Post payments not processed electronically (e.g., over-the-counter deposits, payroll deductions, returned lockbox items, bank credit/debit adjustments, credit card chargebacks) on the day such items are received or in a longer timeframe determined by Ascension to be proper. Identify and reconcile unidentified cash receipts and daily lockbox deposits to payment posting in the patient accounting system on a daily basis.

Third Party Collections and Self-Pay Follow-Up (internal and external collection activities) (AR Follow-up) - Manage the collection process in accordance with Ascension Health Standards, federal, state and local hospital policies and practices. Coordinate with third party collectors for debt in default. Attempt to resolve all issues (e.g. registration, coding, billing, clinical, etc.) which have caused a partial or full denial. Perform denial and appeal service on third party claims, including review Remittance Advice and/or Explanation of Benefits and determine payment discrepancies between actual payment and expected payment. Create and send appeal letters for accounts that have been denied by the insurance payer. As necessary, resubmit all applicable bills to the payer and make improvements to attempt reduction or elimination of re-occurrence of such events. This service includes all non-zero balances.

.- 11 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Denial Management (Operational and Clinical) - Attempt to resolve all issues (e.g., registration, coding, billing, clinical, etc.) which have caused a partial or full denial. Resubmit the applicable bill to the payer as necessary and make systemic improvements to reduce or eliminate re-occurrence. Implement process improvements to reduce future denials based on root cause analysis of current denials.

Customer Service (Patient Billing/Patient Financial Services) – Provide an inbound call center capability and mail response capabilities for patient inquires, complaints, and possible payment/resolutions via a phone number and address listed on the patient bill. Customer service agent shall handle and resolve a wide range of questions or issues to include disputes. Supplier shall record all relevant customer service calls and maintain recordings for a period of a least ninety (90) days after the date of call, making such recordings available to Ascension upon request. Manage all correspondence received by the call center or patient correspondence sent to a physician group within the Alexian Provider Group’s or Presence Provider Group’s lockbox. This function will also include processing post-service financial assistance applications, Medicaid applications, and other patient liability functions (e.g. bankruptcy, attorney requests, etc). This call center will receive calls for both acute care and professional fee patient balances at the mutual agreement of the Alexian Provider Group or Presence Provider Group, as applicable.

Patient Statement/Pre-Collect – Manage processing of patient statements and perform patient/ authorized guarantor non-defaulted receivables collection services.

Bad Debt Management (Self-Pay Collections) - Manage patient bad debt through internal means and/or third party vendors and maintain documentation to support bad debt logging.

Underpayment Review/Recovery – Use a contract management system and other tools or vendors to identify claims (after all efforts related to AR follow-up have been exhausted) that were not technically paid correctly (commonly due to a payer mistake or a misinterpretation of or a vague contractual term). Once such claims have been identified, appeal such claims and follow-up until either the claim is paid correctly or the contract is clarified for re-modeling or changed.

Patient Billing / Secondary Billing – Identified as part of the registration process (preferred) or subsequently from the patient at time of patient billing. Send a secondary payer bill for the patient responsibility portion of such bill after the primary insurance is settled to gain reimbursement from a secondary insurance payer.

AR Oversight Support as Appropriate to Support General Operations – Provide oversight of open accounts receivable and escalate items as appropriate to assist the Alexian Provider Group and Presence Provider Group to timely resolve items and maximize collections.

c.OTHER SERVICES – The Platform-Specific Services and the Medical Group Market Services will include the additional services listed below, which Supplier will provide across all Pre-Service, Time of Service and Post-Service functional areas:

.- 12 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Revenue Cycle Analytics and Reporting - Provide detailed reports and analytical support to revenue cycle functions through data mining, analysis and report creation.

Revenue Cycle Technology and Support - Revenue cycle support services including, but not limited to, technology support, training and special projects.

Revenue Cycle Training - Conduct training and quality assurance across all revenue cycle processes.

Vendor Management - Contracting for and management of vendor relationships specializing in revenue cycle sub-functions including areas such as authorization management, coding and debt collection.

IL Medicaid and State Payor AR Management - As made available by State of Illinois programs defined as traditional Medicaid, managed care organizations, and all commercial payors funded by the State. Upon the request of the finance departments of the Alexian Provider Group or Presence Provider Group, Supplier will request, monitor and maintain payor ‘promise to pay’ status on adjudicated but unpaid claims for accounts receivable management and reporting to finance departments of the Alexian Provider Group or Presence Provider Group to assist with identifying accounts receivable with delayed payment due to State funding.

2.Out of Scope Services.
Without limiting Section 4.1 of the MPSA, the Parties agree that any services that are not described in Section 1 of this Exhibit 1-A shall be considered to be out-of-scope services unless agreed to in writing by Supplier and the Alexian Provider Group or Presence Provider Group, as applicable. Notwithstanding the foregoing, the Parties acknowledge that (i) Supplier shall be responsible for overall performance improvement across the entire revenue cycle with respect to the Alexian Provider Group or the Presence Provider Group and will be accountable for revenue cycle performance of the Alexian Provider Group and Presence Provider Group through the Provider Incentive Fee Payments and Provider Service Levels and (ii) in the future, certain out-of-scope services may be provided by Supplier for the Alexian Provider Group or Presence Provider Group in accordance with Section 4.3(a) of the MPSA.

.- 13 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15



Annex A to Exhibit 1-A

image_2a.jpg


.- 14 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15




Addendum 2
Exhibit 3-A
(Service Levels - For the Alexian Acute Care Group and Presence Acute Care Group)
This Exhibit 3-A shall govern all Service Levels with respect to Dependent Services, solely to the extent provided to the Presence/Alexian Acute Care Units, which comprise the Presence/Alexian Acute Group. Exhibit 3 (excluding, for clarity, this Exhibit 3-A) shall continue to apply to Dependent Services provided to all other Acute Care Eligible Recipients.
1.Definitions.
For purposes of this Exhibit 3-A, the Alexian Acute Group and the Presence Acute Group will be treated as one single Acute Group, known as the Presence/Alexian Acute Group.
Acute Service Level Default” means, in accordance with this Exhibit 3-A, Supplier’s level of performance for a particular Service Level fails to meet the applicable Acute Target Level during the applicable Measurement Window (which Measurement Window starts and ends after the applicable Acute Service Level Effective Date) with respect to an applicable Acute Group.
Acute Service Level Effective Date” means, with respect to each Service Level as applied to a particular Acute Group, in accordance with this Exhibit 3-A, the date that such Service Level will be effective and enforced, which shall be the date that is [*****] after the Acute SLA Measurement Commencement Date applicable to such Service Level; provided that the Acute Service Level Effective Date will be deemed to be: (i) for Service Levels 5 (provided that sub-components of Service Level 5 will [*****], as set forth in Section 3.5 below) and 13, [*****]; (ii) for Service Levels 1, 2, 6, 7, 8 and 10, [*****]; (iii) for Service Levels 4, 11 and 12, [*****]; and (iv) for Service Levels 3 and 9, [*****].
Acute SLA Measurement Commencement Date” means, with respect to each Service Level as applied to a particular Acute Group(s), the date that such Service Level will start to be measured, tracked, and recorded, which shall be the Commencement Date for the Dependent Service against which the applicable Service Level is applied.
Service Level” means, with respect to this Exhibit 3-A only, any service level described in one of the following Sections (and any additional service levels agreed to by the Parties): Section 3.1 (“Service Level 1”), Section 3.2 (“Service Level 2”), Section 3.3 (“Service Level 3”), Section 3.4 (“Service Level 4”), Section 3.5 (“Service Level 5”), Section 3.6 (“Service Level 6”), Section 3.7 (“Service Level 7”), Section 3.8 (“Service Level 8”), Section 3.9 (“Service Level 9”), Section 3.10 (“Service Level 10”), Section 3.11 (“Service Level 11”), Section 3.12 (“Service Level 12”) and Section 3.13 (“Service Level 13”).
2.General.
2.1 As of the Acute SLA Measurement Commencement Date with respect to each Service Level for an Acute Group(s), Supplier will perform the Dependent Services with the intention to meet or exceed the Acute Target Levels (as defined below) for the Service Levels by its applicable Acute Service Level Effective Date, in accordance with this Exhibit 3-A. For the avoidance of doubt, in no event shall Supplier be liable for any Acute Service Level Default (including any Acute Service Level Credits) with respect to any Service Level prior to the applicable Acute Service Level Effective Date for any Acute Group.
As of the Acute SLA Measurement Commencement Date for each Service Level and continuing through the remainder of the applicable Supplement Term, Supplier shall, in accordance with this Exhibit 3-A, monitor, measure, collect, record and report Supplier’s performance of certain Dependent Services with respect to the metric applicable to each Service Level.
.- 15 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


2.2 Supplier shall report to Ascension Health and the Presence/Alexian Acute Group regarding Supplier’s performance, with respect to the applicable Acute Group, against each of the Service Levels for each Measurement Window.
2.3 Ascension Health, with respect to each applicable Acute Group, will have the right to receive Acute Service Level Credits, to be applied against the applicable portion of the Acute Base Fee in accordance with Section 7 below.
2.4 Supplier shall provide Ascension Health and each Acute Group with the performance reporting for the Dependent Services, as specified in Section 6 below and as set forth in Section 9.2 of the MPSA.
The Parties acknowledge and agree that, for purposes of this Exhibit 3-A, the Acute Target Levels and Service Level metrics are intended to reflect rational and reasonable standards of performance in line with industry standards, but are not intended to be in the top quartile of performance standards; provided that the Parties may, in accordance with Section 5, mutually agree to increase any Acute Target Levels or Service Level metrics during the applicable Supplement Term to be in such top quartile.
3.Service Level Criteria - Supplier will measure Supplier’s performance against the following Service Levels.
3.1 Service Level 1 - This Service Level will apply to all existing and new Supplier’s In-Scope Shared Service Centers that receive patient calls and will be composed of the following two (2) equally-weighted components (the “Acute Service Level 1 Components”):
(a)In-Scope Shared Service Centers Mean Speed to Answer (mean wait time, in seconds, to answer calls at Supplier’s In-Scope Shared Service Centers). This Service Level shall mean for a given Measurement Window for all of the Presence/Alexian Acute Care Units in a particular Acute Group, (i) the SSC Acute Aggregate Hold Time divided by (ii) the number of calls to Supplier’s In-Scope Shared Service Center for all such Presence/Alexian Acute Care Units for which the caller requested to speak with a Supplier representative during the Measurement Window.  For purposes of calculating this Service Level, “SSC Acute Aggregate Hold Time” means the aggregated total amount of time during the Measurement Window that all callers to Supplier’s In-Scope Shared Service Center for all of the Presence/Alexian Acute Care Units in a particular Acute Group (including “hang-ups”) remained on hold or in the interactive voice response unit after such callers requested to speak with a Supplier representative with respect to the applicable In-Scope Shared Service Center.
(b)Scheduling Mean Speed to Answer (mean wait time, in seconds, to answer scheduling calls at scheduling departments owned or managed by Supplier). This Service Level shall mean for a given Measurement Window for all of the Presence/Alexian Acute Care Units in a particular Acute Group, (i) the Scheduling Acute Aggregate Hold Time divided by (ii) the number of calls to the scheduling department owned or managed by Supplier for all such Presence/Alexian Acute Care Units for which the caller requested to schedule service with a Supplier representative during the Measurement Window. For purposes of calculating this Service Level, “Scheduling Acute Aggregate Hold Time” means the aggregated total amount of time during the Measurement Window that all callers to the scheduling department owned or managed by Supplier for all of the Presence/Alexian Acute Care Units in a particular Acute Group (including “hang-ups”) remained on hold or in the interactive voice response unit after such callers requested to speak with a Supplier representative with respect to the scheduling department owned or managed by Supplier with respect to all of the Presence/Alexian Acute Care Units in such Acute Group.
.- 16 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


(c)In-Scope Shared Service Centers Abandonment Rate. This Service Level shall mean for a given Measurement Window for all of the Presence/Alexian Acute Care Units in a particular Acute Group, (i) the number of calls to Supplier’s In-Scope Shared Service Center with respect to all such Presence/Alexian Acute Care Units entering the queue that are abandoned after at least 20 seconds in the queue, divided by (ii) the total number of inbound calls.
(d)Scheduling Abandonment Rate. This Service Level shall mean for a given Measurement Window for all of the Presence/Alexian Acute Care Units in a particular Acute Group, (i) the number of calls to Supplier’s scheduling department with respect to all such Presence/Alexian Acute Care Units entering the queue that are abandoned after at least 20 seconds in the queue, divided by (ii) the total number of inbound calls.
3.2 Service Level 2 - Percentage of scheduled patients who have 100% Financial Clearance completion. This Service Level shall mean, for a given Measurement Window for all of the Presence/Alexian Acute Care Units in a particular Acute Group, (a) the number of patients (both inpatient and outpatient) who had an appointment at such facility which appointment (1) was scheduled 48 hours or more prior to such patient’s appointment, and (2) occurs during such Measurement Window and who had 100% Financial Clearance divided by (b) the number of patients, both inpatient and outpatient, who had an appointment at such facility which appointment (1) was scheduled 48 hours or more prior to such patient’s appointment, and (2) occurs during such Measurement Window, expressed as a percentage. “Financial Clearance” shall mean that (i) contact has been made with the patient when applicable, (ii) the patient’s demographics have been confirmed and updated, (iii) the patient’s eligibility has been identified, and (iv) the requisite insurance authorization has been obtained.
3.3 Service Level 3 - [*****]
3.4 Service Level 4 - [*****]
3.5 Service Level 5 - Patient Experience – Patient Survey Response.
(a)     Metric. This Service Level metric shall mean, for all of the Presence/Alexian Acute Care Units in a particular Acute Group during any Measurement Window, each of (i) the Registration Survey Score and (ii) the PFSS Survey Score.
(b)     Definitions. For purposes hereof, the following terms shall have the meanings ascribed to such terms below:
(1)Registration Survey Score” shall mean, for all Presence/Alexian Acute Care Units in a particular Acute Group during any Measurement Window, the percentage of responses to the Press Ganey Outpatient Survey that indicate a score of 5 (best score) on a scale of 1 to 5 in the “Standard Registration” category. The Registration Survey Score calculations will be measured cumulatively during each Measurement Window.
(2)PFSS Survey Score” shall mean, for all of the Presence/Alexian Acute Care Units in a particular Acute Group during any Measurement Window, the percentage of responses to Supplier’s survey question of “Please rate your satisfaction with today’s call (Satisfied, Neutral, Dissatisfied)” completed during such Measurement Period that indicate a score of “Satisfied,” minus “Dissatisfied”. For clarity, this Service Level includes surveys given to callers to Supplier’s Financial Clearance Center, Medical Financial Solutions division, Customer Service Center and care coverage department. For purposes of measuring this Service Level, scores will be excluded for all of the Presence/Alexian Acute Care Units in a particular Acute Group that has less than thirty (30) survey responses during with Measurement Window.
.- 17 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


(c)    Phase-In. Service Level 5 shall be subject to phase-in process as follows: (i) effective as of [*****], the metrics and targets for Service Level 5 will be modified to account for (A) [*****] and (B) [*****] and (ii) effective as of [*****] the metrics and targets for Service Level 5 will be modified to account for [*****] and (ii) effective as of [*****] the metrics and targets for Service Level 5 will be further modified to account for a [*****], (i) and (ii), that will be defined and assigned appropriate targets to be mutually agreed by the parties.
3.6 Service Level 6 – Credit AR Days. This Service Level shall mean, for a given Measurement Window for all of the Presence/Alexian Acute Care Units in a particular Acute Group, (a) the negative balance accounts receivable with respect to all such Presence/Alexian Acute Care Units as of the last day of the Measurement Window, divided by (b) the average daily GPSR with respect to all such Presence/Alexian Acute Care Units for such Measurement Window. Average daily GPSR is calculated by dividing the total GPSR for the applicable Measurement Window by the number of calendar days during such Measurement Window. The source data for measurement will be the Crowe RCA (or to the extent necessary, such other system or method as agreed by the Parties).
3.7 Service Level 7 – Coding Quality. This Service Level will apply to Supplier Personnel and Subcontractors (including any computer-assisted coding vendor).
(a)    Metric. This Service Level shall mean, for any Measurement Window, the lower of the: (i) Inpatient DRG Coding Accuracy Score, (ii) Inpatient Diagnosis Coding Accuracy Score, (iii) Inpatient Procedure Coding Accuracy Score, (iv) Outpatient Diagnosis “First Listed” Coding Accuracy Score, (v) Outpatient Diagnosis Coding Accuracy Score and (vi) Outpatient Procedure Coding Accuracy Score.
(b)     Definitions. For purposes hereof, the following terms shall have the meanings ascribed to such terms below:
(1)     “Inpatient DRG Accuracy Score” shall mean, for any Measurement Window, the result (expressed as a percentage) of (i) the total number of cases within the Coding Audit for such Measurement Window for which the MS-DRGs or equivalent DRGs that impact payment do not require a re-assignment divided by (ii) the total number of cases within the Coding Audit.
(2)    “Inpatient Diagnosis Coding Accuracy Score” shall mean, for any Measurement Window, the result (expressed as a percentage) of (i) the total number of original ICD-10-CM diagnoses minus the number of ICD-10-CM codes that were changed (defined as replaced, deleted, or added) divided by (ii) the total number of original ICD-10-CM diagnoses within the coding audit with changes identified. Accuracy is reflected in the assignment of any secondary diagnosis to the extent such diagnosis impacts the DRG (APR or MS-DRG), SOI, ROM, or other identified quality requirements. Diagnoses outside of the identified criteria is not reflective of the Inpatient Diagnosis Coding Accuracy Score.
(3)Inpatient Procedure Coding Accuracy Score” shall mean, for any Measurement Window, the result (expressed as a percentage) of (i) the total number of original ICD-10-PCS procedure codes minus the number of ICD-10-PCS procedure codes that were changed (defined as replaced, deleted or added) divided by (ii) the total number of original ICD-10-PCS procedure codes within the coding audit.
(4)Outpatient Diagnosis “First Listed” Coding Accuracy Score” shall mean, for any Measurement Window, the result (expressed as a percentage) of (i) the total number of cases within the Coding Audit for such Measurement Window for which the ICD10 - Primary Diagnoses do not require a change divided by (ii) the total number of cases within the Coding Audit for such Measurement Window.
.- 18 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


(5)Outpatient Diagnosis Coding Accuracy Score” shall mean, for any Measurement Window, the result (expressed as a percentage) of (i) the total number of original ICD-10-CM diagnoses minus the number of ICD-10-CM codes that were changed (defined as replaced, deleted, or added) divided by (ii) the total number of original ICD-10-CM diagnoses within the coding audit with changes identified. Accuracy is reflected in the assignment of any secondary diagnosis to the extent such diagnosis impacts the outpatient encounter related to chronic conditions, impacts the APC, or other identified quality requirements. Diagnoses outside of the identified criteria are not reflective of the Outpatient Diagnosis Coding Accuracy Score.
(6)Outpatient Procedure Coding Accuracy Score” shall mean, for any Measurement Window, the result (expressed as a percentage) of (i) the total number of original CPT/HCPCS procedure codes minus the number of CPT/HCPCS procedure codes that were changed (defined as replaced, deleted or added) divided by (ii) the total number of original CPT/HCPCS procedure codes within the coding audit.
(7)Coding Audit” shall mean:
(i)[*****], random sample-based quality assurance audits, conducted by or on behalf of Supplier, of the accuracy of the billing coding performed by Supplier coder. As part of this [*****], random sample-based audit, each Supplier coder shall be audited.
(ii)[*****], random sample-based quality assurance external audits, performed for Ascension Health, whether engaged by Ascension Health or Supplier.
a.With respect to each of the [*****], an external auditor will be engaged to conduct a random, sample-based audit of the [*****] audits referenced in Section 3.7(b)(7)(i) above. The purpose of this [*****] audit, from [*****], will be to confirm Supplier’s [*****] coder audits meet expectations. Supplier shall engage such auditor for the [*****] and Ascension Health shall engage such auditor for the [*****]. After [*****], the Parties shall reevaluate the scope and structure of any annual, random sample-based quality assurance external audits to be performed on a prospective basis.
b.For clarification, the [*****] random sample-based audits will be deemed separate and distinct from the Parties’ individual or collective risk-based, focused Compliance audits, although such audits may be performed at or during the same period of time.
(iii)Any auditing, including as done by external auditors, will utilize random or probability sampling commensurate with nationally recognized audit standards and practices.
(iv)Cases coded by a Transitioned Employee shall be subject to the Coding Audits only after such Transitioned Employee has been employed by Supplier for [*****]. Thereafter, Transitioned Employee Supplier coders shall be audited at least quarterly, consistent with the quarterly coding assurance audits noted in Section 3.7(b)(7)(i) above.
(v)In conducting the Coding Audits, Supplier shall use only personnel holding the following credentials: Auditors of inpatient coding records must have at least [*****] of hospital inpatient coding experience and auditors of outpatient coding records must have at least [*****] of hospital outpatient coding experience. Additionally, each coding auditor must have any one or more of the following coding credentials: (i) RHIA, (ii) RHIT, (iii) CCS, (iv) CPC or (v) CIC.
.- 19 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


(c)    Reporting. [*****] reporting provided for all areas including (a) Inpatient DRG Coding Accuracy Score, (b) Inpatient Diagnosis Coding Accuracy Score, (c) Inpatient Procedure Coding Accuracy Score, (d) Outpatient Diagnosis “First Listed” Coding Accuracy Score, (e) Outpatient Diagnosis Coding Accuracy Score, (f) Outpatient Procedure Coding Accuracy Score and (g) the Gross Improper Payment Rate (IPR). Any measurement not meeting [*****] accuracy requires a specific corrective action plan for identified opportunities, trends and required action.
3.8 Service Level 8 - Remittance Posting.

(a)     Metric. This Service Level metric shall mean, for all of the Presence/Alexian Acute Care Units in a particular Acute Group during any Measurement Window, the absolute value of the quotient of (i) all such Presence/Alexian Acute Care Units’ aggregated Acute Trailing Period Monthly Average Unposted Cash (as defined below) divided by (ii) all such Presence/Alexian Acute Care Units’ aggregated Acute Trailing Period Daily Average NPSR (as defined below).
(b)    Definitions. For purposes of the foregoing:
(1)     “Acute Trailing Period Monthly Average Unposted Cash” shall mean, for all of the Presence/Alexian Acute Care Units in a particular Acute Group, the result of (i) the sum of the aggregate amount of all such Presence/Alexian Acute Care Units’ Acute Unposted Cash as of the last day of each of the most recent three months ended on or prior to the date of measurement divided by (ii) 3.
(2)     “Acute Trailing Period Daily Average NPSR” shall mean, for all of the Presence/Alexian Acute Care Units in a particular Acute Group for any Measurement Window, the result of (i) the aggregate amount of net patient service revenue generated by all such applicable Presence/Alexian Acute Care Units during such Measurement Window (as indicated at the time of measurement by the Crowe RCA System) divided by (ii) the number of calendar days during such Measurement Window.
(3)     “Acute Unposted Cash” shall mean, for all of the Presence/Alexian Acute Care Units in a particular Acute Group, the sum of the balances of all cash deposits related to patient accounts that have not been posted or transferred; provided that certain unposted balances may be excluded by written agreement of the Parties in the event that Supplier did not have sufficient timely information to post or transfer such cash balances.
(a)Reporting. Supplier will provide Ascension Health leadership with access to Supplier’s dashboard reflecting daily Unposted Cash, real time cash posting progress and any escalation items.
(c)    Section 2.2 and Section 6 and the data and reporting requirements of Section 2.4 shall not apply with respect to this Service Level 8 - Remittance Posting. Ascension Health shall provide Supplier, within [*****] following the end of each month, with reports setting forth for each Acute Group the Trailing Period Daily Average NPSR for each Presence/Alexian Acute Care Unit in such Acute Group together with all supporting data reasonably necessary for Supplier to verify such amounts and calculations.
(d)    Governance. The Parties will meet [*****] to discuss cash posting and reconciliation issues. The Parties agree to form a cash posting steering committee that will be responsible for oversight of cash and reconciliation issues and opportunities. The committee will have the power and duty to develop the future state of cash posting across Ascension Health.
3.9        Service Level 9 - [*****]
3.10        Service Level 10 - Transcription. This Service Level shall mean for a given Measurement Window for all of the Presence/Alexian Acute Care Units in a particular Acute Group, the time that elapses from the time that the applicable dictated file for a patient with respect to any of such Presence/Alexian Acute Care Unit is available to Supplier until the time that the transcription of such file is completed and such time that the transcription is uploaded into such Presence/Alexian Acute Care Unit’s EMR or Supplier provides a printable form of such transcription.
.- 20 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


3.11        Service Level 11 - [*****]
3.12        Service Level 12 - [*****]

3.13             Service Level 13 – Illinois Medicaid A/R Follow Up.
(a)Metric. This Service Level shall mean, for a given Measurement Window for all Presence/Alexian Acute Care Units in a particular Acute Group, each of (a) Unworked/ Overdue Illinois Medicaid A/R In Risk Levels 1-2 and (b) Unworked/ Overdue Illinois Medicaid A/R In Risk Levels 3-5.
(b)Definitions. For purposes hereof, the following terms shall have the meanings ascribed to such terms below:
(1)     “Unworked/ Overdue Illinois Medicaid A/R” shall mean: (x) the sum of the aggregate balances of Unworked and Overdue Medicaid Traditional Accounts Receivable, divided by (y) the Average Daily GPSR for all Payers.
(2)     “Unworked and Overdue Medicaid Traditional Accounts Receivable” shall mean, the balance accounts receivable related to Medicaid Claims, excluding Managed Care Organization (MCO)/Medicaid Managed Care, that are past due to be worked according to existing Supplier technology solutions and workflow management criteria.
(3)     “Medicaid Claims” shall mean claims and/or invoices where the primary insurance billed is “Medicaid”.
(4)     “Risk Levels 1 -2” refers to Medicaid Claims with accounts receivable balances less than [*****].
(5)     “Risk Levels 3 -5” refers to Medicaid Claims with accounts receivable balances greater than or equal to [*****].
(6)     “Average Daily GPSR for all Payers” shall mean the average daily GPSR attributed to Payers with respect to all such Presence/Alexian Acute Care Units for such Measurement Window. Average daily GPSR is calculated by dividing the total GPSR for the applicable Measurement Window by the number of calendar days during such Measurement Window. The source data for measurement will be the Crowe RCA (or to the extent necessary, such other system or method as agreed by the Parties).
.- 21 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


4.Acute Target Levels.
The target level for each of the Service Levels for Dependent Services provided to the Presence/Alexian Group (an “Acute Target Level”), will be set as follows:
a) Service Level 1 - The Acute Target Level for each Acute Service Level 1 Component for each applicable period will be set as follows:
Acute Service Level 1 Component[*****][*****][*****][*****]
[*****] - Remainder of term
In-Scope Shared Service Centers Mean Speed to Answer
Less than or equal to [*****].
Less than or equal to [*****].
Less than or equal to [*****].
Less than or equal to [*****].
Less than or equal to [*****].
In-Scope Shared Service Centers Abandonment Rate
Less than or equal to [*****].
Less than or equal to [*****].
Less than or equal to [*****].
Less than or equal to [*****].
Less than or equal to [*****].
Scheduling Mean Speed to AnswerN/AN/AN/AN/A
Less than or equal to [*****].
Scheduling Abandonment RateN/AN/AN/AN/A
Less than or equal to [*****]

b) Service Level 2 - At least [*****].
c) Service Level 3 - As mutually agreed by the Parties.
d) Service Level 4 – As mutually agreed by the Parties.
e) Service Level 5 – Effective as of [*****]: (a) The Acute Target Level for the Registration Survey Score measurement shall be (i) [*****] for the Alexian Acute Group and (ii) [*****] for the Presence Acute Group; and (b) the Acute Target Level for the PFSS Survey Score measurement shall be [*****] for each of the Acute Groups. Supplier must meet (a) and (b) to achieve the Acute Target Level for this Service Level. For clarity, the Acute Target Levels that apply following [*****] will be as mutually agreed by the Parties, subject to the phase-in of additional sub-components of this Service Level as described in Section 3.5(c) above.
f) Service Level 6 – [*****] or less and compliance with CMS refund rules and regulations.
g)    Service Level 7 – At least [*****]. However, the Acute Target Levels for (b) Inpatient Diagnosis Coding Accuracy Score, (c) Inpatient Procedure Coding Accuracy Score and (e) Outpatient Diagnosis Coding Accuracy Score will have a tiered approach to the [*****] Acute Target Level as follows:
TierTimelineTarget
1[*****][*****]
2[*****][*****]
3[*****][*****]

h)     Service Level 8 – Less than or equal to [*****].
.- 22 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


i)     Service Level 9 - As mutually agreed by the Parties.
j)     Service Level 10
[*****] within [*****] (other than for discharge summaries)

a. [*****] within [*****] (for discharge summaries)
b. [*****] within [*****], other than in connection with:
i.Queries to dictating medical staff: discrepancies within text of report, e.g., right/left, request to clarify proper clinician template use, distorted audio quality requiring physician decision on whether to re-dictate or fill in missing information, and incomplete or partial dictations;
ii.Queries to HIM staff: Missing patient information, signing or dictating physician, or date of service;
iii. Workflows for department of cardiology wherein scanned data is required from the hospital side to transcription to be typed into the report prior to upload;
iv. Technical failures outside the reasonable control of Supplier, including with respect to eScription data center, inbound HL7 interface from hospital, or outbound EMR interface.
k)Service Level 11 - As mutually agreed by the Parties, including (a) a target initially in effect for the period beginning on the Service Level Effective Date and ending on [*****], and (b) a revised target as mutually agreed by the Parties for the period beginning on [*****] through the remainder of the Term.
l)Service Level 12 - As mutually agreed by the Parties.
m)Service Level 13 – (a) The Acute Target Level for Unworked/Overdue Illinois Medicaid A/R In Risk Levels 1-2 will be [*****]; and (b) the Acute Target Level for Unworked/Overdue Illinois Medicaid A/R In Risk Levels 3-5 will be [*****]. Supplier must meet (a) and (b) to achieve the Acute Target Level for this Service Level.
5.Changes to Existing Service Levels.
The number of Service Levels will not exceed [*****]. The Parties will work in good faith during the twelve (12) months prior to the following effective dates to discuss any applicable revisions to the following aspects of the Service Level framework:
(a)effective as of [*****];
(b)effective as of [*****];
(c)effective as of [*****]; and
(d)effective as of [*****].
[*****] and may reflect or be derived from the following as mutually agreed upon information and factors:
-    External benchmarks; and/or
-    Then-current performance.
Any adjustment to any Service Level resulting from this Section 5 must be mutually agreed, shall apply prospectively only and shall not be applied to any period of time preceding the written agreement of the Parties with respect to such adjustment.
6.Measurement and Reporting.
6.1 Supplier’s performance against the Service Levels will be measured for each Measurement Window as of the [*****] (or, if later, the date Supplier assumes responsibility for the applicable Dependent Services in accordance with the Transition Plan).
.- 23 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


6.2 Supplier will implement automated or other measurement and monitoring tools and procedures reasonably acceptable to Ascension Health to measure Supplier’s performance against the Service Levels in a manner and at a level of detail approved by Ascension Health. Supplier will provide Ascension Health and the applicable Acute Group with access to up-to-date problem management data and other data reasonably requested by Ascension Health and the applicable Acute Group regarding the status of failures and/or user inquiries.
6.3 If Supplier fails to measure its performance with respect to a Service Level so that it is not possible to confirm whether the level of performance specified for the Service Level has been achieved for a given Measurement Window, then, unless such failure to measure was previously excused in writing by Ascension Health, such failure will be deemed an Acute Service Level Default for the applicable Measurement Window.
6.4 Supplier shall provide to the applicable Acute Group, as part of Supplier’s monthly performance reports, a set of hard- and soft-copy reports to verify Supplier’s performance and compliance with the Service Levels where data is available monthly.
6.5 Supplier shall provide detailed supporting information for each report to the applicable Acute Group in machine-readable form suitable for use on a personal computer. The data and detailed supporting information shall be Ascension Health Confidential Information, and the applicable Acute Group may access such information online, where technically feasible and permissible under Supplier’s applicable third party agreements, at any time.
7.Acute Service Level Credits.
7.1 If Supplier commits an Acute Service Level Default with respect to any Service Level for an Acute Group(s), then Supplier will pay or credit Ascension Health for the amounts described below (each, a “Acute Service Level Credit”). [*****]. Upon the occurrence of an Acute Service Level Default, Supplier will perform the problem analysis described in Section 8. Supplier will also propose a corrective action plan to improve Supplier’s performance in the upcoming Measurement Window, subject to the approval of the affected Acute Groups. Unless mutually agreed upon by Supplier and the affected Acute Group, the measurement of Supplier’s performance for a Measurement Window will be completed no later than [*****] days after the completion of such Measurement Window.
7.2 If Supplier’s performance within a Measurement Window for such Service Level for any Acute Group does not achieve the applicable Acute Target Level, resulting in an Acute Service Level Default for such Service Level with respect to the applicable Acute Group, then Supplier shall apply an Acute Service Level Credit equal to the product of (i)[*****] divided by the number of Service Levels then in effect with respect to the applicable Acute Group, multiplied by (ii) [*****] which Acute Service Level Credit shall be applied on the [*****] following the applicable Measurement Window (e.g., May 1 for a Service Level Default for the first quarter Measurement Window) for such Acute Service Level Default.
7.3 If more than one Service Level within an Acute Group has experienced an Acute Service Level Default for any Measurement Window, Supplier will apply the sum of the Acute Service Level Credit amounts for each such Service Level that had Acute Service Level Defaults during such Measurement Window as described in this Section 7.2. There shall be up to [*****] of [*****], as applicable, at risk with respect to such Measurement Window, and Supplier shall in no event be liable for Service Level Credits in excess of such at-risk amount.
7.3.1 For Service Level 1, Supplier shall calculate and report performance separately for each component. If Supplier’s performance does not achieve the Target Level for any component, then the Service Level Credit to be applied will be proportional to the number of the Target Levels not achieved. For example, if Supplier does not achieve the In-Scope Shared Service Centers Mean Speed to Answer component, but meets the In-Scope Shared Service Centers Abandonment Rate component, then Supplier shall apply [*****] of the Service Level Credit for one Service Level Default calculated in accordance with Section 7.3 of this Exhibit.
.- 24 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


7.3.2 For Service Level 5, with respect to each Acute Group, Supplier shall calculate and report performance separately for each of: (i) the Registration Survey Score; (ii) the PFSS Survey Score for Supplier’s Financial Clearance Ceter; (iii) the PFSS Survey Score for Supplier’s Medical Financial Solutions division; (iv) the PFSS Survey Score for Supplier’s Customer Service Unit and (v) the PFSS Survey Score for Supplier’s Care Coverage team (each, a “Sub-Service Level”). If Supplier’s performance does not achieve the Target Level for any Sub-Service Level for each Acute Group, then the Service Level Credit to be applied will be proportional to the number of the Target Levels not achieved. For example, if Supplier does not achieve the PFSS Survey Score for the Customer Service Unit, but meets the remaining Sub-Service Levels, then Supplier shall apply [*****] of the Service Level Credit for one Service Level Default calculated in accordance with Section 7.3 of Exhibit 3 for the applicable Eligible Recipient.
7.4 Except as otherwise expressly set forth in Section 20.1(b)(ii) of the MPSA, if Supplier’s performance on the Service Level that experienced an Acute Service Level Default achieves the Acute Target Level in the subsequent Measurement Window, the applicable Acute Group will remit the previously paid applicable Acute Service Level Credit on the [*****] following the next Measurement Window (“Acute Earnback”). However, if Supplier’s performance on such Service Level fails to achieve the Acute Target Level during the next Measurement Window, Supplier will no longer have an opportunity to earn back the applicable Acute Service Level Credit.
7.5 The mechanism for applying Acute Service Level Credits and Acute Earnback credits to the [*****].
8.Problem Analysis and Correction.
Supplier shall promptly investigate and correct each failure to meet a Service Level, by (i) promptly investigating and reporting on the causes of the problem; (ii) providing a Root Cause Analysis of such failure as soon as practicable after such failure or at the request of the affected Acute Groups; (iii) correcting the problem as soon as practicable or coordinate the correction of the problem if Supplier does not have responsibility for the cause of the problem; (iv) advising the affected Acute Group of the status of remedial efforts being undertaken with respect to such problem; (v) demonstrating that the causes of such problem have been or will be corrected on a prospective basis; and (vi) taking corrective actions to prevent any recurrence of such problem. Supplier shall complete the Root Cause Analysis as quickly as possible, but in all events within [*****], and shall notify such affected Acute Group prior to the end of the initial [*****] period as to the status of the Root Cause Analysis and the estimated completion date. The Parties shall report on Acute Service Level Defaults at each meeting of the JRB, including any disputes regarding problem analysis and correction steps, and without limiting any obligations of the Parties to implement any other decision of the JRB, each Party shall promptly implement or facilitate implementation of any resolutions determined by the JRB (e.g., Supplier cooperating with any exercise of step-in rights by Ascension Health as required by Section 4.4 of the MPSA).
9.Windfall Situations; Environmental Changes and Other Issues.
If any of the events described in Section 10.1 or Section 10.2 of Exhibit 4-A to the MPSA occurs, and such event significantly affects the Service Level measurement, Supplier’s performance under any Service Level (including the amount of resources required to maintain such performance) or Supplier’s ability to measure its performance with respect to any of the Service Levels, then either Party shall have the right to request that the other Party consider a fair and appropriate adjustment to the affected Service Levels and/or Acute Target Levels. Upon such a request, the Parties will, in good faith, discuss the impact of such event on (a) Supplier’s performance under each such Service Level; (b) the amount of resources required to maintain performance at or above the applicable Acute Target Levels and (c) Supplier’s ability to measure such Service Levels, with the outcome to equitably reflect the impact of such event(s).
Intentionally Left Blank

.- 25 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15



Addendum 3
Exhibit 3-B to Supplement 26
(Service Levels – For the Alexian Provider Group and the Presence Provider Group)

This Exhibit 3-B shall govern all Service Levels with respect to EMG Services provided to the Presence Provider Group under EMG Services Addendum #13 to Supplement 26 and the Alexian Provider Group under EMG Services Addendum #14 to Supplement 26.
1.Definitions.
Provider Service Level Default” means, in accordance with this Exhibit 3-B, Supplier’s level of performance for a particular Service Level fails to meet the applicable Provider Target Level during the applicable Measurement Window (which Measurement Window starts and ends after the applicable [*****]) with respect to an applicable Provider SLA Group.
“[*****]” means, with respect to each Service Level as applied to a particular Provider SLA Group, in accordance with this Exhibit 3-B, the date that such Service Level will be effective and enforced. For each of the Presence Provider Group and the Alexian Provider Group, the [*****] will be deemed to be (i) for Service Levels 2 and 6, [*****]; (ii) for Service Level 1, 5, 8 and 10, [*****]; and (iii) for Service Level 4, [*****]; (iv) for Service Levels 3 and 9, [*****]; and (v) for Service Levels 11 and 12, [*****] following the quarter in which the Parties mutually agree to the respective Target Levels.
Provider SLA Group” means either the Presence Provider Group or the Alexian Provider Group, provided that effective as of [*****], the Alexian Provider Group and the Presence Provider Group will be treated as one single group for purposes of this Exhibit 3-B.
Provider SLA Measurement Commencement Date” means, with respect to each Service Level as applied to a particular Provider SLA Group, the date that such Service Level will start to be measured, tracked, and recorded, which shall be the Commencement Date for the EMG Service against which the applicable Service Level is applied.
Service Level” means, with respect to this Exhibit 3-B only, any service level described in one of the following Sections (and any additional service levels agreed to by the Parties): Section 3.1 (“Service Level 1”), Section 3.2 (“Service Level 2”), Section 3.3 (“Service Level 3”), Section 3.4 (“Service Level 4”), Section 3.5 (“Service Level 5”), Section 3.6 (“Service Level 6”), Section 3.8 (“Service Level 8”), Section 3.9 (“Service Level 9”), Section 3.10 (“Service Level 10”), Section 3.11 (“Service Level 11”) and Section 3.12 (“Service Level 12”).
1.General.
1.1As of the Provider SLA Measurement Commencement Date with respect to each Service Level for a Provider SLA Group, Supplier will perform the EMG Services with the intention to meet or exceed the Provider Target Levels (as defined below) for each of the Service Levels by its applicable [*****], in accordance with this Exhibit 3-B. For the avoidance of doubt, in no event shall Supplier be liable for any Provider Service Level Default (including any Provider Service Level Credits) with respect to any Service Level prior to the applicable [*****] for any Provider SLA Group.
As of the Provider SLA Measurement Commencement Date for each Service Level and continuing through the remainder of the applicable Supplement Term, Supplier shall, in accordance with this Exhibit 3-B, monitor, measure, collect, record and report Supplier’s performance of certain EMG Services with respect to the metric applicable to each Service Level.
.- 26 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


1.2Supplier shall report to Ascension and each Provider SLA Group regarding Supplier’s performance, with respect to the applicable Provider SLA Group, against each of the Service Levels for each Measurement Window.
1.3Ascension, with respect to each applicable Provider SLA Group, will have the right to receive Provider Service Level Credits, to be applied against the [*****], in accordance with Section 7 below.
1.4Supplier shall provide Ascension and the Provider SLA Group with the performance reporting for the EMG Services, as specified in Section 6 below and as set forth in Section 9.2 of the MPSA.
1.5The Parties acknowledge and agree that, for purposes of this Exhibit 3-B, the Provider Target Levels and Service Level metrics are intended to reflect rational and reasonable standards of performance in line with industry standards, but are not intended to be in the top quartile of performance standards; provided that the Parties may, in accordance with Section 5, mutually agree to increase any Provider Target Levels or Service Level metrics during the applicable Supplement Term to be in such top quartile.
2.Service Level Criteria – Supplier will measure Supplier’s performance against the following Service Levels.
2.1 Service Level 1 - This Service Level will apply to all existing and new Supplier In-Scope Shared Service Centers that receive patient calls. In-Scope Shared Service Centers Mean Speed to Answer (mean wait time, in seconds, to answer calls at Supplier’s In-Scope Shared Service Centers). This Service Level shall mean, for a given Measurement Window, for the Provider SLA Group, (a) the Provider Aggregate Hold Time divided by (b) the number of calls to Supplier’s In-Scope Shared Service Centers for the Alexian Provider Group or Presence Provider Group (as applicable) for which the caller requested to speak with a Supplier representative during the Measurement Window.  For purposes of calculating this Service Level, “Provider Aggregate Hold Time” means the aggregated total amount of time during the Measurement Window that all callers to Supplier’s In-Scope Shared Service Centers for all of the Eligible Medical Groups in the Provider SLA Group (including “hang-ups”) remained on hold or in the interactive voice response unit after such callers requested to speak with a Supplier representative with respect to the applicable In-Scope Shared Service Centers.
2.2 Service Level 2 - Percentage of Completed Applications received will be processed in less than [*****] days in compliance with Ascension policies and CMS Refund Rules and Regulations. This Service Level shall mean, for the Provider SLA Group, during any Measurement Window, (a) the number of patients who have submitted Completed Applications for financial assistance that were received by Supplier during such Measurement Window for which, in accordance with the Ascension Billing and Collection Policy: (i) the application has been evaluated and a determination has been made to approve or deny the application; (ii) the patient has been notified of the determination; and (iii) Supplier has updated the Athena Platform or Epic Platform, if and as applicable, to adjust balances, within [*****] days or less from Supplier’s receipt of the Completed Application, divided by (b) the number of patients who have submitted Completed Applications for financial assistance that were received by Supplier during such Measurement Window. “Completed Application” means an application for which all required information has been received, including supporting materials, in order for the application to be fully processed by Supplier.
2.3 Service Level 3 – [*****]
2.4 Service Level 4 - [*****]
2.5 Service Level 5 - Patient Experience – Patient Survey Response. This Service Level shall have the meaning mutually agreed upon by the Parties.
.- 27 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


2.6 Service Level 6 – Credit AR Days. This Service Level shall mean, for a given Measurement Window, for each of the Provider SLA Groups: (a) the negative balance accounts receivable as of the last day of the Measurement Window, divided by (b) the Average Daily GPSR for such Measurement Window. “Average Daily GPSR” means (x) the total GPSR for the applicable Measurement Window, divided by (y) the number of calendar days during such Measurement Window. With respect to the Athena Group, the source data for measurement will be the Athena Platform. With respect to the Epic Group, the source data for measurement will be the Crowe RCA. [*****] will not be measured for purposes of this Service Level.
2.7 Intentionally Deleted.
2.8 Service Level 8– Remittance Resolution: Accountable Unpostables and Provider Unposted Cash.
(a)For the Athena Group during any Measurement Window, this Service Level shall mean each of the two equally weighted components:
(1)The result of the following calculation expressed as a percentage:
(x) The result of the calculation as of the last day of each of the most recent three months ended on or prior to the date of measurement:(a) the number of [*****] Remittance Required Unpostables aged greater than [*****] days from the unpostable create date divided by (b) the total number of [*****] Remittance Required Unpostables appearing in the Unpostables dashboard;
divided by
(y) three (the result of such calculation, the “Average Aged >[*****] Remittance Required Percentage”).
(2)The result of the following calculation expressed as a percentage:
(x) The result of the calculation as of the last day of each of the most recent three months ended on or prior to the date of measurement: (a) the number of total [*****] Unpostables aged greater than [*****] days from the unpostable create date divided by (b) the total number of [*****] Unpostables appearing in the Unpostables dashboard;
divided by
(y) three (the result of such calculation, the “Average Aged >[*****] Total Unpostables Percentage”).
“[*****] Unpostables” shall mean those [*****] appropriate groups from the Unpostables dashboard in the [*****] designated by the Parties to measure unidentified remittances that do not contain sufficient information for payments to be processed and posted.
(b)     For Eligible Medical Groups in the Epic Group: this Service Level shall mean, during any Measurement Window, the absolute value of the quotient of (i) the Provider Trailing Period Monthly Average Unposted Cash (as defined below) as of the last day of such Measurement Window, divided by (ii) the Provider Trailing Period Daily Average NPSR as of the last day of such Measurement Window. For purposes of the foregoing:

Provider Trailing Period Monthly Average Unposted Cash” shall mean, the result of (i) the sum of the aggregate amount of Provider Unposted Cash as of the day before the last day of each of the most recent three month ended on or prior to the date of measurement, divided by (ii) three.
.- 28 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Provider Trailing Period Daily Average NPSR” shall mean, for the Epic Group, for any Measurement Window, the result of (i) the aggregate amount of net patient service revenue generated by the Epic Group during such Measurement Window (as indicated at the time of measurement by the Crowe RCA System) divided by (ii) the number of calendar days during such Measurement Window.
Provider Unposted Cash” shall mean, for the Epic Group, the sum of the balances of all cash deposits related to patient accounts that have not been posted or transferred; provided that certain unposted balances may be excluded by written agreement of the Parties in the event that Supplier did not have sufficient timely information to post or transfer such cash balances.
Ascension shall provide Supplier with, or provide Supplier with direct access to, within [*****] days following the end of each month, with reports setting forth for the Epic Group: (i) the Provider Trailing Period Monthly Average Unposted Cash (including a detailed itemization of the applicable balances of each account holding Provider Unposted Cash) and (ii) the Provider Trailing Period Daily Average NPSR together with all supporting data reasonably necessary for Supplier to verify such amounts and calculations. Additionally, Ascension shall provide (or cause the applicable Eligible Medical Groups within the [*****] Group to provide) Supplier with continuous, direct access to review the balances of each account holding Provider Unposted Cash through PeopleSoft or similar reporting applications.
In the event that Ascension or any Eligible Medical Group changes the manner (including accounting methods, principles or procedures) in which unposted cash is accounted for, or changes any accounting methodology, principles or procedures related to the accounts holding Provider Unposted Cash, then Service Level 8 shall be deemed to be of no effect whatsoever with respect to any such Provider SLA Group or Eligible Medical Group for which such changes have been employed until such time as Supplier and Ascension agree on reasonable modifications to the metrics for Service Level 8 and the Provider Target Level applicable thereto.
2.9 Service Level 9 – [*****]
2.10 Service Level 10 – This Service Level will apply to all existing and new Supplier In-Scope Shared Service Centers - In-Scope Shared Service Centers Abandonment Rate. This Service Level shall mean, for a given Measurement Window, for the Provider SLA Group, (A) the number of calls to Supplier’s In-Scope Shared Service Centers entering the queue that are abandoned after at least 20 seconds in the queue, divided by (B) the total number of inbound calls.
2.11 Service Level 11 – [*****]
2.12 Service Level 12 – [*****]
3.Provider Target Levels.
The target level for each of the Service Levels (a “Provider Target Level”), will be set as follows:
a)Service Level 1 – The Target Level will be set as follows:
[*****][*****]
On and after [*****]
Less than or equal to [*****]
Less than or equal to [*****]
Less than or equal to [*****]
b)Service Level 2 – [*****]
c)Service Level 3 – As mutually agreed by the Parties.
d)Service Level 4 – As mutually agreed by the Parties.
e)Service Level 5 – As mutually agreed by the Parties.
.- 29 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


f)Service Level 6 – Less than or equal to [*****].
g)Service Level 8(a) – The Target Level for each component for each applicable period will be set as follows:
Component[*****][*****]
Average Aged >[*****] Remittance Required Percentage
Less than or equal to [*****]
Less than or equal to [*****]
Average Aged >[*****] Total Unpostables Percentage
Less than or equal to [*****]
Less than or equal to [*****]
a)Service Level 8(b) – [*****] or less.
b)Service Level 9 – As mutually agreed by the Parties.
c)Service Level 10 – Less than or equal to [*****].
d)Service Level 11 – As mutually agreed by the Parties.
e)Service Level 12 – As mutually agreed by the Parties.

4.Changes to Existing Service Levels.
The number of Service Levels will not exceed eleven (11). The Parties will work in good faith during the twelve (12) months prior to the following effective dates to discuss any applicable revisions to the following aspects of the Service Level framework for EMG Services:

(a)effective as of [*****];
(b)effective as of [*****];
(c)effective as of [*****]; and
(d)effective as of [*****].
The baseline reset methodology to be discussed will allow the [*****] for each Service Level [*****], and may reflect or be derived from the following as mutually agreed upon information and factors:
-    External benchmarks; and/or
-    Then-current performance.
Any adjustment to any Service Level resulting from this Section 5 must be mutually agreed, shall apply prospectively only and shall not be applied to any period of time preceding the written agreement of the Parties with respect to such adjustment.
5.Measurement and Reporting.
5.1    Supplier’s performance against the Service Levels will be measured for each Measurement Window as of the Provider SLA Measurement Commencement Date for such Service Level.
.- 30 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


5.2    Supplier will implement automated or other measurement and monitoring tools and procedures reasonably acceptable to Ascension to measure Supplier’s performance against the Service Levels in a manner and at a level of detail approved by Ascension. Supplier will provide Ascension and the applicable Provider SLA Group with access to up-to-date problem management data and other data reasonably requested by Ascension and the applicable Provider SLA Group regarding the status of failures and/or user inquiries.
5.3     If, after the applicable [*****] with respect to a Service Level, Supplier fails to measure its performance with respect to a Service Level so that it is not possible to confirm whether the level of performance specified for the Service Level has been achieved for a given Measurement Window, then, unless such failure to measure was previously excused in writing by Ascension, such failure will be deemed a Provider Service Level Default for the applicable Measurement Window.
5.4 Supplier shall provide to the applicable Provider SLA Groups, as part of Supplier’s monthly performance reports, a set of hard- and soft-copy reports to verify Supplier’s performance and compliance with the Service Levels where data is available monthly.
5.5     Supplier shall provide detailed supporting information for each report to the applicable Provider SLA Groups in machine-readable form suitable for use on a personal computer. The data and detailed supporting information shall be Ascension Health Confidential Information, and the applicable Provider SLA Groups may access such information online, where technically feasible and permissible under Supplier’s applicable third party agreements, at any time.
6.Provider Service Level Credits.
6.1     If Supplier commits a Provider Service Level Default with respect to any Service Level for a Provider SLA Group(s), then Supplier will, subject to Section 2.7, pay or credit Ascension for the amounts described below (each, a “Provider Service Level Credit”). [*****].
6.2    Upon the occurrence of a Provider Service Level Default, Supplier will perform the problem analysis described in Section 8. Supplier will also propose a corrective action plan to improve Supplier’s performance in the upcoming Measurement Window, subject to the approval of the affected Provider SLA Groups. Unless mutually agreed upon by Supplier and the affected Provider SLA Group, the measurement of Supplier’s performance for a Measurement Window will be completed no later than [*****] days after the completion of such Measurement Window.
6.3    If Supplier’s performance within a Measurement Window for such Service Level for any Provider SLA Group does not achieve the applicable Provider Target Level, resulting in a Provider Service Level Default for such Service Level with respect to the applicable Provider SLA Group, then Supplier shall apply a Provider Service Level Credit equal to the product of (i) [*****] divided by the number of Service Levels then in effect with respect to the applicable Provider SLA Group, multiplied by (ii) [*****], for such Measurement Window, which Provider Service Level Credit shall be applied on the [*****] following the applicable Measurement Window (e.g., May 1 for a Provider Service Level Default for the first quarter Measurement Window) for such Provider Service Level Default. If more than one Service Level within a Provider SLA Group has experienced a Provider Service Level Default for any Measurement Window, Supplier will apply the sum of the Provider Service Level Credit amounts for each such Service Level that had Provider Service Level Defaults during such Measurement Window as described in this Section 6.3. There shall be up to [*****] of [*****], as applicable, at risk with respect to such Measurement Window, and Supplier shall in no event be liable for Service Level Credits in excess of such at-risk amount.
.- 31 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


(a)    For Service Level 8(a), Supplier shall calculate and report performance separately for each component, as applicable. If Supplier’s performance does not achieve the Provider Target Level for any component, then the Service Level Credit to be applied will be proportional to the number of the Provider Target Levels not achieved. For example, with respect to Service Level 8(a), if Supplier does not achieve the Average Aged >[*****] Remittance Required Percentage component, but meets the Average Aged >[*****] Total Unpostables Percentage component, then Supplier shall apply [*****] of the Service Level Credit for one Provider Service Level Default calculated in accordance with this Section 6.3 of this Exhibit 3-B.
6.4    Except as otherwise expressly set forth in Section 20.1(b)(ii) of the MPSA, if Supplier’s performance on the Service Level that experienced a Provider Service Level Default achieves the Provider Target Level in the subsequent Measurement Window, the applicable Provider SLA Group will remit the previously paid applicable Provider Service Level Credit on the [*****] following the next Measurement Window (“Provider Earnback”). However, if Supplier’s performance on such Service Level fails to achieve the Provider Target Level during the next Measurement Window, Supplier will no longer have an opportunity to earn back the applicable Provider Service Level Credit.
6.5    The mechanism for applying Provider Service Level Credits and Provider Earnback credits to the [*****].
7.Problem Analysis and Correction.
Supplier shall promptly investigate and correct each failure to meet a Service Level, by (i) promptly investigating and reporting on the causes of the problem; (ii) providing a Root Cause Analysis of such failure as soon as practicable after such failure or at the request of the affected Provider SLA Groups; (iii) correcting the problem as soon as practicable or coordinate the correction of the problem if Supplier does not have responsibility for the cause of the problem; (iv) advising the affected Provider SLA Groups of the status of remedial efforts being undertaken with respect to such problem; (v) demonstrating that the causes of such problem have been or will be corrected on a prospective basis; and (vi) taking corrective actions to prevent any recurrence of such problem. Supplier shall complete the Root Cause Analysis as quickly as possible, but in all events within [*****] days, and shall notify such affected Provider SLA Groups prior to the end of the [*****] day period as to the status of the Root Cause Analysis and the estimated completion date. The Parties shall report on Provider Service Level Defaults at each meeting of the JRB, including any disputes regarding problem analysis and correction steps, and without limiting any obligations of the Parties to implement any other decision of the JRB, each Party shall promptly implement or facilitate implementation of any resolutions determined by the JRB (e.g., Supplier cooperating with any exercise of step-in rights by Ascension as required by Section 4.4 of the MPSA).
8.Windfall Situations; Environmental Changes and Other Issues.
If any of the events described in Section 7.1 or Section 7.2 of Exhibit 4-A-2 occur, and such event significantly affects the Service Level measurement, Supplier’s performance under any Service Level (including the amount of resources required to maintain such performance) or Supplier’s ability to measure its performance with respect to any of the Service Levels, then either Party shall have the right to request that the other Party consider a fair and appropriate adjustment to the affected Service Levels and/or Provider Target Levels. Upon such a request, the Parties will, in good faith, discuss the impact of such event on (i) Supplier’s performance under each such Service Level; (ii) the amount of resources required to maintain performance at or above the applicable Provider Target Levels and (iii) Supplier’s ability to measure such Service Levels, with the outcome to equitably reflect the impact of such event(s).
.- 32 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


With respect to the Athena Group, in the event that the Athena Platform experiences any outage, bugs or other support issue not attributable to Supplier that materially affects Supplier’s ability to meet any Service Levels, as applicable (“Athena Support Issue”), Ascension shall promptly work to resolve the Athena Support Issue. Until such time that the Athena Support Issue is resolved or a reasonable work around is implemented that eliminates the adverse effect of the Athena Support Issue on the Athena Group and Supplier, the impacted Service Levels, as applicable, will be calculated as if failure to meet such Service did not occur due to the Athena Support Issue.

.- 33 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Addendum 4

Exhibit 3-A to Supplement 26
EMG Incentive Fee (for Presence Provider Group and Alexian Provider Group)


1.Incentive Payments
1.1.General. Supplier will deliver a set of core strategies and management services designed to improve and optimize the revenue cycle operations for the Presence Provider Group or Alexian Brothers Provider Group receiving EMG Services (each, the “Provider Incentive Group”). Ascension shall pay to Supplier Provider Incentive Fees in the form of Incentive Fee Payments subject to, and in accordance with, the terms of this Addendum 4. Whether Supplier qualifies for an Incentive Fee Payment will be determined separately for the Provider Incentive Group by measuring, for such Provider Incentive Group, Supplier’s Actual Performance against a pre-determined and mutually agreed set of Provider Operating Metrics for all of the Eligible Medical Groups in each Provider Incentive Group receiving the EMG Services.
The Incentive Fee Payments will relate to Supplier’s ability to deliver the EMG Services efficiently and in compliance with all applicable rules and regulations.

1.2.Definitions.
For purposes of this Addendum 4, the following terms will have the meanings set forth below:

a)Applicable Platform” means the [*****] Platform, the [*****] or the [*****] as applicable.

b)Contract Year” means a period commencing on the Commencement Date for EMG Services (and, for each subsequent Contract Year, each anniversary thereof) and ending twelve (12) months thereafter.

c)Fiscal Year” means Ascension’s fiscal year, which shall begin on July 1 (or, in the initial Contract Year, the Commencement Date for EMG Services) and end on June 30.

d)Lower Bound Score” means: (i) for any Measurement Period in which the YTD Lift Percentage is less than [*****] and (ii) for any Measurement Period in which the YTD Lift Percentage is greater than or equal to [*****].

e)Measurement Period” means Ascension fiscal quarter.

f)Metric Lift” means, with respect to a Provider Incentive Group for any Measurement Period, the dollar value assigned to the Provider Operating Metric representing increased Cash Collections for the Provider Incentive Group during such Measurement Period for such Provider Operating Metric as compared to the Performance Baseline value for such Provider Operating Metric.

g)NextGen Platform” means a Platform licensed, or otherwise provided, by [*****] (or any successor in interest).

h)Performance Baseline” means, with respect to any Provider Operating Metric for any Provider Incentive Group, the Actual Performance for such Provider Operating Metric with respect to such Provider Incentive Group during the applicable baseline period described in Section 3 below.

i)[*****]

.- 34 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


j)Provider Performance Score” means:

(i)if for any Measurement Period the YTD Lift Percentage for a Provider Incentive Group is greater than or equal to [*****], then the result of the following (expressed as a percentage): the sum of (A) the result of (x) the difference of the YTD Lift Percentage and the Lower Bound Score, divided by (y) the difference of the applicable Upper Bound Score and the applicable Lower Bound Score, multiplied by (z) [*****], and (B) [*****]. An illustrated example of this “[*****]” Provider Performance Score is set forth in Appendix D to Exhibit 3 to the AMG Supplement.

[*****] = Provider Performance Score

For example, a YTD Lift Percentage of [*****] would result in a Provider Performance Score of [*****] since

[*****] = [*****]

or

(ii)if for any Measurement Period the YTD Lift Percentage for such Provider Incentive Group is less than [*****] then the result of the following (expressed as a percentage): (A) the difference of the YTD Lift Percentage and the applicable Lower Bound Score, divided by (B) the difference of the applicable Upper Bound Score and the applicable Lower Bound Score, multiplied by (C) [*****]. An illustrated example of this “[*****]” Provider Performance Score is set forth in Appendix E to Exhibit 3 to the AMG Supplement.

[*****] = Provider Performance Score

For example, a YTD Lift Percentage of [*****] would result in a Provider Performance Score of [*****] since

[*****] = [*****]

Notwithstanding the foregoing, in each case, the maximum Provider Performance Score is [*****] and the minimum Provider Performance Score is [*****].

k)Quarterly Aggregate Lift” means, with respect to a Provider Incentive Group for any Measurement Period, the sum of the Metric Lifts for each Provider Operating Metric during such Measurement Period.

l)Upper Bound Score” means with respect to a Provider Incentive Group: (i) for any Measurement Period in which the YTD Lift Percentage is less than [*****], [*****]; and (ii) for any Measurement Period in which the YTD Lift Percentage is greater than or equal to [*****].

m)YTD Aggregate Lift” means, with respect to a Provider Incentive Group, the sum of the Quarterly Aggregate Lifts for each Measurement Period to date in the applicable Fiscal Year. For example, when calculated at the end of the third fiscal quarter in a Fiscal Year, the YTD Aggregate Lift equals the sum of the applicable Quarterly Aggregate Lifts in each of the first, second, and third fiscal quarters in such Fiscal Year.

n)YTD Cash” means, with respect to a Provider Incentive Group, the aggregate Cash Collections to date for such Provider Incentive Group for the applicable Fiscal Year, for the applicable Provider Incentive Group.

o)YTD Lift Percentage” means, with respect to a Provider Incentive Group, the YTD Aggregate Lift divided by the YTD Cash.
.- 35 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15



2.Operating Metrics Scorecard
2.1.General. Operating Metrics Scorecards will be utilized for each Provider Incentive Group to determine the Provider Performance Score for the Provider Incentive Group for each Measurement Period in order to determine the amount of any Incentive Fee Payment earned by Supplier for such Measurement Period. For Metric 1, Metric 2 and Metric 3, the Operating Metrics Scorecard will be populated with the requisite financial performance data from (i) the Applicable Platforms used by the Eligible Medical Groups for each Measurement Period until the Parties mutually agree that the Crowe RCA System (or to the extent necessary, such other system or method as agreed by the Parties) is ready for use in connection with such Metrics, and (ii) thereafter, the Crowe RCA System (or such other system or method as agreed by the Parties). For Metric 4 and Metric 5, the Operating Metrics Scorecards will be populated with the requisite financial performance data from Supplier’s system of record; provided that Ascension will have the right to approve and audit Supplier’s calculations. The Applicable Platform for each Eligible Medical Group will be the sole source of data for the applicable Operating Metrics Scorecard. Each Operating Metrics Scorecard will also include the supporting information that is used to determine the Actual Performance for each Provider Operating Metric and the overall Provider Performance Scores.
2.2.Metrics. The “Provider Operating Metrics” are comprised of the following five (5) revenue cycle operating metrics, as each is further described and defined in Appendix A to Exhibit 3 to the AMG Supplement. The Provider Operating Metrics will be calculated separately for each Provider Incentive Group.
a.Metric 1: [*****]
b.Metric 2: [*****]
c.Metric 3: [*****]
d.Metric 4: [*****]
e.Metric 5: [*****]
3.Operating Metric Performance Baselines
Ascension and Supplier will calculate the Performance Baselines in accordance with this Section 3 for each Provider Operating Metric in the applicable Operating Metrics Scorecard. The Performance Baseline for each Provider Operating Metric will be as follows:

For the Presence Provider Group:

Metric 1 [*****]
Performance Baseline PeriodFY Q1FY Q2FYQ3FY Q4
Total Baseline
[*****][*****][*****][*****][*****][*****]
[*****][*****][*****][*****][*****][*****]
[*****][*****][*****][*****][*****][*****]

The baseline period for Metric 1 will be [*****]
Metric 2 [*****]
.- 36 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Performance Baseline Detail
[*****][*****]
[*****][*****]
[*****][*****]

The baseline period for Metric 2 will be Calendar Year [*****]
The metric calculations will set the [*****] of the metric calculation to zero in all periods, and therefore a baseline for the [*****] is not required.

Metric 3 [*****]
Performance Baseline Detail
[*****][*****]
[*****][*****]
[*****][*****]

The baseline period for Metric 3 will be [*****]
Metric 4 [*****]
Performance Baseline value = [*****]
Metric 5 [*****]
Performance Baseline value = [*****]

For the Alexian Provider Group:

Metric 1 [*****]
Performance Baseline PeriodFY Q1FY Q2FYQ3FY Q4
Total Baseline
[*****][*****][*****][*****][*****][*****]
[*****][*****][*****][*****][*****][*****]
[*****][*****][*****][*****][*****][*****]

The baseline period for Metric 1 will be [*****]

Metric 2 [*****]

[*****].
Additionally, the metric calculations will set the change in [*****] of the metric calculation to zero in all periods, and therefore a baseline for the [*****] is not required.
.- 37 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15



Metric 2a [*****]

Performance Baseline Detail
[*****][*****]
[*****][*****]
[*****][*****]

Metric 2b [*****]
Performance Baseline Detail
[*****][*****]
[*****][*****]
[*****][*****]

The baseline for Metrics 2a and 2b will be [*****]
Metric 3 [*****]
Performance Baseline Detail
[*****][*****]
[*****][*****]
[*****][*****]

The baseline period for Metric 1 will be [*****]
Metric 4 [*****]
Performance Baseline value = [*****]
Metric 5 [*****]
Performance Baseline value = [*****]

4.Operating Metric Scorecard Performance
An Operating Metric Scorecard will be generated at the end of each Measurement Period summarizing Supplier’s overall Provider Operating Metrics performance for the Measurement Period for each Provider Incentive Group, including the Provider Performance Score, Quarterly Aggregate Lift, YTD Aggregate Lift, YTD Lift Percentage, and YTD Cash.

5.Timing of Calculation
The Operating Metrics Scorecard for the Provider Incentive Group will be calculated at the end of each Measurement Period. The calculation will be based on the [*****] of the applicable Measurement Period for each Provider Incentive Group, and will [*****] on the first day of each subsequent Fiscal Year [*****]. The Provider Operating Metrics will be measured quarterly, on a cumulative basis within any single Fiscal Year.

.- 38 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15



6.Calculation of Incentive Fee Payments
Supplier shall be eligible for Incentive Fee Payments as calculated pursuant to this Section 6, in accordance with the Operating Metric Scorecard performance.

Incentive Fee Earned Year-to-Date” means, with respect to a Provider Incentive Group for any Measurement Period, an amount equal to the product of:

(i)YTD Cash for such Provider Incentive Group,
multiplied by

(ii)     [*****]

multiplied by

(iii)     the applicable Provider Performance Score for such Provider Incentive Group in such Measurement Period.

Incentive Fee Earned In Period” means, with respect to a Provider Incentive Group for any Measurement Period, an amount equal to the result of:

(i)The Incentive Fee Earned Year-to-Date for such Provider Incentive Group,
less

(ii)The Incentive Fee Earned Year-to-Date for such Provider Incentive Group as of the end of the prior Measurement Period within the same Fiscal Year.
Incentive Fee Payment” means, with respect to a Provider Incentive Group for any Measurement Period, an amount equal to the result of:

(i)The lesser of:
a.The sum of all Incentive Fees Earned In Period for the applicable Measurement Period for such Provider Incentive Group and all previous Measurement Periods within the applicable Fiscal Year
and

b.[*****] for such Provider Incentive Group for such Measurement Period
less
(ii)The sum of all Incentive Fee Payments for such Provider Incentive Group for all previous Measurement Periods within the applicable Fiscal Year.
For the avoidance of doubt a schedule detailing a sample of this calculation has been included in Appendix C to Exhibit 3 to the AMG Supplement and a range of scenarios for the calculation of Provider Performance Scores has been included in Appendix F to Exhibit 3 to the AMG Supplement.

7.Review and Invoicing Process
Step 1:     Operating Metric Scorecards will be provided and distributed by Supplier to Ascension for each Provider Incentive Group in accordance with Section 2.1
.- 39 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


above by the 15th calendar day of the month following the end of each Measurement Period.

Step 2:    Ascension and Supplier will have [*****] days from the delivery of the Operating Metric Scorecards to review such Operating Metric Scorecards for the Provider Incentive Groups, perform audits of Applicable Platform data as appropriate, and work to reach agreement on the Operating Metrics Scorecards for the Measurement Period. In the event that a potential error is identified in an Operating Metrics Scorecard which error may, as determined by either Party, have a material impact on the measurement of the Operating Metrics Scorecard performance for the Measurement Period, the Parties will work to identify the range of impact of the potential error and shall establish a mutually agreed upon plan to review and resolve such potential error, which error will be resolved effective retroactively as the date that the error impacted the applicable measurement. Absent exceptional circumstances, the Parties will work to resolve all such issues within [*****] of discovery of such issue.

Step 3:    Supplier will invoice Ascension for each Incentive Fee Payment no later than [*****] days following the end of the Measurement Period for which the Provider Incentive Fees accrued. The invoice shall not include amounts associated with unresolved potential errors identified in Step 2 above. If any Incentive Fee Payment amount is negative for any particular Measurement Period, then such amount shall be held as a credit against Provider Incentive Fees owed in future Measurement Periods.

Step 4:    Incentive Fee Payments shall be jointly reviewed quarterly by Ascension and Supplier promptly following the delivery of Operating Metric Scorecard results by Supplier to Ascension. To the extent that neither Party delivers written notice of objection to such results within [*****] days following such delivery to Ascension, the performance results and the resulting Incentive Fee Payments shall be final and binding on the Parties.

8.Adjustments to Measurement Metrics
When appropriate, Ascension and Supplier can mutually agree to a Prospective Adjustment (i.e., an adjustment to the calculation of one or more metrics) when market events or actions outside of either Party’s control compromise the ability to accurately compare Actual Performance to Performance Baselines. Any such adjustments shall only take effect on a prospective basis from and after the Measurement Period during which the Parties agree to such adjustments. The Parties agree that a Prospective Adjustments may take into account any prior Measurement Periods affected by such Prospective Adjustment beginning as of the date either Party provides an Adjustment Request and any Measurement Periods thereafter. For the avoidance of doubt, a Prospective Adjustment may affect any Measurement Period during and after the Adjustment Request is made but not any Measurement Periods prior to the Adjustment Request.

The Parties will work in good faith during the twelve (12) months prior to the following effective
dates to discuss any [*****]
[*****]
[*****]

9.Governance Principles
9.1.Code Mapping.
.- 40 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


a.Ascension will be responsible for mapping the transaction codes and planning codes within the Applicable Platforms to the applicable figures in the Provider Operating Metrics, and shall provide Supplier with sufficient time to review, discuss and concur with such mapping of transaction codes and planning codes before they are implemented.

b.     If Supplier does not agree to any mapping of any transaction code or planning code proposed by Ascension, then the Parties shall seek to resolve the dispute in good faith. However, if the Parties are unable to resolve the dispute, then the issue will be escalated to the Cost Board for resolution.

9.2.    Notification. Supplier agrees to promptly notify Ascension of any proposed changes in the processes or technology under their management that are reasonably likely to impact any of the revenue cycle operating metrics including but not limited to the use of transaction codes or management of accounts receivables. Ascension will have sufficient time to review and discuss the proposed changes before they are implemented and, if requested by Ascension, Supplier will provide an account sampling to ensure that any such proposed changes will be accurate.
9.3.     Records. Supplier and Ascension will maintain a reconciled record of the key assumptions used to derive targets and/or make decisions to support development and management of the Operating Metrics Scorecard.
9.4.    Supplier Access. Ascension shall provide to Supplier access to the Applicable Platform databases to review, reconcile and validate the data used to populate the Operating Metrics Scorecard. Supplier will have the right to audit the Applicable Platform database. In the event the Supplier’s auditor requires information regarding or from the database or access to the database in connection with its audit related to Supplier’s financial or operating controls, Ascension shall reasonably cooperate with Supplier to secure that information for Supplier’s auditors. Any data or database deficiencies will be addressed by Ascension (on behalf of the applicable Eligible Medical Group) in a timely manner.
9.5.    Windfall Situations and Changes in the Environment. In the event that there is a Force Majeure Event, a material change in the environment in which the Eligible Medical Groups are operating their revenue cycles, or a material change in the laws and regulations that apply to Ascension, Supplier, or an individual Eligible Medical Group which significantly impacts the economics of one or more of the Parties or frustrates the ability of a Party to perform its obligations hereunder, through no fault of its own, the applicable Party shall have the right to request that the other Party consider a fair and appropriate adjustment to the Operating Metrics Scorecard. Upon such request, Supplier and Ascension will discuss the impact associated with the change in circumstance, with the outcome to equitably reflect the impact on the Operating Metrics Scorecard. Examples of material matters that could affect one or more metrics on the Operating Metrics Scorecard performance include, but are not limited to, the following:
Payor bankruptcies.
A pattern of services to patients for whom a Eligible Medical Group is not certified by a payor to bill for such services and thus not entitled to reimbursement.
Changes in Self-Pay Discounts and/or changes in Charity Policy.
Material growth or decline in self pay population or patient residual balance after insurance.
Changes in accounts receivable write-off policies or Medicaid Pending aging policies
Implementation of new systems outside the control of Supplier (e.g., new patient accounting system).
Regulatory changes, including changes to the ICD nomenclature (e.g., ICD-11) or changes to the status of Medicaid Expansion in a given state.
.- 41 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15
EX-31.1 3 exhibit311-q32022.htm EX-31.1 Document

Exhibit 31.1


Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted
pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 
I, Joseph Flanagan, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of R1 RCM Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: November 8, 2022
/s/ Joseph Flanagan    
Joseph Flanagan
Chief Executive Officer
(Principal Executive Officer)


EX-31.2 4 exhibit312-q32022.htm EX-31.2 Document

Exhibit 31.2


 
Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted
pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 
I, Rachel Wilson, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of R1 RCM Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: November 8, 2022
/s/ Rachel Wilson
Rachel Wilson
Chief Financial Officer and Treasurer
(Principal Financial Officer)


EX-32.1 5 exhibit321-q32022.htm EX-32.1 Document

Exhibit 32.1

 
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 
In connection with the Quarterly Report on Form 10-Q of R1 RCM Inc. (the “Company”) for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), the undersigned, Joseph Flanagan, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 8, 2022
/s/ Joseph Flanagan        
Joseph Flanagan
Chief Executive Officer
(Principal Executive Officer)




EX-32.2 6 exhibit322-q32022.htm EX-32.2 Document

Exhibit 32.2

 
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 
In connection with the Quarterly Report on Form 10-Q of R1 RCM Inc. (the “Company”) for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), the undersigned, Rachel Wilson, Chief Financial Officer and Treasurer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 8, 2022
/s/ Rachel Wilson    
Rachel Wilson
Chief Financial Officer and Treasurer
(Principal Financial Officer)


 





EX-101.SCH 7 ah-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Business Description and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Goodwill link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Accounts Receivable and Allowance for Credit Losses link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Other Expenses link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Segments and Customer Concentrations link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Supplemental Financial Information link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Business Description and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Accounts Receivable and Allowance for Credit Losses (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Other Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Earnings (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Segments and Customer Concentrations (Tables) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Supplemental Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Business Description and Basis of Presentation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Acquisitions - Fair Value Total Consideration Paid (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Acquisitions - Schedule of Intangible Assets Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Acquisitions - Pro Forma Results (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Intangible Assets - Components of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Intangible Assets - Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Revenue Recognition - Schedule of Disaggregated Revenue by Source (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Revenue Recognition - Changes to Contract Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Revenue Recognition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Accounts Receivable and Allowance for Credit Losses - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Accounts Receivable and Allowance for Credit Losses - Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Leases - Schedule of Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Leases - Schedule of Operating and Finance Lease Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Leases - Schedule of Operating and Finance Lease Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Debt - Carrying Amounts of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Debt - Carrying Amounts of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Debt - Scheduled Maturities of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Derivative Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Derivative Financial Instruments- Schedule Of Derivative Instruments as Hedged on Consolidated Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Share-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Share-Based Compensation - Compensation Expense Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Share-Based Compensation - Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Share-Based Compensation - Other Than Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - Other Expenses - Schedule of Other Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - Earnings (Loss) Per Share - Computation of Basic and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - Earnings (Loss) Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - Related Party Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - Segments and Customer Concentrations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - Segments and Customer Concentrations - Concentration Risk by Customer (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - Supplemental Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 ah-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 ah-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 ah-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total Lessee, Operating Lease, Liability, to be Paid Increase in allowance Provision (recoveries) Accounts Receivable, Credit Loss Expense (Reversal) Related Party Transactions [Abstract] Related Party Transactions [Abstract] Non-current deferred tax assets Deferred Income Tax Assets, Net Long-term debt Total Long-Term Debt, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Facility-exit charges Business Exit Costs 2024 Long-Term Debt, Maturity, Year Two Customer liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Customer Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Customer Liabilities Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Non-Options Awards Activity Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block] Credit agreement, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee [Abstract] Variable rate basis, minimum (not less than) Debt Instrument, Variable Rate Basis, Minimum Percentage Debt Instrument, Variable Rate Basis, Minimum Percentage Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Additional paid-in capital Additional Paid in Capital Ascension and its affiliates Ascension [Member] Ascension [Member] Basis spread on variable rate basis Debt Instrument, Basis Spread on Variable Rate Statistical Measurement [Domain] Statistical Measurement [Domain] Exercise of vested stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Interest rate Debt Instrument, Interest Rate, Stated Percentage Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Conversion of preferred shares Stock Issued During Period, Value, Conversion of Convertible Securities Intermountain Intermountain [Member] Intermountain Schedule of Fair Value of Total Consideration Paid and Schedule of Acquisitions During 2021 Schedule of Business Acquisitions, by Acquisition [Table Text Block] Other Other Noncash Income (Expense) Accounts receivable, gross Accounts Receivable, before Allowance for Credit Loss Property, equipment and software, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Term A Loans Senior Secured Term Loan A [Member] Senior Secured Term Loan A Acquisition of treasury stock related to share-based compensation plans Treasury Stock, Value, Acquired, Cost Method Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive common share equivalents (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Scheduled Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Federal Funds Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, to be Paid [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Leases Lessee, Operating Leases [Text Block] Related Party [Domain] Related Party [Domain] Treasury stock, at cost, 21,664,566 shares as of September 30, 2022; 20,094,686 shares as of December 31, 2021 Treasury Stock, Common, Value Contract assets Total contract assets Balance as of June 30, 2022 Balance as of September 30, 2022 Contract with Customer, Asset, after Allowance for Credit Loss Hedging Designation [Domain] Hedging Designation [Domain] Supplemental disclosures of cash flow information Supplemental Cash Flow Information [Abstract] Canceled/forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Derivative Instrument [Axis] Derivative Instrument [Axis] Number of operating segments Number of Operating Segments Remainder of 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Incentive fees Incentive fees Incentive Fees [Member] Incentive Fees [Member] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Award Type [Axis] Award Type [Axis] Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities Current portion of operating lease liabilities Operating Lease, Liability, Current Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Net sales Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Amounts billed Contract With Customer, Asset, Amounts Billed Contract With Customer, Asset, Amounts Billed Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Canceled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Receivables [Abstract] Receivables [Abstract] Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Legal Entity [Axis] Legal Entity [Axis] Long-term debt Total long-term debt Long-Term Debt, Excluding Current Maturities Accounts Receivable and Allowance for Credit Losses Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Number of deferred payments Payments To Acquire Businesses, Number Of Payments Payments To Acquire Businesses, Number Of Payments Revenue Recognition and Deferred Revenue [Abstract] Total liabilities Liabilities Proceeds from disposal of assets Proceeds from Sale of Productive Assets Performance factor adjustment (in dollars per share) Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Mandatory prepayments, percentage of net cash proceeds of debt incurrence Debt Instrument, Mandatory Prepayments, Percent Of Net Cash Proceeds Of Debt Debt Instrument, Mandatory Prepayments, Percent Of Net Cash Proceeds Of Debt Percentage of business acquired Business Acquisition, Percentage of Voting Interests Acquired Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Issuance of common stock Stock Issued During Period, Value, New Issues Technology Technology-Based Intangible Assets [Member] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Senior Revolver Revolving Credit Facility [Member] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Document Type Document Type Global business services center expansion project in the Philippines Facility Costs, Included In Acquisition Evaluation And Integration Costs Facility Costs, Included In Acquisition Evaluation And Integration Costs Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] SOFR Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Severance and related employee benefits Severance Costs Outstanding and unvested at beginning of period (in dollars per share) Outstanding and unvested at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Debt Debt Disclosure [Text Block] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Other Other Restructuring Costs Concentration Risk [Table] Concentration Risk [Table] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Acquisition, aggregate number of shares of common stock issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Accounts receivable, net of $0.1 million and $0.1 million allowance - related party as of September 30, 2022 and December 31, 2021, respectively Accounts Receivable, Related Parties, Current Non-current Contract With Customer, Liability, Including Related Party, Noncurrent Contract With Customer, Liability, Including Related Party, Noncurrent Issuance of common stock related to inducement Shares Issued During Period, Value, Inducement Shares Issued During Period, Value, Inducement Unrealized gains (losses) reported in accumulated other comprehensive loss Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 2025 Long-Term Debt, Maturity, Year Three Related Party Affiliated Entity [Member] Revenue Revenue Benchmark [Member] Subsequent Event Subsequent Event [Member] Schedule of Contract Assets and Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Less dividends on preferred shares Less dividends on preferred shares Temporary Equity, Dividends, Adjustment Summary Depreciation and Amortization Expense Schedule Of Depreciation And Amortization [Table Text Block] Schedule Of Depreciation And Amortization [Table Text Block] Total assets Assets Write-offs Accounts Receivable, Allowance for Credit Loss, Writeoff Debt Disclosure [Abstract] Debt Disclosure [Abstract] Net income (loss) per common share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] VisitPay VisitPay Inc. [Member] VisitPay Inc. Antidilutive Securities [Axis] Antidilutive Securities [Axis] PBRSUs Performance Shares [Member] Number of years since new country entry Number Of Years Since New Country Entry Number Of Years Since New Country Entry Interest rate swaps Interest Rate Swap [Member] Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Current portion of long-term debt Less: Current maturities Long-Term Debt, Current Maturities Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Gross Carrying Value Finite-Lived Intangible Assets Acquired Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accrued compensation and benefits Employee-related Liabilities, Current Line of Credit Line of Credit [Member] Income (loss) before income tax provision (benefit) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Deferred income taxes Deferred Income Taxes and Tax Credits Earnings (Loss) Per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Add: Effect of dilutive warrants (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Related Party Transaction [Line Items] Related Party Transaction [Line Items] Award Type [Domain] Award Type [Domain] Class of warrant or right, number of securities called by warrants or rights (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Interest Rate Option - Basis Spread Two Interest Rate Option - Basis Spread Two [Member] Interest Rate Option - Basis Spread Two Nonvested award, cost not yet recognized, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Cash consideration Payments to Acquire Businesses, Gross Derivative Contract [Domain] Derivative Contract [Domain] Entity Registrant Name Entity Registrant Name Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues Change in foreign currency rates Goodwill, Foreign Currency Translation Gain (Loss) Net loss Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax Customer Relationships Customer relationships Customer Relationships [Member] Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Leases [Abstract] Deferred tax assets related to operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Replacement awards issued to Cloudmed equity award holders Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Replacement Equity Awards Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Replacement Equity Awards Intermountain Healthcare Customer Not Affiliated with Ascension Health [Member] Customer Not Affiliated with Ascension Health [Member] Minimum Minimum [Member] Interest Rate Option [Axis] Interest Rate Option [Axis] Interest Rate Option Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Emerging Growth Company Entity Emerging Growth Company Other Income And Expenses [Table] Other Income And Expenses [Table] Other Income And Expenses [Table] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Inducement of preferred stock conversion Payments for Repurchase of Convertible Preferred Stock Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Debt covenant, secured obligation pledged, capital stock of certain domestic subsidiaries, percent Debt Instrument, Covenant, Secured Obligation Pledged, Equity Certain Domestic Subsidiaries, Percent Debt Instrument, Covenant, Secured Obligation Pledged, Equity Certain Domestic Subsidiaries, Percent Treasury Stock Treasury Stock, Common [Member] Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Operating lease liabilities Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation Trading Symbol Trading Symbol Entity File Number Entity File Number Intangible Assets Intangible Assets Disclosure [Text Block] Treasury stock, shares (in shares) Beginning Balance (in shares) Ending Balance (in shares) Treasury Stock, Common, Shares Non-current portion of customer liabilities Contract with Customer, Liability, Noncurrent 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period RSUs Restricted Stock Units (RSUs) [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Payments to acquire business, number of payments, refund period, if circumstances met Payments To Acquire Business, Number Of Payments, Refund Period, If Circumstances Met Payments To Acquire Business, Number Of Payments, Refund Period, If Circumstances Met Acquisitions Business Combination Disclosure [Text Block] Accounts payable Increase (Decrease) in Accounts Payable Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Concentration percentage Concentration Risk, Percentage Schedule of Other Expenses Schedule of Other Operating Cost and Expense, by Component [Table Text Block] Income Taxes Income Tax Disclosure [Text Block] Net services revenue, from related parties Revenue from Related Parties Credit Facility [Domain] Credit Facility [Domain] Interest Rate Option - Basis Spread One Interest Rate Option - Basis Spread One [Member] Interest Rate Option - Basis Spread One Intangible asset amortization expense Amortization of Intangible Assets Warrant exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Schedule of Changes in Carrying Value of Goodwill Schedule of Goodwill [Table Text Block] Cloudmed and VisitPay Acquisitions Cloudmed And VisitPay Acquisitions [Member] Cloudmed And VisitPay Acquisitions Basic (in dollars per share) Net income (loss) per common share (basic) (in dollars per share) Earnings Per Share, Basic 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Operating lease right-of-use assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Asset Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Asset Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Cloudmed Cloudmed Acquisition [Member] Cloudmed Acquisition Deferred payment related to acquisition of RevWorks Payments to acquire business Payments To Acquire Businesses, Gross, Financing Activities Payments To Acquire Businesses, Gross, Financing Activities Total stockholders’ equity Beginning Balance Ending Balance Stockholders' Equity Attributable to Parent Schedule of Transaction Price Allocated to the Remaining Performance Obligation Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] TCP-ASC Recapitalization Litigation TCP-ASC Recapitalization Litigation [Member] TCP-ASC Recapitalization Litigation Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Entity Interactive Data Current Entity Interactive Data Current Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three 2027 Long-Term Debt, Maturity, Year Five Accumulated Deficit Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Litigation Status [Domain] Litigation Status [Domain] Total lease cost Lease, Cost Other Income And Expenses [Line Items] Other Income And Expenses [Line Items] Other Income And Expenses [Line Items] Common Stock Common Stock [Member] Schedule of Share-based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Modular and other Modular And Other [Member] Modular And Other Number of reporting segments Number of Reportable Segments Schedule of Components of Lease Costs and Supplemental Cash Flow Information Lease, Cost [Table Text Block] Purchase of treasury stock Payments for Repurchase of Common Stock (Gain)/loss on disposal and right-of-use asset write-downs Gain (Loss) On Disposition Of Assets And Right-Of-Use Asset Write-Downs Gain (Loss) On Disposition Of Assets And Right-Of-Use Asset Write-Downs Thereafter Long-Term Debt, Maturity, after Year Five Statement [Table] Statement [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Document Quarterly Report Document Quarterly Report Letters of Credit Letter of Credit [Member] Current assets: Assets, Current [Abstract] Non-current portion of operating lease liabilities Operating Lease, Liability, Noncurrent Strategic initiatives Acquisition Evaluation And Integration Costs Acquisition Evaluation And Integration Costs Statistical Measurement [Axis] Statistical Measurement [Axis] Acquisition of treasury stock related to share-based compensation plans (in shares) Treasury Stock, Shares, Acquired Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Payment of contingent consideration liability Payment for Contingent Consideration Liability, Financing Activities Current portion of contract assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Contract With Customer Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Contract With Customer Accumulated deficit Retained Earnings (Accumulated Deficit) Non-current portion of contract assets Non-current Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent Contract assets Contract with Customer, Asset, after Allowance for Credit Loss, Classified [Abstract] Accounts receivable, net of $14.5 million and $2.4 million allowance as of September 30, 2022 and December 31, 2021, respectively Accounts Receivable, after Allowance for Credit Loss, Current Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Equity Components [Axis] Equity Components [Axis] Non-current portion of contract assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Assets, Contract With Customer Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Assets, Contract With Customer Litigation Case [Domain] Litigation Case [Domain] Outstanding, vested and exercisable at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Related Party Transactions Related Party Transactions Disclosure [Text Block] Debt covenant, number of offers to extend maturity date, if circumstances met (or more) Debt Instrument, Covenant, Minimum Number Of Offers To Extend Maturity Date, If Circumstances Met Debt Instrument, Covenant, Minimum Number Of Offers To Extend Maturity Date, If Circumstances Met Schedule of Pro Forma Results Business Acquisition, Pro Forma Information [Table Text Block] Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Net interest expense Interest Income (Expense), Nonoperating, Net Document Fiscal Year Focus Document Fiscal Year Focus Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Repurchases of common stock (in shares) Treasury Stock, Excluding Related To Share-Based Compensation, Shares, Acquired Treasury Stock, Excluding Related To Share-Based Compensation, Shares, Acquired Outstanding and unvested at beginning of period (in shares) Outstanding and unvested at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Variable Rate [Domain] Variable Rate [Domain] Gross Carrying Value Finite-Lived Intangible Assets, Gross Selling, general and administrative Selling, General and Administrative Expense Loss Contingencies [Table] Loss Contingencies [Table] Goodwill Goodwill Disclosure [Text Block] Warrant market value price (in dollars per share) Class of Warrant or Right, Market Price of Warrants or Rights Class of Warrant or Right, Market Price of Warrants or Rights Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Third Party Third Party [Member] Third Party Document Transition Report Document Transition Report Local Phone Number Local Phone Number Schedule of Stock Options Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Income from operations Operating Income (Loss) Financing Receivable, Allowance for Credit Loss [Line Items] Financing Receivable, Allowance for Credit Loss [Line Items] Derivative, fair value, net Derivative, Fair Value, Net Recently Issued Accounting Standards and Disclosures New Accounting Pronouncements, Policy [Policy Text Block] Litigation Status [Axis] Litigation Status [Axis] Mandatory prepayments, percentage of non-ordinary course asset sales or other dispositions Debt Instrument, Mandatory Prepayments, Percent Of Cash Proceeds Of Non Ordinary Course Assets Sales Or Other Dispositions Debt Instrument, Mandatory Prepayments, Percent Of Cash Proceeds Of Non Ordinary Course Assets Sales Or Other Dispositions Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Goodwill Goodwill Balance as of December 31, 2021 Balance as of September 30, 2022 Goodwill Interest Rate Option [Domain] Interest Rate Option [Domain] Interest Rate Option [Domain] Adjustments to reconcile net income (loss) to net cash (used in) provided by operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income tax provision (benefit) Income Tax Expense (Benefit) Debt issuance costs incurred Debt Issuance Costs, Line of Credit Arrangements, Gross Non-current deferred tax liabilities Deferred Income Tax Liabilities, Net 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Hedging Relationship [Axis] Hedging Relationship [Axis] Additional Paid-In Capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Lease liabilities Increase (Decrease) In Lease Liabilities Increase (Decrease) In Lease Liabilities Basic: Basic EPS: Earnings Per Share, Basic [Abstract] Cost of services Cost of Goods and Services Sold TCP-ASC TCP-ASC ACHI Series LLLP [Member] TCP-ASC ACHI Series LLLP Derivative [Line Items] Derivative [Line Items] Diluted (in shares) Diluted weighted average common shares (in shares) Weighted Average Number of Shares Outstanding, Diluted Derivative liability Derivative Liability Debt issuance costs, capitalized Debt Issuance Costs, Line of Credit Arrangements, Net Loss Contingencies [Line Items] Loss Contingencies [Line Items] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable Accounts Receivable [Member] Term B Loan Senior Secured Term Loan B [Member] Senior Secured Term Loan B Common stock, $0.01 par value, 750,000,000 shares authorized, 439,386,709 shares issued and 417,722,143 shares outstanding at September 30, 2022; 500,000,000 shares authorized, 298,320,928 shares issued and 278,226,242 shares outstanding at December 31, 2021 Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Integration costs Business Combination, Integration Related Costs Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Non-cash lease expense Lease Expense, Noncash Lease Expense, Noncash Gains (losses) to be reclassified within next 12 months Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Net operating fees Net operating fees Net Operating Fees [Member] Net Operating Fees [Member] Cash, cash equivalents and restricted cash, at beginning of period Cash, cash equivalents and restricted cash, at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Existing Term A Loan Existing Senior Secured Term Loan A [Member] Existing Senior Secured Term Loan A Provision for credit losses Accounts Receivable, Credit Loss Expense (Reversal), Net Of Write-Offs Accounts Receivable, Credit Loss Expense (Reversal), Net Of Write-Offs Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Foreign Currency Hedges Foreign currency forward contracts Foreign Exchange Forward [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Exercise of vested stock options Proceeds from Stock Options Exercised Net income (loss) available/allocated to common shareholders - basic Net Income (Loss) Available to Common Stockholders, Basic Common stock, shares issued (in shares) Beginning Balance (in shares) Ending Balance (in shares) Common Stock, Shares, Issued Concentration Risk [Line Items] Concentration Risk [Line Items] Current portion of customer liabilities Contract with Customer, Liability, Current Property, equipment and software purchases not paid Capital Expenditures Incurred but Not yet Paid Business acquisition costs Business Combination, Acquisition Related Costs Income Statement Location [Domain] Income Statement Location [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Amendment Flag Amendment Flag Useful Life Finite-Lived Intangible Asset, Useful Life Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating lease cost Operating Lease, Cost Number of complaints filed Loss Contingency, New Claims Filed, Number Issuance of senior secured debt, net of discount and issuance costs and Borrowings on revolver Proceeds from Long-Term Lines of Credit Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Cloudmed Acquisition Goodwill, Acquired During Period Net services revenue Business Acquisition, Pro Forma Revenue Entity Current Reporting Status Entity Current Reporting Status Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Deferred income tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Repurchases of common stock Treasury Stock, Excluding Related To Share-Based Compensation, Value, Acquired, Cost Method Treasury Stock, Excluding Related To Share-Based Compensation, Value, Acquired, Cost Method Other assets Other Assets, Noncurrent Net change on derivatives designated as cash flow hedges, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Revenue recognized Contract With Customer, Asset, Revenue Recognized Contract With Customer, Asset, Revenue Recognized Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities Outstanding, vested and exercisable at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Depreciation and amortization Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Federal statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Non-current portion of deferred contract costs Capitalized Contract Cost, Net, Noncurrent Operating expenses: Operating Costs and Expenses [Abstract] Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Fair Value of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Management Units Management Units [Member] Management Units Derivative [Table] Derivative [Table] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Incremental Term A Loan Incremental Senior Secured Term Loan A [Member] Incremental Senior Secured Term Loan A Unamortized discount and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net CoyCo 2 CoyCo 2 [Member] CoyCo 2 Maximum exercisable (in shares) Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Maximum Exercisable Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Maximum Exercisable Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rate changes in cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Operating cash flows for operating leases Operating Lease, Payments Asset, contingently returnable consideration Business Combination, Contingent Consideration, Asset, Noncurrent Schedule of Estimated Annual Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of Intangible Assets Identified with Acquisition Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Other Expenses Other Income and Other Expense Disclosure [Text Block] Contract liabilities Contract with Customer, Liability [Abstract] Accounts receivable, allowance Accounts Receivable, Allowance for Credit Loss, Current Exercise of vested stock options Stock Issued During Period, Value, Stock Options Exercised Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Total debt Long-Term Debt Balance Sheet Location [Axis] Balance Sheet Location [Axis] Number of shares vesting if targets conditions met, potential percentage Share-Based Compensation Arrangement, By Share-Based Payment Award, Equity Instruments Other Than Options, Number Of Shares Vesting, If Target Conditions Met, Percentage Share Based Compensation Arrangement, By Share Based Payment Award, Equity Instruments Other Than Options, Number Of Shares Vesting, If Conditions Met, Percentage Exercise of warrants pursuant to cashless provisions Stock Issued During The Period, Value, Warrants Exercised Stock Issued During The Period, Value, Warrants Exercised Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Maximum Maximum [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Current portion of customer liabilities - related party Contract With Customer, Liability, Related Party, Current Contract With Customer, Liability, Related Party, Current Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Lock-up period Business Combination, Lock-Up Period Business Combination, Lock-Up Period Customer liabilities and customer liabilities - related party Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current Designated as Hedging Instrument Designated as Hedging Instrument [Member] Senior Term Loan Senior Term Loan [Member] Senior Term Loan Accumulated gain, net of tax, recognized in other comprehensive loss Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Revenue recognized Contract with Customer, Liability, Revenue Recognized Business Acquisition [Line Items] Business Acquisition [Line Items] Smaller Reporting Company Entity Small Business Net change on derivatives designated as cash flow hedges, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Net Book Value Finite-Lived Intangible Assets, Net Second A&R Credit Agreement Second A&R Credit Agreement [Member] Second A&R Credit Agreement Investor Investor [Member] Revenue expected to be recognized in the future related to unsatisfied performance obligations, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Schedule of Customer Concentration, Net Services Revenue Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Less: Less, Operating [Abstract] Less, Operating [Abstract] Related tax benefits Share-Based Payment Arrangement, Expense, Tax Benefit Sublease income Sublease Income Title of 12(b) Security Title of 12(b) Security Contract With Customer, Liability, Including Advanced Billings Contract With Customer, Liability, Including Advanced Billings [Member] Contract With Customer, Liability, Including Advanced Billings Business Description and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Replacement awards issued to Cloudmed equity award holders, shares (in shares) Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Replacement Equity Awards, Shares Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Replacement Equity Awards, Shares Total operating expenses Costs and Expenses Mandatory prepayments, percentage of annual excess cash flow Debt Instrument, Mandatory Prepayments, Percent Of Annual Excess Cash Flow Debt Instrument, Mandatory Prepayments, Percent Of Annual Excess Cash Flow Derivative asset, noncurrent Derivative Asset, Noncurrent Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Total contract liabilities Contract With Customer, Liability, Including Related Party Contract With Customer, Liability, Including Related Party Issuance of common stock related to share-based compensation plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Payment of debt issuance costs Payments of Debt Issuance Costs Present value of lease liabilities Operating Lease, Liability Non-current portion of customer liabilities - related party Contract With Customer, Liability, Related Party, Noncurrent Contract With Customer, Liability, Related Party, Noncurrent Segments and Customer Concentrations Segment Reporting Disclosure [Text Block] Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expenses [Member] Income tax benefit Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Financing Receivable, Allowance for Credit Loss [Table] Financing Receivable, Allowance for Credit Loss [Table] Derivatives, net gain (loss) reclassified Derivative, Gain (Loss) on Derivative, Net 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Liabilities Liabilities and Equity [Abstract] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Remainder of 2022 Long-Term Debt, Maturity, Remainder of Fiscal Year Weighted average shares used in calculating net income (loss) per common share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Accounts payable Accounts Payable, Current Consolidated statements of comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Number of units converted in Transaction Agreement (in shares) Share-based Compensation Arrangement By Share-based Payment Award, Number Of Units Converted In Transaction Agreement Share-based Compensation Arrangement By Share-based Payment Award, Number Of Units Converted In Transaction Agreement Hedging Relationship [Domain] Hedging Relationship [Domain] 2026 Long-Term Debt, Maturity, Year Four Hedging Designation [Axis] Hedging Designation [Axis] Warrant Warrant [Member] Entity Filter Category Entity Filer Category Physician Customer Physician Customer [Member] Physician Customer Basic (in shares) Basic weighted-average common shares (in shares) Weighted Average Number of Shares Outstanding, Basic Replacement awards issued in conjunction with acquisitions Adjustments To Additional Paid In Capital, Replacement Awards Allocated To Purchase Price Adjustments To Additional Paid In Capital, Replacement Awards Allocated To Purchase Price Net loss, before income taxes Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Potential business combination, expected purchase price Potential Business Combination, Price Of Acquisition, Expected Potential Business Combination, Price Of Acquisition, Expected Accounting Standards Update 2021-08 Accounting Standards Update 2021-08 [Member] Share-based compensation expense Total share-based compensation expense Share-Based Payment Arrangement, Expense Security Exchange Name Security Exchange Name Outstanding at beginning of period (in dollars per share) Outstanding at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Total depreciation and amortization Depreciation, Depletion, And Amortization, Excluding Intangible Assets Depreciation, Depletion, And Amortization, Excluding Intangible Assets Notional amount Derivative, Notional Amount Issuance of common stock related to inducement (in shares) Shares Issued During Period, Shares, Inducement Shares Issued During Period, Shares, Inducement Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Schedule of Carrying Values Long-Term Debt Schedule of Debt [Table Text Block] Net services revenue ($218.1 million and $657.8 million for the three and nine months ended September 30, 2022, respectively, and $227.5 million and $661.4 million for the three and nine months ended September 30, 2021, respectively, from related party) Net services revenue Revenue from Contract with Customer, Excluding Assessed Tax Conversion of preferred shares (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Current portion of customer liabilities Contract With Customer, Liability, Current, Excluding Advanced Billings Contract With Customer, Liability, Current, Excluding Advanced Billings Stock consideration transferred to the Sellers Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Cover page. Cover [Abstract] Pending Litigation Pending Litigation [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Other Contract With Customer, Asset, Other Contract With Customer, Asset, Other Share-Based Compensation Share-Based Payment Arrangement [Text Block] Allowance for credit loss Beginning balance Ending balance Accounts Receivable, Allowance for Credit Loss Customer employee transition and restructuring expenses Severance Costs, Transitioned Employees Severance Costs, Transitioned Employees Revenue Recognition Revenue from Contract with Customer [Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Contract assets Increase (Decrease) in Contract with Customer, Asset Favorable leasehold interests Leases, Acquired-in-Place, Market Adjustment [Member] Derivative asset, current Derivative Asset, Current Shares withheld for taxes Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders’ equity Liabilities and Equity Debt maturity Debt Instrument, Term Amortization of debt issuance costs Amortization of Debt Issuance Costs Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Goodwill [Roll Forward] Goodwill [Roll Forward] Related Party [Axis] Related Party [Axis] Statute of limitations minimum Statute Of Limitations Minimum Statute Of Limitations Minimum Repayment of senior secured debt and Repayments on revolver Repayments of Long-Term Lines of Credit Add: Effect of dilutive equity awards (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Accounts receivable and related party accounts receivable Increase (Decrease) in Receivables Diluted: Diluted EPS: Earnings Per Share, Diluted [Abstract] Performance factor adjustment (in shares) Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Gross deferred tax assets Deferred Tax Assets, Gross Acquisition of Cloudmed, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Other Other [Member] Other Current Fiscal Year End Date Current Fiscal Year End Date Cloudmed Cloudmed [Member] Cloudmed Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Net income (loss) available/allocated to common shareholders - diluted Net Income (Loss) Available to Common Stockholders, Diluted Diluted (in dollars per share) Net income (loss) per common share (diluted) (in dollars per share) Earnings Per Share, Diluted Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Payment of equity issuance costs Payments of Stock Issuance Costs ASC 326 Accounting Standards Update 2016-13 [Member] Share-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Property, equipment and software Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Property, Plant, Equipment And Software Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Property, Plant, Equipment And Software 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Customer Concentration Risk Customer Concentration Risk [Member] Other expenses Total other expenses Other General Expense Current Contract With Customer, Liability, Including Related Party, Current Contract With Customer, Liability, Including Related Party, Current Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount Revenue, Remaining Performance Obligation, Amount Commitment fee Line of Credit Facility, Commitment Fee Percentage Schedule of Allowance for Credit Losses Accounts Receivable, Allowance for Credit Loss [Table Text Block] Schedule of Operating Lease Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Other Proceeds from (Payments for) Other Financing Activities Contract liabilities Revenue recognized, advanced billings Contract with Customer, Liability Product and Service [Axis] Product and Service [Axis] Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Non-current portion of customer liabilities Contract With Customer, Liability, Noncurrent, Excluding Advanced Billings Contract With Customer, Liability, Noncurrent, Excluding Advanced Billings Borrowing availability Line of Credit Facility, Remaining Borrowing Capacity Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Tradename Trade Names [Member] Credit Facility [Axis] Credit Facility [Axis] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Allocation of consideration to assets acquired and liabilities assumed: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract] Entity Tax Identification Number Entity Tax Identification Number RSUs and PBRSUs Restricted Stock Units (RSUs) And Performance Shares [Member] Restricted Stock Units (RSUs) And Performance Shares Statute of limitations maximum Statute Of Limitations Maximum Statute Of Limitations Maximum Exercise of warrants pursuant to cashless provisions (in shares) Stock Issued During The Period, Shares, Warrants Exercised Stock Issued During The Period, Shares, Warrants Exercised Schedule of Disaggregated Revenue By Source Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Remainder of 2022 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Current portion of contract assets Current Contract with Customer, Asset, after Allowance for Credit Loss, Current Shares surrendered for taxes (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Accrued compensation and benefits Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Compensation And Benefits Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Compensation And Benefits Former Class P Units Former Class P Units [Member] Former Class P Units Weighted- Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Cost of shares surrendered for taxes Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Total purchase consideration Total consideration Business Combination, Consideration Transferred Other accrued expenses Other Accrued Liabilities, Current Entity [Domain] Entity [Domain] Type of Adoption [Domain] Accounting Standards Update [Domain] City Area Code City Area Code Assets Assets [Abstract] COVID-19 related costs, included in Other COVID-19 Pandemic Costs, Included in Other Restructuring Costs COVID-19 Pandemic Costs, Included in Other Restructuring Costs Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Contract with Customer, Asset [Roll Forward] Contract with Customer, Asset [Roll Forward] Contract with Customer, Asset 2023 Long-Term Debt, Maturity, Year One Share-based compensation Share-Based Payment Arrangement, Noncash Expense Variable Rate [Axis] Variable Rate [Axis] Other non-current liabilities Other Liabilities, Noncurrent Other liabilities Increase (Decrease) in Other Operating Liabilities Purchases of property, equipment, and software Payments to Acquire Property, Plant, and Equipment Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] RevWorks RevWorks Acquisition [Member] RevWorks Acquisition 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Schedule of Basic and Diluted Net Income (Loss) Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Right-of-use assets obtained in exchange for operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Cost of services Cost of services Cost of Sales [Member] Inducement dividend Inducement Dividends Inducement Dividends Customer [Domain] Customer [Domain] EX-101.PRE 11 ah-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 image_2a.jpg begin 644 image_2a.jpg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

5\HH'Q< MTIN8#I* ^;_6P9:A!3'#"V6TU.YTG98UWD_FE'.7"9IFF*HD,_-D?;M*J]CJ MP2+!5"7/SBW%3E1>0/9AQ(QA,6,J#8KR0MKWV6$N- /.*-W!7,!4&KAW'$QE M#7Y8+H[EQ8V!F8AEM(#\H=!T]$1K7)1&1^.?"F8WINJ#G=BP2#!5'VS&9B^>,!+7,"TBU&:PU MKJ,"9C>FZH.=V+!(,%4?;,9F)RHO(/LP8L:PF#&5TQ;,!4SEM 5S 5,YBE#+ M0@$Y.8[S>?Z]#^_"V8$G[@*\"V<"_.0^'&7X!WX2C!C;D [\)1 M@AMS =Z%,P+)/O\-Y*3T(Q"M<1T5,+LQ51_LQ(9%@JGZ8#,V.U'Y;R#[,&+& ML)@QE=,6S 5,Y;0%FZH.=V+!(,%4?;,9F)RHO(/LP8L:PF#&50?C?-!\*S 5,Y;0%/U2^5OU\ RN?%\^;NCN5D_@7V:L27*-=I_*1 I\ M)LXJN-W7P%0EWZ>*-%G B<-I%5L]6"28JN39N:78BBE#+Q )R6X7"@?[K.SUK6D*F5H0\B=DK M):3/K[2RI0%C'TF:JMJ\JT9,M3-8?/-S\G&7Y-/-H+PF*0A/PLTYE=N-!=9J MN4-\C$DN,OI.OX(N+9_[H@85#^<>9EOSFX>4R3N?=1IQ5C-!TPQ3RK MLUO&5@<6"::2>6YN*7:B\@*R#R-F#(L94VDP'P;2ODG/"?G&)QPJK(.Y@*E4 M6'VCG@@G''K$<>^L\V!/1:AE8@$9WCYYW,6X,BYV6\5!')G!"U MTD!R2$<(K;)HSWSO%6<]V#3#5#N$S#9Y#=B-#-S+[-,DN1+W)K4>*^\6!&[:L14-8-YI->AXZ;9)5V1 M:SJ?TA00)P'Y( XDAK0ASA8A??36GN^?C/-#3- TPU0[+-GD M^89I&EL56"28:H?'YI9B)RHO(/LP8L:PF#&5!MN&M6YR9/\J-O.T7?;8XAJ MN8"IM B'EVB'?,)9SC?-=I,^8"Y@*FL\U5,1:IGX&\@-=I2__.YK6U$BK''I M5KSB4OZY)34S^"W]]NXB9%Q:#VWS32YR:"*D!KF'ZZ<\>[NNAGE?;D6\R?I! M'$@,Z9BRU6Y\&RIQ5H--,TPELJ2-)J^2AK%5@D6"J40>G%N*G:B\@.S#B!G# M8L94&J0-ZQV.'^G?!,IWR[=TJ+ .Y@*FTF+GI%(2]I-1C/L/=0%36>.IGHI0 MRRX7D,MBM9.5_^:VQ9%$?6YK-__7E[(!)=]UXJP% MFV:82B+F04HI1+O8:L$BP5023\XMQ4Y47D#V8<2,83%C*@W(AA5VM'@>S;?S M;%M+.Y]Q,!KA3(#H1+@#TL) MZW-6Q1OT8>HN+H^LJT9,V PFKSM!OYF.X[*\9V7.0OB/RJQ-R)9!=>0Z!48* M)Q)?_$0SRG/\>KV(.K;(>BH'V@OIF#3JW,^%6:<39QT3-,TP50E/"#!?"UK% M5@\6":8J>79N*7:B\@*R#R-F#(L94VF0;5CSKE?N>7Q7"\UZ['*U8"Y@*BW8 M :<\X10WQF""7,!4UGBJIR(3L8P6D#\4FHZ>:(WKJ(#9C:GZ8"; ML=F)R@O(/HR8,2QF3&6'/S5_ \L,F N8RFD+Y@*F.(NP+MPQN&[@.1V7H#WXCP4;OP%>!>.$MR8 M"_ N'"6X,1?@73@CD.SSWT!.2C\"T1K740&S&U/UP4YL6"28J@\V8[,3E?\& ML@\C9@R+&5,Y;<%FZH.=V+!(,%4? M;,9F)RHO(/LP8L:PF#&5TQ;,!4SEM 5S 5,YBE#+O(!4F\%:XSHJ8'9CJC[8 MB0V+!%/UP69L=J+R K(/(V8,BQE3.6W!7,!43ELP%S"5HPBUS M(M1FL-:ZC M F8WINJ#G=BP2#!5'VS&9B8"T,/(,KWY>/&[J[U=.W /&I)LDU M6A'6X??.=_&=,N'J1%#61%BC/87;?0U,U8?*V#*OP;F\@D6"J?I@,[;*J!HZ M/F(!29>7ZPN=+KH9P\!BOJP*UFWPO6MW_[B]N=<0Z\=X0HDGNKIOW1GU&^AE M%S(P57]&7 &N@[F J>SP;$]%J&6L@%S>'LH#2>3[=5NM"#B#_WR]EM>%LO5? M,6[(_NMT>:<_6_SL9K#QX9]F9GL.F,J*1'SX[0C8-,-4?:B.C1YTJES (L%4 M?; 96W54S1P?L8 DRUOMZW=#.6,06,R7563+2#;.5^_=S>3:YMZ(%&!YHJO8 M*KMPV84,3*7 @"O =3 7,)4A'NVI"+5,+""W)>C[_UY?Z>=J(5,K0I[$[)42 MTN=76LS2@+&/)$UK8-Y5(Z;:&2R^^3GYN$ORZ?I>7I,4A"?AYIS*[<8":[7< M(3[&)!<9?:V]10JZB#"?0BIOEYB@ M:8:I^M @MMG\_7/75;!(,%4?;,;6(*I&C@]90,;%CB[MY4*7+55WEYG&J&<, M (OYLHKN$M1(MG]0RLV=[4W\X\594=Y9I)LDC;C=#'?XF2'?6,6AQ9OEZ/G0 M$3DI(M-5%S(PE0K#K0#7P5S 5*9XL*S_RGO25BTRM-[=4IMOK9-X:%#DOXZ6* M2.:$J)4&DD,Z(764WEBR>_\MI-;E%")T?+L(-LTP51]:Q!9,JE]/L4@P51]L MQM8BJC:.#UI SNO&ZW6\=-%[VNAG[#Y8S)=5.[M$_B1C,S09R_8FOE5=FQ7E MG8"X,<8!I"TL/"PEM(5T4QI=3H!\5^:R"QF82H?15H#K8"Y@*EL\UU,1:IG\ M[T#R)6:YWIXNO,AOQ-CBEWY)E"GF9MEJLB:5+F7L8D7LJA%3U0SFD5Z'CIMF MEW25[P3B--VN\VG*\SMS]"E- 7$2D _B0&)(&^)L";S7;3@)1+OWXZ8C[4ZA M_S[[=J=,T#3#5'UH$=OB-#?J+E@DF*H/-F-K$54;QT ME$;?&9S'>,!TU84,3*7%6"O =3 7,)4UGNJI"+5,_ WD!EM9+K_[VE:4Y#?G M(=.M>,6E_'-+:F;P6_KMW47(N'2MW>:;N-9GB9 :Y!ZNG_+L[;H:YOTF%CS) M/X@#B2&=LV21M!?MWG\+.M+1%!+Z[_!V*]@TPU1]J(]M\80Z@X%%@JGZ8#.V M^JA:.3YN ;FSXI2$)!4U2F\L9.PN6,R7572'R>V1W7R7FSMKR'7\,Z6<%=F= M7%IN4M(61C7BT.+-E9W1:6Z.Y)S++F1@*BVR?!PEI_3:-)@+F,H:3_54A%IV MN8!<3_GT<<9WVV)EDB0LN:')KWA'7H"V=KRK1J S.(18$U,:-TM\?/,\&6L+ MFCYI,Z")$GI:;Z=^Z0N0C^3=LD;D@S20'-(YH6GVWQB0[-Y[BWRD/&LD +VW M6\"F&:;J0W5L,)#(+M[VDW)LRGV_/BNT.BV"_(;W.1.+0XLU$[#3;?.G^>:3.N.Q"!J;2 M8JP5X#J8"YC*&D_U5(1:=KV 7%:"2)F!=_I)6WQ82O@B&U3Q!GV8NHN+$^NJ M$1,V@\GK3M!OIN.X+.]I-XE#A'_'?6VRIB%\DC8#JJ(E$(DO?J(9Y3G^KN?H M!K"UR'HJ!]H+Z92YJZQU:??.6_R7CW0PA=3>;F:"IAFFZD-E;#S;P%=H XL$ M4_7!9FR5435T_"D%I+#0%3V-[&/ MY20H;@AWBKE5;E+2%L940K_"S>+&VHJF9GN:=MM3IJLN9& J+;A+12J+&V,P M02Y@*FL\U5.1B5A&"\@?"DU'3[3&=53 [,94?; 3&Q8)INJ#S=CL1#5N 3D6 M(V8,BQE3F>(/^:? !@5S 5,Y;<%0/9AQ(QA,6,JIRV8"YC*:0OF J9R%*&6A0)R M0W,X+\%Z0/9AQ(QA,6,J@_"_:3X4F N8RFD+Y@*FXOITRJV>K!(,%7)LW-+L1.5%Y!]&#%C6,R82H-Y M(TX;)UMQ\BT]M!UIC\5>;-=X!)@+F,H.S_94A%K&"LCE[:$\D$2^ M7[?5BH S^,_7:WE=*%O_9>.21?^LJ&IT0%VY7$"2EZSZ>\67!WPC4] M,7P8S 5,I4 Z1C7;*>R N8"I#/%H3T6H96(!N:U"H53X"K\<6](2,K4BY$G, M7BDA?7ZEE2T-&/M(TE35YETU8JJ=P>*;GT/&I>]-]H/BE=_Q=\1[.:&69?8E M*RI"+1,+R/#VX2K\/WU]FA[AI+0DJ%B_%C8)[9,.N#U-5R\FL96!18)IMKAL;FEV(G*"\@^C)@Q+&9,I<&ZVVZ; M[O[F*[4P#N8"IM(A6/1Z)9LD^P8RC("Y@*EL\5Q/1:AE\K\#*9S:EP,2X3L; M\1[-S-S++),D^1*W)C7>*R]6Q*X:,57-8![I=2@V8);1 MT)*]J3Q 9[EI&.Z7VQ#X%B:O#.RU[D$;.FZ4/>__:)WBTC M& QLFF$JD<40:DLE#6.K!(L$4XD\.+<4.U%Y =F'$3.&Q8RI-,@*0_IO N7[ M\')@C31:F#X,Y@*FTF+G#%02]I-1C/L/=0%36>.IGHI0RRX7D&>UTA_RGU8A M!4 A8G>N:=Q'4STC M[$9IW-?\V^>D/(F$C)C)Q-'3T98QT+D' M.IGHI0RZX7D'&U6B@S$&H,_K"4\)(EJ.(-^C!U%Y='UE4C)FP&D]>= MH-],DW'I>Y-KZ96+?2%OL--3UO;U>I$1KD:>]+/BPMS8&S$VR?I(^:13(+YK M,3E'8X*F&:8JX:F^ZOH1K6*K!XL$4Y4\.[<4.U%Y =F'$3.&Q8RI-"B/ .5N MRO?+T&R$_1-S 5-IP0]=Q=FIN#$&$^0"IK+&4ST5F8AEM(#\H=!T]$1K7$<% MS&Y,U0<[L6&18*H^V(S-3E1>0/9AQ(QA,6,J._RI^>M:9L!FZH.=V+!(,%4?;,9F)RHO(/LP8L:PF#&5&9Y1/X(N M8"JG+9@+F,I1A%KF!:3:#-8:UU$!LQM3]<%.;%@DF*H/-F.S$Y47D'T8,6-8 MS)C*:0OF J9RVH*Y@*D<1:AEH8"<',?Y//_>AW?A[, 3=P'>A3,.WP4DM_," MO!?GH7#C+\"[<)3@QER =^$HP8VY ._"&8%DG_\&0'9AQ$SAL6,J9RV8"Y@*J0?1@Q8UC,F,II"^8"IG+:@KF MJ1Q%J&5>0*K-8*UQ'14PNS%5'^S$AD6"J?I@,S8[47D!V8<1,X;%C*FA/"D4]O'A]]P!K8> 97/F^ M9-SO!7_MZKRS=53(H8*+.PWS)81[;?Q,2"*O,;I&JPBQ^P:8J@^5L66SZ-O4 M:S-*!(L$4_7!9FR5435T?,0"DBYS M9D\REF99XWS7XQ\OSHKRSB+=)&G$[6:X,V_/1)-OV>+0XLUR]'SHB)P4D>FJ M"QF82H7A5H#K8"Y@*E,\V%,1:IE80(:W#U?A_\6U4EXIEP21!Y*$]DD'W!ZN MS[80-J2N&D'3@8"&0\;-%][U4GYETT8_8_?!8KZLVME_\B<9FZ')6+;K\4WPVJPH[P3$+3<.(&V.X6$IH2VD MF]+H<@+DNS*772+S'+]?9TX3L;\1Y; M_-*OGS+%W"Q;3=:DTJ6,7:R(735BJIK!/-+KD'')Z]&)EUXW/AIX+UNEC<"R#])WRHA "G.K%7ZD'\GMT_TKJ%O[01-,TS5AQ:Q M+7.(3X&[8)%@JC[8C*U%5&T<'[6 7):WDT5^60%K4]0$"QF["Q;S917QC.TM MPF862)O0=L4:87VEK72[)VV.5"(.+=Z41M\9G,=XP'35A0Q,I<58 M*\!U,!ZJD(M4S\#>0&6UDNO_O:5I3D-^.9DD-MBSC'1,[XM][+"\*YDDHCB_23_1Z75DM-!_UBI]R"?L M]HG>+::T'M@TPU1]J(]M<9MZCH%%@JGZ8#.V^JA:.3YN ;FSEI6$)!4U2F\L M9.PN6,R7573ORNV1W:2%U&HH:\AU_#.EG!79G5Q:;G_2YD@UXM#BS96=T6EN MCN2E%Y5)#(+MUVJW/7NG';*6;'=81'L-Z37F4@<6KR9 MB)UFVSK=F8_4&9==R,!46HRU EP'.IGHI0RZX7D,M*$"DS\$X_:8L/ M2PE?9(,JWJ /4W=Q<6)=-6+"9C!YW0GZS309E[XW6WHCZRMG)I4-=GK*VGY7 M@62$&Y'/KYRE_CB PE Z+_:,WHM3'B&)Q7&**:W'!$TS3-6'RMBXCS+ M!%/UP69LE5$U=/PI!:2PA!8W-)D,9.PN6,R75>(6FYT&J&EL!PKFSI_9KG=Z MVBEN"'>*N55N?]+FR%1"O\+-XL;:BJ9F>YKV\5.FJRYD8"HMN$M%*HL;8S!! M+F J:SS54Y&)6$8+R!\*34=/M,9U5,#LQE1]L!,;%@FFZH/-V.Q$-6X!.18C M9@R+&5.9X@_YI\ &!7,!4SEMP5S 5(XBU#(O(-5FL-:XC@J8W9BJ#W9BPR+! M5'VP&9N=J+R [,.(&<-BQE26>$#]"+J J9RV8"Y@*D<1:ID7D&HS6&M<1P7, M;DS5!SNQ89%@JC[8C,U.5%Y ]F'$C&$Q8RJG+9@+F,II"^8"IG(4H9:% G)R M'.?S_'L?WH6S T_A:,$-^8" MO MG!))]_AO(2>E'(%KC.@-A>9+8B0V+!%/UP69L=J+RWT#V8<2,83%C*J:WSN@><)P6\O3[4G".RJ]W>XWO_GCD+;J5.>UY M9^/D1NTTL\B$3LX.5,86IDZOQNZ M&L1RYGZW_LG&%91TJARV84, M3*7 @"O =3 7,)4A'NVI"+5,+""W)2@GQSSI M9CEZ/G1$3HK(=-6%#$REPG KP'4P%S"5*1[LJ0BU3"P@P]N'J_#_XEHIKY1+ M@L@#24+[I -N#]=G6P@;4E>-H.E 0,,AXY*IM75%>TW7,0TD'VS5)M1V[*(<&G#7D7$8*(9"]6M.1S0.YCYS7*A^+-LWF5!5,\I0TNO<+9< 6U MD_.3M(@M)*A^/<4BP51]L!E;BZC:.#YH 3E_Z5^O],67%@1Z3QO]C-T'B_FR M*M\]Z!*^MZ)OAB9CV;YP99LH9T5Y)T"#H'MY#$' ZF N8RA;/]52$6B;_.Y!\B5FNMZ<+W]F(]]CBMW8@2?+59$TJ M787"SWZW5L2!2D9=8/W3V$KK)K>IN;$AM+F1=> M?R<>;+_4K:&+8KUI#KKLZ*\L[N'KG=$S:I3"(.+=Z41M\9G,=XP'35A0Q,I<58 M*\!U,!ZJD(M4S\#>0&6UDNO_O:5I3D-^;L=5'U6FY^P M264:<6CQYLK.Z#0W1W+.91[ M6?EO;ENL3)*$)3Y*[DIAS [V:V3[8ID<*=EGI8DE3N1HIESLO6R_M>=\@@+A=CY?N+N MO((TW"'HY.Q!=6PQ&[?3PL BP51]L!E;=53-'']( 7F6![JFJ& A8W?!8KZL MVM\]I.TGMW#;#]B^<'.;*&<%V6^H<+\AO1U)^@WTV3BJN"::S)1#N)WY+3JCTG5R M\O5ZI1<36K(Y( 2<=2)%L]Q=FZX/LV;2O!(ZS[L6&EQ[!7&X R9L;L55&U=#QIQ20PH)0W-!D,I"QNV Q7U:Q76BY%G;P!;HK M_+>8.W]F^\+I-E'<$.X40/9AQ(QA,6,J2SR@ M?@1=P%1.6S 7,)6C"+7,"TBU&:PUKC,0EB>)G=BP2#!5'VS&9BA3,"R3[_#>2D]",0K7$=%3"[,54? M[,2&18*I^F S-CM1^6\@^S!BQK"8,973%LP%3.6T!7,!4SF*4,N\@%2;P5KC M.BI@=F.J/MB)#8L$4_7!9FQVHO("L@\C9@R+&5,Y;<%FZH.=V+!(,%4?;,9F)RHO(/LP8L:PF#&5TQ;,!4SEM 5S M 5,YBE#+O(!4F\%:XSHJ8'9CJC[8B0V+!%/UP69L=J+R K(/(V8,BQE3.6W! M7,!43ELP%S"5HPBUS M(M1FL-:ZC F8WINJ#G=BP2#!5'VS&9B?+8"Y@*FJS_Y%^>_> ]D?+UKO MK>,CW(UY0F=P9:AD7)K\M;.[;W&=TYYW=JG*UP6AP9Q&;AEB]PTP51\J8PN3 M/G[UZ_[T*!8)INJ#S=@JHVKH^(@%)%V^LE081C=C&%C,F*H:8>M/]_ENE^_, M84/F+48' ZF N8R@[/]E2$6L9_ [E3/'P$X0A!W'B_^,,/ <[@ M/U^O)5)TUI!Q>V;]'"D:\I)_NOZ]8BF8(<&F&:;J0W5LT=O:GPQ@D6"J/MB, MK3JJ9HZ/6$"21;3V];NAG#$(+&9,50W9W]*DF*_>QVP 3-,TP51\:Q+9S M4KH+%@FFZH/-V!I$U%L WG M-Y;&F:36+!<+Y<+66?'4YKA>"U%)7@ONT.'/LD)'9!W MK@\VS3!5'UK$MLS\6K>P2#!5'VS&UB*J-HX/6D#.B]7KE98T:=&SM'SI9^P^ M6,R8JII\3Z.[+-]T\\_;)$F3)7RQR+QA'R_.M/).7S 7,)4.HZT U\%*ZG(M2R.P7D=I6O>7-6EE,!(LRC7;N*]\F)%[*I^ M!H=NLW$N0L;ED>:W:)[(]9RCE;6IT++LFB>/=W(F69 ]%0+8OTF&_&_7'3KT M24[$ 2R\,7525[TBK51 M#PL9NPL6,Z:JALP MF>Q33?_F+:X[>JP^?695M[IR@2Y@*FT&&L%N [F J:R MQE,]%:&6M2L@#S*3'^@OGO/7+L6>A<4TW8I77,H_K]3/X.,7V8.,*T0F))E> MASFZW4Q-A99EUUFFA$X$B?"&LJ=" #LW%T($Z_=+&'5M$6]?R,F"U)$VV#3# M5'VHCVV9@'0:8F"18*H^V(RM/JI6CH];0&;KW,ZB-T/61CTL9.PN6,R8JIHX M XKO1#XW\D]O\G/?=9*PJ<1G%O],*6=:>:<3F N82HNQ5H#K8"Y@*FL\U5,1 M:EFC C)<[.8L>QH2N*:OK$K^D/\^"ZE)BIY9E*')KW@G/21CQ7:\*W@&I__( MC]SM*61<8<9)22;7Y'%XR_5ZI^7>QB1W(D4S[UCI?<.5Z&F>^S0WBJ@(1T;G MP1SGY$_7_[C/;;!IAJGZ4!U;=%RV_CI8))BJ#S9CJXZJF>,/*2#/\B LEWVQ MD+&[8#%CJFKR/8W.A6RB%+,F38MM]V4;/?O(>^>4,ZV\TP',!4RE1>'E/5_, M@KF J:SQ5$]%J&6M"LBU8M@H\O../S)+W4MY3.W2L[)G%N6LBC?HP]3=TEO9 M%3Z#>=]W(>/R]\EOT3REZ_0JK]=FC=R2!4H'DSJ1HEGNKDU)7.P.O1G^*T=+ M $)4D@_R71;M44[(W#G\_NHP0=,,4_6A,K9LFKV/E]P3L$@P51]LQE8954/' MGU) "HM><4.3R4#&[H+%C*FJ$?$.YV9 M(!A3,"R3[_#>2D]",0K7$=%3"[,54? M[,2&18*I^F S-CM1^6\@^S!BQK"8,973%LP%3.6T!7,!4SF*4,N\@%2;P5KC M.BI@=F.J/MB)#8L$4_7!9FQVHO("L@\C9@R+&5,Y;<%FZH.=V+!(,%4?;,9F)RHO(/LP8L:PF#&5TQ;,!4SEM 5S M 5,YBE#+O(!4F\%:XSHJ8'9CJC[8B0V+!%/UP69L=J+R K(/(V8,BQE3.6W! M7,!43ELP%S"5HPBUS M(M1FL-:ZC F8WINJ#G=BP2#!5'VS&9B[&/-7,X#EMMX:+D''C2Z?W_NXX=GO\1N3I]Z7P!Z.H_'JW%Y#GS-X?9*QW M=F@F:)IAJI)@2;1"GB:W:15;/5@DF*KDV;FEV(G*"\@^C)@Q+&9,]3'H'DHW MS+T#!U]WSC9WWMX(F N8JC_L)&;2 1S,!4QEAV=[*D(MX[^!I 7&IQ'6L*P8 MX@\_1,T,?K]^?7V]L(R1<85,0$8(_3!VNMVY?8U<'+Y$V3=J"4G#65-@TPQ3 M2427SHX6EVD76RU8))A*XLFYI=B)R@O(/HR8,2QF3/4QR*::%I7YZBWNU>=; M?\[=]IW 7,!4"J0*H]E.80?,!4QEB$=[*D(M.RD@LV4LU$K3S.L]5P83_5G8 M=B>[&2%/8[*SSPNB!67/WW=>7\N/XK[20K@&2U\A29=&95,A7 M(.,*JSE[B^V:O !YI^31M.0E>\&=KN)UY@T)A;8](FO''0R=AP[Y_1_'!$TS M3"5S;+K3K(UZ]RA:/50[KF:][VF"9=[CF,2^):GI.'Z[,4WH+4%3Z#OWM8EV#V MMAD>N4!J&K[#KO(\_G*:Q/9BH-.7?V9X%-,TRU M0S"GX>+5-+8JL$@PU0Z/S2W%3E1>0/9AQ(QA,6.JCY'OR'37E/=E?IB23P7L M)%'NUMI@+F J'8(%KU>R4#J4#I6F3O! MCOR#W%5V36_S?,;&-&D4UB=KP=XM.?O#P*89IMIA\;!9\IO&5@46":;:X;&Y MI=B)R@O(/HR8,2QF3/4QR&&%[;AL8U[A1XB=4P$]0)1=ZX.Y@*FT"*F/B2<^ M$[<7=P2;+8.Y@*FL\51/1:AE[0K(@\SDBQM=PPX6L+5+L>?\YMQ/NA6ON)1_ M7H%FL#Q';D'&%3)!@\W>;1TOO8E@1_Y![BJ[SE+#\GD*%Y\E7;CU R!VWP!3 MB82YT_2'S@UCJP2+!%.)/#BW%#M1>0'9AQ$SAL6,J3Y&W"2+147>/OD18N=4 MD!V^PK_MTFB]:@7F J;2(C-0=G,A6(^<+)7 7,!4UGBJIR+4LD8%9%$WY)"G M9#WD:][\L%CJI)Y9E*')KW@G/>1KK]15_0SN^!M(FI](;@?YAU6V/L6N\NL\ MH7D^3RG$Z65"%/,SR=F?!3;-,)5$G/SRMP"@76RU8)%@*HDGYY9B)RHO(/LP M8L:PF#'5Q\AW=;JHL,//"M]4Z*JZ))LOG*=P-&F7F]D;A^D]@@J89IBK)/#I9 MWZ[2*K9ZL$@P5)06MP8@PER 5-9XZF>BDS$,EY _D!H.GH"C$NV CYC MFV)K4WD&@-W_H:H^V(D-BP13]<%F;':B\@*R#R-F#(L94SEMP5S 5$Y;,!

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

NH@-F-J?I@)S8L$DS5!YNQV8G*"\@^C)@Q+&9,Y;0%Q #[W9 M2>"Y4,MH 4E>?_W3IHU.0S#I"U7&=LK5X-$9_'[5?;O)N'3AF(O)2X%WX/0G M8J<-K@-8'&D8QJ? IAFFDH@IJB[S-]K%5@L6"::2>')N*7:B\@*R#R-F#(L9 M4VD0%IE?Z:2:GW.*&N3UNG@.,@'F J;2P+WC8"I#I'-KL]W?.-0R4D *KQ_F M\-?VVS$RZ2.;()SXYX;AQEP";2PJ\M4(==?7UL76IR#)5$)LF2A]RV)TY,MW M//H$SN /%9#_96\KO6.Z%V[1-2A>T]=\O3=!&H-TNY\9-G;I.P\N>PW^4!R" M(%A[Y9Q%@GY0^>G^/H?9X*F&::2F3/\;E=JMXRM#BP23"7S MW-Q2[$3E!60?1LP8%C.FTF#>U-)V2?<[=I)8'F4-C(.Y@*DT<.\XF,H4JY_4 M*^F$^4['V6$\%:&6I0*2%3$SX977F]+C=#/D:WL<\T@22M12GY*$BJ3!T[>0 M7*>;LX-K7\>CHS,XS8\,R4 M@:WL-,CS7$0N#[%2W,A)CTDGJ6>JEA(2WEUL<#)L0[!IAJEV"%EHN'@UC:T* M+!),M<-CU,:F$*O+0H^I0D5"/$EONQ?LINI@_' MHU?/X'?YN[,KD''Y^TFOLW[B3:4W"A="ZK:GRUF7D'M KXM%+;+>SAJD#U+D M.T.L%.\U(XR8"7,AS1A-8ZL"BP13[?#8W%+L M1.4%9!]&S!@6,Z;2@&UJ9+\KMNOU =]L[8*Y@*DT<.\XF,H:X: :;9)/F,M9 MMMD)01%J6?Z/L/*9NG,6+R>]?$"72HO=/@\D4FSYG?53=C-].!Z=I@.CC.X* M9-Q\\0C]S1^E=V1-Q3<*%ULCX=V++K*GV35I*OJ>]Y4^2)'O#,$;)>01LW;2 M*TFCT.?RZW\<;)IA*I$EG32IE32,K1(L$DPE\N#<4NQ$Y05D'T;,&!8SIM(@ M;7#O<%#XBA_SG>U-?O@Z]?HQ:2V8"YA* _>.@ZFLL7,.+@EGA%$,W8-:1O\C M.F'6;F_V?H6KD[-X2,9RG=\LTT.>"WU*$F:"&!N-8XN-?"%W_A%6/GKM#$Y9 MN <9-WM9\JHG[[@]6-N05SXL(&FW"2$SW-?2]SSR?*PB\?!5-8H_#LZ!I1GW[&@EN5_QF.=T]-V M1)=/_*G5Z[46*C1_X82_L=TDSZ4^2TEN2(#'1E6I:6PU_R^&920WG3X+O10,I2CHSA"$2 MA<72B$'XBF^\=4'#$!+"II/P^A]G@J89IBKAUK O%T2KV.K!(L%4)<_.+<5. M5%Y ]F'$C&$Q8RH-LJUSWLJ$/8[MKZ%9IXVN"LP%3*6!>\?!5-9@!\SRA%G< M&)B)6,;^#F0#\C+ETF&JE/P1?B?Y*6@Z>J(U[N!(E><(8'9CJC[8B0V+!%/U MP69L=J+R K(/(V8,BQE3V:'GD>ES8"Y@*CNX=\Y 4,O:%Y!9K7WQ:\$E7;]0 M6C-8:]S!\0+2"G9BPR+!5'VP&9N=J+R [,.(&<-BQE1FZ'ID^AR8"YC*#.Z= M,Q+4L@\4D*.A-8.UQG54P.S&5'VP$QL6":;J@\W8[$3E!60?1LP8%C.FV\ ._%>2C< M^ OP+APEN#$7X%TX2G!C+L"[<$8@V>>_@9R4?@2B-:ZC F8WINJ#G=BP2#!5 M'VS&9B0/9AQ(QA,6,JIRV8"YC*:0OF M J9R%*&662\@K_XIR0JT9K#6N(X*F-V8J@]V8L,BP51]L!F;G:B\@.S#B!G# M8L943ELP%S"5TQ;,!4SE*$(M8P7D^S4M+%5;L[^Y]]T15 ?2^I'%=DH*_GAT M= ;'>"Y'E,/'#?W1CIHE_SZ?2O5/AMM]#4S5A\K8PA]_C1.\;K)CD6"J/MB, MK3*JAHY[ =F'$3.&Q8RIG+9@+F JIRV8"YC*481:1@M(LK^O?]JT;I.O)]6/ M96RG7 T>G<'O5UVIQ,8-X;YHR!?CK_D=K:C]8*I_,M@TPU1]J(XM3K_:'SM@ MD6"J/MB,K3JJ9HY[ =F'$3.&Q8RIG+9@+F JIRV8"YC*481:1@I(84\/A<'7 M=STQLY4(\==34_H-5:@TYH;A1JA (HN*5"JA[OK:NMCZ%"292H@M$V5EUWHK M56/'HT_@#&Y;0"XU&*W$LN3'H4CVOUOF*X%9!]&S!@6,Z9RVH*Y@*F5Q1]2A)6&?'8\@ID_93=3!^.1Z^> MP6_I=W;GT'%36-(5^?">4T^'VT_3TI;85*2QN"'>:I?J="_O\R> 33-,U8<6 ML2WE!)]Q=\$BP51]L!E;BZC:..X%9!]&S!@6,Z9RVH*Y@*F4\F7:I5HT^HX%9!]&S!@6,Z9RVH*Y@*F.Z0I*PVD:,C<81ZY-4R>S\0 M?1@Q8UC,F,II"^8"IG+:@KF J1Q%J&7M"TCD=W-P#!>1H M:,U@K7$=%3"[,54?[,2&18*I^F S-CM1>0'9AQ$SAL6,J9RV8"Y@*J0?1@Q8UC,F,II"^8"IG+:@KF J1Q%J&5>0*K-8*UQG8&P/$GLQ(9%@JGZ M8#,V.U%Y =F'$3.&Q8RIG+9@+F JIRV8"YC*481:Y@6DV@S6&M<9",N3Q$YL M6"28J@\V8[,3E1>0?1@Q8UC,F,II"^8"IG+:@KF J1Q%J&76"\@.?RY0:P9K MC>M].#1-3Z5_T/H'XZ\UT?%H OY8A[>_E9_35X?GIP]J(PM6!OG.#C?5[!( M,%4?;,96&55#Q[V [,.(&<-BQE0:S!MQVE'8%ZERVU(&#><3"5'>CI M+MO@G@NUC!:0Y/6_+\-5W29?3_I"E;&=_'! M_!]"EM2:.@R@6,Q?KULO)+Y^WND%T,G9@^K88C9JK<4BP51]L!E;=53-'/<" ML@\C9@R+&5-I$+X[O]))-=]H:KT1B5!2 M+(_+Y%#E4?OT:EQ!WGAI3@;9NSYZ?3%?)TS@Y.Q!@]CFY+^S5"-@D6"J/OQ_ M]LXNP7$5A\)>5R\HZZG59"7SUHOI*?P#0LB.?4PDX:OO828A/G"L0X&IJMOE MTUL'5YT2CP.D#B-6#/.,J2R8MYNR;=&=Z..VY1TL!4QE063'P52N6/.D634/ MG,ME&\-D*D(C*P?(>OHNI%N6GJXW+N8=$3[I#=P?/M2(0]! M)Z<&/;S-=6I2OPKF!%/IX--;#U=]$H\#I XC5@SSC*DL6+<;85/ZO&UY!TL! M4UD0V7$PE2]2=*]7B4^*=: @/T$C^WB S#=-7K^;GV!1<;Z0*':>YINO$JGR M]N SOR!3DBAF\IVV%:M:RH"Y W'$ ME;:WCO5O[H_R5_BI'6DCG[#BD$&/KO^;?A_W_>+FZQLNGTBOA!NI+SB>R,=, M=R?G%^GA;82@>?WGJXZI-X'"!U&+%BF&=,9<&VLZR;"=EU/F]; MWL%2P%061'8<3.6-WY2JI\>I8GLZG.YO?!Z@D=6_PLIGJO24G*K33'HZ^TOY M2K'(YWM]'D@D;W7+^JYJ+&^.1Z?EP&C=G8&,VW8@^-Q>L4/(4CM^I^RBJD5, M<&?$O8:.]1?3WZ W)'1'8<617E&6UOGL^')-3MNYU-*-?+Y]VUM"I?,1 W."J73PZ>V^JUZ)QP%2AQ$KAGG&5!:4G>6=OG7](VTT MRX>4>U]O6F I8"H+(CL.IO)&%=_14U[:^D8)= \:&?U'=-*LW>ZL_:$,>=PG MC\/M3R#GI_%5DR&?"WU*$A:"Z(WZV+R1+\CV6"6.?G<&ERI<@XQ+7;4MY'6Z MZ>TW+@GYBG*GI!0+U4=M@GLCEI9OU5]*/U-+B]6F!&MS*8ZHI*0+ULO?K_0; M"-D%D?YCQ:"W2BI]]O;KGD]P=W)^D]O>9;:,YLVUY!TL!4UD0V7$PE3>:_(YVMRK> :&1U7_&8YW3 MT_:S('JGY76YZO5:_[,Q6K]W^^N1]'.ISU;2/FES;U15+LU7S?]20_L$+XP^ M03.XV$&_GT#&;6>4X'-[72J4#=!%2JO*_#Y> M_52J,[0@H?"@S\![R(P@@=S MY%8 0/Y@2\BV $2GSQ$\C)Z%L@ M5N,&)F!Q8RH=_'C#G& J'7QZ\^,J?@*IPX@5PSQCJJ O6 J8*N@+E@*F"@RA MD<4!TFP&6XT;F(#%C:ET\.,-_+B* Z0.(U8, M\XRI@KY@*6"JH"]8"I@J,(1&YOT J?"7 :UFL-6X@0E8W)A*!S_>,">82@>? MWORXB@.D#B-6#/.,J1RB\,CT/; 4,)5#(KO /S0R=H!\OZ:%91IW^[.#OQU! M7QCT"XIY^T@Q?SPZ.H.SG]..:LBX;-UXO\J[]J[;EHWR!Q6;CU;(GUS5/F;;E6 QTV>"^6>"IAFF:DFUSI7N]&7=R]M],">8JN79M:7X<14'2!U& MK!CF&5-9P'92MN+4SQ+IVBN[M#58"IC*@LB.@ZG\0!^#JR>!YT(CHP=(G<'TF(= QMT[0+9WW;84\E3>F<>IN9KKU_TSHQ^: M*Y*[/_2R)/HC>DV#3#5!(YHXL'_WWZ>;L+Y@1323RYMA0_KN( J<.(%<,\ M8RH+EITT;YSU?@UR I8"I+(CL.)C*$>5IN]ON[QP:&3E "K>? MYO#/]D,K,NDSFR =9N8+4T.J:&91D2^-=#KZV;K8^A0DE4KP5HG*5UEV1[[X MCD>?P!G\_0-D>]=M"V'KI)\[Z)^GI[1Z8$TPE\]S:4ORX MB@.D#B-6#/.,J2R8][BRF]/MCVVZRT?5!<[!4L!4%D1V'$SEBC5/FI6#!\[O M02,K!TCVO#^3;GEME#XNC:E>Y+&_>; G:JE/24)%TN#EJY"\+HUS@FM?QZ.C M,[C,A\;;*MYNQ:9%KP)8(:-2 W)S[H![G3^H M(J7K(QV7*ZLVP:#D/]UM[D3J7.CGNY"X+X"I=EBF6;?;[NKM%I@33+7#8VM+ M\>,J#I ZC%@QS#.FLF#=NJ3MN]XZI2N<@Z6 J2R([#B8RAKQ"?%.E"0 MGZ"1?3Q YILFK]_-3X:H.%](%-()@[R6)%0C>*OS6-]5C>7-\>BW9_#[Z,>" M^Y!QV?VM/X%L[[IM(:1'V#2-RUFZFK#IXWH&-]6O7[^;E&L#._FL/316ZXA8 M8,E5J_3.CI9?$=M>LG^\R0=,,4^VP%*+;+7?U=@O,":;:X;&U MI?AQ%0=('4:L&.894UG ]CBR_=6;;OF [I"^P5+ 5!9$=AQ,Y8WT-)EC\O' M^3UH9/6OL/*9NO-HWDYZ^7F]%(M\OM?G@43R5K>L[ZK&\N9X=%H.C-;=&+QC_P*Z^%=5^2/4C&E7Z=[LW-N?B_41$ZYR5EJ7KI@=[0U;_]?O?G7%&!A MQT/^[,.OL$I&&V@_WP6;9IA*9"DG+>I-.GJ[">8$4XD\N+84/Z[B *G#B!7# M/&,J"R#Q[5P ( 241!5,I^-V_A/_EMO=&]R3=?)YT][CY8"IC*@LB.@ZF\ M4<7GXX'S>]#(Z#^BDV;M=F?O5WKUX=$\%6-Y73>VY2&?"WU*$A:"Z(WZV+R1 M+\B=7V'EH]^=P:4*UR#C-C>[OA/OFK5LT$_HS1?H%?1-&;WHQ)1KH_4EQ']* MIOKG,J#I ZC%@QS#.FLH#L5_.&MVVFS2Y<=K5TG<(>=Q\L!4QE063' MP53>:/([>@S0>>#\'C2R^L]XK'-ZVGX22.^TO"Y7O5[K48?6[]W^VB']7.JS ME=2!)+@WJBJ7YJOFG\$5PP>C3] ,+G:$H]HIR+CL;LD_S]/>==NR0:KXZVB^ MCCNCA5XNJYO3/SRSGW)ME+TF_:7NN#E2>?+E1>*@!=V?:=)5DG]6T4;6-'R= M"9IFF*JEJ@<)X Z]O-T',94%]!F&;//UEE== MM%RFLLW=!$L!4UD0V7$PE3?8\V;[?-DT#,Q$(F-_![(#]9G@U,-4*_DK_$SR M6]!R:&(U;B%-ZE,!7:330_2SP.+&5#KX\88YP50Z^/3FQU4<('48L6*89TSE M!\U'IN^!I8"I_!#9!0-!(^M_@*S.VB>_++A$]0O*:@9;C?MUV#?0@ADL;DRE M@Q]OF!-,I8-/;WY!?!")3XXB>0D]&W0*SS XL94.OCQACG!5#KX].;'5?P$4H<1 M*X9YQE1!7[ 4,%70%RP%3!480B.+ Z39#+8:-S !BQM3Z>#'&^8$4^G@TYL? M5W& U&'$BF&>,570%RP%3!7T!4L!4P6&T,CB &DV@ZWS XL94.OCQACG! M5#KX].;'51P@=1BQ8IAG3!7T!4L!4P5]P5+ 5($A-+(X0)K-8*MQ Q.PN#&5 M#GZ\84XPE0X^O?EQ%0=('4:L&.894P5]P5+ 5$%?L!0P56 (CP"+&U/IX,<;Y@13Z>#3FQ]7<8#48<2*89XQE4.&WD^Q%#!5 MT!75N*'U=Q@-1A MQ(IAGC&5!?-&679(MN+4Y\=T[4B;*98"IM*'/HA6N\8CP%+ 5'YX=J8B-#)Z M@"2WO_YITTY/0S!E,6R]?>2L>70&WYTM9-SV[LZ:OT<[[GGJC0JF='/RECN- MJPXVS3"51*X;7?%NT<_;73 GF$KBR;6E^'$5!T@=1JP8YAE369 6F3_EV:/> M-^OM,7WV.K>O^@!+ 5,94!ZXNNT4?L!2P%2.>'2F(C0RXNVZ5IVW"($)3)G^6BO;>NIE;6>GI'K:]KHSMVJBBX1M=&U8]+AGB MIXAO!_,=)FB:82J9.>YWO^KT]'8/S FFDGEN;2E^7,4!4H<1*X9YQE06S!ME MV;NK?;/>_):/VHW5+U@*F,J$-3>:B?1H1)[#(COO/#A3$1I9.4!*S]WIEM=& MZ>/2F.K5' 1(0>MS0M.G)*$B:?"R@I+7I7%.<.WK>'1P!I/I@$V(/.[.W7&? M%64V.[-E@G&^VXXEP0[_W#79F1X[X$IMHA MU0N;JR)=O=T":GRRV,M@=1,'%<:0BZK./#. MYWLV*@?5*$T+O25Q6JP7R#?E@ F:9IAJAR6&;N7IZNT6F!-,M<-C:TOQXRH. MD#J,6#',,Z:R@.VP9)>L-[_R0;NU>@5+ 5-9D9ZP>.IF8K0R.I?8>6KC/0$GZK3+%CR::$4BWR^U^>!1/)6MZSOJL;RYGAT6HX+ MD)ZP0TL9M[T[R2=2^6-G[;CB$')9:=<[;JDQR4;=W+J1NJ4B0;\SD@.P:8:I M1)9L:<(WZ>CM)I@33"7RX-I2_+B* Z0.(U8,\XRI+"C;XCM]Y[K\UQO-?DCI MM#!]&2P%3&5%%=/1 TO:3T8)[A^: J;RQE,S%:&1T7]$)ZTXVYV]7^F5] 1? M/\"W/P?[*_UK+.1SH4])PD(0O5$?FS>RF$H_Z!)&!V=P&8N,>@4RKGAWW"=4 M>5(E@69<<8CYLO5E==>YY_*ZE)U^+MNHKJAON6W)KVN+K(,_?_:_=(W!IAFF MDL@1B%D@]/-V%\P)II)X<94%I!M<=YNMSV\W@ZK[;1L MV\[!4L!45C0Y'6T9[5.16[ 4,)4WGIJI"(VL_C,>ZWHT;><%\0F>7/5ZO98+ M:?W>[>] TL^E/EL).QLL+:S3HBJ7YJOF?]*B?4)G,*D#,AVJ6]^YB_7*Y7T>.OVK-G,32["UP2.F[O.TV"_"JSKN M;M<P M6;EX5?=H)7^%'Z9]"UH.3;J/VY:Q$VPSZL,7(N[T\/X=L+@QE0Y^O&%.,)4. M/KWY<14'2!U&K!CF&5/YX0O[J0%8"I@JZ N6 J8*#*&1]3] 5F?MDTL:EZ@N MAE8SN/^XO(R]^,8!\@L1?\-F/["X,94.?KQA3C"5#CZ]^7$5!T@=1JP8YAE3 MN>$+^ZD%6 J8*N@+E@*F"@RAD7WA #D:5C/8:MS !"QN3*6#'V^8$TRE@T]O M?ES% 5*'$2N&><9405^P%#!5T!,\ >\E>"@\^!/P+@(C># GX%T$1O!@3L"["$:@Q!<_@9R,O@5B M-6Y@ A8WIM+!CS?,":;2P:_+B* Z0.(U8,\XRI@KY@*6"JH"]8 M"I@J,(1&%@=(LQEL-6Y@ A8WIM+!CS?,":;2P:#'&^8$4^G@ MTYL?5W& U&'$BF&>,95#%!Z9O@>6 J9R2&07^(=&Q@Z0[]>TL$SC;G]9#_T3 M[_0+BGG[2#%_/#HV@^G?7#SOB4+&S;>6_WXC6/F#.SWXZ 3$H= -Z':/>U:= M0N*^ *;2X::W]!649\V]&80YP50Z^/1VTU7'Q., J<.(%<,\8RH+YKVX;)#L M"ZD^@Z1K1]I+L10PE061'0=3^8$^K%8;W'.AD=$#)+G]]<_2WMOD[U.^H%IO M'SEK_O8,!K]M1,;-5O-MGC6OQ;&?XT_/ -9P(+!IAJETN.TMAW[W.P:8$TRE M@T]OMUUU2SP.D#J,6#',,Z:R('WM_"E/JO7FVYQ!7J_;F[,B6 J8RH+(CH.I M'%&.)G"M$I6OLNR.?/$=CS[=G,'HV8>,6]:1K3.A\F2Q6:\B2;1W2LHS M?U@5(>M*687*$.J5+K>M5^=2T\NJFR+]MJ/S(*N*\@_GGH^L.F6"IAFFTJ&# MM_GK^@U^ 14P)YA*!Y_>.KCJE'@<('48L6*89TQEP;RQEB>B:FNN'T:6CZ2] MVRM8"IC*@LB.@ZE9)LR)/K>0)>VL:)U,1&EDY0$KGH'3+:Z/T<6E,]2+' MD^8TP4XOO$])0D72X.6KD+PNC7.":U_'H]^>KCJDW@<('48L6*89TQEP;JQ;OLKW7/K[5"ZPCE8"IC* M@LB.@ZE\D:)[O4I\4JP#!?D)&MG' V2^:?(Z/*OS6-]5C>7-\>CW9C ^+\BXI: '/O,+,B6)8B;?:5NQJJ4,2 ^$[8B9ID4N MM=!)ZT0:O;JJO*F'W=X)H_AG@J89IM*AA[>_\W&"3Y"K8$XPE0X^O?5PU2?Q M.$#J,&+%,,^8RH)MRUNW2;(#UGMM^6"831), 5-9$-EQ,)4WTB-MCFG9X@C; M4^MT?^/S (VL_A56/E.E)_54G6;2T]E?RB<="7;[/)!(WNJ6]5W56-X726;*N^$ M4?R#33-,I<-];\MV^JUZ)QP%2AQ$KAGG&5!94SP/S?\RQ MOJVWVC?Y-NUT_V?^.F I8"H+(CL.IO+&SO-K2]KZ1@ET#QH9_4=TTJS=[NS] M2J^D)W52G52,YKSR5_HW;LCG0I^2A(4@>J,^-F_D"[(]5HFCWYC!Q,-UR+C4 M5=M"7JVVJVZ)QP%2AQ$KAGG&5!:0+6_>9=O-EUW5 M[,%^P5+ 5!9$=AQ,Y8TFOZ/=;9AGUAUH9/6?\5CG]+3])%!^4B]7O5ZOY4): MOW?["XKL2-#TV4KJ0!+<&U652_-5\[_44 P?C#[!,_C#//D &;>=48+/[76I MT';[Y6PMYS!_2C\2$N2CM'X*RV=BJ;WGC*?;Z4+H"I=/#I[::KCHG' 5*'$2N&><94%E1;WKQOMKLFWQ?3 M92/LDU@*F,J"R(Z#J;Q1!TB?<:2W MH.70!!KWWF-78 <4-ZC2P8\WS FFTL&G-S^NX@"IPX@5PSQC*C]H/C)]#RP% M3.6'R"X8"!I9_P-D==8^^67!):I?4%8S&!EWF)^W!1PD;E2E@Q]OF!-,I8-/ M;WY!?! M")3XXB>0D]&W0*SS XL94.OCQACG!5#KX].;'5?P$4H<1*X9YQE1!7[ 4 M,%70%RP%3!480B.+ Z39#+8:-S !BQM3Z>#'&^8$4^G@TYL?5W& U&'$BF&> M,570%RP%3!7T!4L!4P6&T,CB &DV@ZWS XL94.OCQACG!5#KX].;'51P@ M=1BQ8IAG3!7T!4L!4P5]P5+ 5($A-+(X0)K-8*MQ Q.PN#&5#GZ\84XPE0X^ MO?EQ%0=('4:L&.894P5]P5+ 5$%?L!0P56 (C2P.D&8SV&KVW!UA[$G@&EWI!%LFX].]@EMK3>Z>[ GV-UH?U4=W&QQT( M'932?[*=IX?_RTS0-,-4.MSTEB8]G>LWI@'F!%/IT,5;QPHO=''5A3A ZC!B MQ3#/F,J">>LL&QC[PJYW[W2M_EZ'@Z6 J?1A3W3W%V178"E@*C\\.U,1&AD[ M0"YW?[4..R<.4MKWZTI_NH SN-STU7*MD'%) 7<.-WL'2!#1_-_U[]EVZ/\S M\&0;%6R:82H=;GO+$VUGTI\&Z;-7A^\(!DYXN5 MO JE[VJ5-NF*?%U;3W)Y&>+UDUK__/R4M6ZU0-?#(BU'C[HKB F;P56-D/') MN*0'LAVP>__T^OV:"T@K5-6(Y%-44D:UFTRY;F?0UWL;+5]:3Q5*,]G^EFF0 MQ,0XM5TUD6L.1FQ;=OQ_*-I-)FB:82H=.GB;I]\;^_HA8$XPE0[=O'6J\$(W M5[>) Z0.(U8,\XRI+)BWSK)QDR<&_BRR?%1=X!PL!4QEPIH;S>3<8XQ_L!0P ME2L>G*D(C4P\0*:[GU^55:J\%I:C>M4B+"5K5K2%395&*\_SQ<+VX?I9-K4B M=05!RW&)/$EX/5J9Z@>669#/ !7I MLFK16P?);>V+%;$KB F=P>F^YF\%5L4X#1F7WMP[GYUHZXG7-*UFZY"F=/VR MP /)"*KT$SRAL8Q*9!7-9&,U:"8>MRI/@';$MD6T2EZ+1;O-!$TS3*5##V]+ MBN(,N0#F!%/IT,];GPHO]'-UESA ZC!BQ3#/F,J";5M:MS&R2]5[9/F@ZT;V M5; 4,)45Z8F$/HQ-%3N/,0. I8"IO/'43$5H9.)/(.6&^MU2I*6!/]NWK%>( M%PJK7FG*K[B4O\>AY3@/'1_S0L:M.LAUWAMBYS7-A^PQZQPN_EH96X? M8]R"I8"IO/'43$5H9,<'R+EM9:W(NF0MB.M8H8C+1ZV^KOVBR@WTP])=7C!9 M5Q 3.(/)\$>S91$WCVUZ3!-9^>;7IX"5BVO_ZX>LEGQ7%QNTD MMHW=YM-,-F:LF7A5V\X$:!J$EJ7Q6M%Z,$'3#%/I<--;%?C[>,G] .8$4^G0 MQ5O'"B]T<=6%.$#J,&+%,,^8RH)JZYPW..$YBNVOZ3*^!7L$2P%36<&>=-IG ME*9A#"8H!4SEC:=F*C*1R.@!\C\*+8,">82@>?WORXB@.D#B-6#/.,J?SPC)T=2P%3!7W!4L!4@2$TLCA FLU@ MC7'I]SW6[X,\8)?Y,KQH?<#BQE0Z^/&&.<%4.OCTYL=5'"!U&+%BF&=,Y8:' M[.Q8"I@JZ N6 J8*#*&1Q0'2; 9;C1N8@,6-J73PXPUS@JET\.G-CZLX0.HP M8L4PSY@JZ N6 J8*^H*E@*D"0VADZ0 Y!4'P??YW'=Y%L ,OW EX%\$X_!X@ M>9PGX+T$#X4'?P+>16 $#^8$O(O "![,"7@7P0B4^.(GD)/1MT"LQ@U,P.+& M5#KX\88YP50Z^/3FQU7\!%*'$2N&><9405^P%#!5T!.%5[HXJH+<8#48<2*89XQE07SIEUV(/:%73\XI&N!S I8"I_/#L3$5H9.P N=S]U3KL''9(:=^O*_WI L[@*>F7>D04(_'4LXW^KQ)AS2P:8:I=+CM+5<5.Y(7,">82H=.WKI5>*&3 MJP[$ 5*'$2N&><94%J2OY3_ED:/>+IOSX^OE;SO=!TL!4QE0'O3Z+,BNP%+ M5(YX=*8B-#+Q ,D.1RMY%4K?U2IMTA7YNK:>Y/(RQ.LGM?[Y^2EKW6J!KH=% MNES4=@4Q83.XJA$R?AE7*A3IE-2;7%==,)=NYO7>RI(OK?,B[(Q;KB71_*TV MJOPZO9BOJ$;<$)U3M\10OE;8\9+DS4:IO(F305*)EOAML@M(U[.O*F_^X3R$ M=(,3-,TPE0X=O,TS\(U]_1 P)YA*AV[>.E5XH9NKV\0!4H<1*X9YQE06S)MO MV;OIOLR>19:/J@N<@Z6 J4Q8) M Z0.(U8,\XRI+%@WNVW/$_<^>F%UA7.P%#"5#2FBUZO$),4W4& $+ 5,Y8OG M9BI"(Y/_&\BU$O4]D^6H7#)3/6@O/=!:S8+Y@OSQ1KJL6O3607);^V)%[ IB M0F=PNJ_Y6X'BZ>,C>5Q^:VUC2:;ZL=GV,OW(2VA<2]+FQI,G@Z1:7F7$N=5>4%]1WM1.I9LIKR=HFF$J'7IX6Y([ MFIQGP)Q@*AWZ>>M3X85^KNX2!T@=1JP8YAE36;#M*>L^1+:;>B.KMCRVHWH% M2P%369&>+W( M**QZI2F_XE+^'H>6XSQT?,Q+&;8U-,TREPWUO2[%IR3$P M)YA*AU[>>E5XH9>K^\0!4H<1*X9YQE06E#WEG7[II?QW/_4V^";?!YT.MGY7 M8"E@*BMV'B9:TK(]2G#_T!0PE3>>FJD(C>SP +DL4$LEI&>032 7[._ZS\$D MR+-UF,U934)PW:5N;?F0.DT"0$ MQ(I<15-'L5Z6G.\$M.>D42IO8@(?5,42[4J\8*\0=-QR"](- MHM,,4^EPVUNNGAC?!3 GF$J'3MZZ57BADZL.Q %2AQ$KAGG&5!:0_67>+.7O MXU>;/=E??8.E@*FL:'(Z6IFK&'V#I8"IO/'43$5H9,<'R.4A?*$\2F\MY3F_ M6L<*15P^:O5U[1=5;J ?EN[R@LFZ@IC &4R&/YHMNU3CELY*G6D1U@]?+_FL M*#;.-3DLDA!056063?XL_9,SBT#^!V,RDG,ZSS,">82@>?WORXB@.D M#B-6#/.,J?SPM_FVZXA@*6"JH"]8"I@J,(1&%@=(LQEL->Z 8$=!3/4ML+@Q ME0Y^O&%.,)4./KWY<14'2!U&K!CF&5.YX1GG1S %3!7T!4L!4P6&T,CB &DV M@ZWS XL94.OCQACG!5#KX].;'51P@=1BQ8IAG3!7T!4L!4P5]P5+ 5($A M-+)T@)R"(/@^_[L.[R+8@1?N!+R+8!Q^#Y \SA/P7H*'PH,_ >\B,((' M16 $#^8$O(M@!$I\\1/(R>A;(%;C!B9@<6,J'?QXPYQ@*AU\>O/C*GX"J<.( M%<,\8ZJ@+U@*F"KH"Y8"I@H,H9'% =)L!EN-&YB Q8VI=/#C#7."J73PZO/C*@Z0.HQ8,,">82@>?WORXB@.D#B-6#/.,J8*^8"E@JJ O6 J8*C"$1A8'2+,9;#5N M8 (6-Z;2P8\WS FFTL&G-S^NX@"IPX@5PSQC*H?POVD^%%@*F"KH"Y8"I@H, MH9'1 ^3[-6UT^I-"N4=X1?OM =:>!)[!I5Z0Q7I<7JJ/VT"7RO!199 _J'C5 MWM7KAZ..^RR82H>;WGYG>)E6R!0K8$XPE0Y=O'6L\$(75UV( Z0.(U8,\XRI M+)@W[;)9LB_L^L$A73O2OHJE@*GTH0\YU>+\"+ 4,)4?GIVI"(V,'2"7N[]: MAYW##BGM^W6E/UW &5QN^FJY5LBXI(?M#P+OU+0K9P/J\>SYGP>;9IA*A]O> M\AR_^]T#S FFTJ&3MVX57NCDJ@-Q@-1AQ(IAGC&5!>EK^4]YY*AWY^;\^'J- MM'MC*6 J \J#7I\%V158"IC*$8_.5(1&)AX@V>%H):]"Z;M:I4VZ(E_7UI-< M7H9X_:36/S\_9:U;+=#UL$B7B]JN("9L!EI/KJ@OFTLV\ MWEM9\J5U7@1A7+H;Y=?IQ9P0[?;#H+0HK8&VI2JB,*?H<'RB#<$$33-,I4,' M;_,,?&-?/P3,":;2H9NW3A5>Z.;J-G& U&'$BF&>,94%\[Y<]FZZ9;-GD>6C MZ@+G8"E@*A/6W&@FTG-L^X#D'RP%3.6*!VIS(N' MN>#S2YKAOK_#@/+K=!49:WEY."BUUQIH6_CM9$?5<&4F"*7Q#C;-,)4./;PM M7T/-;+@(Y@13Z=#/6Y\*+_1S=9$QK4D;5Z<$E 5.>VA5+=,@Z-!62,ST+:0ZZO1R'""L9'(<5\"4^G0P]OR M97PT.<^ .<%4.O3SUJ?""_UUNF-IW@&)@33*5#+V^]*KS0R]5] MX@"IPX@5PSQC*@O*]O=.OY]3_KN?>L]]D^\Z3P=;ORNP%#"5%55,S7,2H7UD M<@V6 J;RQE,S%:&1'1X@EP4JGQ+XIUD@%^SO^L_!),@QH+F2J=,E?X1C$C<@ M=06!S6!J![-"QDUK?>F,U934)PW:5N;?A[-I '"!U&+%B MF&=,90'9_N9-6OX^?K5)TJ<5UV I8"HKFIR.5N:!GG6P%#"5-YZ:J0B-[/@ M.;>MT'/%AKB.%8JX?-3J^5$CJ7(#_;!TEQ=,UA7$!,Y@,OS1;-FE&K=T5NI, MB[!^^'K)QS:Q<:[)89&D@');^G=SEE;Q'[ Y&I0VM@;:EKH38=;5DU.:J.Z9 MH&F&J72XZ8TG#GT1+6!.,)4.7;QUK/!"%U==B .D#B-6#/.,J2RHMK]Y,Q6> MH]@>F2X;8<_$4L!45M1!"<]#3<,83% *F,H;3\U49"*1T0/D?Q1:#DVLQ@U, MP.+&5#KX\88YP50Z^/3FQU4<('48L6*89TSEA[_D]XG&!4L!4P5]P5+ 5($A M-+(X0)K-8*MQ Q.PN#&5#GZ\84XPE0X^O?EQ%0=('4:L&.894[GA&>=', 5, M%?0%2P%3!8;0R.( :3:#K<8-3,#BQE0Z^/&&.<%4.OCTYL=5'"!U&+%BF&=, M%?0%2P%3!7W!4L!4@2$TLG2 G((@^#[_NP[O(MB!%^X$O(M@''X/D#S.$_!> M@H?"@S\![R(P@@=S MY%8 0/Y@2\BV $2GSQ$\C)Z%L@5N,&)F!Q8RH=_'C# MG& J'7QZ\^,J?@*IPX@5PSQCJJ O6 J8*N@+E@*F"@RAD<4!TFP&6XT;F(#% MC:ET\.,-_+B* Z0.(U8,\XRI@KY@*6"JH"]8 M"I@J,(1&%@=(LQEL-6Y@ A8WIM+!CS?,":;2P:#3VTU7 M'1,?\0!)U[JJ%(ZQK1@&YAE3H>SM^'-[::"7M;OS\?EQ9UM/S>N_Y)'<"Y!Q? IAFFTN&VMSSM/TWZ3V!.,)4./KW==M4M\1$/ MD&1]O7O[:AA7# +SC*E0Q!U_?O6F#U/TR6H^Z='M>>>Q:T/>UE/KBSX"2$[L MGMRP%#"5 0.N .?!4L!4CGATIB(T,O$ 21:5>=5:H&L0:9.NR->U]227ER%> M/\LWWG[*RK9::%90,E#;%<0$S6!JK#V3G8&,N]-9)I%&EA,]D4<\3N87B<]-O,K[&8H&F&J73HX&U>(JI' M)@C,":;2P:>W#JXZ)3[D 3)OB73E/K=R6F%>,0#,,Z9"V=GQV2?UFSQ]A,^$ M6=1LZZ61S;_&236.*E@*F,J$X5: \V I8"I7/#A3$1J9>(!,=]\L)-OK>KF; M8D%^ MG4I>*E9$I(H\OR9WFH@X!\YD0=O:JS;J.V^#36P]7?1(?] YKVRO5_O(OGTFKYQVV%?L.IAG3(4B[OC\$_;F7S4U MZ$?2+&JW==(F]T.&ZF(C0R^;^!7"M1 MWS-9?-C:4M:@Y>E@JA\09L%\0?YX(UU6+9+K(+FM?;$B=@4Q@3.X<@",3L8E M7=&)5[HOGY!,:#SYM=18Y=A.Y"9W6FMI#IS+HITG;0OMZM!YZWHT)FB:82H= M>GA;IDXU)0 P)YA*!Y_>>KCJD_BH!\AE$?RPR OKI!4>*G85S#.F0I%V_/Q) M29[OM&4;I)\YEO4*\<*Z<1ZE-.577,K?X]!R8*1?OKQNA8Q+[U+:(0@D M!1I(?BTU5LDU*;3@FR^%H_GQIK])M'O5 M2K.MIQ;*\NF^DQFY[Z^!I8"IK#B1W8*+%> \6 J8RAM/S52$1G9X@"0+EKB\ MD,=\H6"_KY6(- #3 MVVU7W1)_R 'R4QW:E5,9#Q6["N894Z&(.S[_I-V)R39.->(L:N9.U4#W+ 5,Y8VG9BI"(SL^0"Z+UL):D?D$LK%=OC9R=1&7 MCUH]6PQG56Z@'Y;NEM[:KB F; :7T<&AR;CT+LEKZ0:KD')%TK]YLS33S\OK MW-/\#U@PPTWN+)%F#E1M.UDT#4++TDBVK\8YF4&'7Y(#,$'3#%/I<--;- MQTON!S GF$H'G]YNNNJ8^%,.D,*RV#18,CFHV%4PSY@*1=SQZ6XG[)EE,O Y M)$X:OJVS]TFQ3K=#)[HS<()2P%16\/2:[)J&,9B@%#"5-YZ:J![)A8WIM+!CS?,":;2P:FTL&/-\P)IM+!IS<_KN(GD#J,6#',,Z8*^H*E@*F" MOF I8*K $!I9'"#-9K#5N($)6-R82@<_WC GF$H'G][\N(H#I XC5@SSC*F" MOF I8*J@+U@*F"HPA$86!TBS&6PU;F "%C>FTL&/-\P)IM+!IS<_KN( J<.( M%<,\8ZJ@+U@*F"KH"Y8"I@H,H9'% =)L!EN-&YB Q8VI=/#C#7."J73PZO/C*@Z0.HQ8, 9?//NR+B_/=&*L[>:R$,_;Z/2!YMFF$J'F][2W_C, M=V?!G& J'7QZN^FJ8^(C'B#I7E:5PC&V%7!GI9^U1V MO"WO/,ZEYF;$E=)^\]D&9H)2P%3ZC+@"G =+ 5/YX=F9BM#(V %RN?NK==A9 MR$AIWZ\K_>D"SN!R=^ AEXRK=H#<2:H@#_U1%GP$FV:82H?;WO*T K^",I@3 M3*6#3V^W775+?,0#)-E7[]Z^&L85@\ \8RH4LJ.R!XDWW6OIQCN?].CF_&%7 MEA_G4NN+;O*2$[LG-RP%3&7 @"O >; 4,)4C'IVI"(U,/$"2165>M1;H&D3: MI"OR=6T]R>5EB-?/\HVWG[*RK1::%90,U'8%,4$SF!J33UV?(..R#O+;]VNN M";WII?&]W7JUUZP7GDR*?%BZ24//852M]&;%LM<#!0(3-,TPE0X=O,U+1/7( M!($YP50Z^/36P56GQ(<\0.8MD:[WOI=3\XH!8)XQ%N3#];-L:D7J"H*6XSS4#K;>DG%93?/;5+]R^^LK MTEA&OI?4A\[;':B6"0,%'&R:82H=>GA;%MJ[LP=S@JET\.FMAZL^B0]Z@)R7 MS->K?63?/O.VG-I7[#J89TR%4N^H=$^NMFB^7Y.I03^29E%I)(\J6YO<#W&2 MG@/N?5\> TL!4]DPV@IP'BP%3.6+YV8J0B.3_QO(M1+U/9/%AZTM90U:G@ZF M]K?NE^OSQQOILFJ17 ?);>V+%;$KB F36J_+ M2)'G-T+ &SL#!9P)FF:82H<>WI;Y='?F8$XPE0X^O?5PU2?Q40^0RUJ9EUCW MRZF'BET%\XRI4$CP[-&AVJ+Y4T_9GNDG1[,HD2\L\JJC2D:9NU"=AQ.4 J:R M8JP5X#Q8"IC*&T_-5(1&)OX$4FZHWRU%6AKX,M>R7B%>6#?.HY2F_(I+^7L< M6@Z,]$NEUZV0<=_U-R%SI6G)Q<;M#9!4:MZN*LU2Y_3SH[+3@0(.-LTPE0[W MO2USD,Y$#,P)IM+!I[?[KGHE/NX!LEI!W2^G'BIV%>FJD(C>SP $D/ M-M+RL@GD@OVV9L%V)>DP(RR2?W)+^9 ;D+J"N#N#42-TW+2T;S=';I0FDE^G M:YN:7$^J?KFIQ<[IM1_NMIU#P0(VS3"5#K>]Y;GT85)]!'."J73PZ>VVJVZ) M/^0 ^:D.YLNIAXI=!?.,J5#V=]1J?E1OR$."\,S4S*)F[E0->7<7G/P5GMR4 MP%+ 5%:,M0*C.P E* 5-9P=-K MLFL:QF""4L!4WGAJIB(3B8P>(/^CT')H@H[+-X9@"+"X,94.?KQA3C"5#CZ] M^7$U[@%R+$:L&.894YGPE_R$\&%@*6"JH"]8"I@J,(1&%@=(LQF,CAL'R"'! MXL94.OCQACG!5#KX].;'51P@=1BQ8IAG3&7!@\^/8 J8*N@+E@*F"@RAD<4! MTFP&6XT;F(#%C:ET\.,-1; #+]P)>!?!./P>('F<)^"]! ^%!W\"WD5@! _F M!+R+P @>S EX%\$(E/CB)Y"3T;= K,8-3,#BQE0Z^/&&.<%4.OCTYL=5_ 12 MAQ$KAGG&5$%?L!0P5= 7+ 5,%1A"(XL#I-D,MAHW, &+&U/IX,<;Y@13Z>#3 MFQ]7<8#48<2*89XQ5= 7+ 5,%?0%2P%3!8;0R.( :3:#K<8-3,#BQE0Z^/&& M.<%4.OCTYL=5'"!U&+%BF&=,%?0%2P%3!7W!4L!4@2$TLCA FLU@JW$#$["X M,94.?KQA3C"5#CZ]^7$5!T@=1JP8YAE3!7W!4L!405^P%#!58 B-+ Z09C/8 M:MS !"QN3*6#'V^8$TRE@T]O?ES% 5*'$2N&><94#N%_TWPHL!0P5= 7+ 5, M%1A"(Z,'R/=KVNCT=X9RC_"*]ML#K#T)/(-OWET][IW.RE^&/%&N/@.1EHU. M<^8\)V[6$1,TS3"5#C>]_3[HE#G3SJPK8$XPE0Y=O'6L\$(75UV( Z0.(U8, M\XRI+)CWW++SL2_L^OR8KAUHDP13P%3ZT">6:G%^!%@*F,H/S\Y4A$;&#I#+ MW5^MP\[WO$AIWZ\K_>D"SN!R=^!!AHQ+"H[\E6#QV5 ,I?M \)SYSX%-,TRE MPVUO>8J"7T$9S FFTJ&3MVX57NCDJ@-Q@-1AQ(IAGC&5!>EK^4_9;>M-N3D_ MOE[-INT8+ 5,94!Y2NJS(+L"2P%3.>+1F8K0R,0#)%F%4G56\BKTKG[J)%V1 MKVOK22XO0[Q^4NN?GY^RUJT6Z'I8I.7,4G<%,4$SF!IKSU5G*..VA2(U2>WB MG>88R!:QN=H)I1V(AID_8Z-+ Q%Y/?2^\ZP\DV,]Q^06$L'[-4^>ZF/:;S,W M]9F@:8:I=.C@;9Z0;^E;'9? G& J';IYZU3AA6ZN;A,'2!U&K!CF&5-9,.^Y M92NOGC[H8\GV$?9X8@.6 J8R8(-/=SZ_* M*E5>"\M1O6H1EI(U*]H"/>R4@T"QL'VX?I9-K4A=0=!RG(?:H64Z3QY7<$]K M(M]I&7.>J^L%I"NY5]Y$R1_ST86!-IHYLZ,MK\_DV,ZQMJ6ZG331BLMP*8@)G<.4 &#V/RV^--8EW M6D53WA#=AUX+)7;R8T/Q:T'X(FCFS*YV?<<]B' 4L!4UF1'F5R'&>??P8 2P%3>>.IF8K0R,2?0,H-];NE2$L# M/Q2TK%>(%PJK7FG*K[B4O\>AYVS#XZ!S$P M)YA*AU[>>E5XH9>K^\0!4H<1*X9YQE06E,WNG7ZKI_QW/_5>^B;?&)Z@;W$; M@*6 J:RH8KKV_.,:+ 5,Y8VG9BI"(SL\0"X+5#Z/\$_IH[I0L+_D7VG9KB0= M9I@Z7?)'. 9Q U)7$'=G,&J$C)O6^NW>YG]OJ*J)- "IQCPEVRU$#.5HH-3/ M\II*=P;::.;,GO/NE5XH9.K#L0!4H<1*X9YQE06D,UNWI+E[^-7&R??=-V"I8"IK&AR M.EJ9V^QC3E=!CZGJ(*E M@*FL8(]([<--TS &$Y0"IO+&4S,5F4AD] #Y'X660Q.K@W_-QL+5B<6,J'?QXPYQ@*AU\>O/C*@Z0.HQ8,1; #+]P)>!?!./P>('F< M)^"]! ^%!W\"WD5@! _F!+R+P @>S EX%\$(E/CB)Y"3T;= K,8-3,#BQE0Z M^/&&.<%4.OCTYL=5_ 0RZ$O,#0]@*6"JH"]8"I@J,(1&%@=(LQEL-6Y@ A8W MIM+!CS?,":;2P::&![ 4,%70%RP%3!48$@?("JL9;#5N8 (6 M-Z;2P8\WS FFTL&G-S^NX@ 9]"7FA@>P%#!5T!FTL&/-\P)IM+!IS<_KN( &?0EYH8'L!0P5= 7+ 5,%1@2!\@*JQEL-6Y@ M A8WIM+!CS?,":;2P: ?+] MFC8Z_4FAW".\HOWV &M/ L_@FW='QB5_]/XLK:1M@>D_$V[3QY+"=-J#Q'T! M3*7#36_I[W3F*.]-7LP)IM*AB[>.%5[HXJH+<8 ,^C+.W)BWPK*-L2_L^OR8 MKK7:\1"P%#"5/O3QHUJ<'P&6 J;RP[,S%:&1L0/D\WY\?7J]]SP??!4L!4!I2'ESX+LBNP%#"5(QZ=J4BU'4@'2+(*I>JLY%7H M7?TP2+HB7]?6DUQ>AGC]I-8_/S]EK5LMT/6P2,M1HNX*8H)F,#6&'=W(N$T' M4E'KV]\D*8P\?9WB0/D ?0VE]*"/)=M' MS=.%8[ 4,)4):VXT$^&YB#W&C &6 J9RQ8,S%:&1B0?(?+(HJU1Y+2Q']:I% M6$K6K&@+FRJ-5I[JBX7MP_6S;&I%Z@J"EN,\U XMTWG(N*RF4MG%VZ\:4[%) M'9>74E?K"R'(#1I#E S(MXKI)NR]E:DFY-N*>J-_)& M&CK+A7[N@DTS3*5##V\IS?OK*>8$4^G0SUN?"B_TT-[FTD+;IYGC MU_DM:\FO-K+U5Y1?L(]9;;LP7Y_\=@75SVO8H<6.E M%WYC-_L66 J8RH84T>M58I+B&R@P I8"IO+%"-=5BUZZR"YK7VQ(G8%,8$SN'( C$[&E0M-W_';7U-@ M92YOUS=25_\VZW6'E&8F5&U\?I0OD>UJXG8;4\Z+^J/N6FN-)?G6ELODR5F_ MD8;.;77G79B@:8:I=.CA[=-,/ ?F!%/IT,];GPHO]'-UESA 'K,LE?E^\VM6 M =;(7K3M[#5[*ZKRT+21?LH^:MOIV[T7QV_I"_8ZOV6-CB%;:OJR)GM5O7.6 M#[ZPG7T)+ 5,945Z1LEQ[#X73;T6;36P%#"5-YZ:J0B-3/P)I-Q0OUN*M#2( M3_P5ZQ7BA<*J5YKR*R[E[W%H.3#*R>D*9-RC0B_OFMM-S>D75LN5E6Q](W7U M[_-#93,3DF!K(5;JL#X=((7QZ$#477MI8VGGUF:6^Q-Z$XS1UXON.U_GV#3# M5#K<][9,*SJY,# GF$J'7MYZ57BAEZO[Q 'R),LMYQNG+Q;$QK9]><%>L[=, ME1O;:_*+@X\H2R>T*W;-7K>MD+;GU_E_1Z#L7._TBS?EO_NI-\XW^8[O!'V+ MVP L!4QEQ=X320-]C!D + 5,Y8VG9BI"(SL\0"X+5#X3\$\_' Y^6YLG=-)A MAJG3)7]R2_F0&Y"Z@K@[@U$C9%Q6>:GLPNVGM^32M&$TM3KHZL!W,Q-(1DF= M=558AP=(>3@Z4'XM3J?&DGAK])&/E-9VQW<&F&:;2X;:WG* X-RZ M.<%4.G3RUJW""YU<=2 .D =4&_S\.K><>9L1V_>NR:_%SMNN6#MK:=O9V[U^ MQ+=[[(WH&[)SI8UO$K]56F^8T@;I$BP%3&5%D]/1RMP^][@%2P%3>>.IF8K0 MR(X/D'/;REJ1=Q0A&7CUH]/R\D56Z@'Y;N\H+)NH*8L!E<1@>')N.2 M0BV]-66OVM(E.:P\6<5_%4;H*BNW7:6=[L),(+?[(C]PI6$='R#%O.A Y;4T MG01+[:T)(]2]R<;RZ])A_Y]!3M TPU0ZW/16?=VW<_ *F!-,I4,7;QTKO-#% M51?B 'E,7L;RV_9%OB WYG;V5FS)C>QM;LFOZ8N]B]O+Z 7Y-7U[II_VLMS" MKF37.*;:"N?=C>]M_**RUWL'2P%365$')3RU- UC,$$I8"IO/#53D8FNNN0 M^1^%ED,3JW$Y?.Y?HL=CJ1OJPV[G^\+BQE0Z^/&&.<%4.OCTYL=5'""#OHP^ M-_Y^\]=GU,!2P%1!7[ 4,%5@2!P@*ZQFL-6X#.P_X%R1?BXX,/3;1+WO"XL; M4^G@QQOF!%/IX-.;'U=Q@ SZ,OC<>,;Y$4P!4P5]P5+ 5($A-+(X0)K-8*MQ M Q.PN#&5#GZ\84XPE0X^O?EQ%0?(H"\Q-SR I8"I@KY@*6"JP!!^@)R"(/@^ M_[L.[R+8@1?N!+R+8!Q^#Y \SA/P7H*'PH,_ >\B,(('16 $#^8$O(M@ M!$I\\1/(R>A;(%;C!B9@<6,J'?QXPYQ@*AU\>O/C*GX"J<.(%<,\8ZJ@+U@* MF"KH"Y8"I@H,H9'% =)L!EN-&YB Q8VI=/#C#7."J73PZO/C*@Z0 M.HQ8,,">82@>? MWORXB@.D#B-6#/.,J8*^8"E@JJ O6 J8*C"$1A8'2+,9;#5N8 (6-Z;2P8\W MS FFTL&G-S^NX@"IPX@5PSQC*EOZ_[5B:[ 4,%70%RP%3!480B.C!\CW:]KH M]">%*_VCA&(-OO57"P]K_K"_ M_*@'C_LKOIJF/B(QX@Z;I:E<(QMA7#P#QC M*I2]S9T]6M#+VDW^^/RX\SAW[C'C_I,;Q@2E@*GT&7$%. ^6 J;RP[,S%:&1 ML0/D[^I-[KA4Z_#DU<#&3=5_T8%28CCB<]_.! @(%Z?9"J;2X;:W/&V$^7T)S FFTL&GM]NNNB4^X@$2WBD, M,:X8!.894Z&(FWOS:%%MK,TF_V'7E1_G3CUFV#VY82E@*@,&7 '.@Z6 J1SQ MZ$Q%:&3B 9(L*O.JM4#7(-(F79&O:^M)+B]#O'Y2ZY^?G[*RK1::%90,U'8% M,0$SF-AB#L\[J<==BD^/9[0SVKXU5".MLYA<94*/N;>_4,P1XHJEV?7\AG4>F67'GN,8,_7>B!I8"I3!AN M!3@/E@*FN3#];-L M:D7J"H*6XRQD0#KV)1_5N&3IWNZJ7O;K?GDQLI 74*J26'!"&3A_6BY+D99$ MFE?!'L@T0U4Z]/"6YN+]]11S@JET\.FMAZL^B0]Z@)Q7RM>K?63?/DOMTIIL MA7W%KH-YQE0H^YM[M9?RC55^/!!G4?4H0';O^97<#W&2MOE[WY?'P%+ 5#:, MM@*P*8@)F,'%#C7&3A]!Q2Z7+*W*'S;VES^I&MC6L3L0J\8)/;*9@&F&JG3HX6V9H'045 MUV=I3;;"0\6N@GG&5"C[FWNUE_*-M7HZH(\=6V>DRV46)?*%TC:^[V3M0G4> M3E *F,J*L5: \V I8"IO/#53$1J9^!-(N:%^MQ3I[/EAO4*\L&Z<1RE-^167 M\OMG6%53J?G:_FY_A75]7Q50-"0TIB'R5T!5_=52 M%M!9D%\+/0:,"9AFJ$J'^]Z6F2W-[VM@3C"5#CZ]W7?5*_%Q#Y#56GFT<%9K MLA4>*G85S#.F0LG!-U\*1_.C[/I'5ZTTCW/ 8\9>WU\#2P%367$BNP47*\!Y ML!0PE3>>FJD(C>SP $F/*=+RL@GD@OVV-D<-?NY)"(ODG]Q2/N0&I*X@D!E, M/1=CURR5<:O"Y^[(&$+':3/(HJ3)%U0%%)2\X!O91?Z<)MA<15_O]!@0D&F& MJG2X[2U/3FF67@%S@JET\.GMMJMNB3_D /FI#M7.8(&'BET%\XRI4/8W]VI^ M5&_(EB\\,S6SJ)D[5O@N6 J:R8JP5X#Q8"IC*&T_-5(1&=GR M7!:MA;4B:>');)>OC5Q=Q/59IV[EIX^DR@WTP])=/K:PKB"F:S.8W-0V:FXZ MFC4->5Q6]VUII[?.:S1#G.P74*@2Z:S]L/JAY=#$:MSSD"V'?X$$5\'BQE0Z^/&&.<%4.OCTYL?5N ?(L1BQ8IAG3&7" M7^$W@QX"E@*F"OJ"I8"I D-H9'& -)O!5N->@'[;Y*E;EA98W)A*!S_>,">8 M2@>?WORXB@.D#B-6#/.,J2QX\/D13 %3!7W!4L!4@2$TLCA FLU@JW$#$["X M,94.?KQA3C"5#CZ]^7$5!T@=1JP8YAE3!7W!4L!405^P%#!58 B-+!T@IR ( MOL__KL.["';@A3L![R(8A]\#)(_S!+R7X*'PX$_ NPB,X,&<@'<1&,&#.0'O M(AB!$E_\!'(R^A:(U;B!"5C_+B*GT#J,&+%,,^8*N@+ ME@*F"OJ"I8"I D-H9'& -)O!5N,&)F!Q8RH=_'C#G& J'7QZ\^,J#I ZC%@Q MS#.F"OJ"I8"I@KY@*6"JP! :61P@S6:PU;B!"5C_+B* M Z0.(U8,\XRI@KY@*6"JH"]8"I@J,(1&%@=(LQEL-6Y@ A8WIM+!CS?,":;2 MP:Z1]A;&MP_&F![C'/ MVV\&@L=]#DS5DJ9+GIR_,^W*1-WCIK>.EC GF*JEXXUDNGCK;NRFJXY^1CQ MTKVL*H5C6,6.WV;:]E:8H>U[G+QLX=+%&4R%LK=]LT<+>EG[='&\G^\\SIU[ MS+C_Y(8Q02E@*GU&7 '.@Z6 J?SP[$Q%:&3L +G<_=4Z["QDI+3OUY7^=+DX M@^>[>M?'LK5:UTZ[;-Q4_1=]J")5%3K>J7D#O>ZL)O@"%Z?9"J:2R.$+DPGC MMK=NEC GF$JBVXUD.GGK;.RVJVY^1CQ PCN%(:QBQV\S;7OUS'&N$\J9:S*7 M+LY@*A1Q+?CN71\%/VSG\N/G:E( MM9A+!TBRJ,RKU@)=@TB;=$6^KJTGN;P,\?I9OO'V4U:VU4*S@I*!VJX@)F & M$UO,X7DG];A+\4L$=6>TO?V4M&T%$7NI-,W%98P2G#1*92:_?K_FO6_IL-4$ M$S#-4)7,'&OU?'*/#MXZ6<*<8"J93C>2Z>:MJ[$.KCKY&?( F5=6MLPOBR99 M-NL=UA)6L>.WF;:=MK2??N22Y-+%&4R%LK^Y\TV:?J&4C9E_)LRBTBVY37Y\%4*#M;.M3>Z'.$G;N<4W@K$4 M,)4-HZT Y\%2P%2^>&ZF(M5B*_XWD&LEZGLFBP];6\H:M#P=3/4#PBR8+\@? M;Z3+JD5R'22WM2]6Q*X@)F &$S?4&#=Y"!VW5+J\(G'Z&?J"'MSZ6,">8:H<^-Y+I MYZVGL1ZN^O@9]0"Y[(9Y<91WL7:'-8-53'Q+&VE+V]Z^%AOWY,; 4,)4W MGIJI"(U,_ FDW%"_6XJT-/!EKF6]0KRP;IQ'*4WY%9?R]SBT'&?/'R^7QV_+N<(MMQ_]7B_+JZ=D?XGP:99JA* M9)E&XF3"N.^MER7,":82Z74CF5[>^AJ[[ZJ7GW$/D-7"W:SBA%0DX:%>%U8Q M\2UMI"UM>_M:;-R33S7YH_R:7GP53(62@V^^%([FQUO\Q2)^U4J["0./&3M] M?PTL!4QEQ8GL%ERL .?!4L!4WGAJIB(TLL,#)%FPQ.6E/GC4G\VM6;!=23K, M"(OD]AN4]$-N0.H* IG!U',Q=LU2&;R>;63)4 F6:H2B(G+DPFC-O>NEG"G& JB6XWDNGDK;.QVZZZ M^7G( ?)3':J=P0)6,?%M]3Q!6MKV]G5^VUYPW,)H+[X*ID*1MV+V"7N3MEAA M5U\^:6=1,W>JAJ/'C+_"DYL26 J8RHJQ5H#S8"E@*F\\-5.1:K$]/$ NB];" M6I'YS+"Q7;XVVJX@IFLSF-P4/3S-',V:ACPN MJ_NVM--;YS626H2P_AWT(EV\E+3FTL&/ M-\P)IM+!IS<_KN(GD#J,6#',,Z8*^H*E@*F"OF I8*K $!I9'"#-9K#5N($) M6-R82@<_WC GF$H'G][\N(H#I XC5@SSC*F"OF I8*J@+U@*F"HPA$86!TBS M&6PU;F "%C>FTL&/-\P)IM+!IS<_KN( J<.(%<,\8ZJ@+U@*F"KH"Y8"I@H, MH9'% =)L!EN-&YB Q8VI=/#C#7."J73PZO/C*@Z0.HQ8,(,\!002]P4P54M*,6?8Z6]VWO36T1+F M!%.U=+R13!=OW8W==-71SX@'2+I$5Z5P#*O8\=M,V]X*,[1]CY.7+5RZ.(.I M4.B.3[=;]FAQ_&!PO*7O/,ZEYF;$E=)^_\D-8X)2P%3ZC+@"G =+ 5/YX=F9 MBM#(V %RN?NK==A9R$AIWZ\K_>ER<0;/=_4F=URJ]?$05T'&I06<%_0O5&LG M)$:ZA3_TPB3[.'<'6MQ<9JM8"J)7(UKL_2 V]ZZ6<*<8"J);C>2Z>2M ML[';KKKY&?$ ">\4AK"*';_-M.W5,\>Y3BAGKLE=5: MH&L0:9.NR->U]227ER%>/\LWWG[*RK9::%90,E#;%<0$S&!BBSD\[X2,RW2D M<,(]OE]SH19RR4D7)!]2&#I&G2 ES8&?^HY>[SPQQ)Y%/^*5Y&;RE1]N\/7> M+JCNY$BR]$PN4MT!=YF :8:J9.9I53V?W*.#MTZ6,">82J;3C62Z>>MJK(.K M3GZ&/$#FE;WLM.)J=K ^:\,J=OPVT[;3EO;3CUR27+HX@ZE0V&Y,4JZ>!?8? M#-H+MQE3]D2RQ]:-;/XU3JIQ5,%2P%0F#+<"G =+ 5.YXL&9BM#(Q -DNOMF M(=E>U\O=#%OF"DO)R&?2RI5&:Q8]\N'Z63:U(G4%0/BU<-;'TN8$TRU0Y\;R?3SUM-8#U=]_ QZ@)S7I->KK$O2 M:B8MMU:PBDT-K#V_;:]?6NBG#/%*ULC>[K7DU^?!5"AD;WK7I[5JU^);&)D: M]"-I%I7&LG?F-KD?XF3>>0U.D5@*F,J&T5: \V I8"I?/#=3D6JQ%?\;R+42 M]3V3Q8>M+64-6IX.IOH!81;,%^2/-])EU2*Y#I+;VA.MC"7."J7;H_+CEHS8^!%,A4*"SY,A?U*2YUM8V>?H)T>S M*)$O+/*JHTI&F;M0G8<3E *FLF*L%> \6 J8RAM/S52$1B;^!%)NJ-\M13K[ MI+Y>(5Y8-\ZCE*;\BDOY>QQ:CK.0T=E*?MX4&9?IWNMW N7N: [2AI*2V2[8 M\;DUY 0S6X?S_U=O5D7;L^1'O'(9D'X5-9YF/AT@14GK8>=2*Y!IAJI$EDQH M,C>Y[ZV7)?<0^0U:ITM$2E(C7KLS:L8N);VDA; MVO;VM=BX)Y]J\D?Y-;WX*I@*)0???"D#XJI7Z>6UMH;!=LG$R(_?] M-; 4,)45)[);<+$"G =+ 5-YXZF9BM#(#@^09,$2EY?CA_J_\Z\_+I"C2'.E ML$B6?\:E?,@-2%U!(#.8>B[&KEDBXU8E2,O\>J-BA^)AJ2X4#:VM)*&)/#8 M2J+;C60Z>>ML[+:K;GX>ZKIG *B:^K9XG2$O;WK[.;]L+CEL8[<57 MP50H]#-C6)LZB9NY4#6E;YEOUU@W=J9M>O@N6 J:R8JP5X#Q8 M"IC*&T_-5*1:; \/D,NBM;!6)"T\F>WRM9&KB[A\U.KYDN'Q!8 M5Q#3M1E,;HHZD^I6A'ND,977M%!%]'JUAS&ART+ID'P15*,T M/>_ZX5?2R@E>TZ7K#3:>JU%$R8$'?H\V3->FV0JF:JF^R$BT=[CIK:,ES FF M:NEX(YDNWKH;N^FJHY^G'""%U:QIL&2J*[;W-OO=:\\M!^T'+;GQ^&UNI&]/ M@JE0Z"S(K^D&N21?S84R&?@<$B<-W1.%]TFQ3K=#)[HS<()2P%16\/2:[)J& M,9B@%#"5-YZ:J/#Y$4P!4P5]P5+ M5($A-+(X0)K-8*MQ Q.PN#&5#GZ\84XPE0X^O?EQ%0=('4:L&.894P5]P5+ M5$%?L!0P56 (C2P=(*<@"+[/_Z[#NPAVX(4[ >\B&(?? R2/\P2\E^"A\.!/ MP+L(C.#!G(!W$1C!@SD![R(8@1)?_ 1R,OH6B-6X@0E8W)A*!S_>,">82@>? MWORXBI] ZC!BQ3#/F"KH"Y8"I@KZ@J6 J0)#:&1Q@#2;P5;C!B9@<6,J'?QX MPYQ@*AU\>O/C*@Z0.HQ8,,">82@>?WORXB@.D#B-6#/.,J8*^8"E@JJ O6 J8*C"$1A8'2+,9 M;#5N8 (6-Z;2P8\WS FFTL&G-S^NX@"IPX@5PSQCJJ O6 J8*N@+E@*F"@RA MD<4!TFP&6XT;F(#%C:ET\.,-9WXGQXTU!W."J73PZ>VFJXZ)CWB I M@50K' MV%8, _.,J6Y#_S@RW1[;)XK[._ 8"E@*GU&7 '.@Z6 J?SP[$Q%:&3L +G< M_=4Z_%XO+6JDM._7E?YTN3B#Y[MZTSMN6TY!QB4%O_97@GO[PF6 J8R8, 5X#Q8"IC*$8_.5(1&)AX@R1*2JK.25ZW\ MK;"Y3;HB7]?6DUQ>AGC]+-]O^RG?E5XMT,6L2,LYM^X*8@)F<+O&MBV?*.,* MA2I9T-F%;:.(HEP>$'K4F4GIF :8:J=.C@K7U2@L"< M8"H=?'KKX*I3XD,>(/,Z2E=W:>FKUWE+S"L&@'G&5+>ANR*=%LTG[1?,A^U^ M:607D9DE/@4LV_?ZVF#J35 *F,J$X5: \V I8"I7/#A3$1J9>(!,=S^_HNO6 M]KI>Y6;H4E>QE(Q\QFH\?Y)&VRZA%K8/U\^RJ16I*PA:CK.T [8MG\CC2E)Z M=]OK#Y67PIH36$1S%O/+4DFIAC0.PA!1>@:99JA*AQ[>TE2XOYYB3C"5#CZ] M]7#5)_%!#Y#S\O9ZR6>&;>D3UGDS["MV'_H!EY_(FV*N]M]V62; M5Q6YF6_'.]>K@*6 J6P8;04X#Y8"IO+%H5X8;.^S;]JN3;E M5US*W^/07E%ZOY_+\&Y@13Z>#3VWU7O1(?]P!9K79'2U\J4G.JT,9#Q:Z"><94MZ&[ M8ATVG1OM$\+>=B\\-I".Z"!;\O'^022U-HL9Z3##U.F2/W3%6U]R U)7$,@,;N^X;?D$&?=-OG^Q M_",U]7V?JKP8UN$!4JRA=".C1.D99)JA*AUN>\NYWYT F!-,I8-/;[===4O\ M(0?(3W7(*[45'BIV%[+_,EOR8=U2_7#OAV+#T! M:(&E@*FL&&L%. ^6 J;RQE,S%:&1'1\@EX5K8:U(6FTRV^5K(U<7Q,$:4GIFN3;,53*7#36_59/FPY'X \$Y0"IO+&4S,5F4AD] #Y'X660Q.K<0,3L+@QE0Y^O&%. M,)4./KWY<37N 7(L1JP8YAE3!7W!4L!405^P%#!58 B-+ Z09C/8:MS !"QN M3*6#'V^8$TRE@T]O?ES% 5*'$2N&><9405^P%#!5T!N!/P+H)Q^#U \CA/P'L)'@H/_@2\B\ ('LP)>!>! M$3R8$_ N@A$H\<5/(">C;X%8C1N8@,6-J73PXPUS@JET\.G-CZOX":0.(U8, M\XRI@KY@*6"JH"]8"I@J,(1&%@=(LQEL-6Y@ A8WIM+!CS?,":;2P:,.<8"H=?'KSXRH.D#J,6#',,Z8*^H*E@*F"OF I8*K $!I9'"#-9K#5N($) M6-R82@<_WC GF$H'G][\N(H#I XC5@SSC*DT\7KG*^Z0>X17M-\>8.U)KL_@WR6ZNB7L-LFX2.4[5@;S'UR"Q'T! M3*7#36_IJRC/]M\I>'KFMV!.,)4.7;QUK/!"%U==B .D#B-6#/.,J2R8M^NR M5;,O[/K\F*X=:5?'4L!4^M!GMFIQ?@18"IC*#\_.5(1&Q@Z0R]U?KUO+Q8-C+NRZ.2J W& U&'$BF&>,94%Z6OY3WE. MJ ^0S?GQ]>KPG2,UL!0PE0'E^:[/@NP*+ 5,Y8A'9RI"(Q,/D&052M59R:M0 M^JY6:9.NR->U]227ER%>/\O/]'[*6K=:H.MAD9;35MT5Q 3,8/E<(][P+F3< MMO*DQFN?O,Z5!:$4[]=82H=NWCI5>*&;J]O$ 5*'$2N&><94%LQ/"V77+@\/__B# MR?)1=8%SL!0PE0EK;C03X5EHR$<=+ 5,Y8H'9RI"(Q,/D.GNMR=V>OOS:V$Y MDH]3_[:2-2O:PJ9*HY5#1+&P?;A^EDVM2%U!T'*<11Q0;-R'C-M6GE"5H Q MWHBE2+5O=++%)B;YLIU^=D=?6N?.YY?EYG8E3?<[=SD@R#1#53KT\);FQ/WU M%'."J73HYZU/A1?ZN;I+'"!U&+%BF&=,9<&Z$6[[H;B9T@M'VCFQ%#"5#2FB MU^OX\6F@P A8"IC*%\_-5(1&)O\WD&LEZGLFRU&Y9*9ZWE]ZH+6:!?,%^>.- M=%FUZ*V#Y+;VQ8K8%<0$S&#N1FXZAHS;5+YJ$\Y5U1NY%#2\_/K(9(F)77;L M9&]T\OGV7__?!TL!4UE1Q=0^X!0&>]3!4L!4WGAJIB(TLL,#)#T62<\@QP>" MW];F0""=LY@Z7?)'.)YP U)7$,@,YO,%L4+&;2I/^B>]\U&W-V(I3I['Q)CJ MX3\XV1E=Z"#;V)&<,TP_'@ADFJ$J'6Y[R]- G \7P)Q@*ATZ>>M6X85.KCH0 M!T@=1JP8YAE364!VO[0EY^?1>J^L]LATW1 [)I8"IK*BR>EH91[H40=+ 5-Y MXZF9BM#(C@^0<]M*.3IL+>4@7:UCA2(N'[5Z?D9(JMS 3BI5;VU7$-.U&4QN M:AFU:CB<.#53&5>H?+FYUXL>QN:6IFQ"*6B?Y;64E! 3&VC[5'8BCTZNW%X2 M2Z+DT+"@&(KIVC1;P50ZW/163> /2^X',">82H*&+JR[$ 5*'$2N& M><94%E1/"_.VV#X0\$>*=-D(FR:6 J:RH@Y*>!9J&L9@@E+ 5-YX:J8B$XF, M'B#_H]!R:&(U;F "%C>FTL&/-\P)IM+!IS<_KN( J<.(%<,\8RH__"6_230N M6 J8*N@+E@*F"@RAD<4!TFP&6XT;F(#%C:ET\.,-@/<2/!0>_ EX%X$1/)@3\"X"(W@P)^!=!"-0XHN?0$Y&WP*Q M&C

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htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page - shares
9 Months Ended
Sep. 30, 2022
Nov. 04, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-41428  
Entity Registrant Name R1 RCM Inc. /DE  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 87-4340782  
Entity Address, Address Line One 434 W. Ascension Way  
Entity Address, Address Line Two 6th Floor  
Entity Address, City or Town Murray  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84123  
City Area Code 312  
Local Phone Number 324-7820  
Title of 12(b) Security Common stock, par value $0.01 per share  
Trading Symbol RCM  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filter Category Large Accelerated Filer  
Smaller Reporting Company false  
Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   416,510,858
Amendment Flag false  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001910851  
Current Fiscal Year End Date --12-31  

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 131.1 $ 130.1
Accounts receivable, net of $14.5 million and $2.4 million allowance as of September 30, 2022 and December 31, 2021, respectively 209.0 131.3
Accounts receivable, net of $0.1 million and $0.1 million allowance - related party as of September 30, 2022 and December 31, 2021, respectively 29.7 26.1
Current portion of contract assets 74.4 0.0
Prepaid expenses and other current assets 96.9 77.2
Total current assets 541.1 364.7
Property, equipment and software, net 163.0 94.7
Operating lease right-of-use assets 98.9 48.9
Non-current portion of contract assets 30.8 0.0
Non-current portion of deferred contract costs 27.5 23.4
Intangible assets, net 1,567.5 265.4
Goodwill 2,549.3 554.7
Non-current deferred tax assets 9.4 51.8
Other assets 93.6 45.7
Total assets 5,081.1 1,449.3
Current liabilities:    
Accounts payable 25.0 17.7
Current portion of customer liabilities 67.8 41.5
Current portion of customer liabilities - related party 5.6 7.9
Accrued compensation and benefits 105.7 97.0
Current portion of operating lease liabilities 20.8 13.5
Current portion of long-term debt 49.5 17.5
Other accrued expenses 71.6 59.1
Total current liabilities 346.0 254.2
Non-current portion of customer liabilities 5.3 3.3
Non-current portion of customer liabilities - related party 14.1 15.4
Non-current portion of operating lease liabilities 99.2 53.4
Long-term debt 1,728.1 754.9
Non-current deferred tax liabilities 98.2 4.2
Other non-current liabilities 22.4 17.2
Total liabilities 2,313.3 1,102.6
Stockholders’ equity:    
Common stock, $0.01 par value, 750,000,000 shares authorized, 439,386,709 shares issued and 417,722,143 shares outstanding at September 30, 2022; 500,000,000 shares authorized, 298,320,928 shares issued and 278,226,242 shares outstanding at December 31, 2021 4.4 3.0
Additional paid-in capital 3,104.4 628.5
Accumulated deficit (84.8) (64.3)
Accumulated other comprehensive loss (4.0) (5.3)
Treasury stock, at cost, 21,664,566 shares as of September 30, 2022; 20,094,686 shares as of December 31, 2021 252.2 215.2
Total stockholders’ equity 2,767.8 346.7
Total liabilities and stockholders’ equity $ 5,081.1 $ 1,449.3
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Accounts receivable, allowance $ 14.5 $ 2.4
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 750,000,000 500,000,000
Common stock, shares issued (in shares) 439,386,709 298,320,928
Common stock, shares outstanding (in shares) 417,722,143 278,226,242
Treasury stock, shares (in shares) 21,664,566 20,094,686
Related Party    
Accounts receivable, allowance $ 0.1 $ 0.1
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Net services revenue ($218.1 million and $657.8 million for the three and nine months ended September 30, 2022, respectively, and $227.5 million and $661.4 million for the three and nine months ended September 30, 2021, respectively, from related party) $ 496.0 $ 379.7 $ 1,273.6 $ 1,075.7
Operating expenses:        
Cost of services 403.1 304.0 1,009.7 858.2
Selling, general and administrative 60.8 33.2 120.6 87.8
Other expenses 30.1 11.4 136.1 34.2
Total operating expenses 494.0 348.6 1,266.4 980.2
Income from operations 2.0 31.1 7.2 95.5
Net interest expense 23.7 6.5 35.3 13.8
Income (loss) before income tax provision (benefit) (21.7) 24.6 (28.1) 81.7
Income tax provision (benefit) 7.8 7.6 (7.6) 20.5
Net income (loss) $ (29.5) $ 17.0 $ (20.5) $ 61.2
Net income (loss) per common share:        
Basic (in dollars per share) $ (0.07) $ 0.06 $ (0.06) $ (2.03)
Diluted (in dollars per share) $ (0.07) $ 0.05 $ (0.06) $ (2.03)
Weighted average shares used in calculating net income (loss) per common share:        
Basic (in shares) 417,700,782 278,655,269 330,877,880 262,209,929
Diluted (in shares) 417,700,782 320,617,086 330,877,880 262,209,929
Consolidated statements of comprehensive income (loss)        
Net income (loss) $ (29.5) $ 17.0 $ (20.5) $ 61.2
Other comprehensive income (loss):        
Net change on derivatives designated as cash flow hedges, net of tax 9.2 0.5 8.1 0.9
Foreign currency translation adjustments (2.2) 0.0 (6.8) (1.0)
Total other comprehensive income (loss), net of tax 7.0 0.5 1.3 (0.1)
Comprehensive income (loss) (22.5) 17.5 (19.2) 61.1
Basic:        
Net income (loss) (29.5) 17.0 (20.5) 61.2
Less dividends on preferred shares 0.0 0.0 0.0 (592.3)
Net income (loss) available/allocated to common shareholders - basic (29.5) 17.0 (20.5) (531.1)
Diluted:        
Net income (loss) (29.5) 17.0 (20.5) 61.2
Less dividends on preferred shares 0.0 0.0 0.0 (592.3)
Net income (loss) available/allocated to common shareholders - diluted $ (29.5) $ 17.0 $ (20.5) $ (531.1)
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parenthetical) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Net services revenue, from related parties $ 218.1 $ 227.5 $ 657.8 $ 661.4
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Millions
Total
CoyCo 2
Common Stock
Treasury Stock
Additional Paid-In Capital
Additional Paid-In Capital
CoyCo 2
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning Balance (in shares) at Dec. 31, 2020     137,812,559          
Beginning Balance (in shares) at Dec. 31, 2020       (16,668,521)        
Beginning Balance at Dec. 31, 2020 $ 87.9   $ 1.4 $ (139.2) $ 393.7   $ (161.5) $ (6.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share-based compensation expense 12.8       12.8      
Issuance of common stock related to share-based compensation plans (in shares)     6,497          
Issuance of common stock (in shares)     324,212          
Issuance of common stock 7.0       7.0      
Exercise of vested stock options (in shares)     539,795          
Exercise of vested stock options 3.5       3.5      
Acquisition of treasury stock related to share-based compensation plans (in shares)       (2,201)        
Net change on derivatives designated as cash flow hedges, net of tax 0.5             0.5
Foreign currency translation adjustments (0.4)             (0.4)
Conversion of preferred shares (in shares)     117,706,400          
Conversion of preferred shares 251.5   $ 1.2   250.3      
Inducement dividend (592.3)       (592.3)      
Issuance of common stock related to inducement (in shares)     21,582,800          
Issuance of common stock related to inducement 487.3   $ 0.2   487.1      
Net income (loss) 25.8           25.8  
Ending Balance (in shares) at Mar. 31, 2021     277,972,263          
Ending Balance (in shares) at Mar. 31, 2021       (16,670,722)        
Ending Balance at Mar. 31, 2021 283.6   $ 2.8 $ (139.2) 562.1   (135.7) (6.4)
Beginning Balance (in shares) at Dec. 31, 2020     137,812,559          
Beginning Balance (in shares) at Dec. 31, 2020       (16,668,521)        
Beginning Balance at Dec. 31, 2020 87.9   $ 1.4 $ (139.2) 393.7   (161.5) (6.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net change on derivatives designated as cash flow hedges, net of tax 0.9              
Foreign currency translation adjustments (1.0)              
Net income (loss) 61.2              
Ending Balance (in shares) at Sep. 30, 2021     295,885,508          
Ending Balance (in shares) at Sep. 30, 2021       (18,393,186)        
Ending Balance at Sep. 30, 2021 334.1   $ 3.0 $ (175.7) 613.7   (100.3) (6.6)
Beginning Balance (in shares) at Mar. 31, 2021     277,972,263          
Beginning Balance (in shares) at Mar. 31, 2021       (16,670,722)        
Beginning Balance at Mar. 31, 2021 283.6   $ 2.8 $ (139.2) 562.1   (135.7) (6.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share-based compensation expense 24.0       24.0      
Issuance of common stock related to share-based compensation plans (in shares)     539,884          
Exercise of vested stock options (in shares)     396,250          
Exercise of vested stock options 1.3       1.3      
Acquisition of treasury stock related to share-based compensation plans (in shares)       (167,832)        
Acquisition of treasury stock related to share-based compensation plans (4.5)     $ (4.5)        
Net change on derivatives designated as cash flow hedges, net of tax (0.1)             (0.1)
Foreign currency translation adjustments (0.6)             (0.6)
Exercise of warrants pursuant to cashless provisions (in shares)     16,750,000          
Exercise of warrants pursuant to cashless provisions 0.0   $ 0.2   (0.2)      
Net income (loss) 18.4           18.4  
Ending Balance (in shares) at Jun. 30, 2021     295,658,397          
Ending Balance (in shares) at Jun. 30, 2021       (16,838,554)        
Ending Balance at Jun. 30, 2021 322.1   $ 3.0 $ (143.7) 587.2   (117.3) (7.1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share-based compensation expense 25.8       25.8      
Issuance of common stock related to share-based compensation plans (in shares)     54,524          
Exercise of vested stock options (in shares)     172,587          
Exercise of vested stock options 0.7       0.7      
Acquisition of treasury stock related to share-based compensation plans (in shares)       (16,555)        
Acquisition of treasury stock related to share-based compensation plans (0.3)     $ (0.3)        
Repurchases of common stock (in shares)       (1,538,077)        
Repurchases of common stock (31.7)     $ (31.7)        
Net change on derivatives designated as cash flow hedges, net of tax 0.5             0.5
Foreign currency translation adjustments 0.0              
Net income (loss) 17.0           17.0  
Ending Balance (in shares) at Sep. 30, 2021     295,885,508          
Ending Balance (in shares) at Sep. 30, 2021       (18,393,186)        
Ending Balance at Sep. 30, 2021 $ 334.1   $ 3.0 $ (175.7) 613.7   (100.3) (6.6)
Beginning Balance (in shares) at Dec. 31, 2021 298,320,928   298,320,928          
Beginning Balance (in shares) at Dec. 31, 2021 (20,094,686)     (20,094,686)        
Beginning Balance at Dec. 31, 2021 $ 346.7   $ 3.0 $ (215.2) 628.5   (64.3) (5.3)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share-based compensation expense 10.2       10.2      
Issuance of common stock related to share-based compensation plans (in shares)     1,757,955          
Exercise of vested stock options (in shares)     77,438          
Exercise of vested stock options 0.4       0.4      
Acquisition of treasury stock related to share-based compensation plans (in shares)       (727,768)        
Acquisition of treasury stock related to share-based compensation plans (18.7)     $ (18.7)        
Repurchases of common stock (in shares)       (8,000)        
Repurchases of common stock (0.2)     $ (0.2)        
Net change on derivatives designated as cash flow hedges, net of tax 0.1             0.1
Foreign currency translation adjustments (1.4)             (1.4)
Net income (loss) 29.4           29.4  
Ending Balance (in shares) at Mar. 31, 2022     300,156,321          
Ending Balance (in shares) at Mar. 31, 2022       (20,830,454)        
Ending Balance at Mar. 31, 2022 $ 366.5   $ 3.0 $ (234.1) 639.1   (34.9) (6.6)
Beginning Balance (in shares) at Dec. 31, 2021 298,320,928   298,320,928          
Beginning Balance (in shares) at Dec. 31, 2021 (20,094,686)     (20,094,686)        
Beginning Balance at Dec. 31, 2021 $ 346.7   $ 3.0 $ (215.2) 628.5   (64.3) (5.3)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Exercise of vested stock options (in shares) 1,279,460              
Net change on derivatives designated as cash flow hedges, net of tax $ 8.1              
Foreign currency translation adjustments (6.8)              
Net income (loss) $ (20.5)              
Ending Balance (in shares) at Sep. 30, 2022 439,386,709   439,386,709          
Ending Balance (in shares) at Sep. 30, 2022 (21,664,566)     (21,664,566)        
Ending Balance at Sep. 30, 2022 $ 2,767.8   $ 4.4 $ (252.2) 3,104.4   (84.8) (4.0)
Beginning Balance (in shares) at Mar. 31, 2022     300,156,321          
Beginning Balance (in shares) at Mar. 31, 2022       (20,830,454)        
Beginning Balance at Mar. 31, 2022 366.5   $ 3.0 $ (234.1) 639.1   (34.9) (6.6)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share-based compensation expense 11.6       11.6      
Issuance of common stock related to share-based compensation plans (in shares)     505,371          
Issuance of common stock (in shares)     135,929,742          
Issuance of common stock 2,387.5   $ 1.4   2,386.1      
Replacement awards issued in conjunction with acquisitions 11.3       11.3      
Exercise of vested stock options (in shares)     395,425 2,282        
Exercise of vested stock options 2.0     $ (0.1) 2.1      
Acquisition of treasury stock related to share-based compensation plans (in shares)       (153,157)        
Acquisition of treasury stock related to share-based compensation plans (3.5)     $ (3.5)        
Net change on derivatives designated as cash flow hedges, net of tax (1.2)             (1.2)
Foreign currency translation adjustments (3.2)             (3.2)
Net income (loss) (20.4)           (20.4)  
Ending Balance (in shares) at Jun. 30, 2022     436,986,859          
Ending Balance (in shares) at Jun. 30, 2022       (20,985,893)        
Ending Balance at Jun. 30, 2022 2,750.6   $ 4.4 $ (237.7) 3,050.2   (55.3) (11.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share-based compensation expense 24.8 $ 3.0     24.8 $ 3.0    
Issuance of common stock related to share-based compensation plans (in shares)     189,566          
Issuance of common stock (in shares)     1,403,687          
Issuance of common stock 24.3       24.3      
Exercise of vested stock options (in shares)     806,597          
Exercise of vested stock options 2.1       2.1      
Acquisition of treasury stock related to share-based compensation plans (in shares)       (84,547)        
Acquisition of treasury stock related to share-based compensation plans (1.9)     $ (1.9)        
Repurchases of common stock (in shares)       (594,126)        
Repurchases of common stock (12.6)     $ (12.6)        
Net change on derivatives designated as cash flow hedges, net of tax 9.2             9.2
Foreign currency translation adjustments (2.2)             (2.2)
Net income (loss) $ (29.5)           (29.5)  
Ending Balance (in shares) at Sep. 30, 2022 439,386,709   439,386,709          
Ending Balance (in shares) at Sep. 30, 2022 (21,664,566)     (21,664,566)        
Ending Balance at Sep. 30, 2022 $ 2,767.8   $ 4.4 $ (252.2) $ 3,104.4   $ (84.8) $ (4.0)
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - USD ($)
$ in Millions
3 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Accumulated Other Comprehensive Loss            
Net change on derivatives designated as cash flow hedges, tax $ 3.1 $ 0.4 $ 0.0 $ 0.1 $ 0.0 $ 0.2
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Operating activities    
Net income (loss) $ (20.5) $ 61.2
Adjustments to reconcile net income (loss) to net cash (used in) provided by operations:    
Depreciation and amortization 107.8 56.8
Amortization of debt issuance costs 2.2 0.8
Share-based compensation 46.5 62.0
(Gain)/loss on disposal and right-of-use asset write-downs 3.9 (0.3)
Provision for credit losses 10.7 0.6
Deferred income taxes (9.1) 18.0
Non-cash lease expense 10.5 7.4
Other 1.5 0.8
Changes in operating assets and liabilities:    
Accounts receivable and related party accounts receivable (29.7) (18.8)
Contract assets (12.8) 0.0
Prepaid expenses and other assets (38.3) (19.8)
Accounts payable (23.9) 4.5
Accrued compensation and benefits (79.6) 34.3
Lease liabilities (11.4) (9.9)
Other liabilities (3.2) (8.9)
Customer liabilities and customer liabilities - related party 2.9 30.1
Net cash (used in) provided by operating activities (39.5) 218.8
Investing activities    
Purchases of property, equipment, and software (74.6) (33.4)
Proceeds from disposal of assets 0.4 2.6
Net cash used in investing activities (921.9) (325.5)
Financing activities    
Payment of debt issuance costs (1.0) (1.9)
Payment of contingent consideration liability 0.0 (4.8)
Deferred payment related to acquisition of RevWorks 0.0 (12.5)
Inducement of preferred stock conversion 0.0 (105.0)
Exercise of vested stock options 4.6 6.3
Purchase of treasury stock (12.5) (29.5)
Shares withheld for taxes (26.9) (4.8)
Other (0.2) (0.1)
Net cash provided by financing activities 965.5 91.7
Effect of exchange rate changes in cash, cash equivalents and restricted cash (3.1) (0.6)
Net increase (decrease) in cash, cash equivalents and restricted cash 1.0 (15.6)
Cash, cash equivalents and restricted cash, at beginning of period 130.1 174.8
Cash, cash equivalents and restricted cash, at end of period 131.1 159.2
Supplemental disclosures of cash flow information    
Property, equipment and software purchases not paid 27.4 25.7
CoyCo 2    
Adjustments to reconcile net income (loss) to net cash (used in) provided by operations:    
Share-based compensation 3.0 0.0
Senior Term Loan    
Financing activities    
Issuance of senior secured debt, net of discount and issuance costs and Borrowings on revolver 1,016.6 698.6
Repayment of senior secured debt and Repayments on revolver (13.1) (484.6)
Senior Revolver    
Financing activities    
Issuance of senior secured debt, net of discount and issuance costs and Borrowings on revolver 30.0 120.0
Repayment of senior secured debt and Repayments on revolver (30.0) (90.0)
Payment of equity issuance costs (2.0) 0.0
Cloudmed    
Investing activities    
Acquisition of Cloudmed, net of cash acquired (847.7) 0.0
VisitPay    
Investing activities    
Acquisition of Cloudmed, net of cash acquired $ 0.0 $ (294.7)
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Description and Basis of Presentation
9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Description and Basis of Presentation Business Description and Basis of Presentation
Business Description
R1 RCM Inc. (the “Company”) is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. The Company helps healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for its customers.

Cloudmed Acquisition

On June 21, 2022, pursuant to the Transaction Agreement and Plan of Merger (the “Transaction Agreement”), dated as of January 9, 2022, among R1 RCM Inc. (f/k/a Project Roadrunner Parent Inc.), R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.), a wholly-owned subsidiary of the Company (“Old R1 RCM”), Project Roadrunner Merger Sub Inc., formerly a wholly-owned subsidiary of the Company (“R1 Merger Sub”), Revint Holdings, LLC (“Cloudmed”), CoyCo 1, L.P. (“CoyCo 1”), CoyCo 2, L.P. (“CoyCo 2” and, together with CoyCo 1, the “Sellers”), and, solely for certain purposes set forth therein, NMC Ranger Holdings, LLC, the Company purchased Cloudmed, a leader in Revenue Intelligence™ solutions for healthcare providers, and affiliated entities (collectively, the “Cloudmed entities”), through (i) a merger of R1 Merger Sub with and into Old R1 RCM with Old R1 RCM as the surviving entity, which resulted in Old R1 RCM becoming a wholly-owned subsidiary of the Company (the “Holding Company Reorganization”) and (ii) the Sellers contributing 100% of the equity of a blocker parent corporation of the Cloudmed entities in exchange for an aggregate of 135,929,742 shares of common stock, par value $0.01 per share, of the Company (“Company Common Stock”), subject to certain adjustments following the closing as set forth in the Transaction Agreement (the “Cloudmed Acquisition”, and together with the Holding Company Reorganization, the “Transactions”). For further details on the total consideration paid, refer to Note 2, Acquisitions. In October 2022, the Company finalized those adjustments, resulting in an additional 55,846 shares issued to the Sellers.

Cloudmed’s revenue intelligence platform combines cloud-based data architecture and deep domain expertise with intelligent automation to analyze large volumes of medical records, payment data, and complex medical insurance models to identify opportunities to deliver additional revenue to customers. The Company believes this transaction will enable the Company to further its ability to deliver transformative value to healthcare providers through a more fulsome platform of differentiated capabilities by creating a scaled leader across both end-to-end revenue cycle management (“RCM”) and technology-driven revenue intelligence.

Holding Company Reorganization

Pursuant to the Transaction Agreement, immediately prior to the completion of the Cloudmed Acquisition, Old R1 RCM implemented the Holding Company Reorganization, which resulted in the Company owning all of the capital stock of Old R1 RCM. Each share of Old R1 RCM’s common stock that was issued and outstanding immediately prior to the Holding Company Reorganization was automatically exchanged into an equivalent corresponding share of Company Common Stock, having the same designations, rights, powers, and preferences and the qualifications, limitations, and restrictions as the corresponding share of common stock of Old R1 RCM being converted. Accordingly, upon consummation of the Holding Company Reorganization, all Old R1 RCM stockholders became stockholders of the Company. Immediately prior to the consummation of the Holding Company Reorganization, the name of Old R1 RCM was changed to “R1 RCM Holdco Inc.” and the name of the Company was changed to “R1 RCM Inc.” The Company is the successor issuer to Old R1 RCM pursuant to Rule 12g-3(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The shares of Company Common Stock, as successor to Old R1 RCM, began trading on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “RCM” on June 22, 2022.
Basis of Presentation
The accompanying unaudited consolidated financial statements reflect the Company’s financial position as of September 30, 2022, the results of operations of the Company for the three and nine months ended September 30, 2022 and 2021, and the cash flows of the Company for the nine months ended September 30, 2022 and 2021. These financial statements include the accounts of R1 RCM Inc. and its wholly-owned subsidiaries, including Cloudmed and its subsidiaries since the date of the acquisition. All material intercompany amounts have been eliminated in consolidation. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial reporting and as required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the interim financial information, have been included. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2022.
When preparing financial statements in conformity with GAAP, the Company makes a number of significant estimates, assumptions, and judgments in the preparation of the financial statements. Actual results could differ from those estimates. For a more complete discussion of the Company’s significant accounting policies and other information, the unaudited consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements included in the Company’s 2021 Form 10-K.
Recently Issued Accounting Standards and Disclosures

In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 requires companies to apply Topic 606, Revenue from Contracts with Customers, to recognize and measure contract assets and contract liabilities obtained in a business combination. The ASU amendments will generally result in the recognition of contract assets and contract liabilities by the acquirer at amounts consistent with those recorded by the acquiree immediately before the acquisition date. The Company prospectively adopted ASU 2021-08 effective April 1, 2022 and preliminarily recognized contract assets of $92.4 million and contract liabilities of $3.3 million as part of the Cloudmed Acquisition.

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual sale restriction on an equity security should not be considered in measuring the security’s fair value. The Company will adopt ASU 2022-03 prospectively effective January 1, 2024 and is currently evaluating the impact of the standard on its consolidated financial statements.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions
9 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Acquisitions Acquisitions
Assets acquired and liabilities assumed in a business combination are recorded at their estimated fair value on the date of the acquisition. The difference between the purchase price amount and the net fair value of assets acquired and liabilities assumed is recognized as goodwill on the balance sheet if the purchase price exceeds the estimated net fair value or as a bargain purchase gain on the income statement if the purchase price is less than the estimated net fair value. The allocation of the purchase price may be modified up to one year after the acquisition date as more information is obtained about the fair value of assets acquired and liabilities assumed.

Cloudmed

On June 21, 2022, the Company completed the acquisition of Cloudmed for a purchase price of $3.3 billion. The following table summarizes the fair value of the total consideration paid:
Fair Value
Stock consideration transferred to the Sellers (1)$2,389.5 
Cash consideration (2)879.8 
Replacement awards issued to Cloudmed equity award holders (3)11.3 
Total consideration3,280.6 

(1) The stock consideration fair value includes a preliminary discount for lack of marketability factor related to an 18-month lock-up period during which the Sellers may not sell their Company common stock.
(2) Cash consideration includes the repayment of Cloudmed’s pre-existing credit facility that was paid off at closing and was not assumed by the Company.
(3) Represents the pre-acquisition service portion of the fair value of 1,536,220 replacement restricted stock units (“RSUs”) issued to Cloudmed equity award holders at closing.

The Company funded the cash consideration component and the Company’s associated transaction expenses with a combination of cash on hand and the incurrence of additional indebtedness (see Note 8, Debt).

The purchase price has been provisionally allocated to assets acquired and liabilities assumed based on their fair value as of the acquisition date. The fair value estimate of assets acquired and liabilities assumed is pending the completion of various elements, including gathering further information about the identification and completeness of all assets and liabilities acquired, the finalization of an independent appraisal and valuation of the fair value of the assets acquired and liabilities assumed, and final review by the Company’s management. Some of the more significant amounts that are not yet finalized relate to the fair value of intangible assets (including goodwill), contract assets, contract liabilities, and income and non-income related taxes. Accordingly, management considers the balances shown in the following table to be preliminary, and there could be adjustments to the consolidated financial statements, including changes in our amortization expense related to the valuation of intangible assets acquired and their respective useful lives, among other adjustments.

The preliminary fair value of assets acquired and liabilities assumed is:
Purchase Price Allocation
Total purchase consideration$3,280.6 
Allocation of consideration to assets acquired and liabilities assumed:
Cash and cash equivalents$32.1 
Accounts receivable61.8 
Current portion of contract assets68.5 
Property, equipment and software5.0 
Operating lease right-of-use assets25.3 
Non-current portion of contract assets23.9 
Intangible assets1,370.1 
Goodwill1,994.7 
Other assets6.4 
Accounts payable(31.9)
Customer liabilities(3.3)
Accrued compensation and benefits(91.8)
Operating lease liabilities(25.4)
Deferred income tax liabilities(142.0)
Other liabilities(12.8)
Net assets acquired$3,280.6 

The intangible assets identified in conjunction with the Cloudmed Acquisition and their preliminary fair values are as follows:

Useful LifeGross Carrying Value
Customer Relationships
18 years
$318.0 
Technology
7 years
$1,052.0 
Favorable leasehold interestsLife of lease$0.1 

The goodwill recognized is primarily attributable to growth and cost reduction synergies that are expected to be achieved from the integration of Cloudmed. None of the goodwill is expected to be deductible for income tax purposes.

Included in the Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2022 are net sales of $120.2 million and $133.5 million, respectively, and net income before taxes of $1.3 million and $0.9 million, respectively, related to the operations of Cloudmed since the acquisition date of June 21, 2022.

Measurement period adjustments

The Company had various measurement period adjustments due to additional information received since the Cloudmed Acquisition, none of which were material.
Prior Acquisitions

During 2021, the Company acquired the following business:

Company NameDescription of the BusinessDescription of the Acquisition
iVinci Partners, LLC d/b/a VisitPay (“VisitPay”)
Provider of digital payment solutions
Purchased all outstanding equity interests

In 2020, the Company purchased certain assets relating to the RevWorks services business from Cerner Corporation. In accordance with the purchase agreement, the Company paid the first deferred payment of $12.5 million in the third quarter of 2021. The remaining deferred payment of $12.5 million was payable on the second anniversary of the closing date (August 2022) and is included in other accrued expenses on the Consolidated Balance Sheet as of September 30, 2022 as it had not been paid as of such date.

The two deferred payments related to the RevWorks acquisition were contractual obligations of the Company; however, they are refundable to the Company if certain RevWorks customer revenue targets defined in the purchase agreement for the first two years following the acquisition are not achieved. At the time of the acquisition, the Company recorded an asset for the fair value of the contingently refundable consideration of $22.3 million. As of September 30, 2022, the entire amount of the contingently refundable consideration of $25.0 million is included in prepaid expenses and other current assets on the Consolidated Balance Sheet. The parties are currently engaging in arbitration to finalize the remaining deferred payment and contingently refundable consideration amounts.

Pro Forma Results

The following table summarizes, on a pro forma basis, the combined results of the Company as though the Cloudmed Acquisition had occurred as of January 1, 2021 and the VisitPay acquisition had occurred as of January 1, 2020. These pro forma results are not necessarily indicative of the actual consolidated results had the acquisitions occurred as of those dates or of the future consolidated operating results for any period. Pro forma results are:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net services revenue$496.0 $464.6 $1,476.9 $1,321.5 
Net loss$(22.9)$(20.3)$(21.5)$(112.4)

Adjustments were made to earnings to adjust depreciation and amortization to reflect the fair value of identified assets acquired, to adjust share-based compensation expense for awards granted in connection with the acquisitions, to record the effects of extinguishing the debt of the acquired companies and replacing it with the debt of the Company, to adjust timing of acquisition related costs incurred by the Company, and to record the income tax effect of these adjustments.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets
9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Intangible AssetsThe following table provides the gross carrying value and accumulated amortization for each major class of definite-lived intangible assets at September 30, 2022 and December 31, 2021:
September 30, 2022December 31, 2021
Gross Carrying ValueAccumulated AmortizationNet Book ValueGross Carrying ValueAccumulated AmortizationNet Book Value
Customer relationships$418.0 $(30.4)$387.6 $100.0 $(20.8)$79.2 
Technology1,267.5 (88.3)1,179.2 215.5 (30.2)185.3 
Tradename1.0 (0.4)0.6 1.0 (0.1)0.9 
Favorable leasehold interests0.1 — 0.1 — — — 
Total intangible assets$1,686.6 $(119.1)$1,567.5 $316.5 $(51.1)$265.4 

Intangible asset amortization expense was $49.2 million and $68.0 million for the three and nine months ended September 30, 2022, respectively, and $7.1 million and $15.8 million for the three and nine months ended September 30, 2021, respectively. Amortization expense for intangible assets is included in cost of services on the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss). The Company has no indefinite-lived intangible assets.

Estimated annual amortization expense related to intangible assets with definite lives as of September 30, 2022 is as follows:

Remainder of 2022$49.0 
2023196.3 
2024194.5 
2025192.9 
2026192.9 
2027192.9 
Thereafter549.0 
Total$1,567.5 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill
9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill Goodwill
Changes in the carrying amount of goodwill for the nine months ended September 30, 2022 were:

Goodwill
Balance as of December 31, 2021
$554.7 
Cloudmed Acquisition1,994.7 
Change in foreign currency rates(0.1)
Balance as of September 30, 2022
$2,549.3 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition
9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Revenue is measured based on consideration specified in a contract with a customer, and presented net of any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a service to a customer, which is typically over the contact term. Estimates of variable consideration are included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved.

Disaggregation of Revenue

In the following table, revenue is disaggregated by source of revenue:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net operating fees$324.2 $308.5 $965.3 $879.8 
Incentive fees20.8 41.5 80.9 108.0 
Modular and other (1)151.0 29.7 227.4 87.9 
Net services revenue$496.0 $379.7 $1,273.6 $1,075.7 

(1) Modular and other revenue primarily consists of service fees related to Cloudmed and R1 EntriTM Pay, physician advisory services (“PAS”), practice management (“PM”) services, and software subscription revenue.

Contract Balances

The following table provides information about contract assets and contract liabilities from contracts with customers:

September 30, 2022December 31, 2021
Contract assets
Current$74.4 $— 
Non-current30.8 — 
Total contract assets$105.2 $— 
Contract liabilities
Current (1)$28.4 $10.3 
Non-current (2)19.4 18.7 
Total contract liabilities$47.8 $29.0 

(1) Current contract liabilities include $26.5 million and $7.8 million classified in the current portion of customer liabilities and $1.9 million and $2.5 million classified in the current portion of customer liabilities - related party as of September 30, 2022 and December 31, 2021, respectively.
(2) Non-current contract liabilities include $5.3 million and $3.3 million classified in the non-current portion of customer liabilities and $14.1 million and $15.4 million classified in the non-current portion of customer liabilities - related party as of September 30, 2022 and December 31, 2021, respectively.

The contract assets balance will increase or decrease based on the timing of invoices and recognition of revenue. Prior to the Cloudmed Acquisition, the Company did not have significant contract assets. Significant changes in the carrying amount of contract assets for the three months ended September 30, 2022 were as follows:

Contract Assets
Balance as of June 30, 2022$89.6 
Revenue recognized84.4 
Amounts billed(73.0)
Other (1)4.2 
Balance as of September 30, 2022
$105.2 

(1) Other primarily includes measurement period adjustments to the contract assets acquired from the Cloudmed Acquisition.
The Company recognized revenue of $93.4 million and $99.7 million during the nine months ended September 30, 2022 and 2021, which amounts were included in contract liabilities on January 1 of the respective periods. These revenue amounts include $85.8 million and $88.1 million for the nine months ended September 30, 2022 and 2021, respectively, related to advanced billings which become accounts receivable and contract liabilities on the first day of the respective service period.

Refer to Note 2, Acquisitions, for the preliminary contract assets acquired and contract liabilities assumed as part of the Cloudmed Acquisition.

Transaction Price Allocated to the Remaining Performance Obligation

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. The estimated revenue does not include amounts of variable consideration that are constrained.

Net operating feesIncentive fees
Remainder of 2022$36.1 $17.8 
2023109.6 23.3 
202491.2 — 
202539.2 — 
202638.5 — 
202732.9 — 
Thereafter122.0 — 
Total$469.5 $41.1 
    
The amounts presented in the table above include variable fee estimates of the Company’s physician groups RCM services contracts, fixed fees, and forecasted incentive fees. Fixed fees are typically recognized ratably as the performance obligation is satisfied and forecasted incentive fees are measured cumulatively over the contractually defined performance period.

Estimates of revenue expected to be recognized in future periods exclude unexercised customer options to purchase services within the Company’s PAS contracts that do not represent material rights to the customer.
The Company does not disclose information about remaining performance obligations with an original expected duration of one year or less and has elected an exemption to the disclosure requirements related to estimate variable consideration and an exemption where the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the entity’s performance completed to date.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounts Receivable and Allowance for Credit Losses
9 Months Ended
Sep. 30, 2022
Receivables [Abstract]  
Accounts Receivable and Allowance for Credit Losses Accounts Receivable and Allowance for Credit LossesAccounts receivable is comprised of unpaid balances pertaining to modular services and end-to-end RCM customers, net receivable balances for end-to-end RCM customers after considering cost reimbursements owed to such customers, including related accrued balances, and amounts due from physician RCM and PM customers.
The Company evaluates its accounts receivable for expected credit losses quarterly. The Company maintains an estimated allowance for credit losses to reduce its accounts receivable to the amount that it believes will be collected. This allowance is based on the Company’s historical experience, its assessment of each customer’s ability to pay, the length of time a balance has been outstanding, input from key Company resources assigned to each customer, the status of any ongoing operations with each applicable customer, and business and industry factors such as significant shifts in the healthcare environment which the Company believes may have impacted or will impact its customers’ financial health and ability to pay.

During the three months ended September 30, 2022, the Company increased the allowance for credit losses related to a physician customer by $9.5 million due to the customer facing financial challenges and its resulting inability to make a contractually required payment on September 30, 2022. As a result of reviewing the potential expected outcomes related to this customer, the Company recorded an allowance for credit losses of $10.0 million related to an overall receivable balance of $33.3 million as of September 30, 2022.

The Company has presented the rollforward below on a consolidated basis as the currently expected credit losses for its large integrated healthcare system customers are not anticipated to be material.

Movements in the allowance for credit losses are as follows (in millions):

 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Beginning balance$4.4 $2.3 $2.5 $3.8 
Cumulative effect of Cloudmed ASC 326 adoption
— — 1.8 — 
Provision (recoveries)10.4 0.4 10.7 0.6 
Write-offs(0.2)(0.3)(0.4)(2.0)
Ending balance$14.6 $2.4 $14.6 $2.4 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases
9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Leases Leases
The components of lease costs are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Operating lease cost$6.9 $4.0 $16.8 $12.1 
Sublease income(0.4)(0.6)(1.3)(1.7)
Total lease cost$6.5 $3.4 $15.5 $10.4 

Supplemental cash flow information related to leases are as follows:

Nine Months Ended September 30,
20222021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases$17.6 $18.6 
Right-of-use assets obtained in exchange for operating lease obligations:67.6 13.6 

Refer to Note 2, Acquisitions, for the preliminary right-of-use assets acquired and lease liabilities assumed as part of the Cloudmed Acquisition.

Maturities of lease liabilities as of September 30, 2022 are as follows:
Operating Leases
Remainder of 2022$9.3 
202324.6 
202423.9 
202522.6 
202616.8 
202710.8 
Thereafter40.8 
Total148.8 
Less:
Imputed interest(28.8)
Present value of lease liabilities$120.0 
.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt
9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Debt Debt
The carrying amounts of debt consist of the following:

September 30, 2022December 31, 2021
Senior Revolver (1)$80.0 $80.0 
Term A Loans1,222.5 695.6 
Term B Loan500.0 — 
Unamortized discount and issuance costs(24.9)(3.2)
Total debt1,777.6 772.4 
Less: Current maturities(49.5)(17.5)
Total long-term debt$1,728.1 $754.9 

(1) As of September 30, 2022, the Company had $80.0 million in borrowings, $0.9 million letters of credit outstanding, and $519.1 million of availability under the Senior Revolver.

Second Amended and Restated Senior Secured Credit Facilities

On June 21, 2022, the Company, Old R1 RCM, and certain of its subsidiaries entered into a second amended and restated senior credit agreement (the “Second A&R Credit Agreement”) with Bank of America, N.A., as administrative agent, and the lenders named therein, governing the Company’s second amended and restated senior secured credit facilities (the “Senior Secured Credit Facilities”), consisting of the $691.3 million existing senior secured term loan A facility (the “Existing Term A Loan”), a $540.0 million senior secured incremental term loan A facility (the “Incremental Term A Loan”, and together with the Existing Term A Loan, the “Term A Loans”), a $500.0 million senior secured term loan B facility (the “Term B Loan”, and together with the Term A Loans, the “Senior Term Loans”), and a $600.0 million senior secured revolving credit facility (the “Senior Revolver”). In conjunction with entering into the Second A&R Credit Agreement, the Company incurred $7.2 million and capitalized $6.4 million of debt issuance costs.

The Incremental Term A Loan has a five-year maturity and the Term B Loan has a seven-year maturity. The Existing Term A Loan and Senior Revolver mature on July 1, 2026. The Second A&R Credit Agreement provides that the Company may make one or more offers to the lenders, and consummate transactions with individual lenders that accept the terms contained in such offers, to extend the maturity date of the lender’s term loans and/or revolving commitments, subject to certain conditions, and any extended term loans or revolving commitments will constitute a separate class of term loans or revolving commitments.
Borrowings under the Senior Secured Credit Facilities bear interest, at the Company’s option, at: (i) an Alternate Base Rate (“ABR”) equal to the greater of (a) the prime rate of Bank of America, N.A., (b) the federal funds rate plus 0.50% per annum, and (c) the Term Secured Overnight Financing Rate (“SOFR”) for an interest period of one-month beginning on such day plus 100 basis points, plus between 0.25% and 1.50% dependent on the Company’s total net leverage ratio (provided that the Term SOFR rate applicable to the Term A Loans shall not be less than 0.00% per annum, and the Term SOFR rate applicable to the Term B Loan shall not be less than 0.50% per annum); or (ii) the Term SOFR rate (provided that the Term SOFR rate applicable to the Term A Loans shall not be less than 0.00% per annum, and the Term SOFR rate applicable to the Term B Loan shall not be less than 0.50% per annum), plus between 1.25% and 2.50%, dependent on the Company’s total net leverage ratio. The interest rate as of September 30, 2022 was 5.28% for the Term A Loans and Senior Revolver and 6.03% for the Term B Loan. The Company is also required to pay an unused commitment fee to the lenders under the Senior Revolver at a rate between 0.20% and 0.40% of the average daily unutilized commitments thereunder dependent on the Company’s total net leverage ratio.

The Second A&R Credit Agreement requires the Company to make mandatory prepayments, subject to certain exceptions, with: (i) beginning with fiscal year ending December 31, 2023, 50% (which percentage will be reduced upon the Company’s achievement of certain total net leverage ratios) of the Company’s annual excess cash flow, (ii) 100% of net cash proceeds of all non-ordinary course asset sales or other dispositions of property or casualty events, subject to certain exceptions and thresholds, and (iii) 100% of the net cash proceeds of any debt incurrence, other than debt permitted under the Second A&R Credit Agreement.

The Second A&R Credit Agreement contains a number of financial and non-financial covenants. The Company was in compliance with all of the covenants in the Second A&R Credit Agreement as of September 30, 2022. The obligations under the Second A&R Credit Agreement are secured by a pledge of 100% of the capital stock of certain domestic subsidiaries owned by the Company and a security interest in substantially all of the Company’s tangible and intangible assets and the tangible and intangible assets of certain domestic subsidiaries.

The proceeds from the new Senior Secured Credit Facilities were or will be used, in addition to cash on hand, (1) to refinance, in full, all existing indebtedness under the Amended and Restated Credit Agreement, dated as of July 1, 2021, by and among Old R1 RCM and certain of its subsidiaries, Bank of America, N.A., as administrative agent, and the lenders named therein, and amend and restate all commitments thereunder (the “Refinancing”), (2) to pay certain fees and expenses incurred in connection with the entry into the Second A&R Credit Agreement and the Refinancing, (3) to fund the Transactions, and to pay the fees, premiums, expenses, and other transaction costs incurred in connection therewith, and (4) to finance working capital needs of the Company and its subsidiaries for general corporate purposes. Debt amounts presented as of December 31, 2021 were incurred under the 2021 Amended and Restated Credit Agreement.

Debt Maturities

Scheduled maturities of the Company’s long-term debt are summarized as follows:
Scheduled Maturities
Remainder of 2022$12.4 
202353.9 
202467.0 
202567.0 
2026698.3 
2027430.2 
Thereafter473.7 
Total$1,802.5 

For further details on the Company’s 2021 Amended and Restated Credit Agreement, refer to Note 10 of the Company’s 2021 Form 10-K.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Derivative Financial Instruments
9 Months Ended
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments Derivative Financial Instruments
The Company utilizes cash flow hedges to manage its currency risk arising from its global business services centers. As of September 30, 2022, the Company has recorded $1.2 million of unrealized losses in accumulated other comprehensive loss related to foreign currency hedges. The Company estimates that $1.1 million of losses reported in accumulated other comprehensive loss are expected to be reclassified into earnings within the next 12 months. Amounts reclassified into cost of services were a net loss of $0.7 million and $0.6 million during the three and nine months ended September 30, 2022, respectively, and a net gain of $0.4 million and $1.0 million during the three and nine month periods ended September 30, 2021, respectively. As of September 30, 2022, the Company’s currency forward contracts have maturities extending no later than December 31, 2023, and had a total notional value of $76.8 million.

The Company also utilizes cash flow hedges to reduce variability in interest cash flows from its outstanding debt. As of September 30, 2022, the Company has recorded $12.9 million of unrealized gains in accumulated other comprehensive loss related to interest rate swaps. The Company estimates that $3.7 million of gains reported in accumulated other comprehensive loss are expected to be reclassified into earnings within the next 12 months. Amounts reclassified into interest expense were a net loss of $0.4 million and $0.9 million during the three and nine months ended September 30, 2022, respectively and a net loss of $0.3 million and $1.1 million during the three and nine month periods ended September 30, 2021, respectively. As of September 30, 2022, the Company’s interest rate swaps extend no later than June 30, 2025, and had a total notional value of $500.0 million.

The location and fair value of derivative instruments designated as hedges in the Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 are as follows:

September 30, 2022December 31, 2021
Foreign currency forward contracts
Prepaid expenses and other current assets$— $1.7 
Other accrued expenses1.2 — 
Total foreign current forward contracts$1.2 $1.7 
Interest rate swaps
Prepaid expenses and other current assets$3.7 $— 
Other assets9.2 — 
Other accrued expenses— 0.7 
Total interest rate swaps$12.9 $0.7 
As of September 30, 2022 and December 31, 2021, the accumulated gain, net of tax, recognized in accumulated other comprehensive loss was $8.8 million and $0.7 million, respectively.

The Company classifies cash flows from its derivative programs as cash flows from operating activities in the consolidated statements of cash flows. Fair values for derivative financial instruments are based on prices computed using third-party valuation models and are classified as Level 2 in accordance with the three-level hierarchy of fair value measurements.
On July 5, 2022, the Company entered into an agreement with a third party regarding the potential purchase of a business that would expand the service capabilities of the Company. This agreement is effective through approximately the end of 2023 and allows the other party to sell the business to the Company for $150.0 million, subject to the negotiation of a definitive agreement and the satisfaction of agreed upon closing conditions, including the requirement that the purchase price be deemed to be fair value at the time of the potential transaction. The parties, assuming an agreement is reached, would also need to reach agreement as to whether the purchase price would be paid in cash or shares of common stock of the Company.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
The share-based compensation expense relating to the Company’s stock options, RSUs, and performance-based restricted stock units (“PBRSUs”) for the three months ended September 30, 2022 and 2021 was $27.8 million and $25.5 million, respectively, with related tax benefits of approximately $4.6 million and $5.1 million, respectively. The share-based compensation expense relating to the Company’s stock options, RSUs, and PBRSUs for the nine months ended September 30, 2022 and 2021 was $49.5 million and $62.0 million, respectively, with related tax benefits of approximately $8.5 million and $12.2 million, respectively.

The Company accounts for forfeitures as they occur. Excess tax benefits and shortfalls for share-based payments are recognized in income tax expense (benefit) and included in operating activities. The Company recognized $4.3 million and $0.6 million of income tax benefit from windfalls associated with vesting and exercises of equity awards for the three months ended September 30, 2022 and 2021, respectively. The Company recognized $9.2 million and $7.2 million of income tax benefit from windfalls associated with vesting and exercises of equity awards for the nine months ended September 30, 2022 and 2021, respectively.
Total share-based compensation costs that have been included in the Company’s consolidated statements of operations were as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Share-Based Compensation Expense Allocation Details:
Cost of services$12.3 $15.8 $21.7 $38.8 
Selling, general and administrative15.4 9.7 27.7 23.2 
Other0.1 — 0.1 — 
Total share-based compensation expense$27.8 $25.5 $49.5 $62.0 
The Company uses the Black-Scholes option pricing model to estimate the fair value of its service-based options as of their grant dates. The Company assesses current performance on performance-based PBRSUs by reviewing historical performance to date, along with any adjustments which have been approved to the reported performance, and changes to the projections to determine the probable outcome of the awards. The current estimates are then compared to the scoring metrics and any necessary adjustments are reflected in the current period to update share-based compensation expense to the current performance expectations.
Stock options
A summary of the options activity during the nine months ended September 30, 2022 is shown below:

OptionsWeighted-
Average
Exercise
Price
Outstanding at December 31, 20214,386,205 $3.37 
Granted24,344 22.19 
Exercised(1,279,460)3.67 
Canceled/forfeited(13,408)4.59 
Expired(7,500)8.71 
Outstanding at September 30, 20223,110,181 $3.38 
Outstanding, vested and exercisable at September 30, 20223,084,188 $3.22 
Outstanding, vested and exercisable at December 31, 20214,365,759 $3.33 
Restricted stock units and performance-based restricted stock units    
A summary of the RSU and PBRSU activity during the nine months ended September 30, 2022 is shown below:
Weighted-
Average Grant
Date Fair Value
RSUsPBRSUsRSUPBRSU
Outstanding and unvested at December 31, 20212,218,651 3,203,013 $16.28 $16.45 
Granted2,249,157 5,230,483 20.62 19.83 
Performance factor adjustment— 876,109 — 10.46 
Vested(574,564)(1,878,328)14.49 11.19 
Forfeited(164,414)(201,544)17.41 19.87 
Outstanding and unvested at September 30, 20223,728,830 7,229,733 $19.12 $19.44 
Shares surrendered for taxes for the nine months ended September 30, 2022
182,080 783,392 
Cost of shares surrendered for taxes for the nine months ended September 30, 2022 (in millions)
$4.1 $20.0 
Shares surrendered for taxes for the nine months ended September 30, 2021
186,588 — 
Cost of shares surrendered for taxes for the nine months ended September 30, 2021 (in millions)
$4.8 $— 
Upon consummation of the Holding Company Reorganization, outstanding restricted units of Cloudmed were replaced by an aggregate 1,536,220 RSUs of the Company. The Company also issued an aggregate of 3,173,184 inducement RSUs and PBRSUs to certain employees of Cloudmed under Nasdaq Listing Rule 5635(c)(4) pursuant to its newly adopted 2022 Inducement Plan.

The Company’s RSU and PBRSU agreements allow employees to surrender to the Company shares of common stock upon vesting of their RSUs and PBRSUs in lieu of their payment of the required personal employment-related taxes. Shares surrendered for payment of personal employment-related taxes are held in treasury.
Outstanding PBRSUs vest upon satisfaction of both time-based and performance-based conditions. Depending on the award, performance condition targets may include cumulative adjusted EBITDA, end-to-end RCM agreement growth, modular sales revenue, or other specific performance factors. Depending on the percentage level at which the performance-based conditions are satisfied, the number of shares vesting could be between 0% and 200% of the number of PBRSUs originally granted. Based on the established targets, the maximum number of shares that could vest for all outstanding PBRSUs is 14,412,591.
CoyCo 2, L.P. Limited Partnership Units    

As part of the transactions contemplated by the Transaction Agreement, equity awards held by certain employees of Cloudmed (“Former Class P Units”) were modified, through a series of transactions, into awards (“Management Units”) of CoyCo 2. The Management Units issued by CoyCo 2 are treated as share-based compensation under ASC 718, Compensation —Stock Compensation.

The Former Class P Units were originally issued to employees of Cloudmed and its affiliates (“Participants”) in connection with and as a part of the compensation and incentive arrangements between Cloudmed and such Participants prior to the consummation of the Cloudmed Acquisition. A portion of the Former Class P Units immediately vested upon the closing of the Cloudmed Acquisition; however, certain Former Class P Units that were subject to performance-based vesting conditions did not become vested upon the closing of the Cloudmed Acquisition (“Unvested Units”). However, in connection with the Cloudmed Acquisition, Cloudmed caused the Former Class P Units, including the Unvested Units, to be converted into Management Units. At the time of the closing of the Cloudmed Acquisition, 97,875 Unvested Units were converted into 514,986 Management Units.

In general, Unvested Units vest upon the achievement of certain performance criteria, including achievement by the Sellers’ owner, New Mountain Capital, L.L.C. (“New Mountain”), of (i) specified multiples of Base Equity Value (“BEV”) (i.e., generally the aggregate equity value of New Mountain’s investment in Cloudmed as of the original grant date), or (ii) specified Multiples on Invested Capital (“MIC”) with respect to New Mountain Capital’s pre-Cloudmed Acquisition investment in Cloudmed, and subject to continued service with the Company and its affiliates, including Cloudmed through the applicable vesting date. The awards are not awards of the Company and the Participants will receive no additional shares of the Company upon satisfaction of the vesting criteria. However, GAAP requires the Company recognize the cost of share-based compensation granted by an investor (CoyCo 2) to the Company’s employees and service providers for services that benefit the Company’s operations, and a corresponding capital contribution because the costs are incurred on the Company’s behalf.
A Monte Carlo simulation was used to estimate the fair value of the Unvested Units which is being amortized over a period of 4 years on a straight-line basis.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Expenses
9 Months Ended
Sep. 30, 2022
Other Income and Expenses [Abstract]  
Other Expenses Other Expenses Other expenses are incurred in connection with acquisition and integration costs, various exit activities, transformation initiatives, and organizational changes to improve our business alignment and cost structure. The following table summarizes the other expenses (income) recognized for the three and nine months ended September 30, 2022 and 2021.
Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Severance and related employee benefits (1)$— $0.3 $— $2.1 
Business acquisition costs (2)0.2 2.3 74.4 4.2 
Integration costs (3)8.8 — 18.3 2.6 
Strategic initiatives (4)6.2 2.5 9.0 6.4 
Global business services center expansion project in the Philippines (5)10.0 — 20.0 — 
Customer employee transition and restructuring expenses (6)— 3.2 (0.4)3.2 
Facility-exit charges (7)1.3 — 7.3 2.9 
Other (8)3.6 3.1 7.5 12.8 
Total other expenses$30.1 $11.4 $136.1 $34.2 
(1) These costs relate to restructuring and business reorganization events.
(2) These are costs, including legal, consulting, and bank fees, that are directly related to the close of the Cloudmed Acquisition on June 21, 2022 and the close of the VisitPay acquisition on July 1, 2021 and include changes to contingent consideration, if applicable.
(3) These costs reflect efforts to integrate acquisitions from a systems, processes, and people perspective. Costs include consulting fees, IT vendor spend, severance, early lease termination of Cloudmed facilities, and certain payroll costs.
(4) These costs relate to performing portfolio and capital structure analyses and transactions and other business transformation projects (including large scale system projects) as part of the Company’s growth strategy. Costs include vendor spend, employee time and expenses spent on activities, severance, and retention amounts.
(5) These costs include legal and consulting fees related to the establishment of the Company’s inaugural global business services center in the Philippines as well as severance costs for personnel whose roles are being relocated. The entry into the Philippines is the first new organic global business services center country expansion by the Company in approximately 15 years.
(6) As part of the transition of customer personnel to the Company under certain operating partner model contracts, the Company agreed to reimburse the customer, or directly pay affected employees, for severance and retention costs related to certain employees who were not transitioned to the Company, or whose jobs were relocated after the employee transitioned to the Company.
(7) As part of evaluating its footprint, the Company has exited certain leased facilities. Costs include asset impairment charges, early termination fees, and other costs related to exited leased facilities.
(8) For the three and nine months ended September 30, 2022, other includes $0.7 million and $1.8 million, respectively, of expenses related to the COVID-19 pandemic. For the three and nine months ended September 30, 2021, other includes $2.7 million and $7.1 million, respectively, of expenses related to the COVID-19 pandemic.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income TaxesIncome tax provisions for interim periods are based on estimated annual income tax rates, adjusted to reflect the effects of any significant and infrequent or unusual items which are required to be discretely recognized within the current interim period. The effective tax rates in the periods presented are largely based upon the projected annual pre-tax earnings by jurisdiction and the allocation of certain expenses in various taxing jurisdictions where the Company conducts its business. These taxing jurisdictions apply a broad range of statutory income tax rates. The global intangible low-taxed income (“GILTI”) provisions impose taxes on foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company elected to account for GILTI tax in the period in which it is incurred.
The Company recognized income tax expense for the three months ended September 30, 2022 and income tax benefit for the nine months ended September 30, 2022 on the year-to-date pre-tax loss. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for foreign taxes, GILTI, non-deductible expenses, and discrete items.

The Company recognized income tax expense for the three and nine months ended September 30, 2021 on the year-to-date pre-tax income. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for state taxes, GILTI, non-deductible expenses, and discrete items.
The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. U.S. federal income tax returns since 2018 are currently open for examination. State jurisdictions vary for open tax years. The statute of limitations for most states ranges from three to six years.
At December 31, 2021, the Company had gross deferred tax assets of $123.7 million, of which $54.7 million related to net operating loss (“NOL”) carryforwards. The Company expects to be profitable, allowing the Company to utilize its NOL carryforwards and other deferred tax assets.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings (Loss) Per Share
9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Earnings (Loss) Per Share Earnings (Loss) Per Share
Basic net income (loss) per share is computed by dividing net income (loss), less any dividends, accretion or decretion, redemption or induced conversion on the preferred stock, by the weighted average number of common shares outstanding during the period.
Diluted net income (loss) per share is calculated by adjusting the denominator used in the basic net income (loss) per share computation by potentially dilutive securities outstanding during the period plus, when their effect is dilutive, incremental shares consisting of shares subject to stock options and shares issuable upon vesting of RSUs and PBRSUs.
Basic and diluted net income (loss) per common share are calculated as follows:
Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Basic EPS:
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Less dividends on preferred shares (1)— — — (592.3)
Net income (loss) available/(allocated) to common shareholders - basic$(29.5)$17.0 $(20.5)$(531.1)
Diluted EPS:
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Less dividends on preferred shares (1)— — — (592.3)
Net income (loss) available/(allocated) to common shareholders - diluted$(29.5)$17.0 $(20.5)$(531.1)
Basic weighted-average common shares417,700,782 278,655,269 330,877,880 262,209,929 
Add: Effect of dilutive equity awards— 7,281,436 — — 
Add: Effect of dilutive warrants— 34,680,381 — — 
Diluted weighted average common shares417,700,782 320,617,086 330,877,880 262,209,929 
Net income (loss) per common share (basic)$(0.07)$0.06 $(0.06)$(2.03)
Net income (loss) per common share (diluted)$(0.07)$0.05 $(0.06)$(2.03)
(1) The 2021 dividend on preferred shares includes amounts related to the conversion of the preferred shares. See Note 16 of the Company’s 2021 Form 10-K for more information.
Because of their anti-dilutive effect, 21,251,602 common share equivalents comprised of stock options, PBRSUs, and RSUs have been excluded from the diluted earnings per share calculation for the three and nine months ended September 30, 2022. Additionally, for the three and nine months ended September 30, 2022, TCP-ASC ACHI Series LLLP’s (“TCP-ASC” or the “Investor”) and IHC Health Services, Inc.’s (“Intermountain”) exercisable warrants to acquire up to 40.5 million and 1.5 million shares, respectively, of the Company’s common stock have been excluded from the diluted earnings per share calculation because they were anti-dilutive.
For the three and nine months ended September 30, 2021, 890,717 and 15,155,288 common share equivalents, respectively, have been excluded from the diluted earnings per share calculation because of their anti-dilutive effect. Additionally, for the nine months ended September 30, 2021, the Investor’s and Intermountain’s exercisable warrants to acquire up to 40.5 million and 1.5 million shares, respectively, of the Company’s common stock have been excluded from the diluted earnings per share calculation because they were anti-dilutive.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal Proceedings

Other than as described below, the Company is not presently a party to any material litigation or regulatory proceeding and is not aware of any pending or threatened litigation or regulatory proceeding against the Company which, individually or in the aggregate, could have a material adverse effect on its business, operating results, financial condition or cash flows.

On April 13, 2021 and April 19, 2021, respectively, certain purported stockholders of the Company filed two complaints in the Delaware Court of Chancery regarding the Company’s January 15, 2021 recapitalization transaction with TCP-ASC. Both complaints allege that TCP-ASC, Ascension Health (“Ascension”), and TowerBrook Capital Partners (“TowerBrook”) controlled the Company and breached their fiduciary duties by using that alleged control to force the Company to overpay in redeeming TCP-ASC’s preferred stock as part of the recapitalization transaction. The plaintiffs seek an unspecified amount of damages against TCP-ASC, Ascension, and TowerBrook. The plaintiffs also allege that the Company and TCP-ASC entered into amendments to the Investor Rights Agreement that the plaintiffs contend contains provisions that are void under the Company’s charter, bylaws, and the Delaware General Corporation Law. The cases have since been consolidated into a single action. All defendants have answered the complaint and discovery has commenced.

On February 18, 2022, plaintiffs filed a supplement to their complaint, naming certain additional defendants and asserting additional claims related to the Company’s agreement to acquire Cloudmed, which was announced on January 10, 2022. The additional claims assert that: (i) TCP-ASC, Ascension, and TowerBrook, along with the Company’s directors (“Individual Defendants”), breached their fiduciary duties by causing the Company to enter into and approving the Cloudmed acquisition, respectively, which plaintiffs claim will perpetuate TCP-ASC’s, Ascension’s, and TowerBrook’s control over the Company and entrench the Individual Defendants by virtue of certain agreements entered into as part of the transaction, including a Second Amended Investor Rights Agreement with TCP-ASC (the “Seconded Amended Investor Rights Agreement”) and an Investor Rights Agreement with Cloudmed (the “Cloudmed Investor Rights Agreement”); and (ii) Cloudmed’s stockholders aided and abetted such breaches. Plaintiffs also allege that certain provisions in the Cloudmed Investor Rights Agreement and the Second Amended Investor Rights Agreement are void under the Company’s charter, bylaws, and the Delaware General Corporation law. The plaintiffs seek a declaratory judgment and an unspecified amount of damages, as well as attorneys’ fees and costs. The Company believes it has meritorious defenses to all claims against it and intends to vigorously defend itself against these claims.
In May 2016, the Company was served with a False Claims Act case brought by a former emergency department service associate who worked at a hospital of one of the Company’s customers, MedStar Inc.’s Washington Hospital Center (“WHC”), along with WHC and three other hospitals that were PAS customers and a place holder, John Doe hospital, representing all PAS customers (U.S. ex rel. Graziosi vs. Accretive Health, Inc. et. al.), and seeking money damages, False Claims Act penalties, and plaintiff’s attorneys’ fees. The Third Amended Complaint alleges that the Company’s PAS business violates the federal False Claims Act. The case was originally filed under seal in 2013 in the federal district court in Chicago and presented to the U.S. Attorney in Chicago, and the U.S. Attorney declined to intervene. The Company believes that it has meritorious defenses to all claims in the case and intends to vigorously defend itself against these claims. Both the Company’s and plaintiff’s motions for summary judgment were denied in December 2020, and the parties have completed damage and expert discovery. Additional dispositive motions are expected to extend through 2022, with trial, if necessary, in June 2023.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions
9 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
This note encompasses transactions between Ascension and its affiliates, including AMITA Health, and the Company pursuant to the Master Professional Services Agreement, including all supplements, amendments, and other documents entered into in connection therewith. For further details on the Company’s agreements with Ascension, see Note 1 and Note 19 of the Company’s 2021 Form 10-K. In conjunction with the Cloudmed Acquisition, New Mountain became a new related party. There were no material transactions with New Mountain subsequent to the Cloudmed Acquisition.
Net services revenue from services provided to Ascension, as well as corresponding accounts receivable and customer liabilities are presented in the Consolidated Statements of Operations and Comprehensive Income (Loss) and the Consolidated Balance Sheets. Since Ascension is the Company’s largest customer, a significant percentage of the Company’s cost of services is associated with providing services to Ascension. However, due to the nature of the Company’s global business services and information technology operations, it is impractical to assign the dollar amount associated with services provided to Ascension.

On May 27, 2021 and May 28, 2021, the Company issued 16,750,000 shares of common stock to TCP-ASC upon the cashless exercise of a warrant to purchase 19,535,145 shares of common stock at an exercise price of $3.50 per share based upon a market value of $24.54 to $24.64 per share as determined under the terms of the warrant.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segments and Customer Concentrations
9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Segments and Customer Concentrations Segments and Customer Concentrations
The Company has determined that it has a single operating segment in accordance with the way that management operates and views the business. All of the Company’s significant operations are organized around the single business of providing end-to-end management services of revenue cycle operations for U.S.-based healthcare providers. Accordingly, for purposes of segment disclosures, the Company has only one operating and reportable segment.
Customers comprising greater than 10% of net services revenue are as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
Customer Name2022202120222021
Ascension and its affiliates44 %60 %52 %61 %
Intermountain Healthcare11 %14 %13 %14 %
The loss of customers within the Ascension health system or Intermountain network could have a material adverse impact on the Company’s operations.
As of September 30, 2022 and December 31, 2021, the Company had a concentration of credit risk with Ascension, representing 12% and 17% of accounts receivable, respectively.
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Supplemental Financial Information
9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental Financial Information Supplemental Financial Information
The following table summarizes the allocation of depreciation and amortization expense related to property, equipment and software between cost of services and selling, general and administrative expenses:
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Cost of services$14.7 $13.6 $39.0 $38.8 
Selling, general and administrative0.3 0.6 0.8 2.2 
Total depreciation and amortization$15.0 $14.2 $39.8 $41.0 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Description and Basis of Presentation (Policies)
9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited consolidated financial statements reflect the Company’s financial position as of September 30, 2022, the results of operations of the Company for the three and nine months ended September 30, 2022 and 2021, and the cash flows of the Company for the nine months ended September 30, 2022 and 2021. These financial statements include the accounts of R1 RCM Inc. and its wholly-owned subsidiaries, including Cloudmed and its subsidiaries since the date of the acquisition. All material intercompany amounts have been eliminated in consolidation. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial reporting and as required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the interim financial information, have been included. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2022.
When preparing financial statements in conformity with GAAP, the Company makes a number of significant estimates, assumptions, and judgments in the preparation of the financial statements. Actual results could differ from those estimates.
Recently Issued Accounting Standards and Disclosures
Recently Issued Accounting Standards and Disclosures

In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 requires companies to apply Topic 606, Revenue from Contracts with Customers, to recognize and measure contract assets and contract liabilities obtained in a business combination. The ASU amendments will generally result in the recognition of contract assets and contract liabilities by the acquirer at amounts consistent with those recorded by the acquiree immediately before the acquisition date. The Company prospectively adopted ASU 2021-08 effective April 1, 2022 and preliminarily recognized contract assets of $92.4 million and contract liabilities of $3.3 million as part of the Cloudmed Acquisition.

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual sale restriction on an equity security should not be considered in measuring the security’s fair value. The Company will adopt ASU 2022-03 prospectively effective January 1, 2024 and is currently evaluating the impact of the standard on its consolidated financial statements.
Revenue Recognition Revenue RecognitionRevenue is measured based on consideration specified in a contract with a customer, and presented net of any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a service to a customer, which is typically over the contact term. Estimates of variable consideration are included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved.
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions (Tables)
9 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Schedule of Fair Value of Total Consideration Paid and Schedule of Acquisitions During 2021 The following table summarizes the fair value of the total consideration paid:
Fair Value
Stock consideration transferred to the Sellers (1)$2,389.5 
Cash consideration (2)879.8 
Replacement awards issued to Cloudmed equity award holders (3)11.3 
Total consideration3,280.6 

(1) The stock consideration fair value includes a preliminary discount for lack of marketability factor related to an 18-month lock-up period during which the Sellers may not sell their Company common stock.
(2) Cash consideration includes the repayment of Cloudmed’s pre-existing credit facility that was paid off at closing and was not assumed by the Company.
(3) Represents the pre-acquisition service portion of the fair value of 1,536,220 replacement restricted stock units (“RSUs”) issued to Cloudmed equity award holders at closing.
During 2021, the Company acquired the following business:

Company NameDescription of the BusinessDescription of the Acquisition
iVinci Partners, LLC d/b/a VisitPay (“VisitPay”)
Provider of digital payment solutions
Purchased all outstanding equity interests
Schedule of Fair Value of Assets Acquired and Liabilities Assumed The preliminary fair value of assets acquired and liabilities assumed is:
Purchase Price Allocation
Total purchase consideration$3,280.6 
Allocation of consideration to assets acquired and liabilities assumed:
Cash and cash equivalents$32.1 
Accounts receivable61.8 
Current portion of contract assets68.5 
Property, equipment and software5.0 
Operating lease right-of-use assets25.3 
Non-current portion of contract assets23.9 
Intangible assets1,370.1 
Goodwill1,994.7 
Other assets6.4 
Accounts payable(31.9)
Customer liabilities(3.3)
Accrued compensation and benefits(91.8)
Operating lease liabilities(25.4)
Deferred income tax liabilities(142.0)
Other liabilities(12.8)
Net assets acquired$3,280.6 
Schedule of Intangible Assets Identified with Acquisition
The intangible assets identified in conjunction with the Cloudmed Acquisition and their preliminary fair values are as follows:

Useful LifeGross Carrying Value
Customer Relationships
18 years
$318.0 
Technology
7 years
$1,052.0 
Favorable leasehold interestsLife of lease$0.1 
Schedule of Pro Forma Results
The following table summarizes, on a pro forma basis, the combined results of the Company as though the Cloudmed Acquisition had occurred as of January 1, 2021 and the VisitPay acquisition had occurred as of January 1, 2020. These pro forma results are not necessarily indicative of the actual consolidated results had the acquisitions occurred as of those dates or of the future consolidated operating results for any period. Pro forma results are:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net services revenue$496.0 $464.6 $1,476.9 $1,321.5 
Net loss$(22.9)$(20.3)$(21.5)$(112.4)
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets (Tables)
9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets The following table provides the gross carrying value and accumulated amortization for each major class of definite-lived intangible assets at September 30, 2022 and December 31, 2021:
September 30, 2022December 31, 2021
Gross Carrying ValueAccumulated AmortizationNet Book ValueGross Carrying ValueAccumulated AmortizationNet Book Value
Customer relationships$418.0 $(30.4)$387.6 $100.0 $(20.8)$79.2 
Technology1,267.5 (88.3)1,179.2 215.5 (30.2)185.3 
Tradename1.0 (0.4)0.6 1.0 (0.1)0.9 
Favorable leasehold interests0.1 — 0.1 — — — 
Total intangible assets$1,686.6 $(119.1)$1,567.5 $316.5 $(51.1)$265.4 
Schedule of Estimated Annual Amortization Expense
Estimated annual amortization expense related to intangible assets with definite lives as of September 30, 2022 is as follows:

Remainder of 2022$49.0 
2023196.3 
2024194.5 
2025192.9 
2026192.9 
2027192.9 
Thereafter549.0 
Total$1,567.5 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill (Tables)
9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in Carrying Value of Goodwill
Changes in the carrying amount of goodwill for the nine months ended September 30, 2022 were:

Goodwill
Balance as of December 31, 2021
$554.7 
Cloudmed Acquisition1,994.7 
Change in foreign currency rates(0.1)
Balance as of September 30, 2022
$2,549.3 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition (Tables)
9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregated Revenue By Source In the following table, revenue is disaggregated by source of revenue:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net operating fees$324.2 $308.5 $965.3 $879.8 
Incentive fees20.8 41.5 80.9 108.0 
Modular and other (1)151.0 29.7 227.4 87.9 
Net services revenue$496.0 $379.7 $1,273.6 $1,075.7 
(1) Modular and other revenue primarily consists of service fees related to Cloudmed and R1 EntriTM Pay, physician advisory services (“PAS”), practice management (“PM”) services, and software subscription revenue.
Schedule of Contract Assets and Contract Liabilities
The following table provides information about contract assets and contract liabilities from contracts with customers:

September 30, 2022December 31, 2021
Contract assets
Current$74.4 $— 
Non-current30.8 — 
Total contract assets$105.2 $— 
Contract liabilities
Current (1)$28.4 $10.3 
Non-current (2)19.4 18.7 
Total contract liabilities$47.8 $29.0 

(1) Current contract liabilities include $26.5 million and $7.8 million classified in the current portion of customer liabilities and $1.9 million and $2.5 million classified in the current portion of customer liabilities - related party as of September 30, 2022 and December 31, 2021, respectively.
(2) Non-current contract liabilities include $5.3 million and $3.3 million classified in the non-current portion of customer liabilities and $14.1 million and $15.4 million classified in the non-current portion of customer liabilities - related party as of September 30, 2022 and December 31, 2021, respectively.

The contract assets balance will increase or decrease based on the timing of invoices and recognition of revenue. Prior to the Cloudmed Acquisition, the Company did not have significant contract assets. Significant changes in the carrying amount of contract assets for the three months ended September 30, 2022 were as follows:

Contract Assets
Balance as of June 30, 2022$89.6 
Revenue recognized84.4 
Amounts billed(73.0)
Other (1)4.2 
Balance as of September 30, 2022
$105.2 
(1) Other primarily includes measurement period adjustments to the contract assets acquired from the Cloudmed Acquisition.
Schedule of Transaction Price Allocated to the Remaining Performance Obligation
The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. The estimated revenue does not include amounts of variable consideration that are constrained.

Net operating feesIncentive fees
Remainder of 2022$36.1 $17.8 
2023109.6 23.3 
202491.2 — 
202539.2 — 
202638.5 — 
202732.9 — 
Thereafter122.0 — 
Total$469.5 $41.1 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounts Receivable and Allowance for Credit Losses (Tables)
9 Months Ended
Sep. 30, 2022
Receivables [Abstract]  
Schedule of Allowance for Credit Losses
Movements in the allowance for credit losses are as follows (in millions):

 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Beginning balance$4.4 $2.3 $2.5 $3.8 
Cumulative effect of Cloudmed ASC 326 adoption
— — 1.8 — 
Provision (recoveries)10.4 0.4 10.7 0.6 
Write-offs(0.2)(0.3)(0.4)(2.0)
Ending balance$14.6 $2.4 $14.6 $2.4 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Tables)
9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Schedule of Components of Lease Costs and Supplemental Cash Flow Information
The components of lease costs are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Operating lease cost$6.9 $4.0 $16.8 $12.1 
Sublease income(0.4)(0.6)(1.3)(1.7)
Total lease cost$6.5 $3.4 $15.5 $10.4 

Supplemental cash flow information related to leases are as follows:

Nine Months Ended September 30,
20222021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases$17.6 $18.6 
Right-of-use assets obtained in exchange for operating lease obligations:67.6 13.6 
Schedule of Operating Lease Maturity Maturities of lease liabilities as of September 30, 2022 are as follows:
Operating Leases
Remainder of 2022$9.3 
202324.6 
202423.9 
202522.6 
202616.8 
202710.8 
Thereafter40.8 
Total148.8 
Less:
Imputed interest(28.8)
Present value of lease liabilities$120.0 
.
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt (Tables)
9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Carrying Values Long-Term Debt
The carrying amounts of debt consist of the following:

September 30, 2022December 31, 2021
Senior Revolver (1)$80.0 $80.0 
Term A Loans1,222.5 695.6 
Term B Loan500.0 — 
Unamortized discount and issuance costs(24.9)(3.2)
Total debt1,777.6 772.4 
Less: Current maturities(49.5)(17.5)
Total long-term debt$1,728.1 $754.9 

(1) As of September 30, 2022, the Company had $80.0 million in borrowings, $0.9 million letters of credit outstanding, and $519.1 million of availability under the Senior Revolver.
Scheduled Maturities of Long-term Debt Scheduled maturities of the Company’s long-term debt are summarized as follows:
Scheduled Maturities
Remainder of 2022$12.4 
202353.9 
202467.0 
202567.0 
2026698.3 
2027430.2 
Thereafter473.7 
Total$1,802.5 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Derivative Instruments and Hedging Activities (Tables)
9 Months Ended
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location
The location and fair value of derivative instruments designated as hedges in the Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 are as follows:

September 30, 2022December 31, 2021
Foreign currency forward contracts
Prepaid expenses and other current assets$— $1.7 
Other accrued expenses1.2 — 
Total foreign current forward contracts$1.2 $1.7 
Interest rate swaps
Prepaid expenses and other current assets$3.7 $— 
Other assets9.2 — 
Other accrued expenses— 0.7 
Total interest rate swaps$12.9 $0.7 
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-based Compensation Expense
Total share-based compensation costs that have been included in the Company’s consolidated statements of operations were as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Share-Based Compensation Expense Allocation Details:
Cost of services$12.3 $15.8 $21.7 $38.8 
Selling, general and administrative15.4 9.7 27.7 23.2 
Other0.1 — 0.1 — 
Total share-based compensation expense$27.8 $25.5 $49.5 $62.0 
Schedule of Stock Options Activity
A summary of the options activity during the nine months ended September 30, 2022 is shown below:

OptionsWeighted-
Average
Exercise
Price
Outstanding at December 31, 20214,386,205 $3.37 
Granted24,344 22.19 
Exercised(1,279,460)3.67 
Canceled/forfeited(13,408)4.59 
Expired(7,500)8.71 
Outstanding at September 30, 20223,110,181 $3.38 
Outstanding, vested and exercisable at September 30, 20223,084,188 $3.22 
Outstanding, vested and exercisable at December 31, 20214,365,759 $3.33 
Schedule of Non-Options Awards Activity
A summary of the RSU and PBRSU activity during the nine months ended September 30, 2022 is shown below:
Weighted-
Average Grant
Date Fair Value
RSUsPBRSUsRSUPBRSU
Outstanding and unvested at December 31, 20212,218,651 3,203,013 $16.28 $16.45 
Granted2,249,157 5,230,483 20.62 19.83 
Performance factor adjustment— 876,109 — 10.46 
Vested(574,564)(1,878,328)14.49 11.19 
Forfeited(164,414)(201,544)17.41 19.87 
Outstanding and unvested at September 30, 20223,728,830 7,229,733 $19.12 $19.44 
Shares surrendered for taxes for the nine months ended September 30, 2022
182,080 783,392 
Cost of shares surrendered for taxes for the nine months ended September 30, 2022 (in millions)
$4.1 $20.0 
Shares surrendered for taxes for the nine months ended September 30, 2021
186,588 — 
Cost of shares surrendered for taxes for the nine months ended September 30, 2021 (in millions)
$4.8 $— 
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Expenses (Tables)
9 Months Ended
Sep. 30, 2022
Other Income and Expenses [Abstract]  
Schedule of Other Expenses The following table summarizes the other expenses (income) recognized for the three and nine months ended September 30, 2022 and 2021.
Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Severance and related employee benefits (1)$— $0.3 $— $2.1 
Business acquisition costs (2)0.2 2.3 74.4 4.2 
Integration costs (3)8.8 — 18.3 2.6 
Strategic initiatives (4)6.2 2.5 9.0 6.4 
Global business services center expansion project in the Philippines (5)10.0 — 20.0 — 
Customer employee transition and restructuring expenses (6)— 3.2 (0.4)3.2 
Facility-exit charges (7)1.3 — 7.3 2.9 
Other (8)3.6 3.1 7.5 12.8 
Total other expenses$30.1 $11.4 $136.1 $34.2 
(1) These costs relate to restructuring and business reorganization events.
(2) These are costs, including legal, consulting, and bank fees, that are directly related to the close of the Cloudmed Acquisition on June 21, 2022 and the close of the VisitPay acquisition on July 1, 2021 and include changes to contingent consideration, if applicable.
(3) These costs reflect efforts to integrate acquisitions from a systems, processes, and people perspective. Costs include consulting fees, IT vendor spend, severance, early lease termination of Cloudmed facilities, and certain payroll costs.
(4) These costs relate to performing portfolio and capital structure analyses and transactions and other business transformation projects (including large scale system projects) as part of the Company’s growth strategy. Costs include vendor spend, employee time and expenses spent on activities, severance, and retention amounts.
(5) These costs include legal and consulting fees related to the establishment of the Company’s inaugural global business services center in the Philippines as well as severance costs for personnel whose roles are being relocated. The entry into the Philippines is the first new organic global business services center country expansion by the Company in approximately 15 years.
(6) As part of the transition of customer personnel to the Company under certain operating partner model contracts, the Company agreed to reimburse the customer, or directly pay affected employees, for severance and retention costs related to certain employees who were not transitioned to the Company, or whose jobs were relocated after the employee transitioned to the Company.
(7) As part of evaluating its footprint, the Company has exited certain leased facilities. Costs include asset impairment charges, early termination fees, and other costs related to exited leased facilities.
(8) For the three and nine months ended September 30, 2022, other includes $0.7 million and $1.8 million, respectively, of expenses related to the COVID-19 pandemic. For the three and nine months ended September 30, 2021, other includes $2.7 million and $7.1 million, respectively, of expenses related to the COVID-19 pandemic.
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings (Loss) Per Share (Tables)
9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Net Income (Loss) Per Common Share
Basic and diluted net income (loss) per common share are calculated as follows:
Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Basic EPS:
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Less dividends on preferred shares (1)— — — (592.3)
Net income (loss) available/(allocated) to common shareholders - basic$(29.5)$17.0 $(20.5)$(531.1)
Diluted EPS:
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Less dividends on preferred shares (1)— — — (592.3)
Net income (loss) available/(allocated) to common shareholders - diluted$(29.5)$17.0 $(20.5)$(531.1)
Basic weighted-average common shares417,700,782 278,655,269 330,877,880 262,209,929 
Add: Effect of dilutive equity awards— 7,281,436 — — 
Add: Effect of dilutive warrants— 34,680,381 — — 
Diluted weighted average common shares417,700,782 320,617,086 330,877,880 262,209,929 
Net income (loss) per common share (basic)$(0.07)$0.06 $(0.06)$(2.03)
Net income (loss) per common share (diluted)$(0.07)$0.05 $(0.06)$(2.03)
(1) The 2021 dividend on preferred shares includes amounts related to the conversion of the preferred shares. See Note 16 of the Company’s 2021 Form 10-K for more information.
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segments and Customer Concentrations (Tables)
9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Schedule of Customer Concentration, Net Services Revenue
Customers comprising greater than 10% of net services revenue are as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
Customer Name2022202120222021
Ascension and its affiliates44 %60 %52 %61 %
Intermountain Healthcare11 %14 %13 %14 %
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Supplemental Financial Information (Tables)
9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary Depreciation and Amortization Expense
The following table summarizes the allocation of depreciation and amortization expense related to property, equipment and software between cost of services and selling, general and administrative expenses:
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Cost of services$14.7 $13.6 $39.0 $38.8 
Selling, general and administrative0.3 0.6 0.8 2.2 
Total depreciation and amortization$15.0 $14.2 $39.8 $41.0 
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Description and Basis of Presentation - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended
Jun. 21, 2022
Oct. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Apr. 01, 2022
Dec. 31, 2021
Business Acquisition [Line Items]            
Common stock, par value (in dollars per share)     $ 0.01     $ 0.01
Contract assets     $ 105.2 $ 89.6   $ 0.0
Cloudmed            
Business Acquisition [Line Items]            
Percentage of business acquired 100.00%          
Acquisition, aggregate number of shares of common stock issued (in shares) 135,929,742          
Common stock, par value (in dollars per share) $ 0.01          
Cloudmed | Subsequent Event            
Business Acquisition [Line Items]            
Acquisition, aggregate number of shares of common stock issued (in shares)   55,846        
Cloudmed | Accounting Standards Update 2021-08            
Business Acquisition [Line Items]            
Contract assets         $ 92.4  
Contract liabilities         $ 3.3  
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions - Narrative (Details)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 21, 2022
USD ($)
Aug. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
payment
Business Acquisition [Line Items]              
Payments to acquire business         $ 0.0 $ 12.5  
Cloudmed              
Business Acquisition [Line Items]              
Total purchase consideration $ 3,280.6            
Net sales     $ 120.2   133.5    
Net loss, before income taxes     1.3   0.9    
RevWorks              
Business Acquisition [Line Items]              
Payments to acquire business   $ 12.5   $ 12.5      
Number of deferred payments | payment             2
Payments to acquire business, number of payments, refund period, if circumstances met             2 years
Asset, contingently returnable consideration     $ 25.0   $ 25.0   $ 22.3
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions - Fair Value Total Consideration Paid (Details) - Cloudmed
$ in Millions
Jun. 21, 2022
USD ($)
shares
Business Acquisition [Line Items]  
Stock consideration transferred to the Sellers $ 2,389.5
Cash consideration 879.8
Total consideration $ 3,280.6
Cloudmed  
Business Acquisition [Line Items]  
Lock-up period 18 months
RSUs  
Business Acquisition [Line Items]  
Replacement awards issued to Cloudmed equity award holders $ 11.3
Replacement awards issued to Cloudmed equity award holders, shares (in shares) | shares 1,536,220
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Jun. 21, 2022
Sep. 30, 2022
Dec. 31, 2021
Allocation of consideration to assets acquired and liabilities assumed:      
Goodwill   $ 2,549.3 $ 554.7
Cloudmed      
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]      
Total purchase consideration $ 3,280.6    
Allocation of consideration to assets acquired and liabilities assumed:      
Cash and cash equivalents 32.1    
Accounts receivable 61.8    
Current portion of contract assets 68.5    
Property, equipment and software 5.0    
Operating lease right-of-use assets 25.3    
Non-current portion of contract assets 23.9    
Intangible assets 1,370.1    
Goodwill 1,994.7    
Other assets 6.4    
Accounts payable (31.9)    
Customer liabilities (3.3)    
Accrued compensation and benefits (91.8)    
Operating lease liabilities (25.4)    
Deferred income tax liabilities (142.0)    
Other liabilities (12.8)    
Net assets acquired $ 3,280.6    
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions - Schedule of Intangible Assets Information (Details) - Cloudmed
$ in Millions
Jun. 21, 2022
USD ($)
Customer Relationships  
Business Acquisition [Line Items]  
Useful Life 18 years
Gross Carrying Value $ 318.0
Technology  
Business Acquisition [Line Items]  
Useful Life 7 years
Gross Carrying Value $ 1,052.0
Favorable leasehold interests  
Business Acquisition [Line Items]  
Gross Carrying Value $ 0.1
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions - Pro Forma Results (Details) - Cloudmed and VisitPay Acquisitions - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Business Acquisition [Line Items]        
Net services revenue $ 496.0 $ 464.6 $ 1,476.9 $ 1,321.5
Net loss $ (22.9) $ (20.3) $ (21.5) $ (112.4)
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets - Components of Intangible Assets (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 1,686.6 $ 316.5
Accumulated Amortization (119.1) (51.1)
Net Book Value 1,567.5 265.4
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 418.0 100.0
Accumulated Amortization (30.4) (20.8)
Net Book Value 387.6 79.2
Technology    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 1,267.5 215.5
Accumulated Amortization (88.3) (30.2)
Net Book Value 1,179.2 185.3
Tradename    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 1.0 1.0
Accumulated Amortization (0.4) (0.1)
Net Book Value 0.6 0.9
Favorable leasehold interests    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 0.1 0.0
Accumulated Amortization 0.0 0.0
Net Book Value $ 0.1 $ 0.0
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]        
Intangible asset amortization expense $ 49.2 $ 7.1 $ 68.0 $ 15.8
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets - Future Amortization (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]    
Remainder of 2022 $ 49.0  
2023 196.3  
2024 194.5  
2025 192.9  
2026 192.9  
2027 192.9  
Thereafter 549.0  
Net Book Value $ 1,567.5 $ 265.4
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details)
$ in Millions
9 Months Ended
Sep. 30, 2022
USD ($)
Goodwill [Roll Forward]  
Balance as of December 31, 2021 $ 554.7
Cloudmed Acquisition 1,994.7
Change in foreign currency rates (0.1)
Balance as of September 30, 2022 $ 2,549.3
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition - Schedule of Disaggregated Revenue by Source (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation of Revenue [Line Items]        
Net services revenue $ 496.0 $ 379.7 $ 1,273.6 $ 1,075.7
Net operating fees        
Disaggregation of Revenue [Line Items]        
Net services revenue 324.2 308.5 965.3 879.8
Incentive fees        
Disaggregation of Revenue [Line Items]        
Net services revenue 20.8 41.5 80.9 108.0
Modular and other        
Disaggregation of Revenue [Line Items]        
Net services revenue $ 151.0 $ 29.7 $ 227.4 $ 87.9
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition - Schedule of Contract Balances (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Jun. 30, 2022
Dec. 31, 2021
Contract assets      
Current $ 74.4   $ 0.0
Non-current 30.8   0.0
Total contract assets 105.2 $ 89.6 0.0
Contract liabilities      
Current 28.4   10.3
Non-current 19.4   18.7
Total contract liabilities 47.8   29.0
Current portion of customer liabilities 26.5   7.8
Non-current portion of customer liabilities 5.3   3.3
Investor      
Contract liabilities      
Current portion of customer liabilities 1.9   2.5
Non-current portion of customer liabilities $ 14.1   $ 15.4
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition - Changes to Contract Assets (Details)
$ in Millions
3 Months Ended
Sep. 30, 2022
USD ($)
Contract with Customer, Asset [Roll Forward]  
Balance as of June 30, 2022 $ 89.6
Revenue recognized 84.4
Amounts billed (73.0)
Other 4.2
Balance as of September 30, 2022 $ 105.2
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition - Narrative (Details) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Contract With Customer, Liability, Including Advanced Billings    
Disaggregation of Revenue [Line Items]    
Revenue recognized $ 93.4 $ 99.7
Accounts Receivable    
Disaggregation of Revenue [Line Items]    
Revenue recognized, advanced billings $ 85.8 $ 88.1
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details)
$ in Millions
Sep. 30, 2022
USD ($)
Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 469.5
Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 41.1
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period 3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 36.1
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 17.8
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 109.6
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 23.3
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 91.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 0.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 39.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 0.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 38.5
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 0.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01 | Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 32.9
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01 | Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 0.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, period
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01 | Net operating fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 122.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01 | Incentive fees  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount $ 0.0
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounts Receivable and Allowance for Credit Losses - Narratives (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Dec. 31, 2020
Financing Receivable, Allowance for Credit Loss [Line Items]                
Increase in allowance $ 10.4 $ 0.4 $ 10.7 $ 0.6        
Allowance for credit loss 14.6 $ 2.4 14.6 $ 2.4 $ 4.4 $ 2.5 $ 2.3 $ 3.8
Physician Customer                
Financing Receivable, Allowance for Credit Loss [Line Items]                
Increase in allowance 9.5              
Allowance for credit loss 10.0   10.0          
Accounts receivable, gross $ 33.3   $ 33.3          
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounts Receivable and Allowance for Credit Losses - Rollforward (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Accounts Receivable, Allowance for Credit Loss [Roll Forward]        
Beginning balance $ 4.4 $ 2.3 $ 2.5 $ 3.8
Provision (recoveries) 10.4 0.4 10.7 0.6
Write-offs (0.2) (0.3) (0.4) (2.0)
Ending balance 14.6 2.4 14.6 2.4
Cloudmed | ASC 326        
Accounts Receivable, Allowance for Credit Loss [Roll Forward]        
Beginning balance $ 0.0 $ 0.0 $ 1.8 $ 0.0
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Schedule of Lease Costs (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Leases [Abstract]        
Operating lease cost $ 6.9 $ 4.0 $ 16.8 $ 12.1
Sublease income (0.4) (0.6) (1.3) (1.7)
Total lease cost $ 6.5 $ 3.4 $ 15.5 $ 10.4
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Schedule of Supplemental Cash Flow Information (Details) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows for operating leases $ 17.6 $ 18.6
Right-of-use assets obtained in exchange for operating lease obligations $ 67.6 $ 13.6
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Schedule of Operating and Finance Lease Maturity (Details)
$ in Millions
Sep. 30, 2022
USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]  
Remainder of 2022 $ 9.3
2023 24.6
2024 23.9
2025 22.6
2026 16.8
2027 10.8
Thereafter 40.8
Total 148.8
Less:  
Imputed interest (28.8)
Present value of lease liabilities $ 120.0
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt - Carrying Amounts of Debt (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Long-term debt $ 1,802.5  
Unamortized discount and issuance costs (24.9) $ (3.2)
Total debt 1,777.6 772.4
Less: Current maturities (49.5) (17.5)
Total long-term debt 1,728.1 754.9
Line of Credit | Senior Revolver    
Debt Instrument [Line Items]    
Long-term debt 80.0 80.0
Borrowing availability 519.1  
Line of Credit | Term A Loans    
Debt Instrument [Line Items]    
Long-term debt 1,222.5 695.6
Line of Credit | Term B Loan    
Debt Instrument [Line Items]    
Long-term debt 500.0 $ 0.0
Line of Credit | Letters of Credit    
Debt Instrument [Line Items]    
Long-term debt $ 0.9  
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt - Narrative (Details) - Line of Credit - Second A&R Credit Agreement
Jun. 21, 2022
USD ($)
offer
Sep. 30, 2022
Debt Instrument [Line Items]    
Debt covenant, number of offers to extend maturity date, if circumstances met (or more) | offer 1  
Mandatory prepayments, percentage of annual excess cash flow 50.00%  
Mandatory prepayments, percentage of non-ordinary course asset sales or other dispositions 100.00%  
Mandatory prepayments, percentage of net cash proceeds of debt incurrence 100.00%  
Debt covenant, secured obligation pledged, capital stock of certain domestic subsidiaries, percent 100.00%  
Federal Funds Rate    
Debt Instrument [Line Items]    
Basis spread on variable rate basis 0.50%  
SOFR | Interest Rate Option - Basis Spread One    
Debt Instrument [Line Items]    
Basis spread on variable rate basis 1.00%  
SOFR | Minimum | Interest Rate Option - Basis Spread One    
Debt Instrument [Line Items]    
Basis spread on variable rate basis 0.25%  
SOFR | Maximum | Interest Rate Option - Basis Spread One    
Debt Instrument [Line Items]    
Basis spread on variable rate basis 1.50%  
Term A Loans    
Debt Instrument [Line Items]    
Interest rate   5.28%
Term A Loans | SOFR | Interest Rate Option - Basis Spread One    
Debt Instrument [Line Items]    
Variable rate basis, minimum (not less than) 0.00%  
Term A Loans | SOFR | Interest Rate Option - Basis Spread Two    
Debt Instrument [Line Items]    
Variable rate basis, minimum (not less than) 0.00%  
Existing Term A Loan    
Debt Instrument [Line Items]    
Credit agreement, maximum borrowing capacity $ 691,300,000  
Incremental Term A Loan    
Debt Instrument [Line Items]    
Credit agreement, maximum borrowing capacity $ 540,000,000  
Debt maturity 5 years  
Term B Loan    
Debt Instrument [Line Items]    
Credit agreement, maximum borrowing capacity $ 500,000,000  
Debt maturity 7 years  
Interest rate   6.03%
Term B Loan | SOFR | Interest Rate Option - Basis Spread One    
Debt Instrument [Line Items]    
Variable rate basis, minimum (not less than) 0.50%  
Term B Loan | SOFR | Interest Rate Option - Basis Spread Two    
Debt Instrument [Line Items]    
Variable rate basis, minimum (not less than) 0.50%  
Term B Loan | SOFR | Minimum | Interest Rate Option - Basis Spread Two    
Debt Instrument [Line Items]    
Basis spread on variable rate basis 1.25%  
Term B Loan | SOFR | Maximum | Interest Rate Option - Basis Spread Two    
Debt Instrument [Line Items]    
Basis spread on variable rate basis 2.50%  
Senior Revolver    
Debt Instrument [Line Items]    
Credit agreement, maximum borrowing capacity $ 600,000,000  
Debt issuance costs incurred 7,200,000  
Debt issuance costs, capitalized $ 6,400,000  
Senior Revolver | Minimum    
Debt Instrument [Line Items]    
Commitment fee 0.20%  
Senior Revolver | Maximum    
Debt Instrument [Line Items]    
Commitment fee 0.40%  
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt - Scheduled Maturities of Long-Term Debt (Details)
$ in Millions
Sep. 30, 2022
USD ($)
Debt Disclosure [Abstract]  
Remainder of 2022 $ 12.4
2023 53.9
2024 67.0
2025 67.0
2026 698.3
2027 430.2
Thereafter 473.7
Total $ 1,802.5
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.22.2.2
Derivative Financial Instruments - Narrative (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Jul. 05, 2022
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Derivative [Line Items]            
Accumulated gain, net of tax, recognized in other comprehensive loss       $ 8,800,000   $ 700,000
Third Party            
Derivative [Line Items]            
Potential business combination, expected purchase price $ 150,000,000          
Designated as Hedging Instrument | Cash Flow Hedging | Foreign Currency Hedges            
Derivative [Line Items]            
Unrealized gains (losses) reported in accumulated other comprehensive loss       (1,200,000)    
Gains (losses) to be reclassified within next 12 months       (1,100,000)    
Derivatives, net gain (loss) reclassified   $ (700,000) $ 400,000 600,000 $ 1,000,000  
Notional amount   76,800,000   76,800,000    
Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps            
Derivative [Line Items]            
Unrealized gains (losses) reported in accumulated other comprehensive loss       12,900,000    
Gains (losses) to be reclassified within next 12 months       3,700,000    
Derivatives, net gain (loss) reclassified   (400,000) $ (300,000) (900,000) $ (1,100,000)  
Notional amount   $ 500,000,000   $ 500,000,000    
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.22.2.2
Derivative Financial Instruments- Schedule Of Derivative Instruments as Hedged on Consolidated Balance Sheets (Details) - Cash Flow Hedging - Designated as Hedging Instrument - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Foreign currency forward contracts    
Derivative [Line Items]    
Derivative asset, current $ 0.0 $ 1.7
Derivative liability 1.2 0.0
Derivative, fair value, net 1.2 1.7
Interest rate swaps    
Derivative [Line Items]    
Derivative asset, current 3.7 0.0
Derivative asset, noncurrent 9.2 0.0
Derivative liability 0.0 0.7
Derivative, fair value, net $ 12.9 $ 0.7
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Jun. 21, 2022
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based compensation expense   $ 27.8 $ 25.5 $ 49.5 $ 62.0
Related tax benefits   4.6 5.1 8.5 12.2
Income tax benefit   $ 4.3 $ 0.6 $ 9.2 $ 7.2
RSUs and PBRSUs | Cloudmed          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Replacement awards issued to Cloudmed equity award holders, shares (in shares) 3,173,184        
RSUs | Cloudmed          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Replacement awards issued to Cloudmed equity award holders, shares (in shares) 1,536,220        
PBRSUs          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Maximum exercisable (in shares)       14,412,591  
Former Class P Units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of units converted in Transaction Agreement (in shares) 97,875        
Management Units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of units converted in Transaction Agreement (in shares) 514,986        
Nonvested award, cost not yet recognized, period for recognition       4 years  
Minimum | PBRSUs          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares vesting if targets conditions met, potential percentage       0.00%  
Maximum | PBRSUs          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares vesting if targets conditions met, potential percentage       200.00%  
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Compensation Expense Allocation (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total share-based compensation expense $ 27.8 $ 25.5 $ 49.5 $ 62.0
Cost of services        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total share-based compensation expense 12.3 15.8 21.7 38.8
Selling, general and administrative        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total share-based compensation expense 15.4 9.7 27.7 23.2
Other        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total share-based compensation expense $ 0.1 $ 0.0 $ 0.1 $ 0.0
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Stock Options Activity (Details)
9 Months Ended
Sep. 30, 2022
$ / shares
shares
Dec. 31, 2021
$ / shares
shares
Options    
Outstanding at beginning of period (in shares) | shares 4,386,205  
Granted (in shares) | shares 24,344  
Exercised (in shares) | shares (1,279,460)  
Canceled/forfeited (in shares) | shares (13,408)  
Expired (in shares) | shares (7,500)  
Outstanding at end of period (in shares) | shares 3,110,181  
Outstanding, vested and exercisable at end of period (in shares) | shares 3,084,188 4,365,759
Weighted- Average Exercise Price    
Outstanding at beginning of period (in dollars per share) | $ / shares $ 3.37  
Granted (in dollars per share) | $ / shares 22.19  
Exercised (in dollars per share) | $ / shares 3.67  
Canceled/forfeited (in dollars per share) | $ / shares 4.59  
Expired (in dollars per share) | $ / shares 8.71  
Outstanding at end of period (in dollars per share) | $ / shares 3.38  
Outstanding, vested and exercisable at end of period (in dollars per share) | $ / shares $ 3.22 $ 3.33
XML 80 R68.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Other Than Stock Options Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
RSUs    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Outstanding and unvested at beginning of period (in shares) 2,218,651  
Granted (in shares) 2,249,157  
Performance factor adjustment (in shares) 0  
Vested (in shares) (574,564)  
Forfeited (in shares) (164,414)  
Outstanding and unvested at end of period (in shares) 3,728,830  
Weighted- Average Grant Date Fair Value    
Outstanding and unvested at beginning of period (in dollars per share) $ 16.28  
Granted (in dollars per share) 20.62  
Performance factor adjustment (in dollars per share) 0  
Vested (in dollars per share) 14.49  
Forfeited (in dollars per share) 17.41  
Outstanding and unvested at end of period (in dollars per share) $ 19.12  
Shares surrendered for taxes (in shares) 182,080 186,588
Cost of shares surrendered for taxes $ 4.1 $ 4.8
PBRSUs    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Outstanding and unvested at beginning of period (in shares) 3,203,013  
Granted (in shares) 5,230,483  
Performance factor adjustment (in shares) 876,109  
Vested (in shares) (1,878,328)  
Forfeited (in shares) (201,544)  
Outstanding and unvested at end of period (in shares) 7,229,733  
Weighted- Average Grant Date Fair Value    
Outstanding and unvested at beginning of period (in dollars per share) $ 16.45  
Granted (in dollars per share) 19.83  
Performance factor adjustment (in dollars per share) 10.46  
Vested (in dollars per share) 11.19  
Forfeited (in dollars per share) 19.87  
Outstanding and unvested at end of period (in dollars per share) $ 19.44  
Shares surrendered for taxes (in shares) 783,392 0
Cost of shares surrendered for taxes $ 20.0 $ 0.0
XML 81 R69.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Expenses - Schedule of Other Expenses (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Other Income And Expenses [Line Items]        
Severance and related employee benefits $ 0.0 $ 0.3 $ 0.0 $ 2.1
Business acquisition costs 0.2 2.3 74.4 4.2
Integration costs 8.8 0.0 18.3 2.6
Strategic initiatives 6.2 2.5 9.0 6.4
Global business services center expansion project in the Philippines 10.0 0.0 20.0 0.0
Customer employee transition and restructuring expenses 0.0 3.2 (0.4) 3.2
Facility-exit charges 1.3 0.0 7.3 2.9
Other 3.6 3.1 7.5 12.8
Total other expenses 30.1 11.4 $ 136.1 34.2
Number of years since new country entry     15 years  
COVID-19 related costs, included in Other $ 0.7 $ 2.7 $ 1.8 $ 7.1
XML 82 R70.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Income Tax Disclosure [Abstract]          
Federal statutory tax rate 21.00% 21.00% 21.00% 21.00%  
Statute of limitations minimum     3 years    
Statute of limitations maximum     6 years    
Gross deferred tax assets         $ 123.7
Deferred tax assets related to operating loss carryforwards         $ 54.7
XML 83 R71.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings (Loss) Per Share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Basic EPS:                
Net income (loss) $ (29.5) $ (20.4) $ 29.4 $ 17.0 $ 18.4 $ 25.8 $ (20.5) $ 61.2
Less dividends on preferred shares 0.0     0.0     0.0 (592.3)
Net income (loss) available/allocated to common shareholders - basic (29.5)     17.0     (20.5) (531.1)
Diluted EPS:                
Net income (loss) available/allocated to common shareholders - diluted $ (29.5)     $ 17.0     $ (20.5) $ (531.1)
Basic weighted-average common shares (in shares) 417,700,782     278,655,269     330,877,880 262,209,929
Add: Effect of dilutive equity awards (in shares) 0     7,281,436     0 0
Add: Effect of dilutive warrants (in shares) 0     34,680,381     0 0
Diluted weighted average common shares (in shares) 417,700,782     320,617,086     330,877,880 262,209,929
Net income (loss) per common share (basic) (in dollars per share) $ (0.07)     $ 0.06     $ (0.06) $ (2.03)
Net income (loss) per common share (diluted) (in dollars per share) $ (0.07)     $ 0.05     $ (0.06) $ (2.03)
XML 84 R72.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings (Loss) Per Share - Narrative (Details) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive common share equivalents (in shares) 21,251,602 890,717 21,251,602 15,155,288
Warrant | Investor        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive common share equivalents (in shares) 40,500,000 40,500,000 40,500,000  
Warrant | Intermountain        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive common share equivalents (in shares) 1,500,000   1,500,000 1,500,000
XML 85 R73.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies - Narrative (Details)
Apr. 19, 2021
claim
TCP-ASC Recapitalization Litigation | Pending Litigation  
Loss Contingencies [Line Items]  
Number of complaints filed 2
XML 86 R74.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions - Narrative (Details) - $ / shares
3 Months Ended
May 28, 2021
Jun. 30, 2021
Common Stock    
Related Party Transaction [Line Items]    
Exercise of warrants pursuant to cashless provisions (in shares)   16,750,000
Related Party | TCP-ASC    
Related Party Transaction [Line Items]    
Warrant exercise price (in dollars per share) $ 3.50  
Related Party | TCP-ASC | Minimum    
Related Party Transaction [Line Items]    
Warrant market value price (in dollars per share) 24.54  
Related Party | TCP-ASC | Maximum    
Related Party Transaction [Line Items]    
Warrant market value price (in dollars per share) $ 24.64  
Related Party | TCP-ASC | Common Stock    
Related Party Transaction [Line Items]    
Exercise of warrants pursuant to cashless provisions (in shares) 16,750,000  
Class of warrant or right, number of securities called by warrants or rights (in shares) 19,535,145  
XML 87 R75.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segments and Customer Concentrations - Narrative (Details) - segment
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Segment Reporting Information [Line Items]    
Number of operating segments 1  
Number of reporting segments 1  
Customer Concentration Risk | Accounts Receivable | Ascension and its affiliates    
Segment Reporting Information [Line Items]    
Concentration percentage 12.00% 17.00%
XML 88 R76.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segments and Customer Concentrations - Concentration Risk by Customer (Details) - Revenue - Customer Concentration Risk
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Ascension and its affiliates        
Concentration Risk [Line Items]        
Concentration percentage 44.00% 60.00% 52.00% 61.00%
Intermountain Healthcare        
Concentration Risk [Line Items]        
Concentration percentage 11.00% 14.00% 13.00% 14.00%
XML 89 R77.htm IDEA: XBRL DOCUMENT v3.22.2.2
Supplemental Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Property, Plant and Equipment [Line Items]        
Total depreciation and amortization $ 15.0 $ 14.2 $ 39.8 $ 41.0
Cost of services        
Property, Plant and Equipment [Line Items]        
Total depreciation and amortization 14.7 13.6 39.0 38.8
Selling, general and administrative        
Property, Plant and Equipment [Line Items]        
Total depreciation and amortization $ 0.3 $ 0.6 $ 0.8 $ 2.2
XML 90 ah-20220930_htm.xml IDEA: XBRL DOCUMENT 0001910851 2022-01-01 2022-09-30 0001910851 2022-11-04 0001910851 2022-09-30 0001910851 2021-12-31 0001910851 srt:AffiliatedEntityMember 2022-09-30 0001910851 srt:AffiliatedEntityMember 2021-12-31 0001910851 2022-07-01 2022-09-30 0001910851 2021-07-01 2021-09-30 0001910851 2021-01-01 2021-09-30 0001910851 us-gaap:CommonStockMember 2021-12-31 0001910851 us-gaap:TreasuryStockCommonMember 2021-12-31 0001910851 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001910851 us-gaap:RetainedEarningsMember 2021-12-31 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001910851 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001910851 2022-01-01 2022-03-31 0001910851 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001910851 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001910851 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001910851 us-gaap:CommonStockMember 2022-03-31 0001910851 us-gaap:TreasuryStockCommonMember 2022-03-31 0001910851 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001910851 us-gaap:RetainedEarningsMember 2022-03-31 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001910851 2022-03-31 0001910851 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001910851 2022-04-01 2022-06-30 0001910851 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001910851 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001910851 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001910851 us-gaap:CommonStockMember 2022-06-30 0001910851 us-gaap:TreasuryStockCommonMember 2022-06-30 0001910851 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001910851 us-gaap:RetainedEarningsMember 2022-06-30 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001910851 2022-06-30 0001910851 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001910851 us-gaap:AdditionalPaidInCapitalMember ah:CoyCo2Member 2022-07-01 2022-09-30 0001910851 ah:CoyCo2Member 2022-07-01 2022-09-30 0001910851 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001910851 us-gaap:TreasuryStockCommonMember 2022-07-01 2022-09-30 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001910851 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001910851 us-gaap:CommonStockMember 2022-09-30 0001910851 us-gaap:TreasuryStockCommonMember 2022-09-30 0001910851 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001910851 us-gaap:RetainedEarningsMember 2022-09-30 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001910851 us-gaap:CommonStockMember 2020-12-31 0001910851 us-gaap:TreasuryStockCommonMember 2020-12-31 0001910851 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001910851 us-gaap:RetainedEarningsMember 2020-12-31 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001910851 2020-12-31 0001910851 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001910851 2021-01-01 2021-03-31 0001910851 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001910851 us-gaap:TreasuryStockCommonMember 2021-01-01 2021-03-31 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001910851 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001910851 us-gaap:CommonStockMember 2021-03-31 0001910851 us-gaap:TreasuryStockCommonMember 2021-03-31 0001910851 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001910851 us-gaap:RetainedEarningsMember 2021-03-31 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001910851 2021-03-31 0001910851 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001910851 2021-04-01 2021-06-30 0001910851 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001910851 us-gaap:TreasuryStockCommonMember 2021-04-01 2021-06-30 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001910851 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001910851 us-gaap:CommonStockMember 2021-06-30 0001910851 us-gaap:TreasuryStockCommonMember 2021-06-30 0001910851 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001910851 us-gaap:RetainedEarningsMember 2021-06-30 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001910851 2021-06-30 0001910851 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001910851 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001910851 us-gaap:TreasuryStockCommonMember 2021-07-01 2021-09-30 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001910851 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001910851 us-gaap:CommonStockMember 2021-09-30 0001910851 us-gaap:TreasuryStockCommonMember 2021-09-30 0001910851 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001910851 us-gaap:RetainedEarningsMember 2021-09-30 0001910851 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001910851 2021-09-30 0001910851 ah:CoyCo2Member 2022-01-01 2022-09-30 0001910851 ah:CoyCo2Member 2021-01-01 2021-09-30 0001910851 ah:CloudmedMember 2022-01-01 2022-09-30 0001910851 ah:CloudmedMember 2021-01-01 2021-09-30 0001910851 ah:VisitPayIncMember 2022-01-01 2022-09-30 0001910851 ah:VisitPayIncMember 2021-01-01 2021-09-30 0001910851 ah:SeniorTermLoanMember 2022-01-01 2022-09-30 0001910851 ah:SeniorTermLoanMember 2021-01-01 2021-09-30 0001910851 us-gaap:RevolvingCreditFacilityMember 2022-01-01 2022-09-30 0001910851 us-gaap:RevolvingCreditFacilityMember 2021-01-01 2021-09-30 0001910851 ah:CloudmedMember 2022-06-21 0001910851 ah:CloudmedMember 2022-06-21 2022-06-21 0001910851 ah:CloudmedMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-31 0001910851 us-gaap:AccountingStandardsUpdate202108Member ah:CloudmedMember 2022-04-01 0001910851 ah:CloudmedAcquisitionMember 2022-06-21 2022-06-21 0001910851 us-gaap:RestrictedStockUnitsRSUMember ah:CloudmedAcquisitionMember 2022-06-21 2022-06-21 0001910851 ah:CloudmedAcquisitionMember ah:CloudmedMember 2022-06-21 2022-06-21 0001910851 ah:CloudmedAcquisitionMember 2022-06-21 0001910851 ah:CloudmedAcquisitionMember us-gaap:CustomerRelationshipsMember 2022-06-21 2022-06-21 0001910851 ah:CloudmedAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-06-21 2022-06-21 0001910851 ah:CloudmedAcquisitionMember us-gaap:LeasesAcquiredInPlaceMarketAdjustmentMember 2022-06-21 2022-06-21 0001910851 ah:CloudmedAcquisitionMember 2022-07-01 2022-09-30 0001910851 ah:CloudmedAcquisitionMember 2022-01-01 2022-09-30 0001910851 ah:RevWorksAcquisitionMember 2021-07-01 2021-09-30 0001910851 ah:RevWorksAcquisitionMember 2022-08-01 2022-08-31 0001910851 ah:RevWorksAcquisitionMember 2020-12-31 0001910851 ah:RevWorksAcquisitionMember 2020-01-01 2020-12-31 0001910851 ah:RevWorksAcquisitionMember 2022-09-30 0001910851 ah:CloudmedAndVisitPayAcquisitionsMember 2022-07-01 2022-09-30 0001910851 ah:CloudmedAndVisitPayAcquisitionsMember 2021-07-01 2021-09-30 0001910851 ah:CloudmedAndVisitPayAcquisitionsMember 2022-01-01 2022-09-30 0001910851 ah:CloudmedAndVisitPayAcquisitionsMember 2021-01-01 2021-09-30 0001910851 us-gaap:CustomerRelationshipsMember 2022-09-30 0001910851 us-gaap:CustomerRelationshipsMember 2021-12-31 0001910851 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-09-30 0001910851 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-12-31 0001910851 us-gaap:TradeNamesMember 2022-09-30 0001910851 us-gaap:TradeNamesMember 2021-12-31 0001910851 us-gaap:LeasesAcquiredInPlaceMarketAdjustmentMember 2022-09-30 0001910851 us-gaap:LeasesAcquiredInPlaceMarketAdjustmentMember 2021-12-31 0001910851 ah:NetOperatingFeesMember 2022-07-01 2022-09-30 0001910851 ah:NetOperatingFeesMember 2021-07-01 2021-09-30 0001910851 ah:NetOperatingFeesMember 2022-01-01 2022-09-30 0001910851 ah:NetOperatingFeesMember 2021-01-01 2021-09-30 0001910851 ah:IncentiveFeesMember 2022-07-01 2022-09-30 0001910851 ah:IncentiveFeesMember 2021-07-01 2021-09-30 0001910851 ah:IncentiveFeesMember 2022-01-01 2022-09-30 0001910851 ah:IncentiveFeesMember 2021-01-01 2021-09-30 0001910851 ah:ModularAndOtherMember 2022-07-01 2022-09-30 0001910851 ah:ModularAndOtherMember 2021-07-01 2021-09-30 0001910851 ah:ModularAndOtherMember 2022-01-01 2022-09-30 0001910851 ah:ModularAndOtherMember 2021-01-01 2021-09-30 0001910851 us-gaap:InvestorMember 2022-09-30 0001910851 us-gaap:InvestorMember 2021-12-31 0001910851 ah:ContractWithCustomerLiabilityIncludingAdvancedBillingsMember 2022-01-01 2022-09-30 0001910851 ah:ContractWithCustomerLiabilityIncludingAdvancedBillingsMember 2021-01-01 2021-09-30 0001910851 us-gaap:AccountsReceivableMember 2022-09-30 0001910851 us-gaap:AccountsReceivableMember 2021-09-30 0001910851 ah:NetOperatingFeesMember 2022-10-01 2022-09-30 0001910851 ah:IncentiveFeesMember 2022-10-01 2022-09-30 0001910851 ah:NetOperatingFeesMember 2023-01-01 2022-09-30 0001910851 ah:IncentiveFeesMember 2023-01-01 2022-09-30 0001910851 ah:NetOperatingFeesMember 2024-01-01 2022-09-30 0001910851 ah:IncentiveFeesMember 2024-01-01 2022-09-30 0001910851 ah:NetOperatingFeesMember 2025-01-01 2022-09-30 0001910851 ah:IncentiveFeesMember 2025-01-01 2022-09-30 0001910851 ah:NetOperatingFeesMember 2026-01-01 2022-09-30 0001910851 ah:IncentiveFeesMember 2026-01-01 2022-09-30 0001910851 ah:NetOperatingFeesMember 2027-01-01 2022-09-30 0001910851 ah:IncentiveFeesMember 2027-01-01 2022-09-30 0001910851 ah:NetOperatingFeesMember 2028-01-01 2022-09-30 0001910851 ah:IncentiveFeesMember 2028-01-01 2022-09-30 0001910851 ah:NetOperatingFeesMember 2022-09-30 0001910851 ah:IncentiveFeesMember 2022-09-30 0001910851 2022-10-01 2022-09-30 0001910851 2023-01-01 2022-09-30 0001910851 2024-01-01 2022-09-30 0001910851 2025-01-01 2022-09-30 0001910851 2026-01-01 2022-09-30 0001910851 2027-01-01 2022-09-30 0001910851 2028-01-01 2022-09-30 0001910851 ah:PhysicianCustomerMember 2022-07-01 2022-09-30 0001910851 ah:PhysicianCustomerMember 2022-09-30 0001910851 us-gaap:AccountingStandardsUpdate201613Member ah:CloudmedMember 2022-06-30 0001910851 us-gaap:AccountingStandardsUpdate201613Member ah:CloudmedMember 2021-06-30 0001910851 us-gaap:AccountingStandardsUpdate201613Member ah:CloudmedMember 2021-12-31 0001910851 us-gaap:AccountingStandardsUpdate201613Member ah:CloudmedMember 2020-12-31 0001910851 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-09-30 0001910851 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-12-31 0001910851 ah:SeniorSecuredTermLoanAMember us-gaap:LineOfCreditMember 2022-09-30 0001910851 ah:SeniorSecuredTermLoanAMember us-gaap:LineOfCreditMember 2021-12-31 0001910851 ah:SeniorSecuredTermLoanBMember us-gaap:LineOfCreditMember 2022-09-30 0001910851 ah:SeniorSecuredTermLoanBMember us-gaap:LineOfCreditMember 2021-12-31 0001910851 us-gaap:LetterOfCreditMember us-gaap:LineOfCreditMember 2022-09-30 0001910851 ah:ExistingSeniorSecuredTermLoanAMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-06-21 0001910851 ah:IncrementalSeniorSecuredTermLoanAMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-06-21 0001910851 ah:SeniorSecuredTermLoanBMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-06-21 0001910851 us-gaap:RevolvingCreditFacilityMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-06-21 0001910851 ah:IncrementalSeniorSecuredTermLoanAMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-06-21 2022-06-21 0001910851 ah:SeniorSecuredTermLoanBMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-06-21 2022-06-21 0001910851 ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-06-21 0001910851 ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:FederalFundsEffectiveSwapRateMember 2022-06-21 2022-06-21 0001910851 ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember ah:InterestRateOptionBasisSpreadOneMember 2022-06-21 2022-06-21 0001910851 srt:MinimumMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember ah:InterestRateOptionBasisSpreadOneMember 2022-06-21 2022-06-21 0001910851 srt:MaximumMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember ah:InterestRateOptionBasisSpreadOneMember 2022-06-21 2022-06-21 0001910851 ah:SeniorSecuredTermLoanAMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember ah:InterestRateOptionBasisSpreadOneMember 2022-06-21 2022-06-21 0001910851 ah:SeniorSecuredTermLoanBMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember ah:InterestRateOptionBasisSpreadOneMember 2022-06-21 2022-06-21 0001910851 ah:SeniorSecuredTermLoanAMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember ah:InterestRateOptionBasisSpreadTwoMember 2022-06-21 2022-06-21 0001910851 ah:SeniorSecuredTermLoanBMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember ah:InterestRateOptionBasisSpreadTwoMember 2022-06-21 2022-06-21 0001910851 srt:MinimumMember ah:SeniorSecuredTermLoanBMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember ah:InterestRateOptionBasisSpreadTwoMember 2022-06-21 2022-06-21 0001910851 srt:MaximumMember ah:SeniorSecuredTermLoanBMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember ah:InterestRateOptionBasisSpreadTwoMember 2022-06-21 2022-06-21 0001910851 ah:SeniorSecuredTermLoanAMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-09-30 0001910851 ah:SeniorSecuredTermLoanBMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-09-30 0001910851 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-06-21 2022-06-21 0001910851 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ah:SecondARCreditAgreementMember us-gaap:LineOfCreditMember 2022-06-21 2022-06-21 0001910851 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-09-30 0001910851 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-07-01 2022-09-30 0001910851 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-07-01 2021-09-30 0001910851 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-09-30 0001910851 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0001910851 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-09-30 0001910851 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-07-01 2022-09-30 0001910851 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-07-01 2021-09-30 0001910851 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-09-30 0001910851 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0001910851 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001910851 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001910851 2021-01-01 2021-12-31 0001910851 ah:ThirdPartyMember 2022-07-05 2022-07-05 0001910851 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0001910851 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0001910851 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0001910851 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0001910851 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0001910851 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0001910851 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0001910851 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0001910851 ah:OtherMember 2022-07-01 2022-09-30 0001910851 ah:OtherMember 2021-07-01 2021-09-30 0001910851 ah:OtherMember 2022-01-01 2022-09-30 0001910851 ah:OtherMember 2021-01-01 2021-09-30 0001910851 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001910851 us-gaap:PerformanceSharesMember 2021-12-31 0001910851 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001910851 us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0001910851 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0001910851 us-gaap:PerformanceSharesMember 2022-09-30 0001910851 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001910851 us-gaap:PerformanceSharesMember 2021-01-01 2021-09-30 0001910851 ah:RestrictedStockUnitsRSUsAndPerformanceSharesMember ah:CloudmedAcquisitionMember 2022-06-21 2022-06-21 0001910851 srt:MinimumMember us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0001910851 srt:MaximumMember us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0001910851 ah:FormerClassPUnitsMember 2022-06-21 2022-06-21 0001910851 ah:ManagementUnitsMember 2022-06-21 2022-06-21 0001910851 ah:ManagementUnitsMember 2022-01-01 2022-09-30 0001910851 us-gaap:InvestorMember us-gaap:WarrantMember 2022-01-01 2022-09-30 0001910851 us-gaap:InvestorMember us-gaap:WarrantMember 2022-07-01 2022-09-30 0001910851 ah:IntermountainMember us-gaap:WarrantMember 2022-07-01 2022-09-30 0001910851 ah:IntermountainMember us-gaap:WarrantMember 2022-01-01 2022-09-30 0001910851 us-gaap:InvestorMember us-gaap:WarrantMember 2021-07-01 2021-09-30 0001910851 ah:IntermountainMember us-gaap:WarrantMember 2021-01-01 2021-09-30 0001910851 ah:TCPASCRecapitalizationLitigationMember us-gaap:PendingLitigationMember 2021-04-13 2021-04-19 0001910851 ah:TCPASCACHISeriesLLLPMember srt:AffiliatedEntityMember us-gaap:CommonStockMember 2021-05-27 2021-05-28 0001910851 ah:TCPASCACHISeriesLLLPMember srt:AffiliatedEntityMember us-gaap:CommonStockMember 2021-05-28 0001910851 ah:TCPASCACHISeriesLLLPMember srt:AffiliatedEntityMember 2021-05-28 0001910851 ah:TCPASCACHISeriesLLLPMember srt:MinimumMember srt:AffiliatedEntityMember 2021-05-28 0001910851 ah:TCPASCACHISeriesLLLPMember srt:MaximumMember srt:AffiliatedEntityMember 2021-05-28 0001910851 ah:AscensionMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001910851 ah:AscensionMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0001910851 ah:AscensionMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001910851 ah:AscensionMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001910851 ah:CustomerNotAffiliatedwithAscensionHealthMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001910851 ah:CustomerNotAffiliatedwithAscensionHealthMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0001910851 ah:CustomerNotAffiliatedwithAscensionHealthMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001910851 ah:CustomerNotAffiliatedwithAscensionHealthMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001910851 ah:AscensionMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001910851 ah:AscensionMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 shares iso4217:USD iso4217:USD shares pure ah:payment ah:offer ah:claim ah:segment false 2022 Q3 0001910851 --12-31 R1 RCM Inc. /DE P3M P1Y P1Y P1Y P1Y P1Y P3Y 10-Q true 2022-09-30 false 001-41428 DE 87-4340782 434 W. Ascension Way 84123 6th Floor Murray UT 312 324-7820 Common stock, par value $0.01 per share RCM NASDAQ Yes Yes Large Accelerated Filer false false false 416510858 131100000 130100000 14500000 2400000 209000000.0 131300000 100000 100000 29700000 26100000 74400000 0 96900000 77200000 541100000 364700000 163000000.0 94700000 98900000 48900000 30800000 0 27500000 23400000 1567500000 265400000 2549300000 554700000 9400000 51800000 93600000 45700000 5081100000 1449300000 25000000.0 17700000 67800000 41500000 5600000 7900000 105700000 97000000.0 20800000 13500000 49500000 17500000 71600000 59100000 346000000.0 254200000 5300000 3300000 14100000 15400000 99200000 53400000 1728100000 754900000 98200000 4200000 22400000 17200000 2313300000 1102600000 0.01 0.01 750000000 439386709 417722143 500000000 298320928 278226242 4400000 3000000.0 3104400000 628500000 -84800000 -64300000 -4000000.0 -5300000 21664566 20094686 252200000 215200000 2767800000 346700000 5081100000 1449300000 218100000 657800000 227500000 661400000 496000000.0 379700000 1273600000 1075700000 403100000 304000000.0 1009700000 858200000 60800000 33200000 120600000 87800000 30100000 11400000 136100000 34200000 494000000.0 348600000 1266400000 980200000 2000000.0 31100000 7200000 95500000 -23700000 -6500000 -35300000 -13800000 -21700000 24600000 -28100000 81700000 7800000 7600000 -7600000 20500000 -29500000 17000000.0 -20500000 61200000 -0.07 0.06 -0.06 -2.03 -0.07 0.05 -0.06 -2.03 417700782 278655269 330877880 262209929 417700782 320617086 330877880 262209929 -29500000 17000000.0 -20500000 61200000 9200000 500000 8100000 900000 -2200000 0 -6800000 -1000000.0 7000000.0 500000 1300000 -100000 -22500000 17500000 -19200000 61100000 -29500000 17000000.0 -20500000 61200000 0 0 0 592300000 -29500000 17000000.0 -20500000 -531100000 -29500000 17000000.0 -20500000 61200000 0 0 0 592300000 -29500000 17000000.0 -20500000 -531100000 298320928 3000000.0 20094686 -215200000 628500000 -64300000 -5300000 346700000 10200000 10200000 1757955 77438 400000 400000 727768 18700000 18700000 8000 200000 200000 0 100000 100000 -1400000 -1400000 29400000 29400000 300156321 3000000.0 20830454 -234100000 639100000 -34900000 -6600000 366500000 11600000 11600000 505371 135929742 1400000 2386100000 2387500000 11300000 11300000 395425 2282 -100000 2100000 2000000.0 153157 3500000 3500000 400000 -1200000 -1200000 -3200000 -3200000 -20400000 -20400000 436986859 4400000 20985893 -237700000 3050200000 -55300000 -11000000.0 2750600000 24800000 24800000 3000000.0 3000000.0 189566 1403687 24300000 24300000 806597 2100000 2100000 84547 1900000 1900000 594126 12600000 12600000 3100000 9200000 9200000 -2200000 -2200000 -29500000 -29500000 439386709 4400000 21664566 -252200000 3104400000 -84800000 -4000000.0 2767800000 137812559 1400000 16668521 -139200000 393700000 -161500000 -6500000 87900000 12800000 12800000 6497 324212 7000000.0 7000000.0 539795 3500000 3500000 2201 200000 500000 500000 -400000 -400000 117706400 1200000 250300000 251500000 592300000 592300000 21582800 200000 487100000 487300000 25800000 25800000 277972263 2800000 16670722 -139200000 562100000 -135700000 -6400000 283600000 24000000.0 24000000.0 539884 396250 1300000 1300000 167832 4500000 4500000 0 -100000 -100000 -600000 -600000 16750000 200000 -200000 0 18400000 18400000 295658397 3000000.0 16838554 -143700000 587200000 -117300000 -7100000 322100000 25800000 25800000 54524 172587 700000 700000 16555 300000 300000 1538077 31700000 31700000 100000 500000 500000 17000000.0 17000000.0 295885508 3000000.0 18393186 -175700000 613700000 -100300000 -6600000 334100000 -20500000 61200000 107800000 56800000 2200000 800000 46500000 62000000.0 3000000.0 0 -3900000 300000 10700000 600000 -9100000 18000000.0 10500000 7400000 -1500000 -800000 29700000 18800000 12800000 0 38300000 19800000 -23900000 4500000 -79600000 34300000 -11400000 -9900000 -3200000 -8900000 2900000 30100000 -39500000 218800000 74600000 33400000 847700000 0 0 294700000 400000 2600000 -921900000 -325500000 1016600000 698600000 30000000.0 120000000.0 1000000.0 1900000 13100000 484600000 30000000.0 90000000.0 0 4800000 0 12500000 0 105000000.0 2000000.0 0 4600000 6300000 12500000 29500000 26900000 4800000 -200000 -100000 965500000 91700000 -3100000 -600000 1000000.0 -15600000 130100000 174800000 131100000 159200000 27400000 25700000 Business Description and Basis of Presentation<div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Description</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R1 RCM Inc. (the “Company”) is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. The Company helps healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for its customers. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cloudmed Acquisition</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, pursuant to the Transaction Agreement and Plan of Merger (the “Transaction Agreement”), dated as of January 9, 2022, among R1 RCM Inc. (f/k/a Project Roadrunner Parent Inc.), R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.), a wholly-owned subsidiary of the Company (“Old R1 RCM”), Project Roadrunner Merger Sub Inc., formerly a wholly-owned subsidiary of the Company (“R1 Merger Sub”), Revint Holdings, LLC (“Cloudmed”), CoyCo 1, L.P. (“CoyCo 1”), CoyCo 2, L.P. (“CoyCo 2” and, together with CoyCo 1, the “Sellers”), and, solely for certain purposes set forth therein, NMC Ranger Holdings, LLC, the Company purchased Cloudmed, a leader in Revenue Intelligence™ solutions for healthcare providers, and affiliated entities (collectively, the “Cloudmed entities”), through (i) a merger of R1 Merger Sub with and into Old R1 RCM with Old R1 RCM as the surviving entity, which resulted in Old R1 RCM becoming a wholly-owned subsidiary of the Company (the “Holding Company Reorganization”) and (ii) the Sellers contributing 100% of the equity of a blocker parent corporation of the Cloudmed entities in exchange for an aggregate of 135,929,742 shares of common stock, par value $0.01 per share, of the Company (“Company Common Stock”), subject to certain adjustments following the closing as set forth in the Transaction Agreement (the “Cloudmed Acquisition”, and together with the Holding Company Reorganization, the “Transactions”). For further details on the total consideration paid, refer to Note 2, Acquisitions. In October 2022, the Company finalized those adjustments, resulting in an additional 55,846 shares issued to the Sellers. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cloudmed’s revenue intelligence platform combines cloud-based data architecture and deep domain expertise with intelligent automation to analyze large volumes of medical records, payment data, and complex medical insurance models to identify opportunities to deliver additional revenue to customers. The Company believes this transaction will enable the Company to further its ability to deliver transformative value to healthcare providers through a more fulsome platform of differentiated capabilities by creating a scaled leader across both end-to-end revenue cycle management (“RCM”) and technology-driven revenue intelligence.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Holding Company Reorganization</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Transaction Agreement, immediately prior to the completion of the Cloudmed Acquisition, Old R1 RCM implemented the Holding Company Reorganization, which resulted in the Company owning all of the capital stock of Old R1 RCM. Each share of Old R1 RCM’s common stock that was issued and outstanding immediately prior to the Holding Company Reorganization was automatically exchanged into an equivalent corresponding share of Company Common Stock, having the same designations, rights, powers, and preferences and the qualifications, limitations, and restrictions as the corresponding share of common stock of Old R1 RCM being converted. Accordingly, upon consummation of the Holding Company Reorganization, all Old R1 RCM stockholders became stockholders of the Company. Immediately prior to the consummation of the Holding Company Reorganization, the name of Old R1 RCM was changed to “R1 RCM Holdco Inc.” and the name of the Company was changed to “R1 RCM Inc.” The Company is the successor issuer to Old R1 RCM pursuant to Rule 12g-3(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The shares of Company Common Stock, as successor to Old R1 RCM, began trading on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “RCM” on June 22, 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements reflect the Company’s financial position as of September 30, 2022, the results of operations of the Company for the three and nine months ended September 30, 2022 and 2021, and the cash flows of the Company for the nine months ended September 30, 2022 and 2021. These financial statements include the accounts of R1 RCM Inc. and its wholly-owned subsidiaries, including Cloudmed and its subsidiaries since the date of the acquisition. All material intercompany amounts have been eliminated in consolidation. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial reporting and as required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the interim financial information, have been included. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2022.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When preparing financial statements in conformity with GAAP, the Company makes a number of significant estimates, assumptions, and judgments in the preparation of the financial statements. Actual results could differ from those estimates. For a more complete discussion of the Company’s significant accounting policies and other information, the unaudited consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements included in the Company’s 2021 Form 10-K. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards and Disclosures</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 requires companies to apply Topic 606, Revenue from Contracts with Customers, to recognize and measure contract assets and contract liabilities obtained in a business combination. The ASU amendments will generally result in the recognition of contract assets and contract liabilities by the acquirer at amounts consistent with those recorded by the acquiree immediately before the acquisition date. The Company prospectively adopted ASU 2021-08 effective April 1, 2022 and preliminarily recognized contract assets of $92.4 million and contract liabilities of $3.3 million as part of the Cloudmed Acquisition. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual sale restriction on an equity security should not be considered in measuring the security’s fair value. The Company will adopt ASU 2022-03 prospectively effective January 1, 2024 and is currently evaluating the impact of the standard on its consolidated financial statements.</span></div> 1 135929742 0.01 55846 <div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements reflect the Company’s financial position as of September 30, 2022, the results of operations of the Company for the three and nine months ended September 30, 2022 and 2021, and the cash flows of the Company for the nine months ended September 30, 2022 and 2021. These financial statements include the accounts of R1 RCM Inc. and its wholly-owned subsidiaries, including Cloudmed and its subsidiaries since the date of the acquisition. All material intercompany amounts have been eliminated in consolidation. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial reporting and as required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the interim financial information, have been included. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2022.</span></div>When preparing financial statements in conformity with GAAP, the Company makes a number of significant estimates, assumptions, and judgments in the preparation of the financial statements. Actual results could differ from those estimates. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards and Disclosures</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 requires companies to apply Topic 606, Revenue from Contracts with Customers, to recognize and measure contract assets and contract liabilities obtained in a business combination. The ASU amendments will generally result in the recognition of contract assets and contract liabilities by the acquirer at amounts consistent with those recorded by the acquiree immediately before the acquisition date. The Company prospectively adopted ASU 2021-08 effective April 1, 2022 and preliminarily recognized contract assets of $92.4 million and contract liabilities of $3.3 million as part of the Cloudmed Acquisition. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual sale restriction on an equity security should not be considered in measuring the security’s fair value. The Company will adopt ASU 2022-03 prospectively effective January 1, 2024 and is currently evaluating the impact of the standard on its consolidated financial statements.</span></div> 92400000 3300000 Acquisitions<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired and liabilities assumed in a business combination are recorded at their estimated fair value on the date of the acquisition. The difference between the purchase price amount and the net fair value of assets acquired and liabilities assumed is recognized as goodwill on the balance sheet if the purchase price exceeds the estimated net fair value or as a bargain purchase gain on the income statement if the purchase price is less than the estimated net fair value. The allocation of the purchase price may be modified up to one year after the acquisition date as more information is obtained about the fair value of assets acquired and liabilities assumed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cloudmed</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, the Company completed the acquisition of Cloudmed for a purchase price of $3.3 billion. The following table summarizes the fair value of the total consideration paid:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.525%"><tr><td style="width:1.0%"/><td style="width:72.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock consideration transferred to the Sellers (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,389.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash consideration (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">879.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Replacement awards issued to Cloudmed equity award holders (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,280.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The stock consideration fair value includes a</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preliminary discount for lack of marketability factor related to an 18-month lock-up period during which the Sellers may not sell their Company common stock. </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Cash consideration includes the repayment of Cloudmed’s pre-existing credit facility that was paid off at closing and was not assumed by the Company.</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Represents the pre-acquisition service portion of the fair value of 1,536,220 replacement restricted stock units (“RSUs”) issued to Cloudmed equity award holders at closing. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company funded the cash consideration component and the Company’s associated transaction expenses with a combination of cash on hand and the incurrence of additional indebtedness (see Note 8, Debt).</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price has been provisionally allocated to assets acquired and liabilities assumed based on their fair value as of the acquisition date. The fair value estimate of assets acquired and liabilities assumed is pending the completion of various elements, including gathering further information about the identification and completeness of all assets and liabilities acquired, the finalization of an independent appraisal and valuation of the fair value of the assets acquired and liabilities assumed, and final review by the Company’s management. Some of the more significant amounts that are not yet finalized relate to the fair value of intangible assets (including goodwill), contract assets, contract liabilities, and income and non-income related taxes. Accordingly, management considers the balances shown in the following table to be preliminary, and there could be adjustments to the consolidated financial statements, including changes in our amortization expense related to the valuation of intangible assets acquired and their respective useful lives, among other adjustments. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary fair value of assets acquired and liabilities assumed is:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.217%"><tr><td style="width:1.0%"/><td style="width:72.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.294%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,280.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocation of consideration to assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,370.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,994.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(142.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,280.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets identified in conjunction with the Cloudmed Acquisition and their preliminary fair values are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.679%"><tr><td style="width:1.0%"/><td style="width:31.518%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.518%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,052.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Favorable leasehold interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life of lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized is primarily attributable to growth and cost reduction synergies that are expected to be achieved from the integration of Cloudmed. None of the goodwill is expected to be deductible for income tax purposes.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Consolidated Statements of Operations and Comprehensive Income (Loss) for the</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are net sales of</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$120.2 million and $133.5 million, respectively, and net income before taxes of $1.3 million and $0.9 million, respectively,</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the operations of Cloudmed since the acquisition date of June 21, 2022.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement period adjustments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had various measurement period adjustments due to additional information received since the Cloudmed Acquisition, none of which were material. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prior Acquisitions</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company acquired the following business:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"/><td style="width:27.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.789%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Company Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description of the Business</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description of the Acquisition</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iVinci Partners, LLC d/b/a VisitPay (“VisitPay”)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provider of digital payment solutions</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchased all outstanding equity interests</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company purchased certain assets relating to the RevWorks services business from Cerner Corporation. In accordance with the purchase agreement, the Company paid the first deferred payment of $12.5 million in the third quarter of 2021. The remaining deferred payment of $12.5 million was payable on the second anniversary of the closing date (August 2022) and is included in other accrued expenses on the Consolidated Balance Sheet as of September 30, 2022 as it had not been paid as of such date. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The two deferred payments related to the RevWorks acquisition were contractual obligations of the Company; however, they are refundable to the Company if certain RevWorks customer revenue targets defined in the purchase agreement for the first two years following the acquisition are not achieved. At the time of the acquisition, the Company recorded an asset for the fair value of the contingently refundable consideration of $22.3 million. As of September 30, 2022, the entire amount of the contingently refundable consideration of $25.0 million is included in prepaid expenses and other current assets on the Consolidated Balance Sheet. The parties are currently engaging in arbitration to finalize the remaining deferred payment and contingently refundable consideration amounts.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pro Forma Results</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, on a pro forma basis, the combined results of the Company as though the Cloudmed Acquisition had occurred as of January 1, 2021 and the VisitPay acquisition had occurred as of January 1, 2020. These pro forma results are not necessarily indicative of the actual consolidated results had the acquisitions occurred as of those dates or of the future consolidated operating results for any period. Pro forma results are:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.314%"><tr><td style="width:1.0%"/><td style="width:23.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net services revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,476.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,321.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments were made to earnings to adjust depreciation and amortization to reflect the fair value of identified assets acquired, to adjust share-based compensation expense for awards granted in connection with the acquisitions, to record the effects of extinguishing the debt of the acquired companies and replacing it with the debt of the Company, to adjust timing of acquisition related costs incurred by the Company, and to record the income tax effect of these adjustments.</span></div> 3300000000 The following table summarizes the fair value of the total consideration paid:<div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.525%"><tr><td style="width:1.0%"/><td style="width:72.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock consideration transferred to the Sellers (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,389.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash consideration (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">879.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Replacement awards issued to Cloudmed equity award holders (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,280.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The stock consideration fair value includes a</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preliminary discount for lack of marketability factor related to an 18-month lock-up period during which the Sellers may not sell their Company common stock. </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Cash consideration includes the repayment of Cloudmed’s pre-existing credit facility that was paid off at closing and was not assumed by the Company.</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Represents the pre-acquisition service portion of the fair value of 1,536,220 replacement restricted stock units (“RSUs”) issued to Cloudmed equity award holders at closing. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company acquired the following business:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"/><td style="width:27.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.789%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Company Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description of the Business</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description of the Acquisition</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iVinci Partners, LLC d/b/a VisitPay (“VisitPay”)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provider of digital payment solutions</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchased all outstanding equity interests</span></td></tr></table></div> 2389500000 879800000 11300000 3280600000 P18M 1536220 The preliminary fair value of assets acquired and liabilities assumed is:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.217%"><tr><td style="width:1.0%"/><td style="width:72.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.294%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,280.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocation of consideration to assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,370.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,994.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(142.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,280.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3280600000 32100000 61800000 68500000 5000000.0 25300000 23900000 1370100000 1994700000 6400000 31900000 3300000 91800000 25400000 142000000.0 12800000 3280600000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets identified in conjunction with the Cloudmed Acquisition and their preliminary fair values are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.679%"><tr><td style="width:1.0%"/><td style="width:31.518%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.518%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,052.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Favorable leasehold interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Life of lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P18Y 318000000.0 P7Y 1052000000 100000 120200000 133500000 -1300000 -900000 12500000 12500000 2 P2Y 22300000 25000000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, on a pro forma basis, the combined results of the Company as though the Cloudmed Acquisition had occurred as of January 1, 2021 and the VisitPay acquisition had occurred as of January 1, 2020. These pro forma results are not necessarily indicative of the actual consolidated results had the acquisitions occurred as of those dates or of the future consolidated operating results for any period. Pro forma results are:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.314%"><tr><td style="width:1.0%"/><td style="width:23.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net services revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,476.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,321.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 496000000.0 464600000 1476900000 1321500000 -22900000 -20300000 -21500000 -112400000 Intangible AssetsThe following table provides the gross carrying value and accumulated amortization for each major class of definite-lived intangible assets at September 30, 2022 and December 31, 2021:<div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.865%"><tr><td style="width:1.0%"/><td style="width:24.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.314%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,179.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradename</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Favorable leasehold interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,686.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,567.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset amortization expense was $49.2 million and $68.0 million for the three and nine months ended September 30, 2022, respectively, and $7.1 million and $15.8 million for the three and nine months ended September 30, 2021, respectively. Amortization expense for intangible assets is included in cost of services on the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss). The Company has no indefinite-lived intangible assets.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated annual amortization expense related to intangible assets with definite lives as of September 30, 2022 is as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:33.173%"><tr><td style="width:1.0%"/><td style="width:59.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.099%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">549.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,567.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> The following table provides the gross carrying value and accumulated amortization for each major class of definite-lived intangible assets at September 30, 2022 and December 31, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.865%"><tr><td style="width:1.0%"/><td style="width:24.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.314%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,179.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradename</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Favorable leasehold interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,686.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,567.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 418000000.0 30400000 387600000 100000000.0 20800000 79200000 1267500000 88300000 1179200000 215500000 30200000 185300000 1000000.0 400000 600000 1000000.0 100000 900000 100000 0 100000 0 0 0 1686600000 119100000 1567500000 316500000 51100000 265400000 49200000 68000000 7100000 15800000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated annual amortization expense related to intangible assets with definite lives as of September 30, 2022 is as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:33.173%"><tr><td style="width:1.0%"/><td style="width:59.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.099%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">549.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,567.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 49000000.0 196300000 194500000 192900000 192900000 192900000 549000000.0 1567500000 Goodwill<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill for the nine months ended September 30, 2022 were: </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.243%"><tr><td style="width:1.0%"/><td style="width:59.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cloudmed Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,994.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in foreign currency rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of September 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,549.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill for the nine months ended September 30, 2022 were: </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.243%"><tr><td style="width:1.0%"/><td style="width:59.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cloudmed Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,994.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in foreign currency rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of September 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,549.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 554700000 1994700000 -100000 2549300000 Revenue RecognitionRevenue is measured based on consideration specified in a contract with a customer, and presented net of any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a service to a customer, which is typically over the contact term. Estimates of variable consideration are included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved. Revenue Recognition<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured based on consideration specified in a contract with a customer, and presented net of any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a service to a customer, which is typically over the contact term. Estimates of variable consideration are included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the following table, revenue is disaggregated by source of revenue: </span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.461%"><tr><td style="width:1.0%"/><td style="width:22.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.203%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">965.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">879.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incentive fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Modular and other (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net services revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,273.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,075.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Modular and other revenue primarily consists of service fees related to Cloudmed and R1 Entri</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pay, physician advisory services (“PAS”), practice management (“PM”) services, and software subscription revenue. </span></div><div style="padding-left:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about contract assets and contract liabilities from contracts with customers:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.141%"><tr><td style="width:1.0%"/><td style="width:57.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Current contract liabilities include $26.5 million and $7.8 million classified in the current portion of customer liabilities and $1.9 million and $2.5 million classified in the current portion of customer liabilities - related party as of September 30, 2022 and December 31, 2021, respectively. </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Non-current contract liabilities include $5.3 million and $3.3 million classified in the non-current portion of customer liabilities and $14.1 million and $15.4 million classified in the non-current portion of customer liabilities - related party as of September 30, 2022 and December 31, 2021, respectively. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract assets balance will increase or decrease based on the timing of invoices and recognition of revenue. Prior to the Cloudmed Acquisition, the Company did not have significant contract assets. Significant changes in the carrying amount of contract assets for the three months ended September 30, 2022 were as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.115%"><tr><td style="width:1.0%"/><td style="width:57.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contract Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts billed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of September 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Other primarily includes measurement period adjustments to the contract assets acquired from the Cloudmed Acquisition. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $93.4 million and $99.7 million during the nine months ended September 30, 2022 and 2021, which amounts were included in contract liabilities on January 1 of the respective periods. These revenue amounts include $85.8 million and $88.1 million for the nine months ended September 30, 2022 and 2021, respectively, related to advanced billings which become accounts receivable and contract liabilities on the first day of the respective service period.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2, Acquisitions, for the preliminary contract assets acquired and contract liabilities assumed as part of the Cloudmed Acquisition.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligation</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. The estimated revenue does not include amounts of variable consideration that are constrained. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.467%"><tr><td style="width:1.0%"/><td style="width:36.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.088%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.091%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net operating fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incentive fees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">    </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts presented in the table above include variable fee estimates of the Company’s physician groups RCM services contracts, fixed fees, and forecasted incentive fees. Fixed fees are typically recognized ratably as the performance obligation is satisfied and forecasted incentive fees are measured cumulatively over the contractually defined performance period.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates of revenue expected to be recognized in future periods exclude unexercised customer options to purchase services within the Company’s PAS contracts that do not represent material rights to the customer. </span></div>The Company does not disclose information about remaining performance obligations with an original expected duration of one year or less and has elected an exemption to the disclosure requirements related to estimate variable consideration and an exemption where the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the entity’s performance completed to date. In the following table, revenue is disaggregated by source of revenue: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.461%"><tr><td style="width:1.0%"/><td style="width:22.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.203%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">965.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">879.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incentive fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Modular and other (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net services revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,273.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,075.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Modular and other revenue primarily consists of service fees related to Cloudmed and R1 Entri</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span> Pay, physician advisory services (“PAS”), practice management (“PM”) services, and software subscription revenue. 324200000 308500000 965300000 879800000 20800000 41500000 80900000 108000000.0 151000000.0 29700000 227400000 87900000 496000000.0 379700000 1273600000 1075700000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about contract assets and contract liabilities from contracts with customers:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.141%"><tr><td style="width:1.0%"/><td style="width:57.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Current contract liabilities include $26.5 million and $7.8 million classified in the current portion of customer liabilities and $1.9 million and $2.5 million classified in the current portion of customer liabilities - related party as of September 30, 2022 and December 31, 2021, respectively. </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Non-current contract liabilities include $5.3 million and $3.3 million classified in the non-current portion of customer liabilities and $14.1 million and $15.4 million classified in the non-current portion of customer liabilities - related party as of September 30, 2022 and December 31, 2021, respectively. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract assets balance will increase or decrease based on the timing of invoices and recognition of revenue. Prior to the Cloudmed Acquisition, the Company did not have significant contract assets. Significant changes in the carrying amount of contract assets for the three months ended September 30, 2022 were as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.115%"><tr><td style="width:1.0%"/><td style="width:57.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contract Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts billed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of September 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Other primarily includes measurement period adjustments to the contract assets acquired from the Cloudmed Acquisition. 74400000 0 30800000 0 105200000 0 28400000 10300000 19400000 18700000 47800000 29000000.0 26500000 7800000 1900000 2500000 5300000 3300000 14100000 15400000 89600000 84400000 73000000.0 4200000 105200000 93400000 99700000 85800000 88100000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. The estimated revenue does not include amounts of variable consideration that are constrained. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.467%"><tr><td style="width:1.0%"/><td style="width:36.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.088%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.091%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net operating fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incentive fees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 36100000 17800000 109600000 23300000 91200000 0 39200000 0 38500000 0 32900000 0 122000000.0 0 469500000 41100000 Accounts Receivable and Allowance for Credit LossesAccounts receivable is comprised of unpaid balances pertaining to modular services and end-to-end RCM customers, net receivable balances for end-to-end RCM customers after considering cost reimbursements owed to such customers, including related accrued balances, and amounts due from physician RCM and PM customers.<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its accounts receivable for expected credit losses quarterly. The Company maintains an estimated allowance for credit losses to reduce its accounts receivable to the amount that it believes will be collected. This allowance is based on the Company’s historical experience, its assessment of each customer’s ability to pay, the length of time a balance has been outstanding, input from key Company resources assigned to each customer, the status of any ongoing operations with each applicable customer, and business and industry factors such as significant shifts in the healthcare environment which the Company believes may have impacted or will impact its customers’ financial health and ability to pay.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended September 30, 2022, the Company increased the allowance for credit losses related to a physician customer by $9.5 million due to the customer facing financial challenges and its resulting inability to make a contractually required payment on September 30, 2022. As a result of reviewing the potential expected outcomes related to this customer, the Company recorded an allowance for credit losses of $10.0 million related to an overall receivable balance of $33.3 million as of September 30, 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has presented the rollforward below on a consolidated basis as the currently expected credit losses for its large integrated healthcare system customers are not anticipated to be material. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movements in the allowance for credit losses are as follows (in millions):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.506%"><tr><td style="width:1.0%"/><td style="width:43.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.910%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.910%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative effect of Cloudmed ASC 326 adoption</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision (recoveries)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9500000 10000000 33300000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movements in the allowance for credit losses are as follows (in millions):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.506%"><tr><td style="width:1.0%"/><td style="width:43.033%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.910%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.910%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative effect of Cloudmed ASC 326 adoption</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision (recoveries)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4400000 2300000 2500000 3800000 0 0 1800000 0 10400000 400000 10700000 600000 200000 300000 400000 2000000.0 14600000 2400000 14600000 2400000 Leases<div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.512%"><tr><td style="width:1.0%"/><td style="width:42.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.308%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Refer to Note 2, Acquisitions, for the preliminary right-of-use assets acquired and lease liabilities assumed as part of the Cloudmed Acquisition.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of September 30, 2022 are as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.493%"><tr><td style="width:1.0%"/><td style="width:63.557%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.874%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span> <div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.512%"><tr><td style="width:1.0%"/><td style="width:42.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.308%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 6900000 4000000.0 16800000 12100000 400000 600000 1300000 1700000 6500000 3400000 15500000 10400000 17600000 18600000 67600000 13600000 Maturities of lease liabilities as of September 30, 2022 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.493%"><tr><td style="width:1.0%"/><td style="width:63.557%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.874%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span> 9300000 24600000 23900000 22600000 16800000 10800000 40800000 148800000 28800000 120000000.0 Debt<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of debt consist of the following:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"/><td style="width:55.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.669%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.479%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Revolver (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term A Loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,222.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">695.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term B Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,777.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">772.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current maturities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,728.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">754.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) As of September 30, 2022, the Company had $80.0 million in borrowings, $0.9 million letters of credit outstanding, and $519.1 million of availability under the Senior Revolver.</span></div><div><span><br/></span></div><div style="padding-right:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Amended and Restated Senior Secured Credit Facilities</span></div><div style="padding-right:22.5pt"><span><br/></span></div><div style="padding-right:22.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, the Company, Old R1 RCM, and certain of its subsidiaries entered into a second amended and restated senior credit agreement (the “Second A&amp;R Credit Agreement”) with Bank of America, N.A., as administrative agent, and the lenders named therein, governing the Company’s second amended and restated senior secured credit facilities (the “Senior Secured Credit Facilities”), consisting of the $691.3 million existing senior secured term loan A facility (the “Existing Term A Loan”), a $540.0 million senior secured incremental term loan A facility (the “Incremental Term A Loan”, and together with the Existing Term A Loan, the “Term A Loans”), a $500.0 million senior secured term loan B facility (the “Term B Loan”, and together with the Term A Loans, the “Senior Term Loans”), and a $600.0 million senior secured revolving credit facility (the “Senior Revolver”). In conjunction with entering into the Second A&amp;R Credit Agreement, the Company incurred $7.2 million and capitalized $6.4 million of debt issuance costs.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Incremental Term A Loan has a five-year maturity and the Term B Loan has a seven-year maturity. The Existing Term A Loan and Senior Revolver mature on July 1, 2026. The Second A&amp;R Credit Agreement provides that the Company may make one or more offers to the lenders, and consummate transactions with individual lenders that accept the terms contained in such offers, to extend the maturity date of the lender’s term loans and/or revolving commitments, subject to certain conditions, and any extended term loans or revolving commitments will constitute a separate class of term loans or revolving commitments.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Secured Credit Facilities bear interest, at the Company’s option, at: (i) an Alternate Base Rate (“ABR”) equal to the greater of (a) the prime rate of Bank of America, N.A., (b) the federal funds rate plus 0.50% per annum, and (c) the Term Secured Overnight Financing Rate (“SOFR”) for an interest period of one-month beginning on such day plus 100 basis points, plus between 0.25% and 1.50% dependent on the Company’s total net leverage ratio (provided that the Term SOFR rate applicable to the Term A Loans shall not be less than 0.00% per annum, and the Term SOFR rate applicable to the Term B Loan shall not be less than 0.50% per annum); or (ii) the Term SOFR rate (provided that the Term SOFR rate applicable to the Term A Loans shall not be less than 0.00% per annum, and the Term SOFR rate applicable to the Term B Loan shall not be less than 0.50% per annum), plus between 1.25% and 2.50%, dependent on the Company’s total net leverage ratio. The interest rate as of September 30, 2022 was 5.28%</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the Term A Loans and Senior Revolver and</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.03% for the Term B Loan. The Company is also required to pay an unused commitment fee to the lenders under the Senior Revolver at a rate between 0.20% and 0.40% of the average daily unutilized commitments thereunder dependent on the Company’s total net leverage ratio. </span></div><div style="padding-right:22.5pt;text-indent:22.5pt"><span><br/></span></div><div style="padding-right:22.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Second A&amp;R Credit Agreement requires the Company to make mandatory prepayments, subject to certain exceptions, with: (i) beginning with fiscal year ending December 31, 2023, 50% (which percentage will be reduced upon the Company’s achievement of certain total net leverage ratios) of the Company’s annual excess cash flow, (ii) 100% of net cash proceeds of all non-ordinary course asset sales or other dispositions of property or casualty events, subject to certain exceptions and thresholds, and (iii) 100% of the net cash proceeds of any debt incurrence, other than debt permitted under the Second A&amp;R Credit Agreement. </span></div><div style="padding-right:22.5pt;text-indent:22.5pt"><span><br/></span></div><div style="padding-right:22.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Second A&amp;R Credit Agreement contains a number of financial and non-financial covenants. The Company was in compliance with all of the covenants in the Second A&amp;R Credit Agreement as of September 30, 2022. The obligations under the Second A&amp;R Credit Agreement are secured by a pledge of 100% of the capital stock of certain domestic subsidiaries owned by the Company and a security interest in substantially all of the Company’s tangible and intangible assets and the tangible and intangible assets of certain domestic subsidiaries.</span></div><div style="padding-right:22.5pt;text-indent:22.5pt"><span><br/></span></div><div style="padding-right:22.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from the new Senior Secured Credit Facilities were or will be used, in addition to cash on hand, (1) to refinance, in full, all existing indebtedness under the Amended and Restated Credit Agreement, dated as of July 1, 2021, by and among Old R1 RCM and certain of its subsidiaries, Bank of America, N.A., as administrative agent, and the lenders named therein, and amend and restate all commitments thereunder (the “Refinancing”), (2) to pay certain fees and expenses incurred in connection with the entry into the Second A&amp;R Credit Agreement and the Refinancing, (3) to fund the Transactions, and to pay the fees, premiums, expenses, and other transaction costs incurred in connection therewith, and (4) to finance working capital needs of the Company and its subsidiaries for general corporate purposes. Debt amounts presented as of December 31, 2021 were incurred under the 2021 Amended and Restated Credit Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Maturities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities of the Company’s long-term debt are summarized as follows:</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.346%"><tr><td style="width:1.0%"/><td style="width:46.962%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.737%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Scheduled Maturities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">698.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,802.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further details on the Company’s 2021 Amended and Restated Credit Agreement, refer to Note 10 of the Company’s 2021 Form 10-K.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of debt consist of the following:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"/><td style="width:55.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.669%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.479%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Revolver (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term A Loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,222.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">695.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term B Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,777.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">772.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current maturities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,728.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">754.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) As of September 30, 2022, the Company had $80.0 million in borrowings, $0.9 million letters of credit outstanding, and $519.1 million of availability under the Senior Revolver.</span></div> 80000000.0 80000000.0 1222500000 695600000 500000000.0 0 24900000 3200000 1777600000 772400000 49500000 17500000 1728100000 754900000 80000000 900000 519100000 691300000 540000000 500000000 600000000 7200000 6400000 P5Y P7Y 1 0.0050 0.0100 0.0025 0.0150 0.0000 0.0050 0.0000 0.0050 0.0125 0.0250 0.0528 0.0603 0.0020 0.0040 0.50 1 1 1 Scheduled maturities of the Company’s long-term debt are summarized as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.346%"><tr><td style="width:1.0%"/><td style="width:46.962%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.737%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Scheduled Maturities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">698.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,802.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 12400000 53900000 67000000.0 67000000.0 698300000 430200000 473700000 1802500000 Derivative Financial Instruments<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes cash flow hedges to manage its currency risk arising from its global business services centers. As of September 30, 2022, the Company has recorded $1.2 million of unrealized losses in accumulated other comprehensive loss related to foreign currency hedges. The Company estimates that $1.1 million of losses reported in accumulated other comprehensive loss are expected to be reclassified into earnings within the next 12 months. Amounts reclassified into cost of services were a net loss of $0.7 million and $0.6 million during the three and nine months ended September 30, 2022, respectively, and a net gain of $0.4 million and $1.0 million during the three and nine month periods ended September 30, 2021, respectively. As of September 30, 2022, the Company’s currency forward contracts have maturities extending no later than December 31, 2023, and had a total notional value of $76.8 million.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also utilizes cash flow hedges to reduce variability in interest cash flows from its outstanding debt. As of September 30, 2022, the Company has recorded $12.9 million of unrealized gains in accumulated other comprehensive loss related to interest rate swaps. The Company estimates that $3.7 million of gains reported in accumulated other comprehensive loss are expected to be reclassified into earnings within the next 12 months. Amounts reclassified into interest expense were a net loss of $0.4 million and $0.9 million</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three and nine months ended September 30, 2022, respectively and a net loss of $0.3 million and $1.1 million during the three and nine month periods ended September 30, 2021, respectively. As of September 30, 2022, the Company’s interest rate swaps extend no later than June 30, 2025, and had a total notional value of $500.0 million.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The location and fair value of derivative instruments designated as hedges in the Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"><tr><td style="width:1.0%"/><td style="width:46.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.528%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total foreign current forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the accumulated gain, net of tax, recognized in accumulated other comprehensive loss was $8.8 million and $0.7 million, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies cash flows from its derivative programs as cash flows from operating activities in the consolidated statements of cash flows. Fair values for derivative financial instruments are based on prices computed using third-party valuation models and are classified as Level 2 in accordance with the three-level hierarchy of fair value measurements.</span></div>On July 5, 2022, the Company entered into an agreement with a third party regarding the potential purchase of a business that would expand the service capabilities of the Company. This agreement is effective through approximately the end of 2023 and allows the other party to sell the business to the Company for $150.0 million, subject to the negotiation of a definitive agreement and the satisfaction of agreed upon closing conditions, including the requirement that the purchase price be deemed to be fair value at the time of the potential transaction. The parties, assuming an agreement is reached, would also need to reach agreement as to whether the purchase price would be paid in cash or shares of common stock of the Company. -1200000 -1100000 -700000 600000 400000 1000000 76800000 12900000 3700000 -400000 -900000 -300000 -1100000 500000000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The location and fair value of derivative instruments designated as hedges in the Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"><tr><td style="width:1.0%"/><td style="width:46.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.528%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total foreign current forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 1700000 1200000 0 1200000 1700000 3700000 0 9200000 0 0 700000 12900000 700000 8800000 700000 150000000 Share-Based Compensation <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share-based compensation expense relating to the Company’s stock options, RSUs, and performance-based restricted stock units (“PBRSUs”) for the three months ended September 30, 2022 and 2021 was $27.8 million and $25.5 million, respectively, with related tax benefits of approximately $4.6 million and $5.1 million, respectively. The share-based compensation expense relating to the Company’s stock options, RSUs, and PBRSUs for the nine months ended September 30, 2022 and 2021 was $49.5 million and $62.0 million, respectively, with related tax benefits of approximately $8.5 million and $12.2 million, respectively.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for forfeitures as they occur. Excess tax benefits and shortfalls for share-based payments are recognized in income tax expense (benefit) and included in operating activities. The Company recognized $4.3 million and $0.6 million of income tax benefit from windfalls associated with vesting and exercises of equity awards for the three months ended September 30, 2022 and 2021, respectively. The Company recognized $9.2 million and $7.2 million of income tax benefit from windfalls associated with vesting and exercises of equity awards for the nine months ended September 30, 2022 and 2021, respectively. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation costs that have been included in the Company’s consolidated statements of operations were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:54.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Share-Based Compensation Expense Allocation Details:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to estimate the fair value of its service-based options as of their grant dates. The Company assesses current performance on performance-based PBRSUs by reviewing historical performance to date, along with any adjustments which have been approved to the reported performance, and changes to the projections to determine the probable outcome of the awards. The current estimates are then compared to the scoring metrics and any necessary adjustments are reflected in the current period to update share-based compensation expense to the current performance expectations.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the options activity during the nine months ended September 30, 2022 is shown below:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.237%"><tr><td style="width:1.0%"/><td style="width:64.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.656%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,386,205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,279,460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,110,181 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, vested and exercisable at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,084,188 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, vested and exercisable at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,365,759 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted stock units and performance-based restricted stock units    </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU and PBRSU activity during the nine months ended September 30, 2022 is shown below:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.525%"><tr><td style="width:1.0%"/><td style="width:48.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.636%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PBRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RSU</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PBRSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,218,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,203,013 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,249,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,230,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance factor adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876,109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(574,564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,878,328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(164,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201,544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding and unvested at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,728,830 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,229,733 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares surrendered for taxes for the nine months ended September 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">783,392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of shares surrendered for taxes for the nine months ended September 30, 2022 (in millions)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares surrendered for taxes for the nine months ended September 30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of shares surrendered for taxes for the nine months ended September 30, 2021 (in millions)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consummation of the Holding Company Reorganization, outstanding restricted units of Cloudmed were replaced by an aggregate 1,536,220 RSUs of the Company. The Company also issued an aggregate of 3,173,184 inducement RSUs and PBRSUs to certain employees of Cloudmed under Nasdaq Listing Rule 5635(c)(4) pursuant to its newly adopted 2022 Inducement Plan. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s RSU and PBRSU agreements allow employees to surrender to the Company shares of common stock upon vesting of their RSUs and PBRSUs in lieu of their payment of the required personal employment-related taxes. Shares surrendered for payment of personal employment-related taxes are held in treasury.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding PBRSUs vest upon satisfaction of both time-based and performance-based conditions. Depending on the award, performance condition targets may include cumulative adjusted EBITDA, end-to-end RCM agreement growth, modular sales revenue, or other specific performance factors. Depending on the percentage level at which the performance-based conditions are satisfied, the number of shares vesting could be between 0% and 200% of the number of PBRSUs originally granted. Based on the established targets, the maximum number of shares that could vest for all outstanding PBRSUs is 14,412,591.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CoyCo 2, L.P. Limited Partnership Units    </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the transactions contemplated by the Transaction Agreement, equity awards held by certain employees of Cloudmed (“Former Class P Units”) were modified, through a series of transactions, into awards (“Management Units”) of CoyCo 2. The Management Units issued by CoyCo 2 are treated as share-based compensation under ASC 718, Compensation —Stock Compensation.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Former Class P Units were originally issued to employees of Cloudmed and its affiliates (“Participants”) in connection with and as a part of the compensation and incentive arrangements between Cloudmed and such Participants prior to the consummation of the Cloudmed Acquisition. A portion of the Former Class P Units immediately vested upon the closing of the Cloudmed Acquisition; however, certain Former Class P Units that were subject to performance-based vesting conditions did not become vested upon the closing of the Cloudmed Acquisition (“Unvested Units”). However, in connection with the Cloudmed Acquisition, Cloudmed caused the Former Class P Units, including the Unvested Units, to be converted into Management Units. At the time of the closing of the Cloudmed Acquisition, 97,875 Unvested Units were converted into 514,986 Management Units.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In general, Unvested Units vest upon the achievement of certain performance criteria, including achievement by the Sellers’ owner, New Mountain Capital, L.L.C. (“New Mountain”), of (i) specified multiples of Base Equity Value (“BEV”) (i.e., generally the aggregate equity value of New Mountain’s investment in Cloudmed as of the original grant date), or (ii) specified Multiples on Invested Capital (“MIC”) with respect to New Mountain Capital’s pre-Cloudmed Acquisition investment in Cloudmed, and subject to continued service with the Company and its affiliates, including Cloudmed through the applicable vesting date. The awards are not awards of the Company and the Participants will receive no additional shares of the Company upon satisfaction of the vesting criteria. However, GAAP requires the Company recognize the cost of share-based compensation granted by an investor (CoyCo 2) to the Company’s employees and service providers for services that benefit the Company’s operations, and a corresponding capital contribution because the costs are incurred on the Company’s behalf.</span></div>A Monte Carlo simulation was used to estimate the fair value of the Unvested Units which is being amortized over a period of 4 years on a straight-line basis. 27800000 25500000 4600000 5100000 49500000 62000000 8500000 12200000 -4300000 -600000 -9200000 -7200000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation costs that have been included in the Company’s consolidated statements of operations were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:54.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Share-Based Compensation Expense Allocation Details:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12300000 15800000 21700000 38800000 15400000 9700000 27700000 23200000 100000 0 100000 0 27800000 25500000 49500000 62000000.0 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the options activity during the nine months ended September 30, 2022 is shown below:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.237%"><tr><td style="width:1.0%"/><td style="width:64.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.656%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,386,205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,279,460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,110,181 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, vested and exercisable at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,084,188 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, vested and exercisable at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,365,759 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4386205 3.37 24344 22.19 1279460 3.67 13408 4.59 7500 8.71 3110181 3.38 3084188 3.22 4365759 3.33 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU and PBRSU activity during the nine months ended September 30, 2022 is shown below:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.525%"><tr><td style="width:1.0%"/><td style="width:48.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.636%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average Grant<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PBRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RSU</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PBRSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,218,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,203,013 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,249,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,230,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance factor adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876,109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(574,564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,878,328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(164,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201,544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding and unvested at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,728,830 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,229,733 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares surrendered for taxes for the nine months ended September 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">783,392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of shares surrendered for taxes for the nine months ended September 30, 2022 (in millions)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares surrendered for taxes for the nine months ended September 30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of shares surrendered for taxes for the nine months ended September 30, 2021 (in millions)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div> 2218651 3203013 16.28 16.45 2249157 5230483 20.62 19.83 0 876109 0 10.46 574564 1878328 14.49 11.19 164414 201544 17.41 19.87 3728830 7229733 19.12 19.44 182080 783392 4100000 20000000.0 186588 0 4800000 0 1536220 3173184 0 2 14412591 97875 514986 P4Y Other Expenses <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other expenses are incurred in connection with acquisition and integration costs, various exit activities, transformation initiatives, and organizational changes to improve our business alignment and cost structure.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the other expenses (income) recognized for the three and nine months ended September 30, 2022 and 2021.</span><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.660%"><tr><td style="width:1.0%"/><td style="width:54.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severance and related employee benefits (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Business acquisition costs (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Integration costs (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Strategic initiatives (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global business services center expansion project in the Philippines (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer employee transition and restructuring expenses (6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facility-exit charges (7)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) These costs relate to restructuring and business reorganization events.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) These are costs, including legal, consulting, and bank fees, that are directly related to the close of the Cloudmed Acquisition on June 21, 2022 and the close of the VisitPay acquisition on July 1, 2021 and include changes to contingent consideration, if applicable.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) These costs reflect efforts to integrate acquisitions from a systems, processes, and people perspective. Costs include consulting fees, IT vendor spend, severance, early lease termination of Cloudmed facilities, and certain payroll costs. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) These costs relate to performing portfolio and capital structure analyses and transactions and other business transformation projects (including large scale system projects) as part of the Company’s growth strategy. Costs include vendor spend, employee time and expenses spent on activities, severance, and retention amounts. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) These costs include legal and consulting fees related to the establishment of the Company’s inaugural global business services center in the Philippines as well as severance costs for personnel whose roles are being relocated. The entry into the Philippines is the first new organic global business services center country expansion by the Company in approximately 15 years. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) As part of the transition of customer personnel to the Company under certain operating partner model contracts, the Company agreed to reimburse the customer, or directly pay affected employees, for severance and retention costs related to certain employees who were not transitioned to the Company, or whose jobs were relocated after the employee transitioned to the Company.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) As part of evaluating its footprint, the Company has exited certain leased facilities. Costs include asset impairment charges, early termination fees, and other costs related to exited leased facilities. </span></div>(8) For the three and nine months ended September 30, 2022, other includes $0.7 million and $1.8 million, respectively, of expenses related to the COVID-19 pandemic. For the three and nine months ended September 30, 2021, other includes $2.7 million and $7.1 million, respectively, of expenses related to the COVID-19 pandemic. The following table summarizes the other expenses (income) recognized for the three and nine months ended September 30, 2022 and 2021.<div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.660%"><tr><td style="width:1.0%"/><td style="width:54.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.320%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severance and related employee benefits (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Business acquisition costs (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Integration costs (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Strategic initiatives (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global business services center expansion project in the Philippines (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer employee transition and restructuring expenses (6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facility-exit charges (7)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) These costs relate to restructuring and business reorganization events.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) These are costs, including legal, consulting, and bank fees, that are directly related to the close of the Cloudmed Acquisition on June 21, 2022 and the close of the VisitPay acquisition on July 1, 2021 and include changes to contingent consideration, if applicable.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) These costs reflect efforts to integrate acquisitions from a systems, processes, and people perspective. Costs include consulting fees, IT vendor spend, severance, early lease termination of Cloudmed facilities, and certain payroll costs. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) These costs relate to performing portfolio and capital structure analyses and transactions and other business transformation projects (including large scale system projects) as part of the Company’s growth strategy. Costs include vendor spend, employee time and expenses spent on activities, severance, and retention amounts. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) These costs include legal and consulting fees related to the establishment of the Company’s inaugural global business services center in the Philippines as well as severance costs for personnel whose roles are being relocated. The entry into the Philippines is the first new organic global business services center country expansion by the Company in approximately 15 years. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) As part of the transition of customer personnel to the Company under certain operating partner model contracts, the Company agreed to reimburse the customer, or directly pay affected employees, for severance and retention costs related to certain employees who were not transitioned to the Company, or whose jobs were relocated after the employee transitioned to the Company.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) As part of evaluating its footprint, the Company has exited certain leased facilities. Costs include asset impairment charges, early termination fees, and other costs related to exited leased facilities. </span></div>(8) For the three and nine months ended September 30, 2022, other includes $0.7 million and $1.8 million, respectively, of expenses related to the COVID-19 pandemic. For the three and nine months ended September 30, 2021, other includes $2.7 million and $7.1 million, respectively, of expenses related to the COVID-19 pandemic. 0 300000 0 2100000 200000 2300000 74400000 4200000 8800000 0 18300000 2600000 6200000 2500000 9000000.0 6400000 10000000.0 0 20000000.0 0 0 3200000 -400000 3200000 1300000 0 7300000 2900000 3600000 3100000 7500000 12800000 30100000 11400000 136100000 34200000 P15Y 700000 1800000 2700000 7100000 Income TaxesIncome tax provisions for interim periods are based on estimated annual income tax rates, adjusted to reflect the effects of any significant and infrequent or unusual items which are required to be discretely recognized within the current interim period. The effective tax rates in the periods presented are largely based upon the projected annual pre-tax earnings by jurisdiction and the allocation of certain expenses in various taxing jurisdictions where the Company conducts its business. These taxing jurisdictions apply a broad range of statutory income tax rates. The global intangible low-taxed income (“GILTI”) provisions impose taxes on foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company elected to account for GILTI tax in the period in which it is incurred.<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized income tax expense for the three months ended September 30, 2022 and income tax benefit for the nine months ended September 30, 2022 on the year-to-date pre-tax loss. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for foreign taxes, GILTI, non-deductible expenses, and discrete items. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized income tax expense for the three and nine months ended September 30, 2021 on the year-to-date pre-tax income. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for state taxes, GILTI, non-deductible expenses, and discrete items.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. U.S. federal income tax returns since 2018 are currently open for examination. State jurisdictions vary for open tax years. The statute of limitations for most states ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhmNjA0ZTUzN2JiNzRjOWI5NjJiM2E4MjhlNWI4ZjVmL3NlYzo4ZjYwNGU1MzdiYjc0YzliOTYyYjNhODI4ZTViOGY1Zl82NC9mcmFnOjRhZDc0NWUwZjQzMjRlYWY5OTJhNGQ3ZDc5NTA2NTY0L3RleHRyZWdpb246NGFkNzQ1ZTBmNDMyNGVhZjk5MmE0ZDdkNzk1MDY1NjRfMTc5OA_f70d4df8-9433-4317-a81e-67c0db70bef4">three</span> to six years. </span></div>At December 31, 2021, the Company had gross deferred tax assets of $123.7 million, of which $54.7 million related to net operating loss (“NOL”) carryforwards. The Company expects to be profitable, allowing the Company to utilize its NOL carryforwards and other deferred tax assets. 0.21 0.21 0.21 0.21 P6Y 123700000 54700000 Earnings (Loss) Per Share<div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is computed by dividing net income (loss), less any dividends, accretion or decretion, redemption or induced conversion on the preferred stock, by the weighted average number of common shares outstanding during the period. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net income (loss) per share is calculated by adjusting the denominator used in the basic net income (loss) per share computation by potentially dilutive securities outstanding during the period plus, when their effect is dilutive, incremental shares consisting of shares subject to stock options and shares issuable upon vesting of RSUs and PBRSUs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income (loss) per common share are calculated as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.698%"><tr><td style="width:1.0%"/><td style="width:48.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.093%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.093%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.093%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.093%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.181%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Basic EPS:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less dividends on preferred shares (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(592.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) available/(allocated) to common shareholders - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(531.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Diluted EPS:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less dividends on preferred shares (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(592.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) available/(allocated) to common shareholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(531.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted-average common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417,700,782 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">278,655,269 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330,877,880 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262,209,929 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Effect of dilutive equity awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,281,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Effect of dilutive warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,680,381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417,700,782 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320,617,086 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330,877,880 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262,209,929 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per common share (basic)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.03)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per common share (diluted)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.03)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The 2021 dividend on preferred shares includes amounts related to the conversion of the preferred shares. See Note 16 of the Company’s 2021 Form 10-K for more information.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of their anti-dilutive effect, 21,251,602 common share equivalents comprised of stock options, PBRSUs, and RSUs have been excluded from the diluted earnings per share calculation for the three and nine months ended September 30, 2022. Additionally, for the three and nine months ended September 30, 2022, TCP-ASC ACHI Series LLLP’s (“TCP-ASC” or the “Investor”) and IHC Health Services, Inc.’s (“Intermountain”) exercisable warrants to acquire up to 40.5 million and 1.5 million shares, respectively, of the Company’s common stock have been excluded from the diluted earnings per share calculation because they were anti-dilutive.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, 890,717 and 15,155,288</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common share equivalents, respectively, have been excluded from the diluted earnings per share calculation because of their anti-dilutive effect. Additionally, for the nine months ended September 30, 2021, the Investor’s and Intermountain’s exercisable warrants to acquire up to 40.5 million and 1.5 million shares, respectively, of the Company’s common stock have been excluded from the diluted earnings per share calculation because they were anti-dilutive.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income (loss) per common share are calculated as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.698%"><tr><td style="width:1.0%"/><td style="width:48.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.093%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.093%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.093%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.093%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.181%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Basic EPS:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less dividends on preferred shares (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(592.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) available/(allocated) to common shareholders - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(531.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Diluted EPS:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less dividends on preferred shares (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(592.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) available/(allocated) to common shareholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(531.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted-average common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417,700,782 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">278,655,269 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330,877,880 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262,209,929 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Effect of dilutive equity awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,281,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Effect of dilutive warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,680,381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417,700,782 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320,617,086 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330,877,880 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262,209,929 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per common share (basic)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.03)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per common share (diluted)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.03)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) The 2021 dividend on preferred shares includes amounts related to the conversion of the preferred shares. See Note 16 of the Company’s 2021 Form 10-K for more information. -29500000 17000000.0 -20500000 61200000 0 0 0 592300000 -29500000 17000000.0 -20500000 -531100000 -29500000 17000000.0 -20500000 61200000 0 0 0 592300000 -29500000 17000000.0 -20500000 -531100000 417700782 278655269 330877880 262209929 0 7281436 0 0 0 34680381 0 0 417700782 320617086 330877880 262209929 -0.07 0.06 -0.06 -2.03 -0.07 0.05 -0.06 -2.03 21251602 21251602 40500000 40500000 1500000 1500000 890717 15155288 40500000 1500000 Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as described below, the Company is not presently a party to any material litigation or regulatory proceeding and is not aware of any pending or threatened litigation or regulatory proceeding against the Company which, individually or in the aggregate, could have a material adverse effect on its business, operating results, financial condition or cash flows.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2021 and April 19, 2021, respectively, certain purported stockholders of the Company filed two complaints in the Delaware Court of Chancery regarding the Company’s January 15, 2021 recapitalization transaction with TCP-ASC. Both complaints allege that TCP-ASC, Ascension Health (“Ascension”), and TowerBrook Capital Partners (“TowerBrook”) controlled the Company and breached their fiduciary duties by using that alleged control to force the Company to overpay in redeeming TCP-ASC’s preferred stock as part of the recapitalization transaction. The plaintiffs seek an unspecified amount of damages against TCP-ASC, Ascension, and TowerBrook. The plaintiffs also allege that the Company and TCP-ASC entered into amendments to the Investor Rights Agreement that the plaintiffs contend contains provisions that are void under the Company’s charter, bylaws, and the Delaware General Corporation Law. The cases have since been consolidated into a single action. All defendants have answered the complaint and discovery has commenced.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2022, plaintiffs filed a supplement to their complaint, naming certain additional defendants and asserting additional claims related to the Company’s agreement to acquire Cloudmed, which was announced on January 10, 2022. The additional claims assert that: (i) TCP-ASC, Ascension, and TowerBrook, along with the Company’s directors (“Individual Defendants”), breached their fiduciary duties by causing the Company to enter into and approving the Cloudmed acquisition, respectively, which plaintiffs claim will perpetuate TCP-ASC’s, Ascension’s, and TowerBrook’s control over the Company and entrench the Individual Defendants by virtue of certain agreements entered into as part of the transaction, including a Second Amended Investor Rights Agreement with TCP-ASC (the “Seconded Amended Investor Rights Agreement”) and an Investor Rights Agreement with Cloudmed (the “Cloudmed Investor Rights Agreement”); and (ii) Cloudmed’s stockholders aided and abetted such breaches. Plaintiffs also allege that certain provisions in the Cloudmed Investor Rights Agreement and the Second Amended Investor Rights Agreement are void under the Company’s charter, bylaws, and the Delaware General Corporation law. The plaintiffs seek a declaratory judgment and an unspecified amount of damages, as well as attorneys’ fees and costs. The Company believes it has meritorious defenses to all claims against it and intends to vigorously defend itself against these claims.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2016, the Company was served with a False Claims Act case brought by a former emergency department service associate who worked at a hospital of one of the Company’s customers, MedStar Inc.’s Washington Hospital Center (“WHC”), along with WHC and three other hospitals that were PAS customers and a place holder, John Doe hospital, representing all PAS customers (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">U.S. ex rel. Graziosi vs. Accretive Health, Inc. et. al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">), and seeking money damages, False Claims Act penalties, and plaintiff’s attorneys’ fees. The Third Amended Complaint alleges that the Company’s PAS business violates the federal False Claims Act. The case was originally filed under seal in 2013 in the federal district court in Chicago and presented to the U.S. Attorney in Chicago, and the U.S. Attorney declined to intervene. The Company believes that it has meritorious defenses to all claims in the case and intends to vigorously defend itself against these claims. Both the Company’s and plaintiff’s motions for summary judgment were denied in December 2020, and the parties have completed damage and expert discovery. Additional dispositive motions are expected to extend through 2022, with trial, if necessary, in June 2023.</span> 2 Related Party Transactions <div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This note encompasses transactions between Ascension and its affiliates, including AMITA Health, and the Company pursuant to the Master Professional Services Agreement, including all supplements, amendments, and other documents entered into in connection therewith. For further details on the Company’s agreements with Ascension, see Note 1 and Note 19 of the Company’s 2021 Form 10-K. In conjunction with the Cloudmed Acquisition, New Mountain became a new related party. There were no material transactions with New Mountain subsequent to the Cloudmed Acquisition. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net services revenue from services provided to Ascension, as well as corresponding accounts receivable and customer liabilities are presented in the Consolidated Statements of Operations and Comprehensive Income (Loss) and the Consolidated Balance Sheets. Since Ascension is the Company’s largest customer, a significant percentage of the Company’s cost of services is associated with providing services to Ascension. However, due to the nature of the Company’s global business services and information technology operations, it is impractical to assign the dollar amount associated with services provided to Ascension.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2021 and May 28, 2021, the Company issued 16,750,000 shares of common stock to TCP-ASC upon the cashless exercise of a warrant to purchase 19,535,145 shares of common stock at an exercise price of $3.50 per share based upon a market value of $24.54 to $24.64 per share as determined under the terms of the warrant.</span></div> 16750000 19535145 3.50 24.54 24.64 Segments and Customer Concentrations<div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that it has a single operating segment in accordance with the way that management operates and views the business. All of the Company’s significant operations are organized around the single business of providing end-to-end management services of revenue cycle operations for U.S.-based healthcare providers. Accordingly, for purposes of segment disclosures, the Company has only one operating and reportable segment. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers comprising greater than 10% of net services revenue are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.564%"><tr><td style="width:1.0%"/><td style="width:29.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.434%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Customer Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ascension and its affiliates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intermountain Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of customers within the Ascension health system or Intermountain network could have a material adverse impact on the Company’s operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the Company had a concentration of credit risk with Ascension, representing 12% and 17% of accounts receivable, respectively.</span></div> 1 1 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers comprising greater than 10% of net services revenue are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.564%"><tr><td style="width:1.0%"/><td style="width:29.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.434%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Customer Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ascension and its affiliates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intermountain Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.44 0.60 0.52 0.61 0.11 0.14 0.13 0.14 0.12 0.17 Supplemental Financial Information<div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of depreciation and amortization expense related to property, equipment and software between cost of services and selling, general and administrative expenses:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.532%"><tr><td style="width:1.0%"/><td style="width:35.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of depreciation and amortization expense related to property, equipment and software between cost of services and selling, general and administrative expenses:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.532%"><tr><td style="width:1.0%"/><td style="width:35.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14700000 13600000 39000000.0 38800000 300000 600000 800000 2200000 15000000.0 14200000 39800000 41000000.0 EXCEL 91 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 93 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 94 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 268 361 1 false 67 0 false 8 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.r1rcm.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Consolidated Balance Sheets Sheet http://www.r1rcm.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) Sheet http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parenthetical) Sheet http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnauditedParenthetical Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Sheet http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 0000009 - Disclosure - Business Description and Basis of Presentation Sheet http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentation Business Description and Basis of Presentation Notes 9 false false R10.htm 0000010 - Disclosure - Acquisitions Sheet http://www.r1rcm.com/role/Acquisitions Acquisitions Notes 10 false false R11.htm 0000011 - Disclosure - Intangible Assets Sheet http://www.r1rcm.com/role/IntangibleAssets Intangible Assets Notes 11 false false R12.htm 0000012 - Disclosure - Goodwill Sheet http://www.r1rcm.com/role/Goodwill Goodwill Notes 12 false false R13.htm 0000013 - Disclosure - Revenue Recognition Sheet http://www.r1rcm.com/role/RevenueRecognition Revenue Recognition Notes 13 false false R14.htm 0000014 - Disclosure - Accounts Receivable and Allowance for Credit Losses Sheet http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLosses Accounts Receivable and Allowance for Credit Losses Notes 14 false false R15.htm 0000015 - Disclosure - Leases Sheet http://www.r1rcm.com/role/Leases Leases Notes 15 false false R16.htm 0000016 - Disclosure - Debt Sheet http://www.r1rcm.com/role/Debt Debt Notes 16 false false R17.htm 0000017 - Disclosure - Derivative Financial Instruments Sheet http://www.r1rcm.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 17 false false R18.htm 0000018 - Disclosure - Share-Based Compensation Sheet http://www.r1rcm.com/role/ShareBasedCompensation Share-Based Compensation Notes 18 false false R19.htm 0000019 - Disclosure - Other Expenses Sheet http://www.r1rcm.com/role/OtherExpenses Other Expenses Notes 19 false false R20.htm 0000020 - Disclosure - Income Taxes Sheet http://www.r1rcm.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 0000021 - Disclosure - Earnings (Loss) Per Share Sheet http://www.r1rcm.com/role/EarningsLossPerShare Earnings (Loss) Per Share Notes 21 false false R22.htm 0000022 - Disclosure - Commitments and Contingencies Sheet http://www.r1rcm.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 22 false false R23.htm 0000023 - Disclosure - Related Party Transactions Sheet http://www.r1rcm.com/role/RelatedPartyTransactions Related Party Transactions Notes 23 false false R24.htm 0000024 - Disclosure - Segments and Customer Concentrations Sheet http://www.r1rcm.com/role/SegmentsandCustomerConcentrations Segments and Customer Concentrations Notes 24 false false R25.htm 0000025 - Disclosure - Supplemental Financial Information Sheet http://www.r1rcm.com/role/SupplementalFinancialInformation Supplemental Financial Information Notes 25 false false R26.htm 0000026 - Disclosure - Business Description and Basis of Presentation (Policies) Sheet http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationPolicies Business Description and Basis of Presentation (Policies) Policies 26 false false R27.htm 0000027 - Disclosure - Acquisitions (Tables) Sheet http://www.r1rcm.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.r1rcm.com/role/Acquisitions 27 false false R28.htm 0000028 - Disclosure - Intangible Assets (Tables) Sheet http://www.r1rcm.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.r1rcm.com/role/IntangibleAssets 28 false false R29.htm 0000029 - Disclosure - Goodwill (Tables) Sheet http://www.r1rcm.com/role/GoodwillTables Goodwill (Tables) Tables http://www.r1rcm.com/role/Goodwill 29 false false R30.htm 0000030 - Disclosure - Revenue Recognition (Tables) Sheet http://www.r1rcm.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.r1rcm.com/role/RevenueRecognition 30 false false R31.htm 0000031 - Disclosure - Accounts Receivable and Allowance for Credit Losses (Tables) Sheet http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesTables Accounts Receivable and Allowance for Credit Losses (Tables) Tables http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLosses 31 false false R32.htm 0000032 - Disclosure - Leases (Tables) Sheet http://www.r1rcm.com/role/LeasesTables Leases (Tables) Tables http://www.r1rcm.com/role/Leases 32 false false R33.htm 0000033 - Disclosure - Debt (Tables) Sheet http://www.r1rcm.com/role/DebtTables Debt (Tables) Tables http://www.r1rcm.com/role/Debt 33 false false R34.htm 0000034 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Sheet http://www.r1rcm.com/role/DerivativeInstrumentsandHedgingActivitiesTables Derivative Instruments and Hedging Activities (Tables) Tables 34 false false R35.htm 0000035 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.r1rcm.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.r1rcm.com/role/ShareBasedCompensation 35 false false R36.htm 0000036 - Disclosure - Other Expenses (Tables) Sheet http://www.r1rcm.com/role/OtherExpensesTables Other Expenses (Tables) Tables http://www.r1rcm.com/role/OtherExpenses 36 false false R37.htm 0000037 - Disclosure - Earnings (Loss) Per Share (Tables) Sheet http://www.r1rcm.com/role/EarningsLossPerShareTables Earnings (Loss) Per Share (Tables) Tables http://www.r1rcm.com/role/EarningsLossPerShare 37 false false R38.htm 0000038 - Disclosure - Segments and Customer Concentrations (Tables) Sheet http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsTables Segments and Customer Concentrations (Tables) Tables http://www.r1rcm.com/role/SegmentsandCustomerConcentrations 38 false false R39.htm 0000039 - Disclosure - Supplemental Financial Information (Tables) Sheet http://www.r1rcm.com/role/SupplementalFinancialInformationTables Supplemental Financial Information (Tables) Tables http://www.r1rcm.com/role/SupplementalFinancialInformation 39 false false R40.htm 0000040 - Disclosure - Business Description and Basis of Presentation - Narrative (Details) Sheet http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails Business Description and Basis of Presentation - Narrative (Details) Details 40 false false R41.htm 0000041 - Disclosure - Acquisitions - Narrative (Details) Sheet http://www.r1rcm.com/role/AcquisitionsNarrativeDetails Acquisitions - Narrative (Details) Details 41 false false R42.htm 0000042 - Disclosure - Acquisitions - Fair Value Total Consideration Paid (Details) Sheet http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails Acquisitions - Fair Value Total Consideration Paid (Details) Details 42 false false R43.htm 0000043 - Disclosure - Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) Sheet http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details) Details 43 false false R44.htm 0000044 - Disclosure - Acquisitions - Schedule of Intangible Assets Information (Details) Sheet http://www.r1rcm.com/role/AcquisitionsScheduleofIntangibleAssetsInformationDetails Acquisitions - Schedule of Intangible Assets Information (Details) Details 44 false false R45.htm 0000045 - Disclosure - Acquisitions - Pro Forma Results (Details) Sheet http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails Acquisitions - Pro Forma Results (Details) Details 45 false false R46.htm 0000046 - Disclosure - Intangible Assets - Components of Intangible Assets (Details) Sheet http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails Intangible Assets - Components of Intangible Assets (Details) Details 46 false false R47.htm 0000047 - Disclosure - Intangible Assets - Narrative (Details) Sheet http://www.r1rcm.com/role/IntangibleAssetsNarrativeDetails Intangible Assets - Narrative (Details) Details 47 false false R48.htm 0000048 - Disclosure - Intangible Assets - Future Amortization (Details) Sheet http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails Intangible Assets - Future Amortization (Details) Details 48 false false R49.htm 0000049 - Disclosure - Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details) Sheet http://www.r1rcm.com/role/GoodwillScheduleofChangesinCarryingValueofGoodwillDetails Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details) Details 49 false false R50.htm 0000050 - Disclosure - Revenue Recognition - Schedule of Disaggregated Revenue by Source (Details) Sheet http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails Revenue Recognition - Schedule of Disaggregated Revenue by Source (Details) Details 50 false false R51.htm 0000051 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details) Sheet http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails Revenue Recognition - Schedule of Contract Balances (Details) Details 51 false false R52.htm 0000052 - Disclosure - Revenue Recognition - Changes to Contract Assets (Details) Sheet http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails Revenue Recognition - Changes to Contract Assets (Details) Details 52 false false R53.htm 0000053 - Disclosure - Revenue Recognition - Narrative (Details) Sheet http://www.r1rcm.com/role/RevenueRecognitionNarrativeDetails Revenue Recognition - Narrative (Details) Details 53 false false R54.htm 0000054 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details) Sheet http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details) Details 54 false false R55.htm 0000055 - Disclosure - Accounts Receivable and Allowance for Credit Losses - Narratives (Details) Sheet http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesNarrativesDetails Accounts Receivable and Allowance for Credit Losses - Narratives (Details) Details 55 false false R56.htm 0000056 - Disclosure - Accounts Receivable and Allowance for Credit Losses - Rollforward (Details) Sheet http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails Accounts Receivable and Allowance for Credit Losses - Rollforward (Details) Details 56 false false R57.htm 0000057 - Disclosure - Leases - Schedule of Lease Costs (Details) Sheet http://www.r1rcm.com/role/LeasesScheduleofLeaseCostsDetails Leases - Schedule of Lease Costs (Details) Details 57 false false R58.htm 0000058 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Details) Sheet http://www.r1rcm.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails Leases - Schedule of Supplemental Cash Flow Information (Details) Details 58 false false R59.htm 0000059 - Disclosure - Leases - Schedule of Operating and Finance Lease Maturity (Details) Sheet http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails Leases - Schedule of Operating and Finance Lease Maturity (Details) Details 59 false false R60.htm 0000060 - Disclosure - Debt - Carrying Amounts of Debt (Details) Sheet http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails Debt - Carrying Amounts of Debt (Details) Details 60 false false R61.htm 0000061 - Disclosure - Debt - Narrative (Details) Sheet http://www.r1rcm.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 61 false false R62.htm 0000062 - Disclosure - Debt - Scheduled Maturities of Long-Term Debt (Details) Sheet http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails Debt - Scheduled Maturities of Long-Term Debt (Details) Details 62 false false R63.htm 0000063 - Disclosure - Derivative Financial Instruments - Narrative (Details) Sheet http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails Derivative Financial Instruments - Narrative (Details) Details 63 false false R64.htm 0000064 - Disclosure - Derivative Financial Instruments- Schedule Of Derivative Instruments as Hedged on Consolidated Balance Sheets (Details) Sheet http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails Derivative Financial Instruments- Schedule Of Derivative Instruments as Hedged on Consolidated Balance Sheets (Details) Details 64 false false R65.htm 0000065 - Disclosure - Share-Based Compensation - Narrative (Details) Sheet http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails Share-Based Compensation - Narrative (Details) Details 65 false false R66.htm 0000066 - Disclosure - Share-Based Compensation - Compensation Expense Allocation (Details) Sheet http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails Share-Based Compensation - Compensation Expense Allocation (Details) Details 66 false false R67.htm 0000067 - Disclosure - Share-Based Compensation - Stock Options Activity (Details) Sheet http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails Share-Based Compensation - Stock Options Activity (Details) Details 67 false false R68.htm 0000068 - Disclosure - Share-Based Compensation - Other Than Stock Options Activity (Details) Sheet http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails Share-Based Compensation - Other Than Stock Options Activity (Details) Details 68 false false R69.htm 0000069 - Disclosure - Other Expenses - Schedule of Other Expenses (Details) Sheet http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails Other Expenses - Schedule of Other Expenses (Details) Details 69 false false R70.htm 0000070 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.r1rcm.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 70 false false R71.htm 0000071 - Disclosure - Earnings (Loss) Per Share - Computation of Basic and Diluted Earnings Per Share (Details) Sheet http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails Earnings (Loss) Per Share - Computation of Basic and Diluted Earnings Per Share (Details) Details http://www.r1rcm.com/role/EarningsLossPerShareTables 71 false false R72.htm 0000072 - Disclosure - Earnings (Loss) Per Share - Narrative (Details) Sheet http://www.r1rcm.com/role/EarningsLossPerShareNarrativeDetails Earnings (Loss) Per Share - Narrative (Details) Details http://www.r1rcm.com/role/EarningsLossPerShareTables 72 false false R73.htm 0000073 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 73 false false R74.htm 0000074 - Disclosure - Related Party Transactions - Narrative (Details) Sheet http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails Related Party Transactions - Narrative (Details) Details 74 false false R75.htm 0000075 - Disclosure - Segments and Customer Concentrations - Narrative (Details) Sheet http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails Segments and Customer Concentrations - Narrative (Details) Details 75 false false R76.htm 0000076 - Disclosure - Segments and Customer Concentrations - Concentration Risk by Customer (Details) Sheet http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails Segments and Customer Concentrations - Concentration Risk by Customer (Details) Details 76 false false R77.htm 0000077 - Disclosure - Supplemental Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails Supplemental Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details) Details 77 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: ah:StatuteOfLimitationsMinimum, dei:EntityRegistrantName, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 - ah-20220930.htm 4 [ix-0514-Hidden-Fact-Not-Referenced] WARN: 1 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 - ah-20220930.htm 4 ah-20220930.htm ah-20220930.xsd ah-20220930_cal.xml ah-20220930_def.xml ah-20220930_lab.xml ah-20220930_pre.xml ascensionhealth-r1xamendme.htm exhibit311-q32022.htm exhibit312-q32022.htm exhibit321-q32022.htm exhibit322-q32022.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 97 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ah-20220930.htm": { "axisCustom": 1, "axisStandard": 27, "contextCount": 268, "dts": { "calculationLink": { "local": [ "ah-20220930_cal.xml" ] }, "definitionLink": { "local": [ "ah-20220930_def.xml" ] }, "inline": { "local": [ "ah-20220930.htm" ] }, "labelLink": { "local": [ "ah-20220930_lab.xml" ] }, "presentationLink": { "local": [ "ah-20220930_pre.xml" ] }, "schema": { "local": [ "ah-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 569, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 7, "http://www.r1rcm.com/20220930": 1, "http://xbrl.sec.gov/dei/2022": 6, "total": 14 }, "keyCustom": 56, "keyStandard": 305, "memberCustom": 29, "memberStandard": 35, "nsprefix": "ah", "nsuri": "http://www.r1rcm.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "role": "http://www.r1rcm.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Acquisitions", "role": "http://www.r1rcm.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Intangible Assets", "role": "http://www.r1rcm.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Goodwill", "role": "http://www.r1rcm.com/role/Goodwill", "shortName": "Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Revenue Recognition", "role": "http://www.r1rcm.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Accounts Receivable and Allowance for Credit Losses", "role": "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLosses", "shortName": "Accounts Receivable and Allowance for Credit Losses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Leases", "role": "http://www.r1rcm.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Debt", "role": "http://www.r1rcm.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Derivative Financial Instruments", "role": "http://www.r1rcm.com/role/DerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Share-Based Compensation", "role": "http://www.r1rcm.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Other Expenses", "role": "http://www.r1rcm.com/role/OtherExpenses", "shortName": "Other Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Consolidated Balance Sheets", "role": "http://www.r1rcm.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Income Taxes", "role": "http://www.r1rcm.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Earnings (Loss) Per Share", "role": "http://www.r1rcm.com/role/EarningsLossPerShare", "shortName": "Earnings (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Commitments and Contingencies", "role": "http://www.r1rcm.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Related Party Transactions", "role": "http://www.r1rcm.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Segments and Customer Concentrations", "role": "http://www.r1rcm.com/role/SegmentsandCustomerConcentrations", "shortName": "Segments and Customer Concentrations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Supplemental Financial Information", "role": "http://www.r1rcm.com/role/SupplementalFinancialInformation", "shortName": "Supplemental Financial Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Business Description and Basis of Presentation (Policies)", "role": "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationPolicies", "shortName": "Business Description and Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Acquisitions (Tables)", "role": "http://www.r1rcm.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Intangible Assets (Tables)", "role": "http://www.r1rcm.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Goodwill (Tables)", "role": "http://www.r1rcm.com/role/GoodwillTables", "shortName": "Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Revenue Recognition (Tables)", "role": "http://www.r1rcm.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Accounts Receivable and Allowance for Credit Losses (Tables)", "role": "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesTables", "shortName": "Accounts Receivable and Allowance for Credit Losses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Leases (Tables)", "role": "http://www.r1rcm.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Debt (Tables)", "role": "http://www.r1rcm.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Derivative Instruments and Hedging Activities (Tables)", "role": "http://www.r1rcm.com/role/DerivativeInstrumentsandHedgingActivitiesTables", "shortName": "Derivative Instruments and Hedging Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.r1rcm.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Other Expenses (Tables)", "role": "http://www.r1rcm.com/role/OtherExpensesTables", "shortName": "Other Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Earnings (Loss) Per Share (Tables)", "role": "http://www.r1rcm.com/role/EarningsLossPerShareTables", "shortName": "Earnings (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Segments and Customer Concentrations (Tables)", "role": "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsTables", "shortName": "Segments and Customer Concentrations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ah:ScheduleOfDepreciationAndAmortizationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Supplemental Financial Information (Tables)", "role": "http://www.r1rcm.com/role/SupplementalFinancialInformationTables", "shortName": "Supplemental Financial Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "ah:ScheduleOfDepreciationAndAmortizationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)", "role": "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Business Description and Basis of Presentation - Narrative (Details)", "role": "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails", "shortName": "Business Description and Basis of Presentation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i5e9cb61dd16445b8be3fcce68c331379_I20220621", "decimals": "INF", "lang": "en-US", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "ah:PaymentsToAcquireBusinessesGrossFinancingActivities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Acquisitions - Narrative (Details)", "role": "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "shortName": "Acquisitions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i00270bf8fe644845af3e36c6fbdd7c27_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i06522e7885104053b80dca671f8dbecf_D20220621-20220621", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Acquisitions - Fair Value Total Consideration Paid (Details)", "role": "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails", "shortName": "Acquisitions - Fair Value Total Consideration Paid (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i06522e7885104053b80dca671f8dbecf_D20220621-20220621", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "Acquisitions - Fair Value of Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4a5d502dbf044b78b3001d32b9a833d2_I20220621", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "id4484e015d594bebaf5a39bb06c3c2f6_D20220621-20220621", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Acquisitions - Schedule of Intangible Assets Information (Details)", "role": "http://www.r1rcm.com/role/AcquisitionsScheduleofIntangibleAssetsInformationDetails", "shortName": "Acquisitions - Schedule of Intangible Assets Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "id4484e015d594bebaf5a39bb06c3c2f6_D20220621-20220621", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i976b73cebdba4826bcb88c8d922d9013_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Acquisitions - Pro Forma Results (Details)", "role": "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails", "shortName": "Acquisitions - Pro Forma Results (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i976b73cebdba4826bcb88c8d922d9013_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Intangible Assets - Components of Intangible Assets (Details)", "role": "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails", "shortName": "Intangible Assets - Components of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Intangible Assets - Narrative (Details)", "role": "http://www.r1rcm.com/role/IntangibleAssetsNarrativeDetails", "shortName": "Intangible Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Intangible Assets - Future Amortization (Details)", "role": "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails", "shortName": "Intangible Assets - Future Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i09fe3c5b032b460fb26480353c277ace_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details)", "role": "http://www.r1rcm.com/role/GoodwillScheduleofChangesinCarryingValueofGoodwillDetails", "shortName": "Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parenthetical)", "role": "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnauditedParenthetical", "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Revenue Recognition - Schedule of Disaggregated Revenue by Source (Details)", "role": "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails", "shortName": "Revenue Recognition - Schedule of Disaggregated Revenue by Source (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i8006a7cab9f7472a8327b2b32aa7d6bd_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details)", "role": "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails", "shortName": "Revenue Recognition - Schedule of Contract Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "lang": "en-US", "name": "ah:ContractWithCustomerLiabilityIncludingRelatedPartyCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i64b4038da9ea4394a2dba4d978462177_I20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Revenue Recognition - Changes to Contract Assets (Details)", "role": "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails", "shortName": "Revenue Recognition - Changes to Contract Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "ah:ContractWithCustomerAssetRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i58f7748c4d8449b2a96899513a930ffa_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Revenue Recognition - Narrative (Details)", "role": "http://www.r1rcm.com/role/RevenueRecognitionNarrativeDetails", "shortName": "Revenue Recognition - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i58f7748c4d8449b2a96899513a930ffa_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "id0cbbb1fcc0e4b999cb6dee252cc6334_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details)", "role": "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails", "shortName": "Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "id0cbbb1fcc0e4b999cb6dee252cc6334_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProvisionForDoubtfulAccounts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Accounts Receivable and Allowance for Credit Losses - Narratives (Details)", "role": "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesNarrativesDetails", "shortName": "Accounts Receivable and Allowance for Credit Losses - Narratives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i179c651069e44e4f9d718e8a98ba63aa_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ProvisionForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i64b4038da9ea4394a2dba4d978462177_I20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Accounts Receivable and Allowance for Credit Losses - Rollforward (Details)", "role": "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails", "shortName": "Accounts Receivable and Allowance for Credit Losses - Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Leases - Schedule of Lease Costs (Details)", "role": "http://www.r1rcm.com/role/LeasesScheduleofLeaseCostsDetails", "shortName": "Leases - Schedule of Lease Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Details)", "role": "http://www.r1rcm.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails", "shortName": "Leases - Schedule of Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Leases - Schedule of Operating and Finance Lease Maturity (Details)", "role": "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails", "shortName": "Leases - Schedule of Operating and Finance Lease Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i63cbc30bc3f84872964eee9bea67e86b_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "id7953119303c4c41a6ba0515704e10cc_D20210101-20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Debt - Carrying Amounts of Debt (Details)", "role": "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "shortName": "Debt - Carrying Amounts of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i6a29a3c0784f46f2b3268d8baa2b6a36_I20220621", "decimals": "INF", "first": true, "lang": "en-US", "name": "ah:DebtInstrumentCovenantMinimumNumberOfOffersToExtendMaturityDateIfCircumstancesMet", "reportCount": 1, "unique": true, "unitRef": "offer", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Debt - Narrative (Details)", "role": "http://www.r1rcm.com/role/DebtNarrativeDetails", "shortName": "Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i6a29a3c0784f46f2b3268d8baa2b6a36_I20220621", "decimals": "INF", "first": true, "lang": "en-US", "name": "ah:DebtInstrumentCovenantMinimumNumberOfOffersToExtendMaturityDateIfCircumstancesMet", "reportCount": 1, "unique": true, "unitRef": "offer", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Debt - Scheduled Maturities of Long-Term Debt (Details)", "role": "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails", "shortName": "Debt - Scheduled Maturities of Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iba5f019d73854f50aed1998db75c3b33_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Derivative Financial Instruments - Narrative (Details)", "role": "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "shortName": "Derivative Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iaf35e5a025734a20bcb4b1478bab21a3_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Derivative Financial Instruments- Schedule Of Derivative Instruments as Hedged on Consolidated Balance Sheets (Details)", "role": "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails", "shortName": "Derivative Financial Instruments- Schedule Of Derivative Instruments as Hedged on Consolidated Balance Sheets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iaf35e5a025734a20bcb4b1478bab21a3_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Share-Based Compensation - Narrative (Details)", "role": "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails", "shortName": "Share-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Share-Based Compensation - Compensation Expense Allocation (Details)", "role": "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails", "shortName": "Share-Based Compensation - Compensation Expense Allocation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "iefddbac08ecc426ea1b9ed5b80cfcd4d_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i09fe3c5b032b460fb26480353c277ace_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Share-Based Compensation - Stock Options Activity (Details)", "role": "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails", "shortName": "Share-Based Compensation - Stock Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i09fe3c5b032b460fb26480353c277ace_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "ib771bce322b644208615350e24b531dc_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Share-Based Compensation - Other Than Stock Options Activity (Details)", "role": "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails", "shortName": "Share-Based Compensation - Other Than Stock Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "ib771bce322b644208615350e24b531dc_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Other Expenses - Schedule of Other Expenses (Details)", "role": "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails", "shortName": "Other Expenses - Schedule of Other Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i12c9f37bdd9648538731e7eef82fe276_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)", "role": "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i12c9f37bdd9648538731e7eef82fe276_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.r1rcm.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Earnings (Loss) Per Share - Computation of Basic and Diluted Earnings Per Share (Details)", "role": "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails", "shortName": "Earnings (Loss) Per Share - Computation of Basic and Diluted Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "0", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Earnings (Loss) Per Share - Narrative (Details)", "role": "http://www.r1rcm.com/role/EarningsLossPerShareNarrativeDetails", "shortName": "Earnings (Loss) Per Share - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i075d591c4f974db39671ec5a601d2310_D20210413-20210419", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "reportCount": 1, "unique": true, "unitRef": "claim", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Commitments and Contingencies - Narrative (Details)", "role": "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i075d591c4f974db39671ec5a601d2310_D20210413-20210419", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "reportCount": 1, "unique": true, "unitRef": "claim", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i6e94101749154a9eb0530225edd094dc_D20210401-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "ah:StockIssuedDuringThePeriodSharesWarrantsExercised", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Related Party Transactions - Narrative (Details)", "role": "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails", "shortName": "Related Party Transactions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i611a3e445d9d40ecb2fd4ec9d5c27f6f_I20210528", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Segments and Customer Concentrations - Narrative (Details)", "role": "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails", "shortName": "Segments and Customer Concentrations - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i3279e029c28c4f2b8c85cca8ac1d2012_D20220701-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Segments and Customer Concentrations - Concentration Risk by Customer (Details)", "role": "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "shortName": "Segments and Customer Concentrations - Concentration Risk by Customer (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i3279e029c28c4f2b8c85cca8ac1d2012_D20220701-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ah:ScheduleOfDepreciationAndAmortizationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "ah:DepreciationDepletionAndAmortizationExcludingIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Supplemental Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details)", "role": "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails", "shortName": "Supplemental Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ah:ScheduleOfDepreciationAndAmortizationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i0889fcb4c4a44c8398f871d12741177a_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "ah:DepreciationDepletionAndAmortizationExcludingIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Business Description and Basis of Presentation", "role": "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentation", "shortName": "Business Description and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ah-20220930.htm", "contextRef": "i4d166c3a4e724725b3b59214c23babbf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 67, "tag": { "ah_AccountsReceivableCreditLossExpenseReversalNetOfWriteOffs": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Credit Loss Expense (Reversal), Net Of Write-Offs", "label": "Accounts Receivable, Credit Loss Expense (Reversal), Net Of Write-Offs", "terseLabel": "Provision for credit losses" } } }, "localname": "AccountsReceivableCreditLossExpenseReversalNetOfWriteOffs", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_AcquisitionEvaluationAndIntegrationCosts": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherGeneralExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Acquisition Evaluation And Integration Costs", "label": "Acquisition Evaluation And Integration Costs", "terseLabel": "Strategic initiatives" } } }, "localname": "AcquisitionEvaluationAndIntegrationCosts", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ah_AdjustmentsToAdditionalPaidInCapitalReplacementAwardsAllocatedToPurchasePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments To Additional Paid In Capital, Replacement Awards Allocated To Purchase Price", "label": "Adjustments To Additional Paid In Capital, Replacement Awards Allocated To Purchase Price", "terseLabel": "Replacement awards issued in conjunction with acquisitions" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalReplacementAwardsAllocatedToPurchasePrice", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_AscensionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ascension [Member]", "label": "Ascension [Member]", "terseLabel": "Ascension and its affiliates" } } }, "localname": "AscensionMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableReplacementEquityAwards": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Replacement Equity Awards", "label": "Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Replacement Equity Awards", "terseLabel": "Replacement awards issued to Cloudmed equity award holders" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableReplacementEquityAwards", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails" ], "xbrltype": "monetaryItemType" }, "ah_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableReplacementEquityAwardsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Replacement Equity Awards, Shares", "label": "Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Replacement Equity Awards, Shares", "terseLabel": "Replacement awards issued to Cloudmed equity award holders, shares (in shares)" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableReplacementEquityAwardsShares", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ah_BusinessCombinationLockUpPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Lock-Up Period", "label": "Business Combination, Lock-Up Period", "terseLabel": "Lock-up period" } } }, "localname": "BusinessCombinationLockUpPeriod", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails" ], "xbrltype": "durationItemType" }, "ah_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsContractWithCustomer": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Contract With Customer", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Contract With Customer", "terseLabel": "Current portion of contract assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsContractWithCustomer", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ah_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesCompensationAndBenefits": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 12.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Compensation And Benefits", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Compensation And Benefits", "negatedTerseLabel": "Accrued compensation and benefits" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesCompensationAndBenefits", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ah_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesCustomerLiabilities": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 11.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Customer Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Customer Liabilities", "negatedTerseLabel": "Customer liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesCustomerLiabilities", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ah_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsContractWithCustomer": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Assets, Contract With Customer", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Assets, Contract With Customer", "terseLabel": "Non-current portion of contract assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsContractWithCustomer", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ah_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Asset", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ah_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantEquipmentAndSoftware": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Property, Plant, Equipment And Software", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Property, Plant, Equipment And Software", "terseLabel": "Property, equipment and software" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantEquipmentAndSoftware", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ah_COVID19PandemicCostsIncludedInOtherRestructuringCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "COVID-19 Pandemic Costs, Included in Other Restructuring Costs", "label": "COVID-19 Pandemic Costs, Included in Other Restructuring Costs", "terseLabel": "COVID-19 related costs, included in Other" } } }, "localname": "COVID19PandemicCostsIncludedInOtherRestructuringCosts", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ah_CashFlowLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Flow, Lessee [Abstract]", "label": "Cash Flow, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowLesseeAbstract", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "ah_ClassOfWarrantOrRightMarketPriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right, Market Price of Warrants or Rights", "label": "Class of Warrant or Right, Market Price of Warrants or Rights", "terseLabel": "Warrant market value price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightMarketPriceOfWarrantsOrRights", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "ah_CloudmedAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cloudmed Acquisition", "label": "Cloudmed Acquisition [Member]", "terseLabel": "Cloudmed" } } }, "localname": "CloudmedAcquisitionMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails", "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "http://www.r1rcm.com/role/AcquisitionsScheduleofIntangibleAssetsInformationDetails", "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_CloudmedAndVisitPayAcquisitionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cloudmed And VisitPay Acquisitions", "label": "Cloudmed And VisitPay Acquisitions [Member]", "terseLabel": "Cloudmed and VisitPay Acquisitions" } } }, "localname": "CloudmedAndVisitPayAcquisitionsMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails" ], "xbrltype": "domainItemType" }, "ah_CloudmedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cloudmed", "label": "Cloudmed [Member]", "terseLabel": "Cloudmed" } } }, "localname": "CloudmedMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails", "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails", "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails", "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "ah_ContractWithCustomerAssetAmountsBilled": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Asset, Amounts Billed", "label": "Contract With Customer, Asset, Amounts Billed", "negatedTerseLabel": "Amounts billed" } } }, "localname": "ContractWithCustomerAssetAmountsBilled", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerAssetOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Asset, Other", "label": "Contract With Customer, Asset, Other", "terseLabel": "Other" } } }, "localname": "ContractWithCustomerAssetOther", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerAssetRevenueRecognized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Asset, Revenue Recognized", "label": "Contract With Customer, Asset, Revenue Recognized", "terseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerAssetRevenueRecognized", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerAssetRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract with Customer, Asset", "label": "Contract with Customer, Asset [Roll Forward]", "terseLabel": "Contract with Customer, Asset [Roll Forward]" } } }, "localname": "ContractWithCustomerAssetRollForward", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails" ], "xbrltype": "stringItemType" }, "ah_ContractWithCustomerLiabilityCurrentExcludingAdvancedBillings": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Current, Excluding Advanced Billings", "label": "Contract With Customer, Liability, Current, Excluding Advanced Billings", "terseLabel": "Current portion of customer liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrentExcludingAdvancedBillings", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityIncludingAdvancedBillingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Including Advanced Billings", "label": "Contract With Customer, Liability, Including Advanced Billings [Member]", "terseLabel": "Contract With Customer, Liability, Including Advanced Billings" } } }, "localname": "ContractWithCustomerLiabilityIncludingAdvancedBillingsMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_ContractWithCustomerLiabilityIncludingRelatedParty": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Including Related Party", "label": "Contract With Customer, Liability, Including Related Party", "totalLabel": "Total contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityIncludingRelatedParty", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityIncludingRelatedPartyCurrent": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails": { "order": 1.0, "parentTag": "ah_ContractWithCustomerLiabilityIncludingRelatedParty", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Including Related Party, Current", "label": "Contract With Customer, Liability, Including Related Party, Current", "verboseLabel": "Current" } } }, "localname": "ContractWithCustomerLiabilityIncludingRelatedPartyCurrent", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityIncludingRelatedPartyNoncurrent": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails": { "order": 2.0, "parentTag": "ah_ContractWithCustomerLiabilityIncludingRelatedParty", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Including Related Party, Noncurrent", "label": "Contract With Customer, Liability, Including Related Party, Noncurrent", "terseLabel": "Non-current" } } }, "localname": "ContractWithCustomerLiabilityIncludingRelatedPartyNoncurrent", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityNoncurrentExcludingAdvancedBillings": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Noncurrent, Excluding Advanced Billings", "label": "Contract With Customer, Liability, Noncurrent, Excluding Advanced Billings", "terseLabel": "Non-current portion of customer liabilities" } } }, "localname": "ContractWithCustomerLiabilityNoncurrentExcludingAdvancedBillings", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityRelatedPartyCurrent": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Related Party, Current", "label": "Contract With Customer, Liability, Related Party, Current", "terseLabel": "Current portion of customer liabilities - related party" } } }, "localname": "ContractWithCustomerLiabilityRelatedPartyCurrent", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ah_ContractWithCustomerLiabilityRelatedPartyNoncurrent": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Related Party, Noncurrent", "label": "Contract With Customer, Liability, Related Party, Noncurrent", "terseLabel": "Non-current portion of customer liabilities - related party" } } }, "localname": "ContractWithCustomerLiabilityRelatedPartyNoncurrent", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ah_CoyCo2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CoyCo 2", "label": "CoyCo 2 [Member]", "terseLabel": "CoyCo 2" } } }, "localname": "CoyCo2Member", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "ah_CustomerNotAffiliatedwithAscensionHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Not Affiliated with Ascension Health [Member]", "label": "Customer Not Affiliated with Ascension Health [Member]", "terseLabel": "Intermountain Healthcare" } } }, "localname": "CustomerNotAffiliatedwithAscensionHealthMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails" ], "xbrltype": "domainItemType" }, "ah_DebtInstrumentCovenantMinimumNumberOfOffersToExtendMaturityDateIfCircumstancesMet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Minimum Number Of Offers To Extend Maturity Date, If Circumstances Met", "label": "Debt Instrument, Covenant, Minimum Number Of Offers To Extend Maturity Date, If Circumstances Met", "terseLabel": "Debt covenant, number of offers to extend maturity date, if circumstances met (or more)" } } }, "localname": "DebtInstrumentCovenantMinimumNumberOfOffersToExtendMaturityDateIfCircumstancesMet", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "ah_DebtInstrumentCovenantSecuredObligationPledgedEquityCertainDomesticSubsidiariesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Secured Obligation Pledged, Equity Certain Domestic Subsidiaries, Percent", "label": "Debt Instrument, Covenant, Secured Obligation Pledged, Equity Certain Domestic Subsidiaries, Percent", "terseLabel": "Debt covenant, secured obligation pledged, capital stock of certain domestic subsidiaries, percent" } } }, "localname": "DebtInstrumentCovenantSecuredObligationPledgedEquityCertainDomesticSubsidiariesPercent", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "ah_DebtInstrumentMandatoryPrepaymentsPercentOfAnnualExcessCashFlow": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Mandatory Prepayments, Percent Of Annual Excess Cash Flow", "label": "Debt Instrument, Mandatory Prepayments, Percent Of Annual Excess Cash Flow", "terseLabel": "Mandatory prepayments, percentage of annual excess cash flow" } } }, "localname": "DebtInstrumentMandatoryPrepaymentsPercentOfAnnualExcessCashFlow", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "ah_DebtInstrumentMandatoryPrepaymentsPercentOfCashProceedsOfNonOrdinaryCourseAssetsSalesOrOtherDispositions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Mandatory Prepayments, Percent Of Cash Proceeds Of Non Ordinary Course Assets Sales Or Other Dispositions", "label": "Debt Instrument, Mandatory Prepayments, Percent Of Cash Proceeds Of Non Ordinary Course Assets Sales Or Other Dispositions", "terseLabel": "Mandatory prepayments, percentage of non-ordinary course asset sales or other dispositions" } } }, "localname": "DebtInstrumentMandatoryPrepaymentsPercentOfCashProceedsOfNonOrdinaryCourseAssetsSalesOrOtherDispositions", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "ah_DebtInstrumentMandatoryPrepaymentsPercentOfNetCashProceedsOfDebt": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Mandatory Prepayments, Percent Of Net Cash Proceeds Of Debt", "label": "Debt Instrument, Mandatory Prepayments, Percent Of Net Cash Proceeds Of Debt", "terseLabel": "Mandatory prepayments, percentage of net cash proceeds of debt incurrence" } } }, "localname": "DebtInstrumentMandatoryPrepaymentsPercentOfNetCashProceedsOfDebt", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "ah_DebtInstrumentVariableRateBasisMinimumPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Variable Rate Basis, Minimum Percentage", "label": "Debt Instrument, Variable Rate Basis, Minimum Percentage", "terseLabel": "Variable rate basis, minimum (not less than)" } } }, "localname": "DebtInstrumentVariableRateBasisMinimumPercentage", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "ah_DepreciationDepletionAndAmortizationExcludingIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Depreciation, Depletion, And Amortization, Excluding Intangible Assets", "label": "Depreciation, Depletion, And Amortization, Excluding Intangible Assets", "terseLabel": "Total depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortizationExcludingIntangibleAssets", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ah_ExistingSeniorSecuredTermLoanAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Existing Senior Secured Term Loan A", "label": "Existing Senior Secured Term Loan A [Member]", "terseLabel": "Existing Term A Loan" } } }, "localname": "ExistingSeniorSecuredTermLoanAMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_FacilityCostsIncludedInAcquisitionEvaluationAndIntegrationCosts": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": 7.0, "parentTag": "us-gaap_OtherGeneralExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Facility Costs, Included In Acquisition Evaluation And Integration Costs", "label": "Facility Costs, Included In Acquisition Evaluation And Integration Costs", "terseLabel": "Global business services center expansion project in the Philippines" } } }, "localname": "FacilityCostsIncludedInAcquisitionEvaluationAndIntegrationCosts", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ah_FormerClassPUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Class P Units", "label": "Former Class P Units [Member]", "terseLabel": "Former Class P Units" } } }, "localname": "FormerClassPUnitsMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_GainLossOnDispositionOfAssetsAndRightOfUseAssetWriteDowns": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Disposition Of Assets And Right-Of-Use Asset Write-Downs", "label": "Gain (Loss) On Disposition Of Assets And Right-Of-Use Asset Write-Downs", "negatedLabel": "(Gain)/loss on disposal and right-of-use asset write-downs" } } }, "localname": "GainLossOnDispositionOfAssetsAndRightOfUseAssetWriteDowns", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_IncentiveFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive Fees [Member]", "label": "Incentive Fees [Member]", "terseLabel": "Incentive fees", "verboseLabel": "Incentive fees" } } }, "localname": "IncentiveFeesMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails", "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "domainItemType" }, "ah_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Lease Liabilities", "label": "Increase (Decrease) In Lease Liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_IncrementalSeniorSecuredTermLoanAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental Senior Secured Term Loan A", "label": "Incremental Senior Secured Term Loan A [Member]", "terseLabel": "Incremental Term A Loan" } } }, "localname": "IncrementalSeniorSecuredTermLoanAMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_InducementDividends": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inducement Dividends", "label": "Inducement Dividends", "negatedTerseLabel": "Inducement dividend" } } }, "localname": "InducementDividends", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_InterestRateOptionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Option", "label": "Interest Rate Option [Axis]", "terseLabel": "Interest Rate Option [Axis]" } } }, "localname": "InterestRateOptionAxis", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "ah_InterestRateOptionBasisSpreadOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Option - Basis Spread One", "label": "Interest Rate Option - Basis Spread One [Member]", "terseLabel": "Interest Rate Option - Basis Spread One" } } }, "localname": "InterestRateOptionBasisSpreadOneMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_InterestRateOptionBasisSpreadTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Option - Basis Spread Two", "label": "Interest Rate Option - Basis Spread Two [Member]", "terseLabel": "Interest Rate Option - Basis Spread Two" } } }, "localname": "InterestRateOptionBasisSpreadTwoMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_InterestRateOptionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Option [Domain]", "label": "Interest Rate Option [Domain]", "terseLabel": "Interest Rate Option [Domain]" } } }, "localname": "InterestRateOptionDomain", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_IntermountainMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intermountain", "label": "Intermountain [Member]", "terseLabel": "Intermountain" } } }, "localname": "IntermountainMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/EarningsLossPerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_LeaseExpenseNoncash": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease Expense, Noncash", "label": "Lease Expense, Noncash", "terseLabel": "Non-cash lease expense" } } }, "localname": "LeaseExpenseNoncash", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_LessOperatingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Less, Operating [Abstract]", "label": "Less, Operating [Abstract]", "terseLabel": "Less:" } } }, "localname": "LessOperatingAbstract", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails" ], "xbrltype": "stringItemType" }, "ah_ManagementUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Management Units", "label": "Management Units [Member]", "terseLabel": "Management Units" } } }, "localname": "ManagementUnitsMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_ModularAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Modular And Other", "label": "Modular And Other [Member]", "terseLabel": "Modular and other" } } }, "localname": "ModularAndOtherMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails" ], "xbrltype": "domainItemType" }, "ah_NetOperatingFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Operating Fees [Member]", "label": "Net Operating Fees [Member]", "terseLabel": "Net operating fees", "verboseLabel": "Net operating fees" } } }, "localname": "NetOperatingFeesMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails", "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "domainItemType" }, "ah_NumberOfYearsSinceNewCountryEntry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Years Since New Country Entry", "label": "Number Of Years Since New Country Entry", "terseLabel": "Number of years since new country entry" } } }, "localname": "NumberOfYearsSinceNewCountryEntry", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "durationItemType" }, "ah_OtherIncomeAndExpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Income And Expenses [Line Items]", "label": "Other Income And Expenses [Line Items]", "terseLabel": "Other Income And Expenses [Line Items]" } } }, "localname": "OtherIncomeAndExpensesLineItems", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "stringItemType" }, "ah_OtherIncomeAndExpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Income And Expenses [Table]", "label": "Other Income And Expenses [Table]", "terseLabel": "Other Income And Expenses [Table]" } } }, "localname": "OtherIncomeAndExpensesTable", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "stringItemType" }, "ah_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other", "label": "Other [Member]", "terseLabel": "Other" } } }, "localname": "OtherMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails" ], "xbrltype": "domainItemType" }, "ah_PaymentsToAcquireBusinessNumberOfPaymentsRefundPeriodIfCircumstancesMet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Business, Number Of Payments, Refund Period, If Circumstances Met", "label": "Payments To Acquire Business, Number Of Payments, Refund Period, If Circumstances Met", "terseLabel": "Payments to acquire business, number of payments, refund period, if circumstances met" } } }, "localname": "PaymentsToAcquireBusinessNumberOfPaymentsRefundPeriodIfCircumstancesMet", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "ah_PaymentsToAcquireBusinessesGrossFinancingActivities": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Businesses, Gross, Financing Activities", "label": "Payments To Acquire Businesses, Gross, Financing Activities", "negatedLabel": "Deferred payment related to acquisition of RevWorks", "terseLabel": "Payments to acquire business" } } }, "localname": "PaymentsToAcquireBusinessesGrossFinancingActivities", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_PaymentsToAcquireBusinessesNumberOfPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Businesses, Number Of Payments", "label": "Payments To Acquire Businesses, Number Of Payments", "terseLabel": "Number of deferred payments" } } }, "localname": "PaymentsToAcquireBusinessesNumberOfPayments", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ah_PhysicianCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physician Customer", "label": "Physician Customer [Member]", "terseLabel": "Physician Customer" } } }, "localname": "PhysicianCustomerMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesNarrativesDetails" ], "xbrltype": "domainItemType" }, "ah_PotentialBusinessCombinationPriceOfAcquisitionExpected": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential Business Combination, Price Of Acquisition, Expected", "label": "Potential Business Combination, Price Of Acquisition, Expected", "terseLabel": "Potential business combination, expected purchase price" } } }, "localname": "PotentialBusinessCombinationPriceOfAcquisitionExpected", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ah_RestrictedStockUnitsRSUsAndPerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units (RSUs) And Performance Shares", "label": "Restricted Stock Units (RSUs) And Performance Shares [Member]", "terseLabel": "RSUs and PBRSUs" } } }, "localname": "RestrictedStockUnitsRSUsAndPerformanceSharesMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_RevWorksAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RevWorks Acquisition", "label": "RevWorks Acquisition [Member]", "terseLabel": "RevWorks" } } }, "localname": "RevWorksAcquisitionMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_ScheduleOfDepreciationAndAmortizationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Depreciation And Amortization [Table Text Block]", "label": "Schedule Of Depreciation And Amortization [Table Text Block]", "terseLabel": "Summary Depreciation and Amortization Expense" } } }, "localname": "ScheduleOfDepreciationAndAmortizationTableTextBlock", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "ah_SecondARCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second A&R Credit Agreement", "label": "Second A&R Credit Agreement [Member]", "terseLabel": "Second A&R Credit Agreement" } } }, "localname": "SecondARCreditAgreementMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_SeniorSecuredTermLoanAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Term Loan A", "label": "Senior Secured Term Loan A [Member]", "terseLabel": "Term A Loans" } } }, "localname": "SeniorSecuredTermLoanAMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_SeniorSecuredTermLoanBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Term Loan B", "label": "Senior Secured Term Loan B [Member]", "terseLabel": "Term B Loan" } } }, "localname": "SeniorSecuredTermLoanBMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_SeniorTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Term Loan", "label": "Senior Term Loan [Member]", "terseLabel": "Senior Term Loan" } } }, "localname": "SeniorTermLoanMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "ah_SeveranceCostsTransitionedEmployees": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": 8.0, "parentTag": "us-gaap_OtherGeneralExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Severance Costs, Transitioned Employees", "label": "Severance Costs, Transitioned Employees", "terseLabel": "Customer employee transition and restructuring expenses" } } }, "localname": "SeveranceCostsTransitionedEmployees", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ah_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesVestingIfTargetConditionsMetPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement, By Share Based Payment Award, Equity Instruments Other Than Options, Number Of Shares Vesting, If Conditions Met, Percentage", "label": "Share-Based Compensation Arrangement, By Share-Based Payment Award, Equity Instruments Other Than Options, Number Of Shares Vesting, If Target Conditions Met, Percentage", "terseLabel": "Number of shares vesting if targets conditions met, potential percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSharesVestingIfTargetConditionsMetPercentage", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "ah_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceFactorAdjustmentInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period", "terseLabel": "Performance factor adjustment (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceFactorAdjustmentInPeriod", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "ah_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceFactorAdjustmentInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Performance Factor Adjustment In Period, Weighted Average Grant Date Fair Value", "terseLabel": "Performance factor adjustment (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceFactorAdjustmentInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "ah_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsConvertedInTransactionAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Units Converted In Transaction Agreement", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Units Converted In Transaction Agreement", "terseLabel": "Number of units converted in Transaction Agreement (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfUnitsConvertedInTransactionAgreement", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ah_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsMaximumExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Maximum Exercisable", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Maximum Exercisable", "terseLabel": "Maximum exercisable (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsMaximumExercisable", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ah_SharesIssuedDuringPeriodSharesInducement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Issued During Period, Shares, Inducement", "label": "Shares Issued During Period, Shares, Inducement", "terseLabel": "Issuance of common stock related to inducement (in shares)" } } }, "localname": "SharesIssuedDuringPeriodSharesInducement", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ah_SharesIssuedDuringPeriodValueInducement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares Issued During Period, Value, Inducement", "label": "Shares Issued During Period, Value, Inducement", "terseLabel": "Issuance of common stock related to inducement" } } }, "localname": "SharesIssuedDuringPeriodValueInducement", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_StatuteOfLimitationsMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Statute Of Limitations Maximum", "label": "Statute Of Limitations Maximum", "terseLabel": "Statute of limitations maximum" } } }, "localname": "StatuteOfLimitationsMaximum", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "durationItemType" }, "ah_StatuteOfLimitationsMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Statute Of Limitations Minimum", "label": "Statute Of Limitations Minimum", "terseLabel": "Statute of limitations minimum" } } }, "localname": "StatuteOfLimitationsMinimum", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "durationItemType" }, "ah_StockIssuedDuringThePeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During The Period, Shares, Warrants Exercised", "label": "Stock Issued During The Period, Shares, Warrants Exercised", "terseLabel": "Exercise of warrants pursuant to cashless provisions (in shares)" } } }, "localname": "StockIssuedDuringThePeriodSharesWarrantsExercised", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ah_StockIssuedDuringThePeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During The Period, Value, Warrants Exercised", "label": "Stock Issued During The Period, Value, Warrants Exercised", "terseLabel": "Exercise of warrants pursuant to cashless provisions" } } }, "localname": "StockIssuedDuringThePeriodValueWarrantsExercised", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_TCPASCACHISeriesLLLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TCP-ASC ACHI Series LLLP", "label": "TCP-ASC ACHI Series LLLP [Member]", "verboseLabel": "TCP-ASC" } } }, "localname": "TCPASCACHISeriesLLLPMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_TCPASCRecapitalizationLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TCP-ASC Recapitalization Litigation", "label": "TCP-ASC Recapitalization Litigation [Member]", "terseLabel": "TCP-ASC Recapitalization Litigation" } } }, "localname": "TCPASCRecapitalizationLitigationMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_ThirdPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party", "label": "Third Party [Member]", "terseLabel": "Third Party" } } }, "localname": "ThirdPartyMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ah_TreasuryStockExcludingRelatedToShareBasedCompensationSharesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury Stock, Excluding Related To Share-Based Compensation, Shares, Acquired", "label": "Treasury Stock, Excluding Related To Share-Based Compensation, Shares, Acquired", "negatedTerseLabel": "Repurchases of common stock (in shares)" } } }, "localname": "TreasuryStockExcludingRelatedToShareBasedCompensationSharesAcquired", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ah_TreasuryStockExcludingRelatedToShareBasedCompensationValueAcquiredCostMethod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Treasury Stock, Excluding Related To Share-Based Compensation, Value, Acquired, Cost Method", "label": "Treasury Stock, Excluding Related To Share-Based Compensation, Value, Acquired, Cost Method", "negatedTerseLabel": "Repurchases of common stock" } } }, "localname": "TreasuryStockExcludingRelatedToShareBasedCompensationValueAcquiredCostMethod", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ah_VisitPayIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "VisitPay Inc.", "label": "VisitPay Inc. [Member]", "terseLabel": "VisitPay" } } }, "localname": "VisitPayIncMember", "nsuri": "http://www.r1rcm.com/20220930", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r634" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r635" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails", "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filter Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Smaller Reporting Company" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails", "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.r1rcm.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r343", "r548", "r549", "r551", "r628" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "netLabel": "Related Party" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r45", "r47", "r103", "r104", "r265", "r298" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/EarningsLossPerShareNarrativeDetails", "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r178", "r329", "r335", "r610" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesNarrativesDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r238", "r240", "r241", "r242", "r264", "r297", "r345", "r347", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r608", "r611", "r629", "r630" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails", "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r238", "r240", "r241", "r242", "r264", "r297", "r345", "r347", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r608", "r611", "r629", "r630" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails", "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r178", "r329", "r335", "r610" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesNarrativesDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r175", "r240", "r241", "r329", "r333", "r566", "r607", "r609" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails", "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r175", "r240", "r241", "r329", "r333", "r566", "r607", "r609" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails", "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r231", "r238", "r240", "r241", "r242", "r264", "r297", "r342", "r345", "r347", "r379", "r380", "r381", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r608", "r611", "r629", "r630" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails", "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r231", "r238", "r240", "r241", "r242", "r264", "r297", "r342", "r345", "r347", "r379", "r380", "r381", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r608", "r611", "r629", "r630" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails", "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r46", "r47", "r103", "r104", "r265", "r298" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/EarningsLossPerShareNarrativeDetails", "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "ASC 326" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate202108Member": { "auth_ref": [ "r435", "r436" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2021-08 Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.", "label": "Accounting Standards Update 2021-08 [Member]", "terseLabel": "Accounting Standards Update 2021-08" } } }, "localname": "AccountingStandardsUpdate202108Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r30", "r556" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Schedule of Allowance for Credit Losses" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableGross": { "auth_ref": [ "r20", "r180" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, before Allowance for Credit Loss", "terseLabel": "Accounts receivable, gross" } } }, "localname": "AccountsReceivableGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r626" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionNarrativeDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r180", "r181" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of $14.5 million and $2.4 million allowance as of September\u00a030, 2022 and December\u00a031, 2021, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedPartiesCurrent": { "auth_ref": [ "r21", "r102", "r549", "r551" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.", "label": "Accounts Receivable, Related Parties, Current", "terseLabel": "Accounts receivable, net of $0.1 million and $0.1\u00a0million allowance - related party as of September\u00a030, 2022 and December\u00a031, 2021, respectively" } } }, "localname": "AccountsReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r24", "r50", "r52", "r53", "r599", "r619", "r623" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r49", "r53", "r60", "r61", "r62", "r106", "r107", "r108", "r451", "r545", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Supplemental Financial Information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r22", "r556" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r106", "r107", "r108", "r390", "r391", "r392", "r490" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r109", "r110", "r111", "r112", "r121", "r185", "r186", "r189", "r190", "r191", "r192", "r193", "r194", "r390", "r391", "r392", "r409", "r410", "r411", "r412", "r435", "r436", "r437", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r516", "r517", "r524", "r525", "r526", "r527", "r540", "r541", "r542", "r543", "r544", "r545", "r568", "r569", "r570", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails", "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "terseLabel": "Cost of shares surrendered for taxes" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r349", "r394", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash (used in) provided by operations:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r384" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense", "verboseLabel": "Total share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r28", "r182", "r195", "r196", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Allowance for credit loss" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesNarrativesDetails", "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r28", "r182", "r195" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable, allowance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r198" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedTerseLabel": "Write-offs" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r68", "r89", "r284", "r520" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r89", "r218", "r225" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Intangible asset amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive common share equivalents (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsLossPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsLossPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsLossPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsLossPerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r14", "r99", "r159", "r164", "r171", "r187", "r248", "r249", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r259", "r260", "r448", "r452", "r499", "r554", "r556", "r586", "r597" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r29", "r99", "r187", "r248", "r249", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r259", "r260", "r448", "r452", "r499", "r554", "r556" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r353", "r354", "r355", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r462", "r468" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r344", "r346", "r430" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails", "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails", "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails", "http://www.r1rcm.com/role/AcquisitionsScheduleofIntangibleAssetsInformationDetails", "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails", "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r344", "r346", "r426", "r427", "r430" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails", "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails", "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails", "http://www.r1rcm.com/role/AcquisitionsScheduleofIntangibleAssetsInformationDetails", "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails", "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Acquisition, aggregate number of shares of common stock issued (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails", "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails", "http://www.r1rcm.com/role/AcquisitionsScheduleofIntangibleAssetsInformationDetails", "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage of business acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Schedule of Pro Forma Results" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax": { "auth_ref": [ "r424", "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of pro forma income from continuing operations as if the business combination had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax", "terseLabel": "Net loss" } } }, "localname": "BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r424", "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Net services revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r421" ], "calculation": { "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherGeneralExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Business acquisition costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r439", "r440", "r442" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total purchase consideration", "totalLabel": "Total consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails", "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r439", "r440" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Stock consideration transferred to the Sellers" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationAssetNoncurrent": { "auth_ref": [ "r438", "r441" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset recognized arising from contingent consideration in a business combination, expected to be realized beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Asset, Noncurrent", "terseLabel": "Asset, contingently returnable consideration" } } }, "localname": "BusinessCombinationContingentConsiderationAssetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r431", "r445" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherGeneralExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "terseLabel": "Integration costs" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r423" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "negatedLabel": "Net loss, before income taxes" } } }, "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r423" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "terseLabel": "Net sales" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "auth_ref": [ "r428" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 13.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease obligation assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "negatedTerseLabel": "Operating lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r428" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r428" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r428" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 10.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedTerseLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r428" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 14.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred income tax liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r428" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]", "terseLabel": "Allocation of consideration to assets acquired and liabilities assumed:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r428" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 15.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "negatedTerseLabel": "Other liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r428" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r428" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessExitCosts1": { "auth_ref": [ "r89" ], "calculation": { "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_OtherGeneralExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Business Exit Costs", "terseLabel": "Facility-exit charges" } } }, "localname": "BusinessExitCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r92", "r93", "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property, equipment and software purchases not paid" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostNetNoncurrent": { "auth_ref": [ "r201" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.", "label": "Capitalized Contract Cost, Net, Noncurrent", "terseLabel": "Non-current portion of deferred contract costs" } } }, "localname": "CapitalizedContractCostNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r10", "r91" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r86", "r91", "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r86", "r508" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "auth_ref": [ "r480" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months", "verboseLabel": "Gains (losses) to be reclassified within next 12 months" } } }, "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Class of warrant or right, number of securities called by warrants or rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r233", "r234", "r235", "r243", "r627" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r106", "r107", "r490" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails", "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r299" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19", "r556" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01\u00a0par value, 750,000,000\u00a0shares authorized, 439,386,709 shares issued and 417,722,143 shares outstanding at September 30, 2022; 500,000,000 shares authorized, 298,320,928 shares issued and 278,226,242 shares outstanding at December 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r56", "r58", "r59", "r65", "r592", "r603" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Consolidated statements of comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r148", "r149", "r178", "r496", "r497", "r626" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r148", "r149", "r178", "r496", "r497", "r624", "r626" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r148", "r149", "r178", "r496", "r497", "r624", "r626" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r148", "r149", "r178", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r146", "r148", "r149", "r150", "r496", "r498", "r626" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r148", "r149", "r178", "r496", "r497", "r626" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Classified [Abstract]", "terseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of Contract Assets and Contract Liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r307", "r309", "r330" ], "calculation": { "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodEndLabel": "Balance as of September\u00a030, 2022", "periodStartLabel": "Balance as of June 30, 2022", "terseLabel": "Contract assets", "totalLabel": "Total contract assets" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails", "http://www.r1rcm.com/role/RevenueRecognitionChangestoContractAssetsDetails", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r307", "r309", "r330" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails": { "order": 1.0, "parentTag": "us-gaap_ContractWithCustomerAssetNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "Current portion of contract assets", "verboseLabel": "Current" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNetNoncurrent": { "auth_ref": [ "r307", "r309", "r330" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails": { "order": 2.0, "parentTag": "us-gaap_ContractWithCustomerAssetNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Non-current portion of contract assets", "verboseLabel": "Non-current" } } }, "localname": "ContractWithCustomerAssetNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r307", "r308", "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities", "verboseLabel": "Revenue recognized, advanced billings" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails", "http://www.r1rcm.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability [Abstract]", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r307", "r308", "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Current portion of customer liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r307", "r308", "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Non-current portion of customer liabilities" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r331" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r71", "r566" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of services" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of services", "verboseLabel": "Cost of services" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails", "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r69" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r147", "r178" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails", "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships", "verboseLabel": "Customer Relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsScheduleofIntangibleAssetsInformationDetails", "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r97", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r278", "r285", "r286", "r288", "r296" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r15", "r16", "r17", "r98", "r105", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r274", "r275", "r276", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r292", "r293", "r294", "r295", "r521", "r587", "r588", "r596" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate basis" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r17", "r289", "r588", "r596" ], "calculation": { "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "totalLabel": "Total", "verboseLabel": "Long-term debt" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r36", "r262" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r37", "r98", "r105", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r274", "r275", "r276", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r292", "r293", "r294", "r295", "r521" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r37", "r98", "r105", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r274", "r275", "r276", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r287", "r292", "r293", "r294", "r295", "r300", "r301", "r302", "r303", "r518", "r519", "r521", "r522", "r595" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt maturity" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r274", "r290", "r292", "r293", "r520" ], "calculation": { "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedTerseLabel": "Unamortized discount and issuance costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": { "auth_ref": [ "r523" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross", "terseLabel": "Debt issuance costs incurred" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": { "auth_ref": [ "r523" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Net", "terseLabel": "Debt issuance costs, capitalized" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r399", "r400" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "verboseLabel": "Non-current deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r399", "r400" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Non-current deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r90" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r405" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "verboseLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r407", "r408" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Deferred tax assets related to operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r89", "r157" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsCurrent": { "auth_ref": [ "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Current", "terseLabel": "Derivative asset, current" } } }, "localname": "DerivativeAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsNoncurrent": { "auth_ref": [ "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Noncurrent", "terseLabel": "Derivative asset, noncurrent" } } }, "localname": "DerivativeAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "auth_ref": [ "r495" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.", "label": "Derivative, Fair Value, Net", "terseLabel": "Derivative, fair value, net" } } }, "localname": "DerivativeFairValueOfDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r464" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Derivatives, net gain (loss) reclassified" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r47", "r463", "r467", "r471", "r473" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r481", "r494" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r460", "r463", "r471" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r43", "r44", "r47", "r495" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r456", "r458" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r455", "r457", "r458", "r460", "r461", "r469", "r471", "r475", "r476", "r479", "r481" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionNarrativeDetails", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r329", "r333", "r334", "r335", "r336", "r337", "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionNarrativeDetails", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregated Revenue By Source" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r352", "r353", "r385", "r386", "r388", "r397" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Net income (loss) per common\u00a0share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r66", "r113", "r114", "r115", "r116", "r117", "r122", "r125", "r136", "r137", "r138", "r142", "r143", "r491", "r492", "r593", "r604" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Net income (loss) per common share (basic) (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic EPS:", "verboseLabel": "Basic:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r66", "r113", "r114", "r115", "r116", "r117", "r125", "r136", "r137", "r138", "r142", "r143", "r491", "r492", "r593", "r604" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Net income (loss) per common share (diluted) (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted EPS:", "verboseLabel": "Diluted:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r139", "r140", "r141", "r144" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings (Loss) Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r508" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes in cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r100", "r402", "r415" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r396", "r402" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "negatedLabel": "Income tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Nonvested award, cost not yet recognized, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Related tax benefits" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r60", "r61", "r62", "r106", "r107", "r108", "r110", "r118", "r120", "r145", "r192", "r299", "r304", "r390", "r391", "r392", "r411", "r412", "r490", "r509", "r510", "r511", "r512", "r513", "r514", "r545", "r614", "r615", "r616" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical", "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "terseLabel": "Federal Funds Rate" } } }, "localname": "FederalFundsEffectiveSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financing Receivable, Allowance for Credit Loss [Line Items]", "terseLabel": "Financing Receivable, Allowance for Credit Loss [Line Items]" } } }, "localname": "FinancingReceivableAllowanceForCreditLossesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsScheduleofIntangibleAssetsInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r12", "r224" ], "calculation": { "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails": { "order": 7.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r226" ], "calculation": { "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r226" ], "calculation": { "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r226" ], "calculation": { "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r226" ], "calculation": { "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r226" ], "calculation": { "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r219", "r221", "r224", "r227", "r567", "r571" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsScheduleofIntangibleAssetsInformationDetails", "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r224", "r571" ], "calculation": { "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Value" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r219", "r223" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsScheduleofIntangibleAssetsInformationDetails", "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r224", "r567" ], "calculation": { "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net Book Value" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails", "http://www.r1rcm.com/role/IntangibleAssetsFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-Lived Intangible Assets Acquired", "terseLabel": "Gross Carrying Value" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsScheduleofIntangibleAssetsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign currency forward contracts", "verboseLabel": "Foreign Currency Hedges" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r11", "r202", "r203", "r210", "r215", "r556", "r585" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance as of September\u00a030, 2022", "periodStartLabel": "Balance as of December\u00a031, 2021", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.r1rcm.com/role/ConsolidatedBalanceSheets", "http://www.r1rcm.com/role/GoodwillScheduleofChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r204", "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Cloudmed Acquisition" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/GoodwillScheduleofChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillDisclosureTextBlock": { "auth_ref": [ "r211", "r213", "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill.", "label": "Goodwill Disclosure [Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/Goodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Change in foreign currency rates" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/GoodwillScheduleofChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/GoodwillScheduleofChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r460", "r474" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r63", "r159", "r163", "r167", "r170", "r173", "r584", "r590", "r594", "r605" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income tax provision (benefit)" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r230", "r232" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails", "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails", "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r100", "r403", "r404", "r406", "r413", "r416", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r101", "r119", "r120", "r158", "r401", "r414", "r417", "r606" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r88" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "auth_ref": [ "r88" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Increase (Decrease) in Contract with Customer, Asset", "negatedTerseLabel": "Contract assets" } } }, "localname": "IncreaseDecreaseInContractWithCustomerAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r88", "r565" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Customer liabilities and customer liabilities - related party" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r88" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r88" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r88" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r88" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Accounts receivable and related party accounts receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r126", "r127", "r128", "r138" ], "calculation": { "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "terseLabel": "Add: Effect of dilutive warrants (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r126", "r127", "r129", "r138", "r351" ], "calculation": { "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Add: Effect of dilutive equity awards (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r217", "r222" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "negatedLabel": "Net interest expense" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsScheduleOfDerivativeInstrumentsasHedgedonConsolidatedBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r548", "r549" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]", "terseLabel": "Investor" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsLossPerShareNarrativeDetails", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r536", "r538" ], "calculation": { "http://www.r1rcm.com/role/LeasesScheduleofLeaseCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Components of Lease Costs and Supplemental Cash Flow Information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeasesAcquiredInPlaceMarketAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents the identifiable intangible asset or liability established for an assumed above or below-market lease acquired in an acquisition. Such asset or liability is established regardless of whether the acquiree is the lessee or the lessor.", "label": "Leases, Acquired-in-Place, Market Adjustment [Member]", "terseLabel": "Favorable leasehold interests" } } }, "localname": "LeasesAcquiredInPlaceMarketAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsScheduleofIntangibleAssetsInformationDetails", "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Operating Lease Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r537" ], "calculation": { "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r537" ], "calculation": { "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails": { "order": 7.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r537" ], "calculation": { "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r537" ], "calculation": { "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r537" ], "calculation": { "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r537" ], "calculation": { "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r537" ], "calculation": { "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r537" ], "calculation": { "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r537" ], "calculation": { "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letters of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r33", "r99", "r165", "r187", "r248", "r249", "r250", "r253", "r254", "r255", "r256", "r257", "r259", "r260", "r449", "r452", "r453", "r499", "r554", "r555" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r99", "r187", "r499", "r556", "r589", "r601" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "Liabilities" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r9", "r35", "r99", "r187", "r248", "r249", "r250", "r253", "r254", "r255", "r256", "r257", "r259", "r260", "r449", "r452", "r453", "r499", "r554", "r555", "r556" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit agreement, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Borrowing availability" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "terseLabel": "Accounts Receivable and Allowance for Credit Losses" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLosses" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r17", "r275", "r291", "r292", "r293", "r588", "r598" ], "calculation": { "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "negatedTerseLabel": "Less: Current maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets", "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r105", "r246", "r280" ], "calculation": { "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": 7.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r105", "r246", "r280" ], "calculation": { "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r105", "r246", "r280" ], "calculation": { "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r105", "r246", "r280" ], "calculation": { "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r105", "r246", "r280" ], "calculation": { "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r105", "r246", "r280" ], "calculation": { "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r105" ], "calculation": { "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtScheduledMaturitiesofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r17" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Total long-term debt", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets", "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r37", "r247" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r237", "r239" ], "lang": { "en-us": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Number of complaints filed" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r86", "r87", "r90" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r54", "r57", "r62", "r64", "r90", "r99", "r109", "r113", "r114", "r115", "r116", "r119", "r120", "r134", "r159", "r163", "r167", "r170", "r173", "r187", "r248", "r249", "r250", "r253", "r254", "r255", "r256", "r257", "r259", "r260", "r492", "r499", "r591", "r602" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r113", "r114", "r115", "r116", "r122", "r123", "r135", "r138", "r159", "r163", "r167", "r170", "r173" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income (loss) available/allocated to common shareholders - basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r124", "r130", "r131", "r132", "r133", "r135", "r138" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net income (loss) available/allocated to common shareholders - diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards and Disclosures" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reporting segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r159", "r163", "r167", "r170", "r173" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r532", "r538" ], "calculation": { "http://www.r1rcm.com/role/LeasesScheduleofLeaseCostsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r529" ], "calculation": { "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofOperatingandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r529" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r529" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r530", "r534" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r528" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r6", "r454" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Business Description and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r446", "r447", "r450" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r50" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Net change on derivatives designated as cash flow hedges, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "terseLabel": "Net change on derivatives designated as cash flow hedges, tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r48", "r50", "r465", "r470", "r478" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "verboseLabel": "Unrealized gains (losses) reported in accumulated other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "terseLabel": "Accumulated gain, net of tax, recognized in other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "verboseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r55", "r58", "r446", "r447", "r450" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherGeneralExpense": { "auth_ref": [ "r74" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses.", "label": "Other General Expense", "terseLabel": "Other expenses", "totalLabel": "Total other expenses" } } }, "localname": "OtherGeneralExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r341", "r398" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Expenses" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/OtherExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r90" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestructuringCosts": { "auth_ref": [ "r89" ], "calculation": { "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherGeneralExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.", "label": "Other Restructuring Costs", "terseLabel": "Other" } } }, "localname": "OtherRestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedLabel": "Payment of contingent consideration liability" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r81" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchase of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock": { "auth_ref": [ "r81" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury.", "label": "Payments for Repurchase of Convertible Preferred Stock", "negatedTerseLabel": "Inducement of preferred stock conversion" } } }, "localname": "PaymentsForRepurchaseOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r83" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r85" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of equity issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r81" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Shares withheld for taxes" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r76", "r443" ], "calculation": { "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r76" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisition of Cloudmed, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r77" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property, equipment, and software" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "PBRSUs" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r79" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-Term Lines of Credit", "terseLabel": "Issuance of senior secured debt, net of discount and issuance costs and Borrowings on revolver" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r80", "r85" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r75" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Proceeds from disposal of assets" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r78", "r389" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Exercise of vested stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r229", "r531" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property, equipment and software, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r67", "r197" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision (recoveries)", "verboseLabel": "Increase in allowance" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesNarrativesDetails", "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables [Abstract]", "terseLabel": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r343", "r548", "r549" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r343", "r548", "r551", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r546", "r547", "r549", "r552", "r553" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r82" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-Term Lines of Credit", "negatedLabel": "Repayment of senior secured debt and Repayments on revolver" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r304", "r556", "r600", "r618", "r623" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r106", "r107", "r108", "r110", "r118", "r120", "r192", "r390", "r391", "r392", "r411", "r412", "r490", "r614", "r616" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "verboseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r155", "r156", "r162", "r168", "r169", "r175", "r176", "r178", "r328", "r329", "r566" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net services revenue ($218.1\u00a0million and $657.8\u00a0million for the three and nine months ended September 30, 2022, respectively, and $227.5\u00a0million and $661.4\u00a0million for the three and nine months ended September 30, 2021, respectively, from related party)", "verboseLabel": "Net services revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/RevenueRecognitionScheduleofDisaggregatedRevenuebySourceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r96", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r310", "r311", "r312", "r313", "r314", "r315", "r318", "r319", "r332", "r340" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r70", "r251", "r253", "r254", "r258", "r259", "r260", "r625" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Net services revenue, from related parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue expected to be recognized in the future related to unsatisfied performance obligations, amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue expected to be recognized in the future related to unsatisfied performance obligations, period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]", "terseLabel": "Schedule of Transaction Price Allocated to the Remaining Performance Obligation" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Senior Revolver" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/DebtCarryingAmountsofDebtDetails", "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r535", "r538" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r148", "r178" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsConcentrationRiskbyCustomerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsLossPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r426", "r427", "r430" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails", "http://www.r1rcm.com/role/AcquisitionsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.r1rcm.com/role/AcquisitionsNarrativeDetails", "http://www.r1rcm.com/role/AcquisitionsProFormaResultsDetails", "http://www.r1rcm.com/role/AcquisitionsScheduleofIntangibleAssetsInformationDetails", "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Fair Value of Total Consideration Paid and Schedule of Acquisitions During 2021" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Carrying Values Long-Term Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location" } } }, "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Basic and Diluted Net Income (Loss) Per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r383", "r393" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable": { "auth_ref": [ "r200", "r636" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on financing receivable.", "label": "Financing Receivable, Allowance for Credit Loss [Table]", "terseLabel": "Financing Receivable, Allowance for Credit Loss [Table]" } } }, "localname": "ScheduleOfFinancingReceivableAllowanceForCreditLossesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.", "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Schedule of Intangible Assets Identified with Acquisition" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r219", "r223", "r567" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r219", "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r214", "r215" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Changes in Carrying Value of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/GoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Scheduled Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.", "label": "Schedule of Other Operating Cost and Expense, by Component [Table Text Block]", "terseLabel": "Schedule of Other Expenses" } } }, "localname": "ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.", "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]", "terseLabel": "Schedule of Non-Options Awards Activity" } } }, "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Fair Value of Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r550", "r551" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r159", "r160", "r166", "r211" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r348", "r350", "r353", "r354", "r355", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r356", "r372", "r375" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Options Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Estimated Annual Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r146", "r148", "r149", "r150", "r496", "r498" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedule of Customer Concentration, Net Services Revenue" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR" } } }, "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r151", "r153", "r154", "r159", "r161", "r167", "r171", "r172", "r173", "r174", "r175", "r177", "r178", "r179" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segments and Customer Concentrations" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/SegmentsandCustomerConcentrationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationCompensationExpenseAllocationDetails", "http://www.r1rcm.com/role/SupplementalFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r89" ], "calculation": { "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherGeneralExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance and related employee benefits" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/OtherExpensesScheduleofOtherExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r88" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding and unvested at end of period (in shares)", "periodStartLabel": "Outstanding and unvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding and unvested at end of period (in dollars per share)", "periodStartLabel": "Outstanding and unvested at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted- Average\u00a0Grant Date\u00a0Fair\u00a0Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Outstanding, vested and exercisable at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Outstanding, vested and exercisable at end of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Canceled/forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period (in dollars per share)", "periodStartLabel": "Outstanding at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r353", "r354", "r355", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsFairValueTotalConsiderationPaidDetails", "http://www.r1rcm.com/role/ShareBasedCompensationNarrativeDetails", "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Canceled/forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "verboseLabel": "Shares surrendered for taxes (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ShareBasedCompensationOtherThanStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r40", "r60", "r61", "r62", "r106", "r107", "r108", "r110", "r118", "r120", "r145", "r192", "r299", "r304", "r390", "r391", "r392", "r411", "r412", "r490", "r509", "r510", "r511", "r512", "r513", "r514", "r545", "r614", "r615", "r616" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical", "http://www.r1rcm.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r106", "r107", "r108", "r145", "r566" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r39", "r279", "r299", "r300", "r304" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "verboseLabel": "Conversion of preferred shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r18", "r19", "r299", "r304" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Issuance of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r18", "r19", "r299", "r304" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock related to share-based compensation plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r18", "r19", "r299", "r304", "r362" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Exercise of vested stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.r1rcm.com/role/ShareBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r40", "r299", "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of preferred shares" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r18", "r19", "r299", "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r40", "r299", "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of vested stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r25", "r26", "r99", "r183", "r187", "r499", "r556" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r533", "r538" ], "calculation": { "http://www.r1rcm.com/role/LeasesScheduleofLeaseCostsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r515", "r557" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r515", "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r515", "r557" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AcquisitionsScheduleofIntangibleAssetsInformationDetails", "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TemporaryEquityDividendsAdjustment": { "auth_ref": [], "calculation": { "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).", "label": "Temporary Equity, Dividends, Adjustment", "negatedLabel": "Less dividends on preferred shares", "negatedTerseLabel": "Less dividends on preferred shares" } } }, "localname": "TemporaryEquityDividendsAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Tradename" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "negatedPeriodEndLabel": "Ending Balance (in shares)", "negatedPeriodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r42", "r305", "r306" ], "calculation": { "http://www.r1rcm.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "terseLabel": "Treasury stock, at cost, 21,664,566 shares as of September 30, 2022; 20,094,686 shares as of December 31, 2021" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r19", "r299", "r304" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedTerseLabel": "Acquisition of treasury stock related to share-based compensation plans (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r299", "r304", "r305" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Acquisition of treasury stock related to share-based compensation plans" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r109", "r110", "r111", "r112", "r121", "r185", "r186", "r189", "r190", "r191", "r192", "r193", "r194", "r390", "r391", "r392", "r409", "r410", "r411", "r412", "r435", "r436", "r437", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r516", "r517", "r524", "r525", "r526", "r527", "r540", "r541", "r542", "r543", "r544", "r545", "r568", "r569", "r570", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/AccountsReceivableandAllowanceforCreditLossesRollforwardDetails", "http://www.r1rcm.com/role/BusinessDescriptionandBasisofPresentationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/EarningsLossPerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r124", "r138" ], "calculation": { "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted average common shares (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares used in calculating net income (loss) per common share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r122", "r138" ], "calculation": { "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Basic weighted-average common shares (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.r1rcm.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLossUnaudited", "http://www.r1rcm.com/role/EarningsLossPerShareComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1828-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/subtopic&trid=2196772" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144439" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r296": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r341": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "https://asc.fasb.org/topic&trid=49130413" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944" }, "r397": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r398": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "https://asc.fasb.org/topic&trid=2122503" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6411-128476" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r445": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r454": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r494": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r539": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r553": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r631": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r632": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r633": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r634": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r635": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r636": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1405" }, "r637": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 98 0001628280-22-028782-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-028782-xbrl.zip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�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